Antibody polypeptides that antagonize cd40l

ABSTRACT

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V H  or V K  domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.14/510,474, filed Oct. 9, 2014, which is a continuation of U.S.application Ser. No. 13/650,493, filed Oct. 12, 2012, now U.S. Pat. No.8,895,010, issued Nov. 25, 2015, which claims the benefit of U.S.Provisional Application No. 61/546,800, filed Oct. 13, 2011, and U.S.Provisional Application No. 61/655,110, filed Jun. 4, 2012, which areherein incorporated by reference in their entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted in ASCII format via EFS-Web and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Nov. 23, 2015, isnamed 200896-0005-03-US_ST25.txt and is 1,222,204 bytes in size.

TECHNICAL FIELD

Antibodies and fragments thereof that target CD40L, compositionscomprising the same, and methods of using the same for treatment ofdiseases involving CD40L activity are provided.

BACKGROUND

CD40 ligand (CD40L), also known as CD154, gp39, TNF-related activationprotein (TRAP), 5c8 antigen, or T-BAM, is a trimeric transmembraneprotein of the tumor necrosis factor (TNF) superfamily of molecules.CD40L is primarily expressed on activated T cells, as well as onactivated leukocytes, eosinophils, basophils, natural killer cells, mastcells, and non-immune cells such as platelets and activated endothelialcells. CD40L also exists in soluble form (sCD40L) that is produced bymicrosomal stimulus-dependent cleavage of the membrane-bound CD40L. Mostof sCD40L in circulation (>90%) is platelet-derived.

CD40L binds CD40, a type I transmembrane glycoprotein belonging to theTNF receptor (TNFR) family. Although all monomeric, dimeric, andtrimeric forms of sCD40L can bind to CD40, the trimeric form of sCD40Lhas the most potent biological activity through oligomerization of cellsurface CD40, a common feature of TNFR family. The highest expression ofCD40 has been observed on antigen presenting cells (APCs), such as Bcells, macrophages, and dendritic cells, while lower expression of thisreceptor is noted on a variety of other cell types, including stromalcells and thymic epithelium. The CD40-CD40L interaction is essential fornormal T-B cell interactions, including increased co-stimulation, T-cellpriming, cytokine production, antibody-class switching and affinitymaturation, and antibody and autoantibody production.

The crucial role of CD40-CD40L interactions in immune and inflammatoryresponses has made them a promising target for treatment of pathologicalimmuno-inflammatory processes. Blockade of CD40-CD40L interactions bymeans of specific CD40L monoclonal antibodies (mAbs) successfullyprevents allograft rejection in primates and treats autoimmune diseasesand atherosclerosis in animal models. Montgomery et al., Transplantation74: 1365-1369 (2002).

In humans, two different anti-CD40L mAb clones have been used inclinical trials for treatment of different autoimmune diseases. Maribelet al., Mol. Immunol. 45: 937-44 (2008). Monoclonal antibodies, however,can display unusually high incidence of thromboembolic (TE)complications, such as atherothrombotic central nervous system events,myocardial infarction, pulmonary embolism, and deep vein thrombosis. Forexample, the usefulness of the anti-CD40L mAb clone hu5c8 (anti-CD40LmAb, Biogen) is limited by an unusually high incidence of TEcomplications. TE by these antibodies is thought to result from theformation of higher-order immune complexes (IC) of the mAbs withmembrane-bound CD40L on platelets, or sCD40L shed from platelets, thatcan ligate and thereby aggregate neighboring platelets via their FcgRIIareceptors, resulting in thrombi formation. The risk of thromboembolismhas led to a halt in all ongoing clinical trials. Boumpas et al.,Arthritis & Rheumatism 48: 719-727 (2003).

SUMMARY

Anti-CD40L antibody antagonists that are less likely to cause plateletaggregation and thus cause thromboembolism are still needed in aclinical setting. Novel antibody polypeptides that specifically bindhuman CD40L are provided. The antibody polypeptides advantageously donot cause platelet aggregation. The antibody polypeptides are useful inthe treatment of diseases involving CD40L activation, includingautoimmune diseases, transplant rejection, and allergic responses. Theantibody polypeptides comprise a variable domain. Exemplary antibodypolypeptides are in the form of a domain antibody (dAb) that contains asingle variable domain. Alternatively, the dAbs can be bi-specificreagents that comprise a second variable domain that can bind anotherantigen, such as human serum albumin (HSA), for example.

An antibody polypeptide is provided comprising a first variable domainthat specifically binds human CD40L, wherein the first variable domaincomprises the amino acid sequence of one of the variable domainsselected from the BMS2h lineage. Further provided is an isolatedantibody polypeptide comprising a first variable domain thatspecifically binds human CD40L, wherein CD40L comprises the amino acidsequence of SEQ ID NO: 1, wherein the amino acid sequence of the firstvariable domain comprises: (a) a CDR1 region which differs from the CDR1region of BMS2h-572-633 by up to three amino acids, (b) a CDR2 regionwhich differs from the CDR2 region of BMS2h-572-633 by up to three aminoacids, (c) a CDR3 region which differs from the CDR3 region ofBMS2h-572-633 by up to three amino acids, (d) a FR1 region which differsfrom the FR1 region of BMS2h-572-633 by up to three amino acids, (e) aFR2 region which differs from the FR2 region of BMS2h-572-633 by up tothree amino acids, (f) a FR3 region which differs from the FR3 region ofBMS2h-572-633 by up to three amino acids, and (g) a FR4 region whichdiffers from the FR4 region of BMS2h-572-633 by up to three amino acids;and wherein the antibody polypeptide inhibits binding of CD40L to CD40with an EC50 of 100 pM to 100 nM. Also provided is an antibodypolypeptide, wherein the amino acid sequence of the first variabledomain comprises: (a) a CDR1 region which differs from the CDR1 regionof BMS2h-572-633 by up to three amino acids, (b) a CDR2 region whichdiffers from the CDR2 region of BMS2h-572-633 by up to three aminoacids, and (c) a CDR3 region which differs from the CDR3 region ofBMS2h-572-633 by up to three amino acids. Alternatively, the amino acidsequence of the first variable domain can differ from the amino acidsequence of BMS2h-572-633 by up to and including 10 amino acids.Furthermore, the amino acid sequence of the first variable domain candiffer from the amino acid sequence of BMS2h-572-633 by up to andincluding 5 amino acids. The amino acid sequence of the first variabledomain can also differ from the amino acid sequence of BMS2h-572-633 byup to and including 2 amino acids. Alternatively, the first variabledomain differs from the amino acid sequence of BMS2h-572-633 by 1 aminoacid.

Also provided is an antibody polypeptide selected from the lineage groupof BMS2h-572, wherein the amino acid sequence of the first variabledomain further comprises: (a) a CDR1 region having a sequenceTrp-X₁-Leu-Met-Gly (SEQ ID NO: 2), wherein X₁ is Glu or Gln; (b) a CDR2region having a sequenceGly-Ile-Glu-Gly-Pro-Gly-Asp-Val-Thr-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (SEQID NO: 3); and (c) a CDR3 region having a sequenceLys-X₂-Y₂-Z₂-Ser-Asp-Tyr (SEQ ID NO: 4), wherein X₂ is Asp or Glu, Y₂ isAla or Ser, and Z₂ is Lys, Asn, or Arg. Also provided is the antibodypolypeptide, wherein the amino acid sequence of the first variabledomain further comprises: (a) a FR1 region having a sequenceGlu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Asn(SEQ ID NO: 5); (b) a FR2 region having a sequenceTrp-X₁-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser (SEQ ID NO: 6),wherein X₁ is Ala or Val; (c) a FR3 region having a sequenceArg-Thr-Phe-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Val-Lys-Val-Gly(SEQ ID NO: 7); and (d) a FR4 region having a sequenceArg-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser (SEQ ID NO: 8).

Alternatively, the first variable domain of the antibody polypeptide cancomprise the amino acid sequence of BMS2h-572-633.

Also provided is an antibody polypeptide selected from the lineage groupof BMS2h-719, comprising a first variable domain with the followingconsensus sequence:Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-X₁-Y₁-Tyr-Glu-Met-Z₁-Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser-Ser-Ile-Ser-Ser-Asp-Gly-Ser-Phe-Thr-Tyr-Tyr-Ala-A₁-Ser-Val-Lys-Gly-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Ala-B₁-Pro-Phe-Thr-Glu-C₁-Asp-Tyr-Trp-Gly-His-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser(SEQ ID NO: 9), wherein X₁ is Lys or Asn; Y₁ is Arg, Lys, Ser, or Thr;Z₁ is Met or Gln; A₁ is Asp or Glu; B₁ is Asp or Glu; and C₁ is Phe,Met, or Leu.

Also provided is an antibody polypeptide selected from the lineage groupof BMS2h-503, comprising a first variable domain with the followingconsensus sequence:Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-Ser-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-Arg-Ala-Ser-His-X₁-Ile-Gln-Arg-Tyr-Leu-Ser-Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-Ile-Leu-Trp-Gly-Ser-Gln-Leu-Gln-Ser-Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Gly-Thr-Asp-Phe-Thr-Leu-Thr-Ile-Ser-Ser-Leu-Gln-Pro-Glu-Asp-Phe-Ala-Thr-Tyr-Tyr-Cys-Gly-Gln-Trp-Trp-Ala-Pro-Pro-Gln-Thr-Phe-Gly-Gln-Gly-Thr-Lys-Val-Glu-Ile-Lys-Arg(SEQ ID NO: 10), wherein X₁ is His or Asp.

Also provided is an antibody polypeptide selected from the lineage groupof BMS2h-116, comprising a first variable domain with the followingconsensus sequence:Asp-Ile-Gln-Met-Thr-Gln-Ser-Pro-Ser-Ser-Leu-Ser-Ala-X₁-Val-Gly-Asp-Arg-Val-Thr-Ile-Thr-Cys-Arg-Ala-Ser-Gln-Pro-Ile-Gly-Pro-Asp-Leu-Leu-Trp-Tyr-Gln-Gln-Lys-Pro-Gly-Lys-Ala-Pro-Lys-Leu-Leu-Ile-Tyr-Gln-Thr-Ser-Ile-Leu-Arg-Ser-Gly-Val-Pro-Ser-Arg-Phe-Ser-Gly-Ser-Gly-Ser-Glu-Thr-Asp-Phe-Thr-Leu-Thr-Ile-Ser-Asn-Leu-Gln-Pro-Glu-Asp-Y₁-Ala-Z₁-Tyr-Tyr-Cys-Gln-Gln-Tyr-Trp-Ala-Phe-Pro-Val-Thr-Phe-Gly-A₁-Gly-Thr-Lys-Val-Val-Ile-Lys-Arg(SEQ ID NO: 11), wherein X₁ is Ser or Tyr; Y₁ is Leu or Phe; Z₁ is Thror Lys; and A₁ is Lys, Arg, or Gln.

Also provided is an antibody polypeptide comprising a first variabledomain that specifically binds human CD40L, wherein the antibodypolypeptide is a domain antibody (dAb). The antibody polypeptide can bea fusion polypeptide comprising the first variable domain and an Fcdomain. Alternatively, the fusion polypeptide can comprise an IgG4 Fcdomain. The fusion polypeptide also can comprise an IgG1 Fc domain. Thefusion polypeptide can also comprise an IgG1 Fc domain. Alternatively,the fusion polypeptide can comprise a CT-Long domain. The fusionpolypeptide can also comprise a CT-short domain. Alternatively, thefusion polypeptide can comprise a N297Q Long Fc domain. The fusionpolypeptide can alternatively comprise a N297Q Short Fc domain.

Also provided is an antibody polypeptide comprising a first variabledomain that specifically binds human CD40L, wherein the antibodypolypeptide further comprises a second variable domain that specificallybinds a second antigen, wherein the second antigen is an antigen otherthan human CD40L. The second antigen can be a cluster of differentiation(CD) molecule or a Major Histocompatibility Complex (MHC) Class IImolecule. Alternatively, the second antigen can be serum albumin (SA).

Also provided is a nucleic acid encoding any of the antibodypolypeptides provided herein. Further contemplated is a vectorcomprising the nucleic acid. An isolated host cell can comprise suchvector.

A pharmaceutical composition is provided comprising atherapeutically-effective amount of the presently provided antibodypolypeptide and a pharmaceutically acceptable carrier. Thepharmaceutical composition can further comprise animmunosuppressive/immunomodulatory and/or anti-inflammatory agent.

A method of treating an immune disease in a patient in need of suchtreatment is provided comprising administering to the patient atherapeutically effective amount of the pharmaceutical compositiondescribed herein. An exemplary method administers the pharmaceuticalcomposition in combination with an immunosuppressive/immunomodulatoryand/or anti-inflammatory agent. The immune disease can be an autoimmunedisease or a graft-related disease. Alternatively, the immune disease isa graft-related disease. Furthermore, the graft-related disease cancomprise solid organ, tissue and/or cell transplant rejection.Alternatively, the graft-related disease is graft versus host disease(GVHD). The graft-related disease can further be an acute transplantrejection. Alternatively, the graft-related disease can be a chronictransplant rejection.

Also provided is the method of treating a graft-related disease, whereinthe pharmaceutical composition is co-administered with a CTLA4 mutantmolecule. The CTLA4 mutant molecule can be L104EA29Y-Ig (belatacept).

A method of treating an immune disease in a patient in need of suchtreatment is also provided comprising administering to the patient atherapeutically effective amount of the pharmaceutical compositionprovided herein, wherein the immune disease is selected from the groupconsisting of selected from the group consisting of Addison's disease,allergies, ankylo sing spondylitis, asthma, atherosclerosis, autoimmunediseases of the ear, autoimmune diseases of the eye, autoimmunehepatitis, autoimmune parotitis, colitis, coronary heart disease,Crohn's disease, diabetes, including Type 1 and/or Type 2 diabetes,epididymitis, glomerulonephritis, Graves' disease, Guillain-Barresyndrome, Hashimoto's disease, hemolytic anemia, idiopathicthrombocytopenic purpura, inflammatory bowel disease, immune response torecombinant drug products, systemic lupus erythematosus, maleinfertility, multiple sclerosis, myasthenia gravis, pemphigus,psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis,scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis,transplant rejection, vasculitis, AIDS, atopic allergy, bronchialasthma, eczema, leprosy, schizophrenia, inherited depression,transplantation of tissues and organs, chronic fatigue syndrome,Alzheimer's disease, Parkinson's disease, myocardial infarction, stroke,autism, epilepsy, Arthus's phenomenon, anaphylaxis, alcohol addiction,and drug addiction. Alternatively, the immune disease can be myastheniagravis, idiopathic thrombocytopenic purpura, or systemic sclerosis.

Also provided is a use of an isolated antibody polypeptide disclosedherein for the preparation of a medicament for the treatment of apatient, wherein the patient has or is at risk of having an immunedisease. Further provided is a use of an isolated antibody polypeptidedisclosed herein for preparation of a medicament for alleviating atleast one symptom of an immune disease in a patient in need thereof.

Further provided herein is an isolated antibody polypeptide comprising afirst variable domain, wherein said antibody polypeptide specificallybinds human CD40L, wherein CD40L comprises the amino acid sequence ofSEQ ID NO: 1, wherein the antibody polypeptide competes with the bindingof BMS2h-572-633, and wherein the antibody polypeptide inhibits bindingof CD40L to CD40 with an EC50 of 100 pM to 100 nM. In one aspect, thefirst variable domain comprises the amino acid sequence of one of theantibody polypeptides selected from the lineage group consisting ofBMS2h-572, BMS2h-719, BMS2h-503, and BMS2h-116. In another aspect, thefirst variable domain comprises an amino acid sequence at least 95%identical to BMS2h-572-6, BMS2h-572-608, BMS2h-572-614, BMS2h-572-619,BMS2h-572-633, BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202,BMS2h-719-203, BMS2h-719-213, BMS2h-719-214, BMS2h-719-215,BMS2h-719-218, BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312,BMS2h-116-1313, or BMS2h-116-1320. In yet another aspect, the firstvariable domain comprises the amino acid sequence of BMS2h-572-6,BMS2h-572-608, BMS2h-572-614, BMS2h-572-619, BMS2h-572-633,BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202, BMS2h-719-203,BMS2h-719-213, BMS2h-719-214, BMS2h-719-215, BMS2h-719-218,BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312, BMS2h-116-1313,or BMS2h-116-1320.

BRIEF DESCRIPTION OF THE FIGURES

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

FIG. 1A depicts the domain antibody that comprises a V_(H) variabledomain BMS2h-572-633 fused to a modified Fc tail from Abatacept IgG1.

FIG. 1B shows the amino acid sequence (SEQ ID NO: 1355) of the variabledomain BMS2h-572-633 (in blue). The Fc fusion protein is a dimer ofmolecular weight 77,984 Daltons, with each polypeptide chain consistingof 354 amino acids. The variable domain is fused by a linker (green) tothe mutated Fc construct of human IgG1, wherein three cysteine residues(shown in purple) are substituted with serine, and one proline (shown inred) is substituted with a serine residue.

FIG. 2 depicts a working model for the CD40-40L pathway. The top paneldemonstrates initial stages of an encounter between a T cell and an APC.The initial encounter driven by T cell receptor (TCR) engagement of pMHCcomplex (signal 1) coupled with an early CD28-CD80 interaction (signal2) is sufficient for the cell surface expression of trimeric CD40L(bottom panel). Engagement of CD40 by CD40L results in numerousbiological responses outlined in the grey box.

FIG. 3 provides sequences (SEQ ID NOS 1356-1361, respectively, in orderof appearance) of various Fc domains. Linker regions are shown in boxes.

FIG. 4 shows examples of various Fc-formatted domain antibodies (SEQ IDNOS 1362-1365, respectively, in order of appearance). Linker regions areindicated by boxes.

FIG. 5 depicts SPR sensorgram data for the binding of 12.5-0.39 nMBMS-986004 (2:1 dilution series) to biot-IZ-hCD40L captured on astreptavidin SPR sensor chip at 25° C. Colored lines show thedouble-referenced sensorgram data, and black lines show the 1:1 Langmuirfit to the data, with an avidity-influenced apparent Kd value of 0.11nM.

FIG. 6 shows ITC data for titrations of 19 μM IZ-hCD40L into 2 μMBMS-986004 (black) or 18 μM BMS-986004 into 2 μM IZ-hCD40L (blue). Themolar ratio (apparent stoichiometry) is defined per mole of IZ-hCD40Ltrimer and per mole of bivalent BMS-986004 Fc-dimer. Molar ratio valuesobtained as the equivalence points on the abscissa suggest more than onemole of BMS-986004 can bind per mole of IZ-hCD40L trimer; however, anexact structural model for the complex cannot be determined from the ITCdata alone. Squares represent the integrated heat of binding data andsolid lines represent the best fit to a “2 sets of sites model.”

FIG. 7 shows in vivo efficacy of mouse CD40L surrogate dAb-Fc(KLH-induced antibody response.

FIG. 8 demonstrates that mouse dAb BMS-2m-126-24-Fc and antibody MR-1inhibit TNBS-induced colitis in mice.

FIG. 9 shows that BMS-2m-126-24-Fc and CTLA4-Ig work synergistically toprolong the survival of cardiac allografts.

FIG. 10 provides a hypothetic model for anti-CD40 monoclonalantibody-mediated platelet aggregation.

FIG. 11A shows plasma concentration vs. time profile of BMS-986004 afterIV dosing of 11 mg/kg in monkeys.

FIG. 11B demonstrates plasma concentration vs. time profiles ofBMS-986003 after IV dosing of 2 mg/kg in monkeys.

FIG. 12 presents plasma concentrations vs. time profiles of BMS-986003(after SC dosing at 0.2, 2 and 20 mg/kg in monkeys) and of 5c8 IgG1(after IV dosing at 20 mg/kg in monkeys).

FIG. 13 shows plasma concentrations vs. time profiles ofBMS-2m-126-24-CT after 1 mg/kg IV and SC dosing, and 10 mg/kg SC dosingto mice.

FIG. 14 demonstrates PK/PD modeling of BMS-986003 and 5c8-IgG1 plasmaexposures and anti-KLH antibody response (IgG Titers).

FIG. 15 shows PK/PD modeling of BMS-986004 plasma exposures and ex vivoRO on peripheral blood mononuclear cells (PBMC).

FIG. 16 demonstrates that IV.3 blocks 5c8/sCD40L IC-mediated activationof platelets in human blood.

FIG. 17 shows the effect of Fc variants on platelet activation in humanblood.

FIG. 18 demonstrates activation of platelets with 5c8-CT/sCD40L IC inblood from human donors genotyped for FcgRIIa polymorphism.

FIG. 19 diagrams platelet activation by various antibodies in blood fromhuman donors.

FIG. 20 shows levels of platelet activation by various antibodies,including BMS-986003, in hFcgRIIa-expressing transgenic mice.

FIGS. 21, 22, 23, and 24 show is ClustalW2 alignments of representativedomain antibody polypeptides from lineages BMS2h-572, BMS2h-719,BMS2h-503, and BMS2h-116, respectively. FIG. 21 discloses SEQ ID NOS243, 251, 257, 262 and 274-276, respectively, in order of appearance,FIG. 22 discloses SEQ ID NOS 352, 354-355 and 357-361, respectively, inorder of appearance, FIG. 23 discloses SEQ ID NOS 1087-1088,respectively, in order of appearance, and FIG. 24 discloses SEQ ID NOS970-971 and 974, respectively, in order of appearance.

FIG. 25 shows SPR sensorgram data for binding experiments usingmonovalent dAbs BMS2h-503-1, BMS2h-572-6, BMS2h-719-17, and monovalentFab fragment of 5c8, where the indicated molecules compete with eachother for binding to CD40L (biotinylated IZ-hCD40L).

FIG. 26 shows SPR sensorgram data for experiments testing the binding ofBMS2h-572-619-CT-long, BMS2h-572-633-CT-long, BMS2h-572-6-CT-long,BMS2h-719-202-CT-long, BMS2h-572-608-CT-long, BMS2h-572-634-CT-long,BMS2h-572-614-CT-long, BMS2h-572-635-CT-long, and 5c8-CT-long moleculesto either CD40L monomer (upper 3 panels) or CD40L trimer (lower 3panels).

DETAILED DESCRIPTION

Antibody polypeptides that specifically bind to human CD40L areprovided. The antibody polypeptides do not activate platelets, and theantibody polypeptides are useful in the treatment of diseases involvingCD40L activation, such as graft-related diseases and autoimmunediseases. The antibody polypeptides may be selected using a primaryscreen that utilizes cell binding assays, followed by one or more roundsof error-prone or degenerate oligonucleotide-directed affinitymaturation. As a result, a genus of antibody polypeptides thatspecifically bind CD40L are provided.

A “lineage” is a set of related antibody polypeptides that were preparedfrom a common precursor by error-prone or degenerateoligonucleotide-directed affinity maturation, as disclosed in theexamples below, and that are expected to bind CD40L. The nomenclature ofthe antibody polypeptides is used to designate the various lineages. Thenomenclature “BMS2h-572,” for example, refers to antibody polypeptidesof lineage 572, which were raised against human CD40L. “LineageBMS2h-572” antibody polypeptides include BMS2h-572-1 throughBMS2h-572-19, BMS2h-572-21 through BMS2h-572-24, BMS2h-572-601 throughBMS2h-572-627, and BMS2h-572-630 through BMS2h-572-635.

Accordingly, in one aspect, an antibody polypeptide comprises a variabledomain that specifically binds human CD40L, where the antibodypolypeptide competes with the binding of any one of the domainantibodies (dAbs) listed in TABLE 1 or TABLE 3. For example, theantibody polypeptide may compete with a dAb selected from the 2hlineage. The dAb also may be selected from a lineage selected from thegroup consisting of BMS2h-116, BMS2h-503, BMS2h-572, and BMS2h-719, suchas the dAb BMS2h-572-633, BMS2h-572-608, or BMS2h-572-614, for instance.In another aspect, an antibody polypeptide specifically binds humanCD40L as any one of the dAbs listed in TABLE 1 and TABLE 3. For example,the antibody polypeptide may comprise a variable domain thatspecifically binds human CD40L as the dAb BMS2h-572-633, BMS2h-572-608,or BMS2h-572-614, for instance.

The antibody polypeptides may be a domain antibody containing a singlevariable domain. The antibody polypeptides also may comprise additionaldomains, such as an Fc domain. For instance, the antibody polypeptidemay comprise a second variable domain that specifically binds humanserum albumin (HSA). Such dual specific antibody polypeptides may havean increased half-life, for example.

As used herein, “specific binding” refers to the binding of an antigenby an antibody polypeptide with a dissociation constant (K) of about 1μM or lower as measured, for example, by surface plasmon resonance(SPR). Suitable assay systems include the BIAcore™ surface plasmonresonance system and BIAcore™ kinetic evaluation software (e.g., version2.1). The affinity or K_(d) for a specific binding interaction may beabout 1 μM or lower, about 500 nM or lower or about 300 nM or lower.

The term “about” will be understood by persons of ordinary skill in theart and will vary to some extent on the context in which it is used.Generally, about encompasses a range of values that are plus/minus 10%of a referenced value.

In accordance with this detailed description, the followingabbreviations and definitions apply. It must be noted that as usedherein, the singular forms “a”, “an”, and “the” include plural referentsunless the context clearly dictates otherwise. Thus, for example,reference to “an antibody” includes a plurality of such antibodies andreference to “the dosage” includes reference to one or more dosages andequivalents thereof known to those skilled in the art, and so forth.

1. CD40L and CD40L Activities

Antibody polypeptides are provided that bind human CD40L. CD40L is alsoknown as CD154, gp39, TNF-related activation protein (TRAP), 5c8antigen, or T-BAM. Relevant structural information for human CD40L canbe found, for example, at UniProt Accession Number P29965. “Human CD40L”refers to the CD40L comprising the following amino acid sequence:

(SEQ ID NO: 1)         10         20         30         40 MIETYNQTSPRSAATGLPIS MKIFMYLLTV FLITQMIGSA        50         60         70         80 LFAVYLHRRL DKIEDERNLHEDFVFMKTIQ RCNTGERSLS         90        100        110        120LLNCEEIKSQ FEGFVKDIML NKEETKKENS FEMQKGDQNP       130        140        150        160 QIAAHVISEA SSKTTSVLQWAEKGYYTMSN NLVTLENGKQ        170        180        190        200LTVKRQGLYY IYAQVTFCSN REASSQAPFI ASLCLKSPGR       210        220        230        240 FERILLRAAN THSSAKPCGQQSIHLGGVFE LQPGASVFVN        250        260 VTDPSQVSHG TGFTSFGLLK L

CD40L has also been sequenced in Sus scrofa, Mus musculus, Canisfamiliaris, Bos ffini, Macaca mulatta, Aotus tivirgatus, Callithrixjacchus, Cercocebus torquatus atys, Macaca nemestrina, Rattusnorvegicus, Gallus gallus, Felis catus, and Sus scrofa.

Binding of the present antibody polypeptides to CD40L antagonizes CD40Lactivity. “CD40L activities” include, but are not limited to,costimulation and activation an APC in association with T cell receptorstimulation by MHC molecules on the APC, secretion of all immunoglobulinisotypes in the presence of cytokines, stimulation of B cellproliferation, cytokine production, antibody class switching andaffinity maturation. For example, patients with X-linked hyper-IgMsyndrome express functional CD40 on their B cells, but their activated Tcells have a defective CD40L protein, resulting in its inability toactivate B cells and induce immunoglobulin isotype switching. Aruffo etal., Cell 72:291-300 (1993).

CD40L activities can be mediated by interaction with other molecules.“CD40 activities” include the functional interaction between CD40L andthe following molecules: CD40 (CD40L receptor), α5β1 integrin, andαIIbβ3. For example, CD40L binds its receptor, CD40, which is expressedon a variety of APCs, such as B cells, macrophages, and dendritic cells,as well as on stromal cells, vascular endothelial cells, and platelets.

As used herein, the terms “activate,” “activates,” and “activated” referto an increase in a given measurable CD40L activity by at least 10%relative to a reference, for example, at least 10%, 25%, 50%, 75%, oreven 100%, or more. A CD40L activity is “antagonized” if the activity isreduced by at least 10%, and in an exemplary embodiment, at least 20%,30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, or even 100% (i.e., nodetectable activity), relative to the absence of the antagonist. Forexample, an antibody polypeptide may antagonize some or all CD40Lactivity. In one embodiment, the antibody polypeptide does not activateB cell proliferation. In another embodiment, the antibody polypeptidedoes not activate cytokine secretion by T cells or dendritic cells(DCs), where the cytokine is at least one cytokine selected from thegroup consisting of IL-2, IL-6, IL-10, IL-12, IL-13, IL-17, IL-23,TNF-α, and IFN-γ.

2. Antibody Polypeptides

The antibody polypeptides comprise a variable domain. In one embodiment,the antibody polypeptides are in the form of a dAb that contains asingle variable domain. Antibody polypeptides may be full-lengthanti-CD40L immunoglobulin molecules comprising two heavy (H) chains andtwo light (L) chains interconnected by disulfide bonds. In thisembodiment, the amino terminal portion of each chain includes a variabledomain (V_(L) or V_(H)) of about 100-120 amino acids. Thecomplementarity determining regions (CDRs) contained therein areprimarily responsible for antigen recognition, although frameworkresidues can play a role in epitope binding. The carboxy-terminal “half”of each heavy chain defines a constant region (Fc) primarily responsiblefor effector function.

Antibody polypeptides also may be “fragments” comprising a portion ofthe full-length anti-CD40L immunoglobulin molecule that comprises avariable domain that specifically binds CD40L. Thus, the term “antibodypolypeptides” includes an antigen-binding heavy chain, light chain,heavy chain-light chain dimer, Fab fragment, F(ab′)₂ fragment, Fvfragment, single chain Fv (scFv), and dAb, for example. The term“antibody polypeptides” thus includes polypeptides made by recombinantengineering and expression, as well as monoclonal antibodies produced bynatural recombination and secretion by hybridoma cell clones.

Light chains are classified as kappa (κ) or lambda (λ), and arecharacterized by a particular constant region, C_(L), as known in theart. Heavy chains are classified as γ, μ, α, δ, or ε, and define theisotype of an antibody as IgG, IgM, IgA, IgD, or IgE, respectively. Theheavy chain constant region is comprised of three domains (CH1, CH2, andCH3) for IgG, IgD, and IgA; and four domains (CH1, CH2, CH3, and CH4)for IgM and IgE. Anti-CD40L antibodies may have a heavy chain constantregion selected from any of the immunoglobulin classes (IgA, IgD, IgG,IgM, and IgE).

Each light chain variable domain (V_(L)) and heavy chain variable domain(V_(H)) is composed of three CDRs and four framework regions (FRs),arranged from amino-terminus to carboxy-terminus in the following order:FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The three CDRs of the lightchain are referred to as “LCDR1, LCDR2, and LCDR3” and the three CDRs ofthe heavy chain are referred to as “HCDR1, HCDR2, and HCDR3.”

As used herein, the term “Fc domain” refers to the constant regionantibody sequences comprising CH2 and CH3 constant domains as delimitedaccording to Kabat et al., Sequences of Immunological Interest, 5^(th)ed., U.S. Dept. Health & Human Services, Washington, D.C. (1991). The Fcdomain may be derived from an IgG1 or an IgG4 Fc region, for example.

A variable domain may be fused to an Fc domain. Examples of variousFc-formatted domain antibodies and their potency are provided in TABLE6. FIG. 3 provides sequences of various Fc domains provided herein.Linker regions are shown in boxes. As used in TABLE 6, “Fc” indicatesthat the dAb is fused to a human IgG1 short Fc. “CT Long Fc,” alsocalled CT-L2, refers to the Fc from CTLA4. The underlined S arecysteine-to-serine point mutations made to eliminate the disulfides inthe Fc hinge. “CT Short,” also called CT-S1, is shorter than CT Long by7 amino acids. “N297Q Long Fc,” also referred to as N297Q-L4, is the Fcdomain of human IgG1 with a N297Q mutation made to eliminate theN-linked carbohydrate in the Fc. “N297Q Short Fc,” also called N297Q-S3,is short than N297Q Long Fc by 7 amino acids, and is a human IgG1 with aN297Q point mutation made to eliminate the N-linked carbohydrate in theFc domain. “CT-Fc SP5” is the CT Long Fc, where SP5 refers to theocteonectin signal peptide used for secretion from the mammalianexpression host. Cleavage site is indicated by “̂”. FIG. 4 furtherprovides examples of various Fc domain formats.

When a variable domain is fused to an Fc domain, the carboxyl terminusof the variable domain (either a V_(L) or V_(H) domain, including dAbs)may be linked or fused to the amino terminus of the Fc CH2 domain.Alternatively, the carboxyl terminus of the variable domain may belinked or fused to the amino terminus of a CH1 domain, which itself isfused to the Fc CH2 domain. The protein may comprise the hinge regionbetween the CH1 and CH2 domains in whole or in part.

The CDRs contain most of the residues that form specific interactionswith the antigen. In one embodiment, the variable domain of an antibodypolypeptide comprises CDR1, CDR2, and CDR3 regions that have the sameamino acid sequence as the CDR1, CDR2, and CDR3 regions of one of thedAbs listed in TABLE 1 or TABLE 3 or that each differ from the CDR1,CDR2, and CDR3 regions by one, two, or three amino acids. For example,the antibody polypeptide may comprise CDR1, CDR2, and CDR3 regions thathave the same amino acid sequence as the CDR1, CDR2, and CDR3 regions ofBMS2h-572-633, BMS2h-572-608, or BMS2h-572-614, for example.

A “domain antibody” (dAb) comprises a single variable (V_(L) or V_(H))domain that is capable of specifically and monovalently binding anantigen, such as CD40L. For example, a dAb may have a V_(HH) structure,characteristic of a camelid dAb. A “V_(H) domain” as used herein ismeant to include a V_(HH) structure. In another embodiment, the V_(H)domains (including all features and combination of features presented asembodiments herein) are other than V_(HH) domains. dAbs may form homo-or heterodimers in solution. While not limited by any particular theory,it is believed that the dAbs disclosed herein do not cause plateletaggregation, because the antibodies containing mutated Fc constructs donot bind FcγRIIa (also known as CD32a) on the platelet surface and donot activate platelets.

As used herein, the term “variable domain” refers to immunoglobulinvariable domains defined by Kabat et al., Sequences of ImmunologicalInterest, 5^(th) ed., U.S. Dept. Health & Human Services, Washington,D.C. (1991). The numbering and positioning of CDR amino acid residueswithin the variable domains is in accordance with the well-known Kabatnumbering convention.

The term “human,” when applied to antibody polypeptides, means that theantibody polypeptide has a sequence, e.g., framework regions and/or CHdomains, derived from a human immunoglobulin. A sequence is “derivedfrom” a human immunoglobulin coding sequence when the sequence iseither: (a) isolated from a human individual or from a cell or cell linefrom a human individual; (b) isolated from a library of cloned humanantibody gene sequences or of human antibody variable domain sequences;or (c) diversified by mutation and selection from one or more of thepolypeptides above. An “isolated” compound as used herein means that thecompound is removed from at least one component with which the compoundis naturally associated with in nature.

Antibody polypeptides can be administered to human patients whilelargely avoiding the anti-antibody immune response often provoked by theadministration of antibodies from other species, e.g., mouse. Forexample, murine antibodies can be “humanized” by grafting murine CDRsonto a human variable domain FR, according to procedures well known inthe art. Human antibodies as disclosed herein, however, can be producedwithout the need for genetic manipulation of a murine antibody sequence.

Variable domains may comprise one or more FR with the same amino acidsequence as a corresponding framework region encoded by a human germlineantibody gene segment. For example, a domain antibody may comprise theV_(H) germline gene segments DP47, DP45, or DP38, the V_(κ) germlinegene segment DPK9, the J_(H) segment JH4b, or the J_(κ) segment J_(κ)1.

Changes may be made to antibody polypeptide sequences while retainingthe ability to bind CD40L specifically. Specifically, the antibodypolypeptides (e.g., a dAb) may comprise a variant variable domain thatretains the function of specifically binding CD40L as the dAbBMS2h-572-633. In one embodiment, the variant variable domain maycompete with BMS2h-572-633 for specific binding to CD40L. Error-proneaffinity maturation, as disclosed in the examples below, provides oneexemplary method for making and identifying antibody polypeptides withvariant sequences that specifically bind CD40L.

For example, a variant variable domain may differ from one of thevariable domains listed in TABLE 1 and TABLE 3 by up to 10 amino acidsor any integral value between, where the variant variable domainspecifically binds CD40L. Alternatively, the variant variable domain mayhave at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, or 99% sequence identity) relative to a sequencelisted in the present Sequence Listing. Non-identical amino acidresidues or amino acids that differ between two sequences may representamino acid substitutions, additions, or deletions. Residues that differbetween two sequences appear as non-identical positions, when the twosequences are aligned by any appropriate amino acid sequence alignmentalgorithm, such as BLAST.

In one embodiment, amino acid substitutions may be made to individual FRregions, such that a FR comprises 1, 2, 3, 4, or 5 amino aciddifferences relative to the amino acid sequence of the corresponding FRencoded by a human germline antibody gene segment. In anotherembodiment, the variant variable domain may contain one or two aminoacid substitutions in a CDR. In other embodiments, amino acidsubstitutions to FR and CDR regions may be combined. Representativevariable domains that specifically bind CD40L are listed in TABLE 1 andTABLE 3.

The information regarding the boundaries of the V_(L) or V_(H) domainsof heavy and light chain genes may be used to design PCR primers toamplify the variable domain from a cloned heavy or light chain codingsequence encoding an antibody polypeptide known to bind CD40L. Theamplified variable domain may be inserted into a suitable expressionvector, e.g., pHEN-1 (Hoogenboom et al. (1991) Nucleic Acids Res.19:4133-4137) and expressed, either alone or as a fusion with anotherpolypeptide sequence, using techniques well known in the art. Based onthe disclosed amino acid and polynucleotide sequences, the fusionprotein can be produced and purified using only ordinary skill in anysuitable mammalian host cell line, such as CHO, 293, COS, NSO, and thelike, followed by purification using one or a combination of methods,including protein A affinity chromatography, ion exchange, reverse phasetechniques, or the like.

In one aspect, the antibody polypeptide is a “dual specific” antibodypolypeptide comprising a first variable domain that specifically bindshuman CD40L. Dual specific antibody polypeptides comprise a secondvariable domain that specifically binds a second antigen that is otherthan human CD40L.

In another embodiment, the second antigen may be a cell surface moleculeof an immune effector cell or a soluble molecule such as a cytokine, forexample. Binding of the dual specificity antibody polypeptide could beused to antagonize CD40L and antagonize a biological activity of thesecond antigen. Cell surface molecules of immune effector cells includethe cluster of differentiation (CD) molecules. Representative CD markersare listed on the Internet at hypertext transfer protocolhttp://en.wikipedia.org/wiki/List_of human_clusters_of_differentiation(last modified on Aug. 8, 2012). Cell surface molecules of immuneeffector cells also include Major Histocompatibility Complex (MHC) ClassII molecules. Antibodies against these cell surface molecules are knownin the art and can be used a source of a variable domain to construct adual specific antibody polypeptide.

In one embodiment, antibody polypeptides of a dual specific ligand maybe linked by an “amino acid linker” or “linker.” For example, a dAb maybe fused to the N-terminus of an amino acid linker, and another dAb maybe fused to the C-terminus of the linker. Although amino acid linkerscan be any length and consist of any combination of amino acids, thelinker length may be relatively short (e.g., five or fewer amino acids)to reduce interactions between the linked domains. The amino acidcomposition of the linker also may be adjusted to reduce the number ofamino acids with bulky side chains or amino acids likely to introducesecondary structure. Suitable amino acid linkers include, but are notlimited to, those up to 3, 4, 5, 6, 7, 10, 15, 20, or 25 amino acids inlength. Representative amino acid linker sequences include (GGGGS). (SEQID NO: 12), where n may be any integer between 1 and 5. Other suitablelinker sequences may be selected from the group consisting of AS, AST,TVAAPS (SEQ ID NO: 13), TVA, and ASTSGPS (SEQ ID NO: 14).

The binding of the second antigen can increase the in vivo half-life ofthe antibody polypeptide. For example, the second variable domain of thedual specific antibody polypeptide may specifically bind serum albumin(SA), e.g., human serum albumin (HSA). The antibody polypeptideformatted to bind I can have an increased in vivo t-α (“alphahalf-life”) or t-β (“beta half-life”) half-life relative to the sameunformatted antibody polypeptide. The t-α and t-β half-lives measure howquickly a substance is distributed in and eliminated from the body. Thelinkage to I may be accomplished by fusion of the antibody polypeptidewith a second variable domain capable of specifically binding I, forexample. Anti-human serum albumin antibodies are well-known in the art.See, e.g., Abcam®, Human Serum Albumin antibodies ab10241, ab2406, andab8940, available on the Internet at hypertext transfer protocolwww.abcam.com/index.html, or GenWay, ALB antibody, available on theInternet at hypertext transfer protocol www.genwaybio.com. Variabledomains that specifically bind I can be obtained from any of theseantibodies, and then fused to an antibody polypeptide of the disclosureusing recombinant techniques that are well known in the art.

Alternatively, the linking of the antibody polypeptide to I can beaccomplished by directly fusing the antibody polypeptide sequence to anI coding sequence using techniques well known to the skilled artisan.The I coding sequences can be obtained by PCR using primers derived fromthe cDNA sequence available at GenBank Accession No. NM000477, forexample.

In one embodiment, the tα-half-life of the I-linked domain antibodycomposition is increased by 10% or more. In another embodiment, thetα-half-life of the I-linked domain antibody composition is in the rangeof 0.25 hours to 6 hours. In another embodiment, the tβ-half-life of theI-linked domain antibody composition is increased by 10% or more. Inanother embodiment, the tβ-half-life of the I-linked domain antibodycomposition is in the range of 12 to 48 hours.

In another embodiment, an antibody polypeptide may be formatted toincrease its in vivo half-life by PEGylation. In one embodiment, the PEGis covalently linked. In another embodiment, the PEG is linked to theantibody polypeptide at a cysteine or lysine residue. In yet anotherembodiment, the PEG-linked antibody polypeptide has a hydrodynamic sizeof at least 24 kD. In yet another embodiment, the total PEG size is from20 to 60 kD, inclusive. In yet another embodiment, the PEG-linked domainantibody has a hydrodynamic size of at least 200 kD.

PEGylation can be achieved using several PEG attachment moietiesincluding, but not limited to N-hydroxylsuccinimide active ester,succinimidyl propionate, maleimide, vinyl sulfone, or thiol. A PEGpolymer can be linked to an antibody polypeptide at either apredetermined position, or can be randomly linked to the domain antibodymolecule. PEGylation can also be mediated through a peptide linkerattached to a domain antibody. That is, the PEG moiety can be attachedto a peptide linker fused to an antibody polypeptide, where the linkerprovides the site (e.g., a free cysteine or lysine) for PEG attachment.Methods of PEGylating antibodies are well known in the art, as disclosedin Chapman, et al., “PEGylated antibodies and antibody fragments forimproved therapy: a review,” Adv. Drug Deliv. Rev. 54(4):531-45 (2002),for example.

Antibody polypeptides also may be designed to form a dimer, trimer,tetramer, or other multimer. Antibody polypeptides, e.g., dAbs, can belinked to form a multimer by several methods known in the art,including, but not limited to, expression of monomers as a fusionprotein, linkage of two or more monomers via a peptide linker betweenmonomers, or by chemically joining monomers after translation, either toeach other directly, or through a linker by disulfide bonds, or bylinkage to a di-, tri- or multivalent linking moiety (e.g., a multi-armPEG). In one embodiment, the multimer can bind a single molecule ofCD40.

3. Pharmaceutical Compositions and Methods of Treatment

A pharmaceutical composition comprises a therapeutically-effectiveamount of one or more antibody polypeptides and optionally apharmaceutically acceptable carrier. Pharmaceutically acceptablecarriers include, for example, water, saline, phosphate buffered saline,dextrose, glycerol, ethanol and the like, as well as combinationsthereof. Pharmaceutically acceptable carriers can further comprise minoramounts of auxiliary substances, such as wetting or emulsifying agents,preservatives, or buffers that enhance the shelf-life or effectivenessof the fusion protein. The compositions can be formulated to providequick, sustained, or delayed release of the active ingredient(s) afteradministration. Suitable pharmaceutical compositions and processes forpreparing them are well known in the art. See, e.g., Remington, THESCIENCE AND PRACTICE OF PHARMACY, A. Gennaro, et al., eds., 21^(st) ed.,Mack Publishing Co. (2005).

The pharmaceutical composition further may comprise animmunosuppressive/immunomodulatory and/or anti-inflammatory agent. Amethod of treating an immune disease in a patient in need of suchtreatment may comprise administering to the patient a therapeuticallyeffective amount of the pharmaceutical composition. AntagonizingCD40L-mediated T cell activation could inhibit undesired T cellresponses occurring during autoimmunity, transplant rejection, orallergic responses, for example. Inhibiting CD40L-mediated T cellactivation could moderate the progression and/or severity of thesediseases.

As used herein, a “patient” means an animal, e.g. mammal, includinghumans. The patient may be diagnosed with an immune disease. “Treatment”or “treat” or “treating” refers to the process involving alleviating theprogression or severity of a symptom, disorder, condition, or disease.An “immune disease” refers to any disease associated with thedevelopment of an immune reaction in an individual, including a cellularand/or a humoral immune reaction. Examples of immune diseases include,but are not limited to graft-related disease, inflammation, allergy, andautoimmune disease. The autoimmune disease may be selected from thegroup consisting of systemic lupus erythematosus, multiple sclerosis,rheumatoid arthritis, diabetes, psoriasis, scleroderma, atherosclerosis,inflammatory bowel disease, and ulcerative colitis.

Diseases that can be treated by administering the pharmaceuticalcomposition may be selected from the group consisting of Addison'sdisease, allergies, ankylosing spondylitis, asthma, atherosclerosis,autoimmune diseases of the ear, autoimmune diseases of the eye,autoimmune hepatitis, autoimmune parotitis, colitis, coronary heartdisease, Crohn's disease, diabetes, including Type 1 and/or Type 2diabetes, epididymitis, glomerulonephritis, Graves' disease,Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia,idiopathic thrombocytopenic purpura, inflammatory bowel disease, immuneresponse to recombinant drug products (e.g., Factor VII inhemophiliacs), systemic lupus erythematosus, male infertility, multiplesclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever,rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome,spondyloarthropathies, thyroiditis, transplant rejection, andvasculitis. Autoimmune-mediated conditions include, but are not limitedto, conditions in which the tissue affected is the primary target, andin some cases, the secondary target. Such conditions include, but arenot limited to, AIDS, atopic allergy, bronchial asthma, eczema, leprosy,schizophrenia, inherited depression, transplantation of tissues andorgans, chronic fatigue syndrome, Alzheimer's disease, Parkinson'sdisease, myocardial infarction, stroke, autism, epilepsy, Arthus'phenomenon, anaphylaxis, alcohol addiction, and drug addiction.

Preferred indications for administration of the present pharmaceuticalcompositions are, for example, immune thrombocytopenic purpura, systemicsclerosis, myasthenia gravis, allograft rejection, and graft-versus-hostdisease.

The pharmaceutical composition may be administered alone or incombination therapy, (i.e., simultaneously or sequentially) with animmunosuppressive/immunomodulatory and/or anti-inflammatory agent.Different immune diseases can require use of specific auxiliarycompounds useful for treating immune diseases, which can be determinedon a patient-to-patient basis. For example, the pharmaceuticalcomposition may be administered in combination with one or more suitableadjuvants, e.g., cytokines (IL-10 and IL-13, for example) or otherimmune stimulators, e.g., chemokines, tumor-associated antigens, andpeptides. Suitable adjuvants are known in the art.

For example, the disclosed pharmaceutical composition may beco-administered, concomitantly or sequentially, with a cytotoxicT-lymphocyte antigen 4 (CTLA4) mutant molecule, such as L104EA29Y-Ig(belatacept). CTLA4 binds to CD80 (B7-1) and CD86 (B7-2) with higheravidity than CD28, and it is transiently expressed on T cells followingtheir activation, where it interrupts the interaction between CD28 andCD80/86. Oosterwegel et al., Curr. Opin. Immunol. 11: 294-300 (1999).This creates a negative feedback signal for T cell activation.

CTLA4 mutant molecules, including L104EA29Y-Ig, have increased bindingavidity to CD80/86 compared to wild-type CTLA4. Intervention of theCD28-CD80/86 pathway by L104EA29Y-Ig has been successfully pursued, forexample, to treat graft-related diseases in non-human primate transplantmodels, alone or in combination with other immunosuppressive agents.Larsen et al., Amer. J. Transplant. 5: 443 (2005). U.S. PatentApplication number 2010/0166774 describes the structure of L104EA29Y-Ig,methods of producing it, and a formulation comprising a CTLA4 molecule;and the application is herein incorporated by reference. U.S. Pat. Nos.7,094,874 and 7,482,327 further disclose administration (includingco-administration with one or more other drugs) and dosage schedule ofL104EA29Y-Ig, and the disclosures of these patents are hereinincorporated by reference.

Any suitable method or route can be used to administer the antibodypolypeptide or the pharmaceutical composition. Routes of administrationinclude, for example, oral, intravenous, intraperitoneal, subcutaneous,or intramuscular administration. A therapeutically effective dose ofadministered antibody polypeptide(s) depends on numerous factors,including, for example, the type and severity of the immune diseasebeing treated, the use of combination therapy, the route ofadministration of the antibody polypeptide(s) or pharmaceuticalcomposition, and the weight of the patient. A non-limiting range for atherapeutically effective amount of a domain antibody is 0.1-20 mg/kg,and in an aspect, 1-10 mg/kg, relative to the body weight of thepatient. The dose of antibody polypeptide(s) can be further guided bythe amount of antibody polypeptide(s) required for CD40 antagonism in invitro and/or in vivo models of disease states. Representative models aredescribed below and in the examples.

4. In Vitro and In Vivo Models

The ability of antibody polypeptides of the disclosure to antagonizeCD40L can be tested in one of several available in vitro or in vivomodel systems. Appropriate human, animal, and cell model systems aredescribed below. Further cell assay systems are described in theexamples.

4.1. Immune Thrombocytopenic Purpura (ITP) In Vivo Model:

The potential role of CD40-CD40L in the pathogenesis of ITP is reportedby Patel et al., British J. Haematology 141: 545-548 (2008).Antiplatelet autoantibodies in patients with ITP bind to circulatingplatelets and accelerate their destruction. The primary mechanism bywhich anti-CD40L antibodies are thought to increase the platelet countin ITP is by blocking T-cell based activation of autoreactive B cellsthat produce anti-platelet antibodies. Anti-CD40L antibodies may alsoblock expression of CD40L on platelets, thus preventing autopresentationof platelet glycoprotein antigens to macrophages. Furthermore,anti-CD40L mAbs inhibit direct interactions between platelet CD40L andother cells, such as plasmacytoid dendritic cells (DCs), which haverecently been implicated in driving the type 1 interferon (IFN) responsein human lupus patients. Duffau et al., Sci. Transl. Med. 2: 47 (2010).

Patel et al. demonstrated efficacy of two humanized anti-CD40Lmonoclonal antibodies, hu5c8 and IDEC-131, in 46 human patients withchronic ITP refractory to conventional therapies. The patients had anoverall 24% response rate, characterized by increased platelet counts.This demonstrated the potential role of CD40-CD40L in the pathogenesisof ITP.

4.2. Lupus In Vivo and In Vitro Models:

Glomerular and tubular CD40 expression is markedly upregulated inproliferative nephritis. Several studies have reported hyperexpressionof CD40L by T cells and elevated soluble sCD40L concentrations in humanlupus. Kimura et al., Therapeutic Apheriss and Dialysis 9: 64-68 (2005);Vakkalanka et al., Arthritis & Rheumatism 42: 871-881 (1999).

Systemic lupus erythematosus (SLE) is a chronic autoimmune diseasecharacterized by the production of multiple autoantibodies and by B cellhyperactivity. Grammer et al., J. Clin. Invest. 112: 1506-1520 (2003)reports the results of treatment of patients with SLE with humanizedanti-CD40L mAb 5c8 (BG9588). See also Huang et al., Arthritis &Reumatism 46: 1554-1562 (2002). Grammer et al. report that CD19+peripheral B cells were examined before and after treatment with theanti-CD40L mAb. Before treatment, SLE patients manifested activated Bcells that expressed CD40L, CD69, CD38, CD5, and CD27. The activated Bcells disappeared from the periphery during and post-treatment. Beforetreatment, active SLE patients had circulating CD38^(bright)Ig-secreting cells that were not found in normal individuals.Disappearance of these plasma cells during treatment was associated withdecreases in anti-double stranded DNA (anti-dsDNA) Ab levels,proteinuria, and SLE disease activity index. Consistent with thisfinding, peripheral B cells cultured in vitro spontaneously proliferatedand secreted Ig in a manner that was inhibited by anti-CD40L mAb. TheCD38+/++IgD+, CD38+++, and CD38+IgD− B cell subsets present in theperipheral blood of SLE patients also disappeared following treatmentwith the anti-CD40L mAb. Together, these results suggest thatspontaneous CD40L-CD40 interactions in active SLE patients drive B cellactivation, proliferation, and differentiation to autoantibody-secretingplasma cells that mediate proteinuria and disease activity.

Proliferative lupus glomerulonephritis is a protracted autoimmunedisease with a waxing and waning course, characterized by increasedlevel of anti-dsDNA antibodies, decreased serum C3 concentrations, andhematuria. Boumpas et al, Arthritis & Rheumatism 48: 719-727 (2003)report results of a phase II, multicenter, open-label study evaluatingthe toxicity and efficacy of BG9688, a humanized anti-CD40L monoclonalantibody, in patients with proliferative lupus glomerulonephritis.Although the study had to be terminated prematurely because ofthromboembolic events occurring in patients in several BG9588 protocols,a short course of the anti-CD40L antibody treatment in patients withproliferative lupus nephritis reduced anti-dsDNA antibodies, increasedC3 concentrations, and decreased hematuria, suggesting that the drug hasimmunomodulatory function.

4.3. Inflammatory Bowel Disease (IBD) In Vivo Models:

Crohn's disease (CD) and ulcerative colitis (UC) are IBDs that arecharacterized by leukocytic infiltrates in inflamed intestinal mucosa,which consists primarily of activated CD25+ cells, B cells, andmacrophages. Ludwiczek et al., Int. J. Colorectal Dis. 18: 142-147(2003) report that in CD patients, plasma levels of sCD40L weresignificantly higher than in healthy individuals. Moreover, CD patientswith fistulas and/or abscesses had significantly higher levels of sCD40Lthan patients with uncomplicated CD. It has also been reported that theCD40-CD40L pathway contributes to the proinflammatory function ofintestinal epithelial cells in IBD. Borcherding et al., Am. J. Pathol.176: 1816-1827 (2010). Patients with CD also have an increased risk ofsystemic thromboembolism, and the hyperactive state of platelets fromsuch patients likely results from the enhanced release of sCD40L as aconsequence of their higher endogenous content of CD40L. Menchen et al.,Gut 58: 920-928 (2009); see also Danese et al., Gut 52: 1435-1441(2003).

Kasran et al., Aliment. Pharmacol. Ther. 22: 111-122 (2005) investigatedthe use of a chimeric anti-human CD40 mAb ch5D12 to treat Crohn'sdisease. The mAb was administered to 18 patients with moderate to severeCD in a single dose, open-label dose escalation phase I/Iia study. Ofthe 18 patients, 13 (or 72%) experienced a favorable response to theantibody infusion, and 4 patients (or 22%) experienced a remission.Treatment with the anti-CD40 mAb reduced microscopic disease activityand intensity of the lamina propria cell infiltrate, and the mAb waswell tolerated.

4.4. Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), andPsoriatic Arthritis (PsA) In Vivo Models:

Rheumatoid arthritis is a systemic autoimmune disease withintra-articular inflammation as a dominant feature that affects up to 1%of the population. The disease can be subdivided clinically by thepresence or absence of autoantibodies (antibodies to cycliccitrullinated peptide (CCP) or rheumatoid factor (RF), both of which arehighly correlated to each other. Raychaudhuri et al., Nature Genetics40: 1216-1223 (2008) reported that they conducted a meta-analysis of twopublished genome-wide association (GWA) studies totaling 3,393 cases and12,462 controls, in order to identify RA risk loci in Europeanpopulations. They genotyped 31 top-ranked short nucleotide polymorphisms(SNPs) not previously associated with RA in an independent replicationof 3,929 autoantibody-positive RA cases and 5,807 matched controls fromeight separate collections. They identified a common variant at the CD40gene locus, which implied a central role for the CD40 signaling pathwayin RA pathogenesis. The strong association of the CD40 gene withsusceptibility to RA was robustly replicated in another study in a largeUK cohort of 3,962 patients with RA. Orozso et al., Ann. Rheum. Dis. 69:813-816 (2010).

A major role of CD40L has also been found in the pathogenesis ofjuvenile idiopathic arthritis (JIA). Prahalad et al., PediatricRheumatology 6: 1-8 (2008). JIA is a heterogeneous group ofarthropathies of unknown etiology. It was found that sCD40L wassignificantly elevated in the serum of children with JIA, along withsome cytokines. Logistic regression analysis suggested that sCD40L, aswell as IL-6 and TNFα, were positively associated with JIA.

sCD40L was elevated in all JIA subtypes, with highest levels among moresevere subtypes. These results implicated sCD40L as a potentialbiomarker for treatment and monitoring of patients with JIA.

It has also been demonstrated that activated T cells from patients withpsoriatic arthritis (PsA), and particularly those with active disease,have a significantly increased expression of CD40L. Daoussis et al.,Rheumatology 46: 227-231 (2007). These results indicate a role of theCD40-CD40L pathway in the pathogenesis of PsA and that a therapyselectively targeting CD40L could benefit PsA patients.

4.5. Systemic Sclerosis In Vivo Models:

Systemic sclerosis (SSc) is an autoimmune connective tissue disordercharacterized by fibrous and vascular changes in the skin and internalvisceral organs. In a study involving 52 Japanese patients with SSc,serum sCD40L levels were elevated when compared with healthy controls.Komura et al., J. Reumatol. 31: 514-519 (2004). Moreover, levels ofsCD40L in patients with SSc were higher than in patients with systemiclupus erythematosus (SLE) who had elevated sCD40L levels compared tocontrols, and sCD40L levels correlated positively with C reactivepeptide levels in SSc patients. It has also been reported that blockadeof CD40L with anti-CD40L antibody in cultured T and B cells from SScpatients inhibited anti-topoisomerase I antibody production. Kuwana etal., J. Immunol. 155: 2703-2714 (1995). These results suggest thatinhibition of CD40-CD40L interactions may be potential therapeutictargets in therapy of SSc as well as SLE.

4.6. Atherosclerosis In Vivo Models:

Several studies have suggested a role of CD40-CD40L signaling pathwayduring atherogenesis. Mach et al. demonstrated that in mice, treatmentwith monoclonal anti-CD40L antibody limited atherosclerosis in micelacking receptor for low-density lipoprotein that had been fed ahigh-cholesterol diet for 12 weeks. Nature 394: 200-203 (1998). Theantibody reduced the size of aortic atherosclerotic lesions by 59% andtheir lipid content by 79%. Additionally, atheroma of mice treated withanti-CD40L antibody contained significantly fewer macrophages and Tlymphocytes, and exhibited decreased expression of vascular celladhesion molecule-1.

Anti-CD40L antibody treatment of low-density lipoproteinreceptor-deficient mice during the second half of a 26-week regimen of ahigh-cholesterol diet did not regress, but did significantly reducefurther progression of established atherosclerotic lesions within theaortic arch and particularly the thoracic and abdominal aorta, ascompared to control treatment. Schonbeck et al., Proc. Natl. Acad. Sci.97: 7458-7463 (2000). Furthermore, anti-CD40L treatment changed thecomposition of atheroma in manners thought to favor plaque stability,e.g., reduced relative content of macrophages and lipid, as well asincreased relative content of smooth muscle cells and collagen. Thesestudies lend support to the importance of the CD40-CD40L signalingpathway in atherosclerosis and its complications, such as coronaryartery disease.

4.7. Allograft Rejection In Vivo Models:

Targeting the CD40-CD40L pathway has long been of much interest forprevention of rejection of solid organ transplants (SOT), particularlyin light of the promising data from numerous published transplantstudies in non-human primates. It has been demonstrated that reducedCD40L expression on ex vivo activated CD4+ T lymphocytes correlates withexcellent renal allograft function. Lederer et al., Int. Arch. AllergyImmunol. 133: 276-284 (2004). Furthermore, several studies havedemonstrated that anti-CD40L mAbs can both prevent and reverse acuteallograft rejection in primates. For example, Kirk et al., Proc. Natl.Acad. Sci. USA 94: 8789-8794 (1997) reported that, in rhesus monkeystransplanted with renal allografts, anti-CD40L mAb 5C8 alone or incombination with CTLA4-Ig significantly prolonged rejection-freesurvival. The CD40L-specific mAb hu5c8 alone also allowed for allogeneicislet engraftment and long-term insulin independence in rhesus monkeysthat were transplanted an adequate number of viable pancreatic islets.Kenyon et al., Proc. Natl. Acad. Sci. USA 96: 8132-8137 (1999). Prestonet al., Amer. J. Transplantation 5: 1032-1041 (2005) performed renaltransplants in MHC-mismatched rhesus monkeys and treated the recipientswith combinations of CD40L-specific mAb IDEC-131, and/or sirolimus,and/or pre-transplant donor-specific transfusion. IDEC-131 was highlyeffective in preventing renal allograft rejection in primates. Incynomolgus monkeys that underwent renal allotransplantation, treatmentwith anti-CD40L mAb ABI793 effectively prevented graft rejection.Schuler et al., Transplantation 77: 717-726 (2004). In addition topreventing allograft rejection, CD40L-specific mAbs induced donorspecific tolerance in primate transplant models. Preston et al., Amer.J. Transplantation 5: 1032-1041 (2005); Kenyon et al., Proc. Natl. Acad.Sci. USA 96: 8132-8137 (1999).

In pediatric human patients that were undergoing acute graft rejectionafter liver or small-bowel transplantation, a correlation was observedbetween the expression of CD40L on CD8+ T cells and the risk oftransplant rejection. Ashokkumar et al., Amer. J. Transplantation 9:179-191 (2009) and Ashokkumar et al., Surgery 146: 166-173 (2009).Similarly, in adult patients that were undergoing allograft rejectionfollowing liver or renal transplantation, histological analysisdemonstrated an association between CD40L expression and acute orchronic rejection. Bartlett et al., Amer. J. Transplantation 3:1363-1368 (2003) and Biancone et al., Nephrol. Diall. Translpant. 13:716-722 (1998).

Several studies support targeting CD40L over CD40 to achieve betterefficacy in transplantation. For example, graft survival is longer andmore durable when CD40L is selectively blocked, compared to CD40. Gilsonet al., J. Immunol. 183: 1625-35 (2009). Furthermore, recent datasuggest that CD40L blockade may enhance induction of Tregs and/orsuppressor cells to promote graft survival. Garcia et al., J. Clin. Inv.120: 2486-96 (2010). Also, blockade of CD40L, but not CD40, hasdemonstrated induction of long-lived immunological tolerance resultingin indefinite graft survival, particularly when combined with blockadeof the B7 pathway. Kenyon et al., Proc. Natl. Acad. Sci. USA 96:8132-8137 (1999); Kawai et al., Amer. J. Transplantation 4: 1391-1398(2004); Preston et al., Amer. J. Transplantation 5: 1032-1041 (2005);Adams et al., J. Immunol. 174: 542-50 (2005). The synergy of blockingCD40-40L and B7-CD28 pathways in enhancing graft survival is especiallyimportant, because it presents the presently disclosed domain antibodiesas a natural choice for combination with belatacept (CTLA4-Ig) for SOT.

4.8. Graft-Versus-Host Disease In Vivo Model:

Chronic and acute graft-versus-host disease (cGVHD and aGVHD) arecomplications that can occur after a stem cell or bone marrow transplantin which the transplanted donor cells attack the transplant recipient'sbody. Acute GVHD in humans takes place withing about 60 dayspost-transplantation and results in damage to the skin, liver, and gutby the action of cytolytic lymphocytes. Chronic GVHD occurs later and isa systemic autoimmune disease that affects primarily the skin, resultingin the polyclonal activation of B cells and the hyperproduction of Igand autoantibodies.

CD40L-CD40 interactions appear to be critical in the development of bothcGVHD and aGVHD. Durie et al., J. Clin. Invest. 94: 1333-1338 (1994). Ina mouse in vivo model, anti-CD40L antibodies blocked the followingcGVHD-associated phenomena: splenomegaly, in vitro polyclonal Igproduction, elevated levels of serum IgE and serum anti-DNAautoantibodies, and the generation of anti-host cytotoxic T cells.Antibody production remained inhibited for extended periods of timeafter the end of anti-CD40L antibody administration. In mice with aGVHD,which is associated with the induction of a profound antiallogeniccytotoxic T cell (CTL) response, treatment with anti-CD40L prevented thegeneration of H-2b-derived CTL. The results of the study suggest thatCD40L-CD40 interactions are critical in GVHD and that CD40L may be avaluable ligand for targeting immunotherapeutic agents to control GVHD.

4.9. Myasthenia Gravis In Vivo Model:

Myasthenia gravis (MG) and its animal model, experimental autoimmune MG(EAMG), are T-cell dependent autoimmune disorders caused byautoantibodies against the nicotinic acetylcholine receptors (AChR) atthe neuromuscular junction of skeletal muscle. The role of CD40-CD40L inEAMG was shown in CD40L (CD40L−/−) knockout mice. Shi et al, Eur. J.Immunol. 28: 3587-3593 (1998). The CD40L knockout mice were completelyresistant to EAMG induction and had diminished Th1 and Th2 responses aswell as severely impaired T-cell dependent AChR-reactive B cellresponses.

It has also been demonstrated that blockade of CD40L-CD40 signaling byanti-CD40L antibodies is capable of suppressing EAMG. Im et al., J.Immunol. 166: 6893-6898 (2001). Antibodies given to rats at the chronicstage of EAMG suppress the clinical progression of the autoimmuneresponse and lead to a decrease in the AChR-specific humoral responseand delayed-type hypersensitivity. The effect of anti-CD40L treatmentduring the chronic phase of EAMG is of particular relevance to human MG,which is a chronic disease. It suggests that antagonizing CD40L can beused for immunotherapy of MG and other antibody-mediated autoimmunediseases.

5. Thromboembolism

CD40-CD40L interactions on T and antigen presenting cells are importantfor adaptive immune responses, such as B-cell proliferation,immunoglobulin (Ig) production, upregulation of co-stimulatory activity(CD80, CD86), cytokine production, and Ig class-switching. The receptorand ligand are also expressed on platelets (off-target cell population),where CD40 is constitutively found on platelets, while CD40L isexpressed on activated platelets and cleaved to sCD40L (>90% ofcirculating sCD40L is derived from platelets). Feroni et al., Curr. Med.Chem. 14: 2170-2180 (2007). At least three anti-CD40L monoclonalantibodies (mAb) caused TE in the clinic and/or nonclinical studiesconducted in non-human primates (NHP). hu5c8 (BG9588) caused TE inmultiple clinical trials (lupus and renal transplantation). Boumpas etal., Arthritis & Rheumatism 48: 719-727 (2003). IDEC131 caused TE in onepatient in a Crohn's disease trial, leading to termination of ongoingtrials at the time. Sidiropoulus & Boumpas, Lupus 13: 391-397 (2004).Both hu5c8 and ABI1793 (which binds CD40 at a different epitope from5c8) caused TE/thrombosis in renal transplantation studies in cynomolgusor rhesus monkeys. Schuler et al., Transplantation 77: 717-726 (2004);Kanmaz et al., Transplantation 77: 914-920 (2004); Koyama et al.,Transplantation 77: 460-461 (2004). In a non-published disclosure,Biogen reported a thrombosis incidence of ¼ and 6/12 in rhesus monkeysgiven 5 and 20 mg/kg weekly, respectively, for 6-months, but not incynomolgus monkeys given 50 mg/kg at the same frequency and duration.The basis for the species difference is not clear.

One of the hypotheses is that the TE associated with administration ofthese antibodies is mediated by anti-CD40Lmab-CD40L immune complex(IC)-mediated cross linking of platelets, facilitated by IC binding toFcgRIIa, an IgG Fc receptor, causing activation and aggregation (FIG.10). Blocking the interaction of Fc moiety of IgG with FcgRIIa is,therefore, expected to mitigate platelet cross linking and thrombosis.Approaches and methods developed to evaluate the risk for TE/thrombosisare described in Examples below.

EXAMPLES

TABLE 1 lists representative anti-human CD40L VH domain amino acidsequences useful for the disclosed antibody polypeptides. TABLE 2discloses representative nucleic acids that encode the VH domainsequences listed in TABLE 1. TABLE 3 lists representative anti-humanCD40L VK domain amino acid sequences useful for the antibodypolypeptides of the present disclosure. TABLE 4 in turn disclosesrepresentative nucleic acids that encode the VK domain sequences listedin TABLE 3. As well known in the art, multiple codons can encode thesame amino acid. Nucleic acids encoding a protein sequence thus includenucleic acids having codon degeneracy. The antibody polypeptidesdisclosed in TABLE 1 and TABLE 3 specifically bind CD40L. They were madeusing the reiterative initial/primary screening and affinitymethodologies described in the examples that follow.

TABLE 1 Anti-human CD40L VH Domain Amino Acid Sequences BMS2h-10 (SEQ IDNO: 15) EVQLLESGGG LVQPGGSLRL SCAASGFTFI AYDMSWVRQA PGKGLEWVSWIDEWGLQTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKKT PEE-------FDYWGQGTLV TVSS BMS2h-11 (SEQ ID NO: 16) EVQLLESGGG LVQPGGSLRLSCAASGFTFG DYEMSWVRQA PGKGLEWVSG IDGEGSDTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPG RS-------- FDYWGQGTLV TVSS BMS2h-111 (SEQ ID NO:17) EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYPMTWVRQA PGKGLEWVST IHGSGSATYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGP YTSRHNSLGH FDYWGQGTLV TVSSBMS2h-112 (SEQ ID NO: 18) EVQLLESGGG LVQPGGSLRL SCAASGFTFM DYPMGWVRQAPGKGLEWVSS IGPVGMSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYGGTSGRHNTK- FDYWGQGTLV TVSS BMS2h-113 (SEQ ID NO: 19) EVQLLESGGGLVQPGGSLRL SCAASGFTFT EYPMSWVRQA PGKGLEWVSV ISPLGFTTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKWT GGSGILNSS- FDYWGQGTLV TVSS BMS2h-114(SEQ ID NO: 20) EVQLLESGGG LVQPGGSLRL SCAASGFRVS NYDLTWVRQA PGKGLEWVSTISATNGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAAVT WWLLRHNDN-LGFWGQGTLV TVSS BMS2h-115 (SEQ ID NO: 21) EVQLLESGGG LVQPGGSLRLSCAASGFSIS YKNMAWVRQA PGKGLEWVSA IKAANGSTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCATGS QKKRTYT--- FDFWGQGTLV TVSS BMS2h-12 (SEQ ID NO:22) EVQLLESGGG LVQPGGSLRL SCAASGFTFR LYEMAWVRQA PGKGLEWVSG IDILGSRTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDL SWQG------ FDYWGQGTLV TVSSBMS2h-120 (SEQ ID NO: 23) EVQLLESGGG LVQPGGSLRL SCAASGFTFR SYTMGWVRQAPGKGLEWVSS INPMGYQTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHGVGKGTKPHN FDYWGQGTLV TVSS BMS2h-121 (SEQ ID NO: 24) EVQLLESGGGLVQPGGSLRL SCAASGFTFE LYRMSWVRQA PGKGLEWVSE ISGSGFPTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKSL HDKTQHHQE FDYWGQGTLV TVSS BMS2h-123(SEQ ID NO: 25) EVQLLESGGG LVQPGGSLRL SCAASGFTFI EYPMSWVRQA PGKGLEWVSLISPSGVFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD ESST FDYWGQGTLVTVSS BMS2h-124 (SEQ ID NO: 26) EVQLLESGGG LVQPGGSLRL SCAASGFTFKRYDMDWVRQA PGKGLEWVST IGSSGYPTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAEDTAVYYCAERM PGYFPGFARQ FDYWGQGTLV TVSS BMS2h-125 (SEQ ID NO: 27)EVQLLESGGG LVQPGGSLRL SCAASGFTFW RYAMGWVRQA PGKGLEWVST INDEGRETYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKKR VSSSVNAPYE FDYWGQGTLV TVSSBMS2h-126 (SEQ ID NO: 28) EVQLLESGGG LVQPGGSLRL SCAASGFTFA NYSMSWVRQAPGKGLEWVSS IDRLGTHTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVLADLIAGHAE FDYWGQGTLV TVSS BMS2h-127 (SEQ ID NO: 29) EVQLLESGGGLVQPGGSLRL SCAASGFTFP SYDMAWVRQA PGKGLEWVSG ISRSGSMTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKGV DAHVYYMEPF FDYWGQGTLV TVSS BMS2h-128(SEQ ID NO: 30) EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYQMAWVRQA PGKGLEWVSTISSDGGGTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG TV FDYWGQGTLVTVSS BMS2h-129 (SEQ ID NO: 31) EVQLLESGGG LVQPGGSLRL SCAASGFTFPKYEMAWVRQA PGKGLEWVSS IDGDGKSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAEDTAVYYCAKPD QF FDYWGQGTLV TVSS BMS2h-13 (SEQ ID NO: 32) EVQLLESGGGLVQPGGSLRL SCAASGFTFS YYSMYWVRQA PGKGLEWVSS ISPFGWGTYY ADSVKGRFTISRDNSKDTLY LQMNSLRAED TAVYYCAKYG ETSGPISEN FDYWGQGTLV TVSS BMS2h-130(SEQ ID NO: 33) EVQLLESGGG LVQPGGSLRL SCTASGFTFA GYQMSWVRQA PGKGLEWVSSITNEGVSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG KY FDYWGQGTLVTVSS BMS2h-131 (SEQ ID NO: 34) EVQLLESGGG LVQPGGSLRL SCAASGFTFGEYEMVWVRQA PGKGLEWVSS ITSDGLSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAEDTAVYYCAKPG IRFDYWGQGTLV TVSS BMS2h-132 (SEQ ID NO: 35) EVQLLESGGGLVQPGGSLRL SCAASGFTFA DYDMAWVRQA PGKGLEWVSG IVDDGLMTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPD VAFDYWGQGTLVTVSN BMS2h-133 (SEQ ID NO:36) EVQLLESGGG LVQPGGSLRL SCAASGFTFI GYAMAWVRQA PGKGLEWVSS IGPLGATTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLP AGTSSHSVDFDYWGQGTLV TVSSBMS2h-134 (SEQ ID NO: 37) EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYEMTWVRQAPGKGLEWVSS ITSDGVSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPS VQFDYWGQGTLV TVSS BMS2h-135 (SEQ ID NO: 38) EVQLLESGGG LVQPGGSLRLSCAASGFTFR RYVMGWVRQA PGKGLEWVSW IEADGRTTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKGL TDQHVIE FDYWGQGTLV TVSS BMS2h-136 (SEQ ID NO: 39)EVQLLESGGG LVQPGGSLRL SCAASGFTFD GYRMGWVRQA PGKGLEWVSS IAPDGNYTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFW GMQFDYWGQGTLV TVSS BMS2h-137(SEQ ID NO: 40) EVQLLESGGG LVQPGGSLRL SCAASGFTFA SYPMGWVRQA PGKGLEWVSSIGPIGFTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEMK SPYKPQ----FDYWGQGTLV TVSS BMS2h-138 (SEQ ID NO: 41) EVQLLESGGG LVQPGGSLRLSCAASGFTFL AYWMVWVRQA PGKGLEWVSS ISPSGTHTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRVED TAVYYCAKYT EPGLGS---- FDYWGQGTLV TVSS BMS2h-139 (SEQ ID NO:42) EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYEMGWVRQA PGKGLEWVSV ISEVGSLTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPH DSSIG----- FDYWGQGTLV TVSSBMS2h-14 (SEQ ID NO: 43) EVQLLESGGG LVQPGGSLRL SCAASGFTFW SYDMTWVRQAPGKGLEWVSS IMASGDDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWDRD-------- FDYWGQGTLV TVSS BMS2h-15 (SEQ ID NO: 44) EVQLLESGGGLVQPGGSLRL SCAASGFTFE EYVMSWVRQA PGKGLEWVST ISPIGLTTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEFP LIILPD---- FDYWGQGTLV TVSS BMS2h-16(SEQ ID NO: 45) EVQLLESGGG LVQPGGSLRL SCAASGFTFM EYAMIWVRQA PGKGLEWVSIISPLGLSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYQ DSSDSQYTN-FDYWGQGTLV TVSS BMS2h-17 (SEQ ID NO: 46) EVQLLESGGG LVQPGGSLRLSCAASGFTFE DYGMGWARQA PGKGLEWVSS IGPLGLWTYY ADSAKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKSP LEGLITN--- FDYWGQGTLV TVSS BMS2h-176 (SEQ ID NO:47) EVQLLESGGG LVQPGGSLRL SCAASGFTFD AYEMGWVRQA PGKGLEWVSI IDWDGNSTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG DNVGI----- FDYWGQGTLV TVSSBMS2h-177 (SEQ ID NO: 48) EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYYMVWVRQAPGKGLEWVSA IDEWGFATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHWEFTSDTSR-FDYWGQGTLV TVSS BMS2h-178 (SEQ ID NO: 49) EVQLLESGGG LVQPGGSLRLSCAASGFTFE DFDMAWVRQA PGKGLEWVSS INDQGSLTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPD QF-------- FDYWGQGTLV TVSS BMS2h-179 (SEQ ID NO:50) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYDMMWVRQA PGKGLEWVSR ISPQGQRTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR GQSRIPMR-FDYWGQGTLV TVSSBMS2h-18 (SEQ ID NO: 51) EVQLLESGGG LVQPGGSLRL SCAASGFTFP EYDMTWVRQAPGKGLEWVSY ISSDGYSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPHGSPRE----- FDYWGQGTLV TVSS BMS2h-180 (SEQ ID NO: 52) EVQLLESGGGLVQPGGSLRL SCAASGFTFT DYEMGWVRQA PGKGLEWVST ITSLGESTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPG RI-------- FDYWGQGTLV TVSS BMS2h-181(SEQ ID NO: 53) EVQLLESGGG LVQPGGSLRL SCAASGFTFA FYPMMWVRQA PGKGLEWVSWIDATGTRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGN YGSSYTMGV-FDYWGQGTLV TVSS BMS2h-182 (SEQ ID NO: 54) EVQLLESGGG LVQPGGSLRLSCAASGFTFD EYPMYWVRQA PGKGLEWVSS IGPSGPNTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKSP YFDVIPSY-FDYWGQGTLV TVSS BMS2h-183 (SEQ ID NO: 55)EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYGMGWVRQA PGKGLEWVSS IQSSGLRTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRA NSRRG----- FDYWGQGTLV TVSSBMS2h-184 (SEQ ID NO: 56) EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYEMMWVRQAPGKGLEWVSS ITSHGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPDKD-------- FDYWGQGTLV TVSS BMS2h-185 (SEQ ID NO: 57) EVQLLESGGGLVQPGGSLRL SCAASGFTFA HYPMSWVRQA PGKGLEWVSS IGRLGNRTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKRA TPVPIKGL-FDYWGQGTLV TVSS BMS2h-186 (SEQID NO: 58) EVQLLESGGG LVQPGGSLRL SCAASGLTFG RYEMAWVRQA PGKGLEWVSSIDSDGWVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQPD SL--------FDYWGQGTLV TVSS BMS2h-187 (SEQ ID NO: 59) EVQLLESGGG LVQPGGSLRLSCAASGFTFS SYSMVWVRQA PGKGLEWVSG INRGGTRTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKGW RRG------- FDYWGQGTLV TVSS BMS2h-188 (SEQ ID NO:60) EVQLLESGGG LVQPGGSLRL SCAASGFTFT RYRMSWVRQA PGKGLEWVSG ISRDGYRTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGM TAS------- FDYWGQGTLV TVSSBMS2h-189 (SEQ ID NO: 61) EVQLLESGGG LVQPGGSLRL SCAASGFTFQ MYPMGWVRQAPGKGLEWVSM IEPAGDLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYQEQPW------ FDYWGQGTLV TVSS BMS2h-19 (SEQ ID NO: 62) EVQLLESGGGLVQPGGSLRL SCAASGFPFP QYQMAWVRQA PGKGLEWVSM ITSDGLDTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPE PL-------- FDYWGQGTLV TVSS BMS2h-190(SEQ ID NO: 63) EVQLLESGGG LVQPGGSLRL SCAASGFTFS MYDMHWVRQA PGKGLEWVSTILSDGTDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYG AM--------FDYWGQGTLV TVSS BMS2h-191 (SEQ ID NO: 64) EVQLLESGGG LVQPGGSLRLSCAASGFTFK LYPMTWVRQA PGKGLEWVSS IDAGGHETYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKDW WDYL------ FDYWGQGTLV TVSS BMS2h-192 (SEQ ID NO:65) EVQLLESGGG LVQPGGSLRL SCAASGFTFS RYPMSWVRQA PGKGLEWVSS INRSGMRTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGH QAP------- FDYWGQGTLV TVSSBMS2h-193 (SEQ ID NO: 66) EVQLLESGGG LVQPGGSLRL SCAASGFTFT GYAMSWVRQAPGKGLEWVST INANGIRTYY ADSVKGRFTI SRDNSKNTLY LQMNGLRAED TAVYYCAKGGVWRWGTGHK- FDYWGQGTLV TVSS BMS2h-194 (SEQ ID NO: 67) EVQLLESGGGLVQPGGSLRL SCAASGFTFK QYDMRWVRQA PGKGLEWVST ISQNGTKTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKSR TGRY------ FDYWGQGTLV TVSS BMS2h-195(SEQ ID NO: 68) EVQLLESGGG LVQPGGSLRL SCAASGFTFG TYDMGWVRQA PGKGLEWVSRINWQGDRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG FGHYVDGLG-FDYWGQGTLV TVSS BMS2h-196 (SEQ ID NO: 69) EVQLLESGGG LVQPGGSLRLSCAASGFTFS GYEMAWVRQA PGKGLEWVSS ITDMGDSTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPG TA-------- FDYWGPGTLV TVSS BMS2h-197 (SEQ ID NO:70) EVQLLESGGG LVQPGGSLRL SCAASGFTFA KYKMWWVRQA PGKGLEWVSS ITPKGHSTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRP MTP------- FDYWGQGTLV TVSSBMS2h-198 (SEQ ID NO: 71) EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYNMSWVRQAPGKGLEWVSS IRPRGGKTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWRREGYTGSK-FDYWGQGTLV TVSS BMS2h-199 (SEQ ID NO: 72) EVQLLESGGG LVQPGGSLRLSCAASGFTFE RYGMTWVRQA PGKGLEWVSS IWPRGQKTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKGN SRYV------ FDYWGQGTLV TVSS BMS2h-2 (SEQ ID NO: 73)EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYEMMWVRQA PGKGLEWVST ITSDGISTYYADSVKGRFTI FRDNSKNTLY LQMNSLRAED TAVYYCAKSG RF-------- FDYWGQGTLV TVSSBMS2h-20 (SEQ ID NO: 74) EVQLLESGGG LVQPGGSLRL SCAASGFTFS GYQMAWVRQAPGKGLEWVSG ISSEGLTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLGRR-------- FDYWGQGTLV TVSS BMS2h-200 (SEQ ID NO: 75) EVQLLESGGGLVQPGGSLRL SCAASGFTFT NYSMGWVRQA PGKGLEWVST IRPNGTKTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKRS SAHLQR---- FDYWGQGTLV TVSS BMS2h-201(SEQ ID NO: 76) EVQLLESGGG LVQPGGSLRL SCAASGFTFG NYSMGWVRQA PGKGLEWVSSIGRHGGRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKKG STYPR-----FDYWGQGTLV TVSS BMS2h-202 (SEQ ID NO: 77) EVQLLESGGG LVQPGGSLRLSCTASGFTFS HYEMGWVRQA PGKGLEWVSS IEPFGGGTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKVY PQGS------ FDYWGQGTLV TVSS BMS2h-203 (SEQ ID NO:78) EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYTMGWVRQA PGKGLEWVSS IRPDGKITYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEVY SSCAMCTPLL FDYWGQGTLV TVSSBMS2h-204 (SEQ ID NO: 79) EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYSMAWVRQAPGKGLEWVSD IGPRGFSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVGRGQRDTSQP- FDYWGQGTLV TVSS BMS2h-205 (SEQ ID NO: 80) EVQLLESGGGLVQPGGSLRL SCAASGFTFA SYQMAWVRQA PGKGLEWVSG ITSGGLSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPG RG-------- FDYWGQGTLV TVSS BMS2h-206(SEQ ID NO: 81) EVQLLESGGG LVQPGGSLRL SCAASGFTFA SYEMTWVRQA PGKGLEWVSGISSDGLSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG VL--------FDYWGQGTLV TVSS BMS2h-207 (SEQ ID NO: 82) EVQLLESGGG LVQPGGSLRLSCAASGFTFD KYLMSWVRQA PGKGLEWVSG IEPLGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKEA SGD------- FDYWGQGTLV TVSS BMS2h-208 (SEQ ID NO:83) EVQLLESGGG LVQPGGSLRL SCAASGFTFT EYEMSWVRQA PGKGLEWVSS IDNVGSSTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG KL-------- FDYWGQGTLV TVSSBMS2h-209 (SEQ ID NO: 84) EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYEMWWVRQAPGKGLEWVSA ISRQGFATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDLERDD------ FDYWGQGTLV TVSS BMS2h-21 (SEQ ID NO: 85) EVQLLESGGGLVQPGGSLRL SCAASGFTFA NYEMGWARQA PGKGLEWVSV ISEWGYSTYY ADSAKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKLV GGTQYE---- FDYWGQGTLV TVSS BMS2h-22(SEQ ID NO: 86) EVQLLESGGG LVQPGGSLRL SCAASGFTFH NYEMSWVRQA PGKGLEWVSSISSGGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG VK--------FDYWGQGTLV TVSS BMS2h-23 (SEQ ID NO: 87) EVQLLESGGG LVQPGGSLRLSCAASGFTFG LYEMTWVRQA PGKGLEWVSS ITGDGISTYY ADSVKGRFTI SRDNSRNTLYLQMNSLRAED TAVYYCAKAG RK-------- FDYWGQGTLV TVSS BMS2h-24 (SEQ ID NO:88) EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYQMAWVRQA PGKGLEWVSS ITSEGGSTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG KN-------- FDYWGQGTLV TVSSBMS2h-24-1 (SEQ ID NO: 89) EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYQMAWVRQAPGKGLEWVSS ITSEGGSTYY ADSVKGRFTI SRDNSKNTVY LQMNSLRAED TAVYYCAKPGKN-------- FDYWGQGTLV TVSS BMS2h-25 (SEQ ID NO: 90) EVQLLESGGGLVQPGGSLRL SCAASGFTFD NYEMTWVRQA PGKGLEWVST ITSQGTSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPD RS-------- FDYWGQGTLV TVSS BMS2h-26(SEQ ID NO: 91) EVQLLESGGG LVQPGGSLRL SCAASGFTFR SYEMTWVRQA PGKGLEWVSSITSDGGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD KT--------FDYWGQGTLV TVSS BMS2h-27 (SEQ ID NO: 92) EVQLLESGGG LVQPGGSLRLSCAASGFTFN LYEMTWVRQA PGKGLEWVSS ITSDGVSTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPD SP-------- FDYWGQGTLV TVSS BMS2h-28 (SEQ ID NO:93) EVQLLESGGG LVQPGGSLRL SCAASGFTFG HYDMAWVRQA PGKGLEWVST ISDNGNGTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG RD-------- FDYWGQGTLV TVSSBMS2h-29 (SEQ ID NO: 94) EVQLLESGGG LVQPGGSLRL SCAASGFTFG RYQMAWVRQAPGKGLEWVSS ISSDGGGTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPGRA-------- FDYWGQGTLV TVSS BMS2h-30 (SEQ ID NO: 95) EVQLLESGGGLVQPGGSLRL SCAASGFTFA RYQMAWVRQA PGKGLEWVST ISDDGDSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKLD KL-------- FDYWGQGTLV TVSS BMS2h-300(SEQ ID NO: 96) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NDEMTWVRQA PGKGLEWVSAIDTTGGQTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG KE--------FDYWGQGTLV TVSS BMS2h-301 (SEQ ID NO: 97) EVQLLESGGG LVQPGGSLRLSCAASGFTFG ESEMSWVRQA PGKGLEWVSS ILDEGSGTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPD KD-------- FDYWGQGTLV TVSS BMS2h-302 (SEQ ID NO:98) EVQLLESGGG LVQPGGSLRL SCAASGFTFG EEEMSWVRQA PGKGLEWVSA ITDDGDDTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPN AGA------- FDYWGQGTLV TVSSBMS2h-303 (SEQ ID NO: 99) EVQLLESGGG LVQPGGSLRL SCAASGFTFE VYDMAWVRQAPGKGLEWVSG IVNDGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPDKD-------- FDYWGQGTLV TVSS BMS2h-304 (SEQ ID NO: 100) EVQLLESGGGLVQPGGSLRL SCAASGFTFG NTEMTWVRQA PGKGLEWVSS IADDGSSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPG QA-------- FDYWGQGTLV TVSS BMS2h-31(SEQ ID NO: 101) EVQLLESGGG LVQPGGSLRL SCAASGFTFE EYQMAWVRQA PGKGLEWVSTISDDGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD LY--------FDYWGQGTLV TVSS BMS2h-32 (SEQ ID NO: 102) EVQLLESGGG LVQPGGSLRLSCAASGFTFE VYQMGWVRQA PGKGLEWVSF IVPGGDLTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAETW PE-------- FDYWGQGTLV TVSS BMS2h-4 (SEQ ID NO:103) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NYEMTWVRQA PGKGLEWVSS ITSDGTSTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPN PP-------- FDYWGQGTLV TVSSBMS2h-40 (SEQ ID NO: 104) EVQLLESGGG LVQPGGSLRL SCAASGFTFK AYDMGWVRQAPGKGLEWVSQ IGRDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPRRYAIF----- TFDRGQGTLV TVSS BMS2h-400 (SEQ ID NO: 105) EVQLLESGGGLVQPGGSLRL SCAASGFTFK QYPMVWVRQA PGKGLEWVST ISTNGVRTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKWT DIISSSE--- FDYWGQGTLV TVSS BMS2h-401(SEQ ID NO: 106) EVQLLESGGG LVQPGGSLRL SCAASGFTFF NYDMSWVRQA PGKGLEWVSAISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVF VWSADIDFD-FDYWGQGTLV TVSS BMS2h-402 (SEQ ID NO: 107) EVQLLESGGG LVQPGGSLRLSCAASGFTFS WYDMSWVRQA PGKGLEWVSH IASWGGKTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKVT VKDGGYLMD- FDYWGQGTLV TVSS BMS2h-403 (SEQ ID NO:108) EVQLLESGGG LVQPGGSLRL SCAASGFTFA EYAMAWVRQA PGKGLEWVSS IGRDGAVTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWK AAKERGSW-FDYWGQGTLV TVSSBMS2h-404 (SEQ ID NO: 109) EVQLLESGGG LVQPGGSLRL SCAASGFTFQ AYQMQWVRQAPGKGLEWVST ISPNGLFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWLSS-------- FDYWGQGTLV TVSS BMS2h-407 (SEQ ID NO: 110) EVQLLESGGGLVQPGGSLRL SCAASGFTFA MYSMAWVRQA PGKGLEWVSG ISPRGVETYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKTN WNGVDL---- FDYWGQGTLV TVSS BMS2h-408(SEQ ID NO: 111) EVQLLESGGG LVQPGGSLRL SCAASGFTFP TYMMSWVRQA PGKGLEWVSTINTNGRDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGD SNMSF-----FDYWGQGTLV TVSS BMS2h-409 (SEQ ID NO: 112) EVQLLESGGG LVQPGGSLRLSCAASGFTFE GYSMTWVRQA PGKGLEWVSS INASGTLTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKDG NRSEVF---- FDYWGQGTLV TVSS BMS2h-41 (SEQ ID NO:113) EVQLLESGGG LVQPGGSLRL SCAASGFTFF EYEMTWVRQA PGKGLEWVSS IANDGSTTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPD RQ-------- FDYWGQGTLV TVSSBMS2h-410 (SEQ ID NO: 114) EVQLLESGGG LVQPGGSLRL SCAASGFTFQ DYLMAWVRQAPGKGLEWVSE INQDGTVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAESSPY-------- FDYWGQGTLV TVSS BMS2h-411 (SEQ ID NO: 115) EVQLLESGGGLVQPGGSLRL SCAASGFTFD NYAMSWVRQA PGKGLEWVSS ISRDGHVTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKLS SKGGTFASS- FDYWGQGTLV TVSS BMS2h-412(SEQ ID NO: 116) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AVPMTWVRQA PGKGLEWVSAITDDGLRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGH IYGDY-----FDYWGQGTLV TVSS BMS2h-413 (SEQ ID NO: 117) EVQLLESGGG LVQPGGSLRLSCAASGFTFE LYRMMWVRQA PGKGLEWVSA ISSDGDTTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEHW LGTTLSLRD- FDYWGQGTLV TVSS BMS2h-414 (SEQ ID NO:118) EVQLLESGGG LVQPGGSLRL SCAASGFTFY RYTMAWVRQA PGKGLEWVSQ ISPRGNITYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSG VAGAESPEY- FDYWGQGTLV TVSSBMS2h-415 (SEQ ID NO: 119) EVQLLESGGG LVQPGGSLRL SCAASGFTFL GYYMSWIRQAPGKGLEWVST IGPIGGGTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSQNIYGP----- FDYWGQGTLV TVSS BMS2h-416 (SEQ ID NO: 120) EVQLLESGGGLVQPGGSLRL SCAASGFTFE QYDMAWVRQA PGKGLEWVSE ISRDGGRTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEEY PY-------- FDYWGQGTLV TVSS BMS2h-417(SEQ ID NO: 121) EVQLLESGGG LVQPGGSLRL SCAASGFTFP QYSMVWVRQA PGKGLEWVSTISPLGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKMS KLLLSRE---FDYWGQGTLV TVSS BMS2h-418 (SEQ ID NO: 122) EVQLLESGGG LVQPGGSLRLSCAASGFTFA MYSMAWVRQA PGKGLEWVSG ISPRGVETYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKTN WNGVDL---- FDYWGQGTLV TVSS BMS2h-419 (SEQ ID NO:123) EVQLLESGGG LVQPGGSLRL SCAASGFTFT RHGMAWVRQA PGKGLEWVST ITPTGNTTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDA HDEGY----- FDYWGQGTLV TVSSBMS2h-42 (SEQ ID NO: 124) EVQLLESGGG LVQPGGSLRL SCAASGFTFG PYEMTWVRQAPGKGLEWVSS IVGDGLDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPDRV-------- FDYWGQGTLV TVSS BMS2h-420 (SEQ ID NO: 125) EVQLLESGGGLVQPGGSLRL SCAASGFTFG STPMMWVRQA PGKGLEWVSE IRDTGLATYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCASVS ---------- FDYWGQGTLV TVSS BMS2h-421(SEQ ID NO: 126) EVQLLESGGG LVQPGGSLRL SCAASGFTFH LGDMHWVRQA PGKGLEWVSSISGTGHTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPM NDQG------FDYWGQGTLV TVSS BMS2h-422 (SEQ ID NO: 127) EVQLLESGGG LVQPGGSLRLSCAASGFTFM DEDMLWVRQA PGKGLEWVSR INSLGTHTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKSF MM-------- FDYWGQGTLV TVSS BMS2h-423 (SEQ ID NO:128) EVQLLESGGG LVQPGGSLRL SCAASGFTFR NYQMHWVRQA PGKGLEWVSG IDATGRATYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARST RS-------- FDYWGQGTLV TVSSBMS2h-424 (SEQ ID NO: 129) EVQLLESGGG LVQPGGSLRL SCAASGFTFT NADMVWVRQAPGKGLEWVSS ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGYLTSH------ FDYWGQGTLV TVSS BMS2h-425 (SEQ ID NO: 130) EVQLLESGGGLVQPGGSLRL SCAASGFTFR DYSMAWVRQA PGKGLEWVST ITPSGLTTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEWS QAVTRS---- FDYWGQGTLV TVSS BMS2h-426(SEQ ID NO: 131) EVQLLESGGD LVQPGGSLRL SCAASGFTFS DEGMMWVRQA PGKGLEWVSEINQQGSATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTI GM--------FDYWGQGTLV TVSS BMS2h-427 (SEQ ID NO: 132) EVQLLESGGG LVQPGGSLRLSCAASGFTFT DQPMVWVRQA PGKGLEWVSS IGARGGPTYY ADSVKGRFTV SRDNSKNTLYLQMNSLRAED TAVYYCAKWF DIIAWDPFS- FDYWGQGTLV TVSS BMS2h-428 (SEQ ID NO:133) EVQLLESGGG LVQPGGSLRL SCAASGFTFN QYPMMWVRQA PGKGLEWVSS ITPSGFLTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWN PFITT----- FDYWGQGTLV TVSSBMS2h-429 (SEQ ID NO: 134) EVQLLESGGG LVQPGGSLRL SCAASGFTFG HQQMAWVRQAPGKGLEWVST ITPNGYYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFDYSLR------ FDYWGQGTLV TVSS BMS2h-43 (SEQ ID NO: 135) EVQLLESGGGLVQPGGSLRL SCAASGFTFA SYEMAWVRQA PGKGLEWVSS IGSDGGPTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED SAVYYCAKPD RA-------- FDYWGQGTLV TVSS BMS2h-430(SEQ ID NO: 136) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AEQMTWARQA PGKGLEWVSTITPHGDSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWR TLVDWPTSESFDYWGQGTLV TVSS BMS2h-44 (SEQ ID NO: 137) EVQLLESGGG LVQPGGSLRLSCAASGFTFT SYEMGWVRQA PGKGLEWVSS IEPTGITTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPH FTELG----- FDYWGQGTLV TVSS BMS2h-449 (SEQ ID NO:138) EVQLLESGGG LVQPGGSLRL SCAASGFTFE GEQMAWVRQA PGKGLEWVST ITLPGPYTFYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGN GTF------- FDYWGQGTLV TVSSBMS2h-45 (SEQ ID NO: 139) EVQLLESGGG LVQPGGSLRL SCAASGFTFG NYAMAWVRQAPGKGLEWVSK IGAQGLHTYY AGSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQTTMDYER---- FDYWGQGTLV TVSS BMS2h-450 (SEQ ID NO: 140) EVQLLESGGGLVQPGGSLRL SCAASGFTFD EVDMSWVRQA PGKGLEWVSA IGNNGLKTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKSA LSYRPPV--- FDYWGQGTLV TVSS BMS2h-451(SEQ ID NO: 141) EVQLLESGGG LVQPGGSLRL SCAASGFTFQ DDTMSWVRQA PGKGLEWVSTITLKGPSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSR DGLY------FDYWGQGTLV TVSS BMS2h-452 (SEQ ID NO: 142) EVQLLESGGG LVQPGGSLRLSCAASGFTFA SSPMAWVRQA PGKGLEWVSS IGRDGSTTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPS PYRR------ FDYWGQGTLV TVSS BMS2h-453 (SEQ ID NO:143) EVQLLESGGG LVQPGGSLRL SCAASGFTFT DYSMVWVRQA PGKGLEWVST IVSHGGTTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGK GYNAQY---- FDYWGQGTLV TVSSBMS2h-454 (SEQ ID NO: 144) EVQLLESGGG LVQPGGSLRL SCAASGFTFG HQQMAWVRQAPGKGLEWVST ITPNGYYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFDYSLR------ FDYWGQGTLV TVSS BMS2h-455 (SEQ ID NO: 145) EVQLLESGGGLVQPGGSLRL SCAASGFTFN DYDMIWVRQA PGKGLEWVST ISSHGDSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKGD VF-------- FDYWGQGTLV TVSS BMS2h-456(SEQ ID NO: 146) EVQLLESGGG LVQPGGSLRL SCAASGFTFG HQQMAWVRQA PGKGLEWVSTITPNGYYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWS DS--------FDYRGQGTLV TVSS BMS2h-457 (SEQ ID NO: 147) EVQLLESGGG LVQPGGSLRLSCAASGFTFA DYEMAWVRQA PGKGLEWVSG IQSNGNITYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKAN SQVEY----- FDYWGQGTLV TVSS BMS2h-458 (SEQ ID NO:148) EVQLLESGGG LVQPGGSLRL SCAASGFTFG VEPMSWVRQA PGKGLEWVSN IGRDGSMTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG KHGT------ FDYWGQGTLV TVSSBMS2h-459 (SEQ ID NO: 149) EVQLLESGGG LVQPGGSLRL SCAASGFTFP EYRMMWVRQAPGKGLEWVSW IDERGSLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRRKGTKQ----- FDYWGQGTLV TVSS BMS2h-46 (SEQ ID NO: 150) EVQLLESGGGLVQPGGSLRL SCAASGFTFE LYAMAWVRQA PGKGLEWVSG IGAVGETTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKEA NNLSDNLV-FDYWGQGTLV TVSS BMS2h-460 (SEQID NO: 151) EVQLLESGGG LVQPGGSLRL SCAASGFTFG HQQMAWVRQA PGKGLEWVSTITPNGYYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWS VEW-------FDYWGQGTLV TVSS BMS2h-461 (SEQ ID NO: 152) EVQLLESGGG LVQPGGSLRLSCAASGFTFN SYTMNWVRQA PGKGLEWVSS INPWGSRTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKGL VL-------- FDYWGQGTLV TVSS BMS2h-462 (SEQ ID NO:153) EVQLLESGGG LVQPGGSLRL SCAASGFTFD GDMMSWVRQA PGKGLEWVSS ITQLGSRTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQN WRTLT----- FDYWGQGTLV TVSSBMS2h-463 (SEQ ID NO: 154) EVQLLESGGG LVQPGGSLRL SCAASGFTFN AYGMMWVRQAPGKGLEWVSS ILSDGVITYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSARGANF----- FDYWGQGTLV TVSS BMS2h-464 (SEQ ID NO: 155) EVQLLESGGGLVQPGGSLRL SCAASGFTFG HYMMVWVRQA PGKGLEWVSS ITPHGTSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEFN AIFSEA---- FDYWGQGTLV TVSS BMS2h-465(SEQ ID NO: 156) EVQLLESGGG LVQPGGSLRL SCAASGFTFR DYSMAWVRQA PGKGLEWVSTITPSGLTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWS QAVTRS----FDYWGQGTLV TVSS BMS2h-466 (SEQ ID NO: 157) EVQLLESGGG LVQPGGSLRLSCAASGFTFD LYAMAWVRQA PGKGLEWVSM IGRDGRFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKLA GSLRGR---- FDYWGQGTLV TVSS BMS2h-467 (SEQ ID NO:158) EVQLLESGGG LVQPGGSLRL SCAASGFTFN KASMGWVRQA PGKGLEWVST ITPHGSSTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQR WGVE------ FDYWGQGTLV TVSSBMS2h-468 (SEQ ID NO: 159) EVQLLESGGG LVQPGGSLRL SCAASGFTFQ GYSMGWVRQAPGKGLEWVSS IAGRGGVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGLYIYHSL---- FDYWGQGTLV TVSS BMS2h-469 (SEQ ID NO: 160) EVQLLESGGGLVQPGGSLRL SCAASGFTFP GMEMSWVRQA PGKGLEWVSA ITGTGSTTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKGY HP-------- FDYWGQGTLV TVSS BMS2h-470(SEQ ID NO: 161) EVQLLESGGG LVQPGGSLRL SCAASGFTFP MVAMSWVRQA PGKGLEWVSSIARDGNVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED AAVYYCAKVS PTG-------FDYWGQGTLV TVSS BMS2h-471 (SEQ ID NO: 162) EVQLLESGGG LVQPGGSLRLSCAASGFTFG HQDMSWVRQA PGKGLEWVSG ITDDGESTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKGD YD-------- FDYWGQGTLV TVSS BMS2h-472 (SEQ ID NO:163) EVQLLESGGG LVQPGGSLRL SCAASGFTFG EYNMMWVRQA PGKGLEWVSQ ITRDGSRTYYADSVRGRFTI SRDNSRNTLY LQMNSLRAED SAVYYCAKLS NIG------- FDYWGQGTLV TVSSBMS2h-473 (SEQ ID NO: 164) EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYSMIWARQAPGKGLEWVSS ITPYGSYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTDYL-------- FDYWGQGTLV TVSS BMS2h-474 (SEQ ID NO: 165) EVQLLESGGGLVQPGGSLRL SCAASGFTFD TYSMMWVRQA PGKGLEWVST ITPYGSSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKWG LV-------- FDYWGQGTLV TVSS BMS2h-475(SEQ ID NO: 166) EVQLLESGGG LVQPGGSLRL SCAASGFTFT TGPMMWVRQA PGKGLEWVSAIGIGGDTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLT PSNQ------FDYWGQGTLV TVSS BMS2h-476 (SEQ ID NO: 167) EVQLLESGGG LVQPGGSLRLSCAASGFTFK QYQMMWVRQA PGKGLEWVSS ITPSGFLTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEWN PFIST----- FDYWGQGTLV TVSS BMS2h-477 (SEQ ID NO:168) EVQLLESGGG LVQPGGSLRL SCAASGFTFP NYDMVWVRQA PGKGLEWVSS ISALGNVTYYADSVKGRFTI SRDNSKNTLY LQTNSLRAED TAVYYCAKWR SAITGN---- FDYWGQGTLV TVSSBMS2h-478 (SEQ ID NO: 169) EVQLLESGGG LVQPGGSLRL SCAASGFTFK EYQMSWVRQAPGKGLEWVST ISPSGMNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWRSVVRPWPGV- FDYWGQGTLV TVSS BMS2h-479 (SEQ ID NO: 170) EVQLLESGGGLVQPGGSLRL SCAASGFTFD DESMAWVRQA PGKGLEWVSS ITPHGTFTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKLH LKLYESH--- FDYWGQGTLV TVSS BMS2h-480(SEQ ID NO: 171) EVQLLESGGG LVQPGGSLRL SCAASGFTFE GGEMGWVRQA PGKGLEWVSMIPMDGSATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG ST--------FDYWGQGTLV TVSS BMS2h-481 (SEQ ID NO: 172) EVQLLESGGG LVQPGGSLRLSCAASGFTFD FMPMAWVRQA PGKGLEWVSS IGRDGAYTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKLA SPAQ------ FDYWGQGTLV TVSS BMS2h-482 (SEQ ID NO:173) EVQLLESGGG LVQPGGSLRL SCAASGFTFG DEPMLWVRQA PGKGLEWVSS IGGTGTTTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGN QGDFINR--- FHYWGQGTLV TVSSBMS2h-483 (SEQ ID NO: 174) EVQLLESGGG LVQPGGSLRL SCAASGFTFH AYNMAWVRQAPGKGLEWVST ISPRGSYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWPPPSSH----- FDYWGQGTLV TVSS BMS2h-5 (SEQ ID NO: 175) EVQLLESGGGLVQPGGSLRL SCAASGFTFD GYEMAWVRQA PGKGLEWVSS ITSDGTSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPG LR-------- FDYWGQGTLV TVSS BMS2h-505(SEQ ID NO: 176) EVQLLESGGG LVQPGGSLRL SCAASGFTFE GYMMYWVHQA PGKGLEWVSSISPQGHFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAELR ELPRL-----FDYWGQGTLV TVSS BMS2h-506 (SEQ ID NO: 177) EVQLLESGGG LVQPGGSLRLSCAASGFTFS SYAMGWVRQA PGKGLEWVSS IDASGGPTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKAN GKKFPFTKY- FDYWGQGTLV TVSS BMS2h-507 (SEQ ID NO:178) EVQLLESGGG LVQPGGSLRL SCAASGFTFP SVHMAWVRQA PGKGLEWVSG INLTGVDTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSA TTRQAHPLY- FDYWGQGTLV TVSSBMS2h-515 (SEQ ID NO: 179) EVQLLESGGG LVQPGGSLRL SCAASGFTFK EGEMYWVRQAPGKGLEWVST ISTNGLTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSTRDLG------ FAYWGQGTLV TVSS BMS2h-516 (SEQ ID NO: 180) EVQLLESGGGLVQPGGSLRL SCAASGFTFE EYEMAWARQA PGKGLEWVSF ISPRGHFTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPA KT-------- FDYWGQGTLV TVSS BMS2h-517(SEQ ID NO: 181) EVQLLESGGG LVQPGGSLRL SCAASGFTFD TYEMLWVRQA PGKGLEWVSRISVDGSITYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTR MR--------FDYWGQGTLV TVSS BMS2h-518 (SEQ ID NO: 182) EVQLLESGGG LVQPGGSLRLSCAASGFTFS SYAMSWVRQA PGKGLEWVSN ISRDGSKTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEAQ SGGLRSGLTT FDYWGQGTLV TVSS BMS2h-519 (SEQ ID NO:183) EVQLLESGGG LVQPGGSLRL SCADSGFTFS SYAMSWVRQA PGKGLEWVSS IGRDGAYTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG PKGIA----- FDYWGQGTLV TVSSBMS2h-520 (SEQ ID NO: 184) EVQLLESGGG LVQPGGSLRL SCAASGFTFS PHAMAWVRQAPGKGLEWVSG IDGGGSMTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSDPP-------- FDYWGQGTLV TVSS BMS2h-521 (SEQ ID NO: 185) EVQLLESGGGLVQPGGSLRL SCAASGFTFH AGEMHWVRQA PGKGLEWVSS ITLPGDMTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPN TGYT------ FDYWGQGTLV TVSS BMS2h-522(SEQ ID NO: 186) EVQLLESGGG LVQPGGSLRL SCAASGFTFG NYGMSWVRQA PGKGLEWVSSISWDGSLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQNT RL--------FDYWGQGTLV TVSS BMS2h-523 (SEQ ID NO: 187) EVQLLESGGG LVQPGGSLRLSCAASGFTFH DADMLWVRQA PGKGLEWVSG ILSPGEDTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKFG LP-------- FDYWGQGTLV TVSS BMS2h-524 (SEQ ID NO:188) EVQLLESGGG LVQPGGSLRL SCAASGFTFR TDQMNWVRQA PGKGLEWVSS ISPSGAYTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL GA-------- FDYWGQGTLV TVSSBMS2h-525 (SEQ ID NO: 189) EVQLLESGGG LVQPGGSLRL SCAASGFIFE QYQMVWVRQAPGKGLEWVSW ISPDGTHTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFSLRKMEK---- FDYWGQGTLV TVSS BMS2h-526 (SEQ ID NO: 190) EVQLLESGGGLVQPGGSLRL SCAASGFTFQ DEQMAWVRQA PGKGLEWVSS IASDGMSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAQPG KN-------- FDHWGQGTLV TVSS BMS2h-527(SEQ ID NO: 191) EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYAMSWVRQA PGKGLEWVSSITTGGERTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKRW NLYTES----FDYWGQGTLV TVSS BMS2h-528 (SEQ ID NO: 192) EVQLLESGGG LVQPGGSLRLSCAASGFTFG GQPMDWVRQA PGKGLEWVSS IAPDGIHTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKNL GQG------- FDYWGQGTLV TVSS BMS2h-529 (SEQ ID NO:193) EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYQMTWVRQA PGKGLEWVSS ISPSGTFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWK AL-------- FDYWGQGTLV TVSSBMS2h-530 (SEQ ID NO: 194) EVQLLESGGG LVQPGGSLRL SCAASGFTFP HSTMYWVRQAPGKGLEWVSL ILPSGSRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFSDER------- FDYWGQGTLV TVSS BMS2h-531 (SEQ ID NO: 195) EVQLSESGGGLVQPGGSLRL SCAASGFTFG DGNMDWVRQA PGKGLEWVSG ISSDGVTTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKDR GQG------- FDYWGQGTLV TVSS BMS2h-532(SEQ ID NO: 196) EVQLLESGGG LVQPGGSLRL SCAASGFTFD DYMMWWVRQA PGKGLEWVSSISPHGVYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWL HT--------FDYWGQGTLV TVSS BMS2h-533 (SEQ ID NO: 197) EVQLLESGGG LVQPGGSLRLSCAASGFTFS NYTMAWGRQA PGKGLEWVSF IAGPGNYTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPG STATYNNGQ- FDYWGQGTLV TVSS BMS2h-534 (SEQ ID NO:198) EVQLLESGGG LVQPGGSLRL SCAASGFTFT EYSMVWVRQA PGKGLEWVSS ISGSGRVTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKWL KLVRAPNP-FDYWGQGTLV TVSSBMS2h-535 (SEQ ID NO: 199) EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYQMAWVRQAPGKGLEWVSG ISKTGHSTYY ADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAKASHSLGPL---- FDYWGQGTLV TVSS BMS2h-54 (SEQ ID NO: 200) EVQLLESGGGLVQPGGSLRL SCAASGFTFT AYRMAWVRQA PGKGLEWVSW ISPSGSGTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKTL TDSPSGHYE- FDYWGQGTLV TVSS BMS2h-55(SEQ ID NO: 201) EVQLLESGGG LVQPGGSLRL SCAASGFTFA RYEMGWVRQA PGKGLEWVSRITAQGLGTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYL TDFSSGHQE-FDYWGQGTLV TVSS BMS2h-553 (SEQ ID NO: 202) EVQLLESGGG LVQPGGSLRLSCAASGFTFD DYGMSWVRQV PGKGLEWVSG ISHNGMLTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKYW PSTSWETD-FDYWGQGTLV TVSS BMS2h-554 (SEQ ID NO:203) EVQLLESGGG SVQPGGSLRL SCAASGFTFG NEPMAWVRQA PGKGLEWVSS IEMQGKNTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDR GQG------- FDYWGQGTLV TVSSBMS2h-555 (SEQ ID NO: 204) EVQLLESGGG LVQPGGSLRL SCAASGFTFG EEEMSWVRQAPGKGLEWVSC IDNLGSPTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED AAVYYCAKTISHQYDR---- FDYWGQGTLV TVSS BMS2h-556 (SEQ ID NO: 205) EVQLLESGGGLVQPGGSLRL SCAASGFTFG EEEMSWVRQA PGKGLEWVSS IDEGGRWTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKWT PHKQLS---- FDYWGQGTLV TVSS BMS2h-557(SEQ ID NO: 206) EVQLLESGGG LVQPGGSLRL SCAASGFSFA DEYMVWARQA PGKGLEWVSEIDPLGTGTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKYG TA--------FDYWGQGTLV TVSS BMS2h-558 (SEQ ID NO: 207) EVQLLESGGG LVQPGGSLRLSCAASGFTFS THDMMWVRQA PGKGLEWVSS ISDDGISTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPD MSLIE----- FDYWGQGTLV TVSS BMS2h-559 (SEQ ID NO:208) EVQLLESGGG LVQPGGSLRL SCAASGFTFD GTPMVWVRQA PGKGLEWVSG ISGDGRNTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPY ALTSSKP--- FDYWGQGTLV TVSSBMS2h-56 (SEQ ID NO: 209) EVQLLESGGG LVQPGGSLRL SCAASGFTFN DYTMGWVRQAPGKGLEWVSW IHGTGGQTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKALADRSGGVVE- FDYWGQGTLV TVSS BMS2h-560 (SEQ ID NO: 210) EVQLLESGGGLVQPGGSLRL SCAASGFTFE AETMAWVRQA PGKGLEWVSC ISNDGNTTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKES LISPGL---- FDYWGQGTLV TVSS BMS2h-561(SEQ ID NO: 211) EVQLLESGGG LVQPGGSLRL SCAASGFTFT GEYMNWVRQA PGKGLEWVSTINETGYMTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLS TRGVP-----FDYWGQGTLV TVSS BMS2h-562 (SEQ ID NO: 212) EVQLLESGGG LVQPGGSLRLSCAASGFTFR SYDMGWVRQA PGKGLEWVST ISPMGVFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKSN QHAHDP---- FDYWGQGTLV TVSS BMS2h-563 (SEQ ID NO:213) EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYDMGWVRQA PGKGLEWVSS ISPMGTFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAA LTEPM----- FDYWGQGTLV TVSSBMS2h-564 (SEQ ID NO: 214) EVQLLESGGG LVQPGGSLRL SCAASGFTFR DYDMGWVRQAPGKGLEWVST ISPLGHFTYY ADSVKGRSTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAEEA-------- FDYWGQGTLV TVSS BMS2h-565 (SEQ ID NO: 215) EVQLLESGGGLVQPGGSLRL SCAASGFAFP RYGMTWVRQA PGKGLEWVSN IDQFGMKTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEEY AS-------- FDYWGQGTLV TVSS BMS2h-566(SEQ ID NO: 216) EVQLLESGGG LVQPGGSLRL SCAASGFTFD KYDMGWVRQA PGKGLEWVSTISPMGVFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGR GNTSD-----FDYWGQGTLV TVSS BMS2h-567 (SEQ ID NO: 217) EVQLLESGGG LVQPGGSLRLSCAASGFTFS NYDMAWVRQA PGKGLEWVST ISGAGHFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKSF PRDE------ FDYWGQGTLV TVSS BMS2h-568 (SEQ ID NO:218) EVQLLESGGG LVQPGGSLRL SCAASGFTFP KYEMRWVRQA PGKGLEWVSE IGLDGSPTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG DPNG------ FDYWGQGTLV TVSSBMS2h-569 (SEQ ID NO: 219) EVQLLESGGG LVQPGGSLRL SCAASGFTFP TSEMDWVRQAPGKGLEWVSG IGPDGLTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHADW-------- FDYWGQGTLV TVSS BMS2h-57 (SEQ ID NO: 220) EVQLLESGGGLVQPGGSLRL SCAASGFTFS EYDMYWVRQA PGKGLEWVSW IDTDGGDTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPG LK-------- FDYWGQGTLV TVSS BMS2h-570(SEQ ID NO: 221) EVQLLESGGG LVQPGGSLRL SCTASGFTFE NASMQWVRQA PGKGLEWVSSIEGQGNATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSS SWS-------FDYWGQGTLV TVSS BMS2h-571 (SEQ ID NO: 222) EVQLLESGGG LVQPGGSLRLSCAASGFTFT RNEMGWVRQA PGKGLEWVST ITPTGTFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKTD PGNRY----- FDYWGQGTLV TVSS BMS2h-572 (SEQ ID NO:223) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSSBMS2h-572-1 (SEQ ID NO: 224) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWFRQAPGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVGKESN------ FDYRGQGTLV TVSS BMS2h-572-10 (SEQ ID NO: 225) EVQLLESGGGLVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTVSRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS BMS2h-572-11(SEQ ID NO: 226) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------SDYRGQGTQV TVSS BMS2h-572-12 (SEQ ID NO: 227) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS BMS2h-572-13 (SEQ IDNO: 228) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWARQA PGKGLEWVSGIEGPGDVTYY ADSVKDRFTI SRDNSKNTLY LLMNSLRAED TAVYYCAKVG KESN------FDYWGQGTLV TVSS BMS2h-572-14 (SEQ ID NO: 229) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNTKNTLYLQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS BMS2h-572-15 (SEQ IDNO: 230) EVRLLESGGG LVQPGGSLRL SCAASGFNFN WQLMGWIRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------SDYRGQGTLV TVSS BMS2h-572-16 (SEQ ID NO: 231) EVQLLESGGG LVRPGGSLRLSCVASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS BMS2h-572-17 (SEQ IDNO: 232) EVQLLESGGG LVQTGGSLRL SCAASGFTYN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRADD TAVYYCVKVG KESN------FDYRGHGTLV TVSS BMS2h-572-18 (SEQ ID NO: 233) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRKA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS BMS2h-572-19 (SEQ IDNO: 234) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNTKNTLY LQMNSLRAED TAVYYCAKVG KESN------FDYRGQGTLV TVSS BMS2h-572-2 (SEQ ID NO: 235) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKVG KESK------ FDYLGQGTLV TVSS BMS2h-572-21 (SEQ IDNO: 236) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY AESVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------LDYRGQGTLV TVSS BMS2h-572-22 (SEQ ID NO: 237) EVQLFESGGG SVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS BMS2h-572-23 (SEQ IDNO: 238) EVQLLESGGG LVQPGGSLRL TCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFII SRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------SDYRGQGTLV TVSS BMS2h-572-24 (SEQ ID NO: 239) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSTNTLYLQMNSLRAED TAVYYCAKVG KESE------ FDYRGQGTLV TVSS BMS2h-572-3 (SEQ ID NO:240) EVRLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYYADSVKGRFTI TRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------ LDYRGQGTLV TVSSBMS2h-572-4 (SEQ ID NO: 241) EVQLLVSGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQAPGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVGKESN------ FDYRGQGTLV TVSS BMS2h-572-5 (SEQ ID NO: 242) EVQLLVSGGGLVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTISRDNSKNMLY LQMNGLRAED TAVYYCAKVG KESN------ FDYRGQGTLV TVSS BMS2h-572-6(SEQ ID NO: 243) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------SDYRGQGTLV TVSS BMS2h-572-601 (SEQ ID NO: 244) EVQLLESGGG LVQPGGSLRLSCAASGFTFK WQLMGWARQA PGKGLEWVSG IEGPGDVTYY ADPVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS BMS2h-572-602 (SEQ IDNO: 245) EVQLLESGGG LVQPGGSLRL SCAASGFTFK WHLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESS------SDYRGQGTLV TVSS BMS2h-572-603 (SEQ ID NO: 246) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WHLMAWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS BMS2h-572-604 (SEQ IDNO: 247) EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------SDYRGQGTLV TVSS BMS2h-572-605 (SEQ ID NO: 248) EVQLLESGGG LVQPGGSLRLSCAASGFTFK WQLMAWARQA PGKGLEWVSG IEGPGDITYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS BMS2h-572-606 (SEQ IDNO: 249) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WHLMGWARQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------SDYRGQGTLV TVSS BMS2h-572-607 (SEQ ID NO: 250) EVQLLESGGG LVQPGGSLRLSCAASGFTFK WQLMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS BMS2h-572-608 (SEQ IDNO: 251) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESN------SDYRGQGTLV TVSS BMS2h-572-609 (SEQ ID NO: 252) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KESN------ SDYRGQGTLV TVSS BMS2h-572-610 (SEQ IDNO: 253) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSK------SDYRGQGTLV TVSS BMS2h-572-611 (SEQ ID NO: 254) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRRA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KDSK------ SDYRGQGTLV TVSS BMS2h-572-612 (SEQ IDNO: 255) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSN------SDYRGQGTLV TVSS BMS2h-572-613 (SEQ ID NO: 256) EVQLLESGGG LAQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KDSK------ SDYRGQGTLV TVSS BMS2h-572-614 (SEQ IDNO: 257) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDAK------SDYRGQGTLV TVSS BMS2h-572-615 (SEQ ID NO: 258) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KDKN------ SDYRGQGTLV TVSS BMS2h-572-616 (SEQ IDNO: 259) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KESK------SDYRGQGTLV TVSS BMS2h-572-617 (SEQ ID NO: 260) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG RDSK------ SDYRGQGTLV TVSS BMS2h-572-618 (SEQ IDNO: 261) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KYSN------SDYRGQGTLV TVSS BMS2h-572-619 (SEQ ID NO: 262) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KDSR------ SDYRGQGTLV TVSS BMS2h-572-620 (SEQ IDNO: 263) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDDS------SDYRGQGTLV TVSS BMS2h-572-621 (SEQ ID NO: 264) EVQLLEFGGG LVQPGGSLRFSCAASGFTFN WQLMGWFRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG RDSN------ SDYRGQGTLV TVSS BMS2h-572-622 (SEQ IDNO: 265) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDST------SDYRGQGTLV TVSS BMS2h-572-623 (SEQ ID NO: 266) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KESS------ SDYRGQGTLV TVSS BMS2h-572-624 (SEQ IDNO: 267) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI FRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSA------SDYRGQGTLV TVSS BMS2h-572-625 (SEQ ID NO: 268) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG NDSY------ SDYRGQGTLV TVSS BMS2h-572-626 (SEQ IDNO: 269) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNGLRAED TAVYYCVKVG KDSS------SDYRGQGTLV TVSS BMS2h-572-627 (SEQ ID NO: 270) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAIYYCVKVG KDSA------ SDYRGQGTLV TVSS BMS2h-572-630 (SEQ IDNO: 271) EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDAK------SDYRGQGTLV TVSS BMS2h-572-631 (SEQ ID NO: 272) EVQLLESGGG LVQPGGSLRLSCAASGFTFK WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KDSR------ SDYRGQGTLV TVSS BMS2h-572-632 (SEQ IDNO: 273) EVQLLESGGG LVQPGGSLRL SCAASGFTFK WQLMGWVRQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSK------SDYRGQGTLV TVSS BMS2h-572-633 (SEQ ID NO: 274) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KDAK------ SDYRGQGTLV TVSS BMS2h-572-634 (SEQ IDNO: 275) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSGIEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDSR------SDYRGQGTLV TVSS BMS2h-572-635 (SEQ ID NO: 276) EVQLLESGGG LVQPGGSLRLSCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCVKVG KDSK------ SDYRGQGTLV TVSS BMS2h-572-7 (SEQ ID NO:277) EVQLLESGGG LVQPGGSLRL SCAASGFTFN WQLMGWARQA PGKGLEWVSG IEGPGDVTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED SAVYYCAKVG KESN------ FDYLGQGTLV TVSSBMS2h-572-8 (SEQ ID NO: 278) EVQLLESGGG LVQPGGSLRL SCVASGFTFN WQLMGWVRQAPGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVGKESN------ SDYRGQGTLV TVSS BMS2h-572-9 (SEQ ID NO: 279) EVQLLESGGGLVQPGGSLRL SCAASGFTFN WQLMGWVRQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKVG KESN------ SDYRGQGTLV TVSS BMS2h-573(SEQ ID NO: 280) EVQLLESGGG LVQPGGSLRL SCAASGFTFS GWEMGWVRQA PGKGLEWVSSIDESGLNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGA PQYQIT----FDYWGQGTLV TVSS BMS2h-574 (SEQ ID NO: 281) EVQLLESGGG LVQPGGSLRLSCAASGFTFP NYGMYWVRQA PGKGLEWVSY ISRRGLLTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKTS HYMNNG---- FDYWGQGTLV TVSS BMS2h-575 (SEQ ID NO:282) EVQLLESGGG LVQPGGSLRL SCAASGFTFV DYTMAWVRQA PGKGLEWVSS ISPIGTFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDP YGMEDGLTW- FDYWGQGTLV TVSSBMS2h-576 (SEQ ID NO: 283) EVQLLESGGG LVQPGGSLRL SCAASGFTFD AYDMQWVRQAPGKGLEWVST ITSEGLSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPSDL-------- FDYWGQGTLV TVSS BMS2h-577 (SEQ ID NO: 284) EVQLLESGGGLVQPGGSLRL SCAASGFTFD GYDMGWVRQA PGKGLEWVST ISRGGWFTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKGT SQSSTGS--- FDYWGQGTLV TVSS BMS2h-578(SEQ ID NO: 285) EVQLLESGGG LVQPGGSLRL SCAASGFTFR RYDMLWARQA PGKGLEWVSEISPTGALTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLG ST--------FDYWGQGTLV TVSS BMS2h-579 (SEQ ID NO: 286) EVQLLESGGG LVQPGGSLRLSCAASGFTFF PYYMSWVRQA PGKGLEWVSS ISGTGGLTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKTT QNATL----- FDYWGQGTLV TVSS BMS2h-58 (SEQ ID NO:287) EVQLLESGGG LVQPGGSLRL SCAASGFTFE VYTMAWVRQA PGKGLEWVST IDESGRDTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG VW-------- FDYWGQGTLV TVSSBMS2h-580 (SEQ ID NO: 288) EVQLLESGGG LVQPGGSLRL SCAASGFTFA FYKMGWVRQAPGKGLEWVST ITPKGHHTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVFKGKGWTRPSG FDYWGQGTLV TVSS BMS2h-581 (SEQ ID NO: 289) EVQLLESGGGLVQPGGSLRL SCAASGFTFN EYSMMWVRQA PGKGLEWVSS IGRRGWLTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKAV LLDSTK---- FDYWGQGTLV TVSS BMS2h-582(SEQ ID NO: 290) EVQLLESGGG LVQPGGSLRL SCAASGFTFD EYPMTWVRQA PGKGLEWVSTISARGPFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGR HWLRNGR---FDYWGQGTLV TVSS BMS2h-583 (SEQ ID NO: 291) EVQLLESGGG LVQPGGSLRLSCAASGFTFG MQSMQWVRQA PGKGLEWVSS ITDDGTSTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPD RV-------- FDYWGQGTLV TVSS BMS2h-584 (SEQ ID NO:292) EVQLLESGGG LVQPGGSLRL SCAASGFTFG AADMQWVRQA PGKGLEWVSL ITNDGISTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG DR-------- FDYWGQGTLV TVSSBMS2h-586 (SEQ ID NO: 293) EVQLLESGGG LVQPGGSLRL SCAASGFTFN KYRMQWVRQAPGKGLEWVSS IDSSGELTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEEVPMGNQTF--- FDYWGQGTLV TVSS BMS2h-587 (SEQ ID NO: 294) EVQLLESGGGLVQPGGSLRL SCAASGFTFT DYTMGWVRQA PGKGLEWVSS ITSQGAFTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKAT GTDSS----- FDYWGQGTLV TVSS BMS2h-588(SEQ ID NO: 295) EVQLLESGGG LVQPGGSLRL SCAASGFTFE DYEMSWVRQA PGKGLEWVSCIGPGGKPTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKVD GH--------FDYWGQGTLV TVSS BMS2h-589 (SEQ ID NO: 296) EVQLLESGGG LVQPGGSLRLSCAASGFTFS QYDMGWVRQA PGKGLEWVST ISSRGWLTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKGP GGRRR----- FDYWGQGTLV TVSS BMS2h-59 (SEQ ID NO:297) EVQLLESGGG LVQPGGSLRL SCAASGFTFL DYAMGWVRQA PGKGLEWVST ISPMGMGTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSS AISFTSDISN FDYWGQGTLV TVSSBMS2h-590 (SEQ ID NO: 298) EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYPMSWVRQAPGKGLEWVSS ISWSGFQTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPGVARMPTGIA- FDYWGQGTLV TVSS BMS2h-591 (SEQ ID NO: 299) EVQLLESGGGLVQPGGSLRL SCAASGFTFS AYEMQWVRQA PGKGLEWVSS IDSAGTFTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEPF GM-------- FDYWGQGTLV TVSS BMS2h-592(SEQ ID NO: 300) EVQLLESGGG LVQPGGSLRL SCAASGFTFS EYPMKWVRQA PGKGLEWVSTIDRQGDRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKTV RRGLPRPSRYFDYWGQGTLV TVSS BMS2h-593 (SEQ ID NO: 301) EVQLLESGGG LVQPGGSLRLSCAASGFTFS DYDMGWVRQA PGKGLEWVSS ISPMGTFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKGL SVYSGLD--- FDYWGQGTLV TVSS BMS2h-594 (SEQ ID NO:302) EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYDMGWVRQA PGKGLEWVSD IDYIGKTTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAS DEVGVNTSK- FDYWGQGTLV TVSSBMS2h-595 (SEQ ID NO: 303) EVQLLESGGG LVQPGGSLRL SCAASGFTFA RYDMGWVRQAPGKGLEWVST ISPTGVLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGFED-------- FDYWGQGTLV TVSS BMS2h-596 (SEQ ID NO: 304) EVQLLESGGGLVQPGGSLRL SCAASGFTFE AYPMSWVRQA PGKGLEWVSL ISHTGHATYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKGH WP-------- FDYRGQGTLI TVSS BMS2h-597(SEQ ID NO: 305) EVQLLESGGG LVQPGGSLRL SCAASGFTFE DEWMSWVRQA PGKGLEWVSDISPGGWTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGY RPFDE-----FDYWGQGTLV TVSS BMS2h-598 (SEQ ID NO: 306) EVQLLESGGG LVQPGGSLRLSCAASGVTFD AIEMSWVRQA PGKGLEWVSS ISRHGEYTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEDA WSRH------ FDYWGQGTLV TVSS BMS2h-599 (SEQ ID NO:307) EVQLLESGGG LVQPGGSLRL SCAASGFTFD STDMSWVRQA PGKGLEWVSG ILDNGSNTYYADSVKGRFTI SRDNSKNMLY LQMNSLRAED TAVYYCAKGA RD-------- FDYWGQGTLV TVSSBMS2h-600 (SEQ ID NO: 308) EVQLLESGGG LVQPGGSLRL SCAASGFTFG RQSMQWVRQAPGKGLEWVSS IDDDGFSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGDPWG------- FDYWGQGTLV TVSS BMS2h-601 (SEQ ID NO: 309) EVQLLESGGGLVQPGGSLRL SCTASGFTFS DTQMAWVRQA PGKGLEWVSG IDDGGVSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPD RH-------- FDYWGQGTLV TVSS BMS2h-602(SEQ ID NO: 310) EVQLLESGGG LVQPGGSLRL SCAASGFTFG STTMGWVRQA PGKGLEWVSVISDDGGFTYY ADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAKVD GYGV------FDYWGQGTLV TVSS BMS2h-603 (SEQ ID NO: 311) EVQLLESGGG LVQPGGSLRLSCAASGFTFR SGDMNWVRQA PGKGLEWVST ITNDGTSTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKSD SD-------- FDYWGQGTLV TVSS BMS2h-61 (SEQ ID NO:312) EVQLLESGGG LVQPGGSLRL SCAASGFTFA AYAMTWVRQA PGKGLEWVSY ISPNGTATYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEYV GMRWNS---- FDYWGQGTLV TVSSBMS2h-62 (SEQ ID NO: 313) EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYEMAWVRQAPGKGLEWVSS ITSLGTSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPGRK-------- FDYWGQGTLV TVSS BMS2h-65 (SEQ ID NO: 314) EVQLLESGGGLVQPGGSLRL SCAASGFTFN EYEMTWVRQA PGKGLEWVST ITSEGSGTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKPN GK-------- FDYWGQGTLV TVSS BMS2h-66(SEQ ID NO: 315) EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYEMLWVRQA PGKGLEWVSTITSEGHSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG TS--------FDYWGQGTLV TVSS BMS2h-67 (SEQ ID NO: 316) EVQLLESGGG LVQPGGSLRLSCAASGFTFS DYEMSWVRQA PGKGLEWVST IDSDGSFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPG VK-------- FDYWGQGTLV TVSS BMS2h-68 (SEQ ID NO:317) EVQLLESGGG LVQPGGSLRL SCAASGFTFK DYEMTWVRQA PGKGLEWVSS ISSTGQSTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPG NK-------- FDYWGQGTLV TVSSBMS2h-69 (SEQ ID NO: 318) EVQLLESGGG LVQPGGSLRL SCAASGFTFL DYGMAWVRQAPGKGLEWVSA ISPLGLSTYY ADSVKSRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKEVRVGRGVHPPK FDYWGQGTLV TVSS BMS2h-7 (SEQ ID NO: 319) EVQLLESGGGLVQPGGSLRL SCAASGFTFN LYEMTWVRQA PGKGLEWVSS ITSDGVSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKAG VI-------- FDYWGQGTLV TVSS BMS2h-70(SEQ ID NO: 320) EVQLLESGGG LVQPGGSLRL SCAASGFTFE NYAMSWVRQA PGKGLEWVSTIAPLGVPTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKKK VGAWLQSRS-FDYWGQGTLV TVSS BMS2h-701 (SEQ ID NO: 321) EVQLLESGGG LVQPGGSLRLSCAASGFTFM DYEMHWVRQA PGKGLEWVST IGASGHYTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKYL DMLLFG---- FDYWGQGTLV TVSS BMS2h-702 (SEQ ID NO:322) EVQLLESGGG LVQPGGSLRL SCAASGFTFA EYEMMWARQA PGKGLEWVSR IAGNGSRTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIML SH-------- FDYWGQGTLV TVSSBMS2h-703 (SEQ ID NO: 323) EVQLLESGGG LVQPGGSLRL SCAASGFTFY NYDMSWVRQAPGKGLEWVSG IDSMGLVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGSNASDWVV--- FDYWGQGTLV TVSS BMS2h-704 (SEQ ID NO: 324) EVQLLESGGGLVQPGGSLRL SCAASGFTFA SYHMTWVRQA PGKGLEWVSS IADTGDRTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKLR GMARVWG--- FDYWGQGTLV TVSS BMS2h-705(SEQ ID NO: 325) EVQLLESGGG LVQPGGSLRL SCAASGFTFS YYDMMWVRQA PGKGLEWISSISDRGLQTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFT EIPLDWLEV-FDYWGQGTLV TVSS BMS2h-706 (SEQ ID NO: 326) EVQLLESGGG LVQPGGSLRLSCAASGFTFG SYKMLWVRQA PGKGLEWVSS ITNSGTETYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKSM YPDLEIVH-FDYWGQGTLV TVSS BMS2h-707 (SEQ ID NO:327) EVQLLESGGG LVQPGGSLRL SCAASGFTFE TYRMSWVRQA PGKGLEWVSA IDQEGSATYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNS GTRPGLR--- FDYWGQGTLV TVSSBMS2h-708 (SEQ ID NO: 328) EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYDMLWVRQAPGKGLEWVSR IDASGYFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQLLKLSLNPN--- FDYWGQGTLV TVSS BMS2h-709 (SEQ ID NO: 329) EVQLLESGGGLVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSS IHNTGLSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKGT QHRFVV---- FDYWGQGTLV TVSS BMS2h-71(SEQ ID NO: 330) EVQLLESGGG LVQPGGSLRL SCAASGFTFE GYPMSWVRQA PGKGLEWVSTISPLGPDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLL MGEYLNSRT-FDYWGQGTLV TVSS BMS2h-710 (SEQ ID NO: 331) EVQLLESGGG LVQPGGSLRLSCAASGFTFN TYSMSWVRQA PGKGLEWVSW IDADGWVTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAQTG HT-------- FDYWGQGTLV TVSS BMS2h-711 (SEQ ID NO:332) EVQLLESGGG LVQPGGSLRL SCAASGFTFT DGEMGWARQA PGKGLEWVSR IVDPGDSTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG DQ-------- FDYWGQGTLV TVSSBMS2h-712 (SEQ ID NO: 333) EVQLLESGGG LVQPGGSLRL SCAASGFTFP EYEMKWVRQAPGKGLEWVST ITPSGGHTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED AAVYYCAIPLSS-------- FDYWGRGTLV TVSS BMS2h-713 (SEQ ID NO: 334) EVQLLESGGGLVQPGGSLRL SCAASGFTFS NYVMIWVRQA PGKGLEWVSL INGAGDMTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEGG ARSFGVPPN- FDYWGQGTLV TVSS BMS2h-714(SEQ ID NO: 335) EVQLLESGGG LVQPGGSLRL SCAASGFTFT DGEMGWARQA PGKGLEWVSRIVDPGDSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG DQ--------FDYWGQGTLV TVSS BMS2h-715 (SEQ ID NO: 336) EVQLLESGGG LVQPGGSLRLSCVASGFTFT LYNMSWVRQA PGKGLEWVSV ISSKGDSTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAQTS SV-------- FDYWGQGTLV TVSS BMS2h-716 (SEQ ID NO:337) EVQLLESGGG LVQPGGSLRL SCAASGFTFE AYYMSWVRQA PGKGLEWVSG IVNNGLLTYYADSVKGRFTI SRDNSKNMLY LQMNSLRAED TAVYYCAKSA VHPSYRAEL- FDYWGQGTLV TVSSBMS2h-717 (SEQ ID NO: 338) EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYEMAWVRQAPGKGLEWVSR IEPDGSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGPDNFTM----- FDYWGQGTLV TVSS BMS2h-718 (SEQ ID NO: 339) EVQLLESGGGLVQPGGSLRL SCAASGFTFN KYMMGWVRQA PGKGLEWVSS IDSLGHYTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEAE FP-------- FDYWGQGTLV TVSS BMS2h-719(SEQ ID NO: 340) EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMTWVRQA PGKGLEWVSSISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE--------FDYWGQGTLV TVSS BMS2h-719-1 (SEQ ID NO: 341) EVQLLESGGG MVQPGGSLRLSCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEPF TE-------- FDYWGQGTQV TVSS BMS2h-719-10 (SEQ IDNO: 342) EVQLLESGGG MVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSSISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE--------FDYWGQGTLV TVSS BMS2h-719-11 (SEQ ID NO: 343) EVQLLESGGG LVQPGGSLRLSCAASGFTFK RYEMMWVRKA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSENTLYLQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSS BMS2h-719-12 (SEQ IDNO: 344) EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSSISSDGSFTYY ADSVKGRFTV SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE--------FDYWGQGTLV TVSS BMS2h-719-13 (SEQ ID NO: 345) EVQLLESGGG LVQPGGSLRLSCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNTKNTLYLQMNSLRAED TAVYYCADPF TE-------- LDYWGHGTLV TVSS BMS2h-719-14 (SEQ IDNO: 346) EVQLLESGGG LVRPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSSISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCADPF TE--------FDYWGQGTLV TVSS BMS2h-719-15 (SEQ ID NO: 347) EVQLLESGGG LVQPGGSLRLSCAASGFAFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLYLHMNSLRAED TAVYYCADPF TE-------- IDYWGQGTLV TVSS BMS2h-719-16 (SEQ IDNO: 348) EVQLLESGGG LVQPGGSLRL SCAASGFPFK RYEMTWVRQA PGKGLEWVSSISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE--------FDYRAQGTLV TVSS BMS2h-719-17 (SEQ ID NO: 349) EVQLLESGGG LVQPGGSLRLSCAASGFTFK RYEMSWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCADPF TE-------- IDYWGQGTQV TVSS BMS2h-719-18 (SEQ IDNO: 350) EVQLLESGGG LVHPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSSISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRDED TAVYYCAEPF TE--------FDYGGQGTLV TVSS BMS2h-719-19 (SEQ ID NO: 351) EVQLLESGGG WVQPGGSLRLSCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSS BMS2h-719-2 (SEQ ID NO:352) EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSSBMS2h-719-20 (SEQ ID NO: 353) EVQLLESGGG LVQPGGSLRL SCAASGFTFKRYEMTWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAEDTAVYYCAEPF TE-------- IDYRGQGTLV TVSS BMS2h-719-202 (SEQ ID NO: 354)EVQLLESGGG LVQPGGSLRL SCAASGFTFK KYEMMWVRQA PGKGLEWVSS ISSDGSFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSSBMS2h-719-203 (SEQ ID NO: 355) EVQLLESGGG LVQPGGSLRL SCAASGFTFNSYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAEDTAVYYCAEPF TE-------- FDYWGHGTLV TVSS BMS2h-719-21 (SEQ ID NO: 356)EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSSBMS2h-719-213 (SEQ ID NO: 357) EVQLLESGGG LVQPGGSLRL SCAASGFTFKRYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAEDTAVYYCADPF TE-------- MDYWGHGTLV TVSS BMS2h-719-214 (SEQ ID NO: 358)EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGHGTLV TVSSBMS2h-719-215 (SEQ ID NO: 359) EVQLLESGGG LVQPGGSLRL SCAASGFTFKRYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAEDTAVYYCAEPF TE-------- LDYWGHGTLV TVSS BMS2h-719-218 (SEQ ID NO: 360)EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYYAESVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSSBMS2h-719-225 (SEQ ID NO: 361) EVQLLESGGG LVQPGGSLRL SCAASGFTFNTYEMQWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAEDTAVYYCAEPF TE-------- FDYWGHGTLV TVSS BMS2h-719-226 (SEQ ID NO: 362)EVQLLESGGG LVQPGGSLRL SCAASGFTFN KYEMMWARQA PGKGLEWVSS ISSDGSFTYYADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGHGTLV TVSSBMS2h-719-3 (SEQ ID NO: 363) EVQLSESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQAPGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPFTE-------- FDYWGQGTLV TVSS BMS2h-719-4 (SEQ ID NO: 364) EVQLLESGGGLVQPGGSLRL SCAASGFTFK RYEMMWVRQT PGKGLEWVSS ISSDGSFTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGQGTLV TVSS BMS2h-719-5(SEQ ID NO: 365) EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYEMMWVRQA PGKGLEWVSSISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LEMNSMRAED TAVYYCAEPF TE--------FDNWGQGTLV TVSS BMS2h-719-6 (SEQ ID NO: 366) EVQLLESGGG LVQPGGSLRLSCAASGFTFK RYEMMWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEPF TE-------- FDYWGQGTQV TVSS BMS2h-719-7 (SEQ ID NO:367) EVQLLESGGG LVQPGGSLRL SCAASGFNFK RYEMTWVRQA PGKGLEWVSS ISSDGSFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPF TE-------- FDYWGQGTLV TVSSBMS2h-719-8 (SEQ ID NO: 368) EVQLLESGGD LVQPGGSLRL SCAASGFTFK RYEMMWVRQAPGKGLEWVSS ISSDGSFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPFTE-------- FDYRGQGTLV TVSS BMS2h-719-9 (SEQ ID NO: 369) EVQLLESGGGLVQPGGSLRL SCAASGFTFK RYEMSWVRQA PGKGLEWVSS ISSDGSFTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEPF TE-------- FDYWGRGTLV TVSS BMS2h-72(SEQ ID NO: 370) EVQLLESGGG LVQPGGSLRL SCAASGFTFE AYPMSWVRQA PGKGLEWVSSISPLGLWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLS AGAETHVYRLFDYWGQGTLV TVSS BMS2h-720 (SEQ ID NO: 371) EVQLLESGGG LVQPGGSLRLSCAASGFTFG NYEMMWVRQA PGKGLEWVSS IGVLGHTTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKLM SLRTFENL-FDYWGQGTLV TVSS BMS2h-722 (SEQ ID NO:372) EVQLLESGGG LVQPGGSLRL SCAASGFTFT KYPMAWVRQA PGKGLEWVSG IDANGNRTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEGT WRRHFAI--- FDYWGQGTLV TVSSBMS2h-723 (SEQ ID NO: 373) EVQLLESGGG LVQPGGSLRL SCAASGFTFD LYDMMWVRQAPGKGLEWVSS ISDLGTLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNGFRVTSNDRR- FDYWGQGTLV TVSS BMS2h-724 (SEQ ID NO: 374) EVQLLESGGGLVQPGGSLRL SCAASGFTFT GGDMWWVRQA PGKGLEWVSM IEGGGVTTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAELD LRTGQ----- FDYWGQGTLV TVSS BMS2h-725(SEQ ID NO: 375) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSLIGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------FDYWGQGTLV TVSS BMS2h-725-1 (SEQ ID NO: 376) EVQLLESGGG LVQPGGSLHLSCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYFCADPS DPTK------ FDYWGQGTLV TVSS BMS2h-725-10 (SEQ IDNO: 377) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSLIGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK------FDYWGQGTLV TVSS BMS2h-725-11 (SEQ ID NO: 378) EVQLLESGGG LVQPGGSLRLSCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLYLQMSSLRAED TAVYYCADPS DPTK------ FDYWGQGTLV TVSS BMS2h-725-12 (SEQ IDNO: 379) EVQLLESGGG LVQPGGSLRL SCAASGFTFP AYTMGWVRQA PGKGLEWVSLIGDRGSWTYY ADSVKGRFTI SRDDSKNTLY LQMNSLRVED TAVYYCAEPS DPTM------FVYWGQGTLV TVSS BMS2h-725-13 (SEQ ID NO: 380) EVQLLESGGG LVQPGGSLRLSCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEPS DPTM------ FVYWGQGTLV TVSS BMS2h-725-14 (SEQ IDNO: 381) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSLIGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTM------FDYWGQGTLV TVSS BMS2h-725-15 (SEQ ID NO: 382) EVQLLESGGG MVQPGGSLRLSCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLYLQMNSMRAED TAVYYCADPS DPTK------ FDYWGQGTLV TVSS BMS2h-725-16 (SEQ IDNO: 383) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVTLIGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTM------FDYWGQGTLV TVSS BMS2h-725-17 (SEQ ID NO: 384) EVQLLESGGG LVQPGGSLRLSCAASGFTFT AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEPS DPTK------ LDYWGQGTLV TVSS BMS2h-725-18 (SEQ IDNO: 385) EVQLSESGGG LVQPGGSLRL TCAASGFTFS AYTMGWVRQA PGKGLEWVSLIGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK------FVYWGQGTLV TVSS BMS2h-725-19 (SEQ ID NO: 386) EVQLLESGGG LVQPGGSLRLSCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCADPS DPTK------ FVYWGQGTLV TVSS BMS2h-725-2 (SEQ ID NO:387) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------ FVYWGQGTPV TVSSBMS2h-725-3 (SEQ ID NO: 388) VQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQAPGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSRNMLY LQMKSLRAED TAVYYCADPSDPTK------ FVYWGQGTQV TVSS BMS2h-725-4 (SEQ ID NO: 389) EVQLLESGGGLVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTIFRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK------ FVYWGQGTLV TVSS BMS2h-725-5(SEQ ID NO: 390) EVQLLESGGG LLQPGGSLRL SCAASGFTFS DYTMGWVRQA PGKGLEWVSLIGDRGSWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------FDYWGRGTLV TVSS BMS2h-725-6 (SEQ ID NO: 391) EVQLLESGGG LVQPGGSLRLSCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGSWTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEPS DPTK------ FVYWGQGTLV TVSS BMS2h-725-7 (SEQ ID NO:392) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGKGLEWVSL IGDRGTWTYYADPVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCADPS DPTK------ FDYWGQGTLV TVSSBMS2h-725-8 (SEQ ID NO: 393) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMGWVRQAPGKGLEWVSL IGDRGSWTYY ADSVKGRFTV SRDNSKNTLY LQMNSLRAED TAVYYCAEPSDPTK------ FDYWGQGTLV TVSS BMS2h-725-9 (SEQ ID NO: 394) EVQLLESGGGLVQPGGSLRL SCAASGFTFS AYTMGWVRQA PGMGLEWVSL IGDRGSWTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEPS DPTK------ FDYWGQGTLV TVSS BMS2h-726(SEQ ID NO: 395) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NYKMYWVRQA PGKGLEWVSSISEIGNLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIAL TR--------FDYWGQGTLV TVSS BMS2h-727 (SEQ ID NO: 396) EVQLLESGGG LVQPGGSLRLSCAASGFTFA SYRMYWVRQA PGKGLEWVSY IDPPGSRTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKSL NLSFPYIN-FDYWGQGTLV TVSS BMS2h-728 (SEQ ID NO:397) EVQLLESGGG LVQPGGSLRL SCAASGFTFE RYEMLWVRQA PGKGLEWVSR ISHSGRTTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAQLD GP-------- FDYWGQGTLV TVSSBMS2h-729 (SEQ ID NO: 398) EVQLLESGGG LVQPGGSLRL SCAASGFTFK RYYMDWVRQAPGKGLEWVSR INHNGSVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKMPQGTSDWYY-FDYWGQGTLV TVSS BMS2h-73 (SEQ ID NO: 399) EVQLLESGGG LVQPGGSLRLSCAASGFTFS KYDMSWVRQA PGKGLEWVST ILEDGLTTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPG RL-------- FDYWGQGTLV TVSS BMS2h-74 (SEQ ID NO:400) EVQLLESGGG LVQPGGSLRL SCAASGFTFS DYPMTWVRQA PGKGLEWVST ILSPGTETYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAE KD-------- FDYWGQGTLV TVSSBMS2h-741 (SEQ ID NO: 401) EVQLLESGGG LVQPGGSLRL SCAASGFTFE GGEMGWVRQAPGKGLEWVSM IPMDGSATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAGEV-------- FDYWGQGTLV TVSS BMS2h-742 (SEQ ID NO: 402) EVQLLESGGGLVQPGGSLRL SCAASGFTFR EYHMKWARQA PGKGLEWVSG ISRDGMNTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAIQL AL-------- FDYWGQGTLV TVSS BMS2h-743(SEQ ID NO: 403) EVQLLESGGG LVQPGGSLRL SCAASGFTFR DYEMLWARQA PGKGLEWVSGILPSGGATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKAG SGNGPIL---FDYWGQGTLV TVSS BMS2h-744 (SEQ ID NO: 404) EVQLLESGGG LVQPGGSLRLSCAASGFTFK EHDMFWVRQA PGKGLEWVSG IGAEGVWTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEPT MSNGSQSR-FDYWGQGTLV TVSS BMS2h-745 (SEQ ID NO:405) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG IIEDGNRTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSSBMS2h-745-1 (SEQ ID NO: 406) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQAPGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIRNLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-745-10 (SEQ ID NO: 407) EVQLLESGGGLVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTISRDNSKNTLY LQMNNLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-745-11(SEQ ID NO: 408) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSGITEDGNRTYY ADSVKGRFTI SRDNFKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ-FDYWGQGTLV TVSS BMS2h-745-12 (SEQ ID NO: 409) EVQLLESGGG LVQPGGSLRLSCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSMNTLYLQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FVYWGQGTLV TVSS BMS2h-745-13 (SEQ IDNO: 410) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSGIIEDGNRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ-FDYWGQGTLV TVSS BMS2h-745-14 (SEQ ID NO: 411) EVQLLESGGG LVQPGGSLRLSCAASGFTFD NTEMAWIRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-745-15 (SEQ IDNO: 412) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSGITEDGNRTYY ADSVKGRFTI SRDNSKNALY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ-FDYWGLGTLV TVSS BMS2h-745-16 (SEQ ID NO: 413) EVQLLESGGG LVQPGGSLRLSCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNTKNTLYLQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FVYWGQGTLV TVSS BMS2h-745-17 (SEQ IDNO: 414) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSGIIEDGNRTYY ADSVKGRFTI SRDNSKNRLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ-FDYWGQGTLV TVSS BMS2h-745-18 (SEQ ID NO: 415) EVQLLESGGG LVQPGGSLRLSCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYHCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-745-19 (SEQ IDNO: 416) EVQLLESGGG LVQPEGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSGIIEDGNRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ-FDYWGQGTLV TVSS BMS2h-745-2 (SEQ ID NO: 417) EVQLLESGGG LVQPGGSLRLSCAASGFTFD NTEMAWVRQA PGKGLEWVSG ISEDGNRTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED SAVYYCAKIR NLHWDVGRQ- FVYWGQGTLV TVSS BMS2h-745-3 (SEQ ID NO:418) EVQLLESGGG LVEPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYYADSVKGRFTI SRDNSKNTLY LQMSSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSSBMS2h-745-4 (SEQ ID NO: 419) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWVRQAPGKGLEWVSG ISEDGNRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYHCAKIRNLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-745-5 (SEQ ID NO: 420) EVQLLESGGGLVQPGGSLRL SCAASGFTFD NTEMAWVRQA PGKGLEWVSG ITEDGNRTYY ADSVKGRFIISRDNSKNTLN LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-745-6(SEQ ID NO: 421) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGRGLEWVSGVTEDGNRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ-FDYWGQGTLV TVSS BMS2h-745-7 (SEQ ID NO: 422) EVQLLESGGG LVQPGGSLRLSCEASGFTFD NTEMAWIRQA PGKGLEWVSG IIEDGNRTYY ADSVKGRFTI SRDNTKNTLYLQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-745-8 (SEQ ID NO:423) EVQLLESGGG LVQPGGSLRL SCAASGFTFD NTEMAWIRQA PGKGLEWVSG ITEDGDRTYYADSVKGRFTI SRDNSKSSLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSSBMS2h-745-9 (SEQ ID NO: 424) EVQLLESGGG SVQPGGSLRL SCAASGFTFD NTEMAWVRQAPGKGLEWVSG ITEDGNRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKIRNLHWDVGRQ- FVYWGQGTLV TVSS BMS2h-746 (SEQ ID NO: 425) EVQLLESGGGLVQPGGSLRL SCAASGFTFG SAEMGWVRQA PGKGLEWVSG ISRPGQVTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-747(SEQ ID NO: 426) EVQLLESGGG LVQPGGSLRL SCAASGFTFD DGTMGWARQA PGKGLEWVSLILPSGSRTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKHS LTNRP-----FDYWGQGTLV TVSS BMS2h-748 (SEQ ID NO: 427) EVQLLESGGG LVQPGGSLRLSCAASGFTFS KYDMRWARQA PGKGLEWVSD IDAVGTRTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAIPG GT-------- FDYWGQGTLV TVSS BMS2h-749 (SEQ ID NO:428) EVQLLESGGG LVQPGGSLRL SCAASGFTFE MYGMMWARQA PGKGLEWVSS IEGAGHATYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAIVL GM-------- FDYWGQGTLV TVSSBMS2h-75 (SEQ ID NO: 429) EVQLLESGGG LVQPGGSLRL SCAASGFTFL QYPMGWVRQAPGKGLEWVST ISPVGLTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLFEGSRIQRDVG FDYWGQGTLV TVSS BMS2h-750 (SEQ ID NO: 430) EVQLLESGGGLVQPGGSLRL SCAASGFTFE KYQMGWARQA PGKGLEWVSS IRGSGLVTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKVH TTLHTEVIG- FDYWGQGTLV TVSS BMS2h-751(SEQ ID NO: 431) EVQLLESGGG LVQPGGSLRL SCAASGFTFS QYTMYWARQA PGKGLEWVSEISHSGSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAISG LH--------FDYWGQGTLV TVSS BMS2h-752 (SEQ ID NO: 432) EVQLLESGGG LVQPGGSLRLSCAASGFTFS DYAMAWVRQA PGKGLEWVSR IGVEGGDTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKLL RLYRLG---- FDYWGQGTLV TVSS BMS2h-753 (SEQ ID NO:433) EVQLLESGGG LVQPGGSLRL SCAASGFTFA KYDMTWVRQA PGKGLEWVSK INSDGGLTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGL HGRGFVI--- FDYWGQGTLV TVSSBMS2h-754 (SEQ ID NO: 434) EVQLLESGGG LVQPGGSLRL SCAASGFTFS RYDMVWVRQAPGKGLEWVSR INSMGLATYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDYSVAPHGYPLG FDYWGQGTLV TVSS BMS2h-755 (SEQ ID NO: 435) EVQLLESGGGLVQPGGSLRL SCAASGFTFK DYSMMWVRQA PGKGLEWVST ITDNGTSTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKHM SLATYLQF-FDYWGQGTLV TVSS BMS2h-756 (SEQID NO: 436) EVQLLESGGG LVQPGGSLRL SCAASGFTFM EYDMLWVRQA PGKALEWVSRISSDGLWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGV SALAPFDIG-FDYWGQGTLV TVSS BMS2h-757 (SEQ ID NO: 437) EVQLLESGGG LVQPGGSLRLSCAASGFTFK EYNMAWVRQA PGKGLEWVSS INFAGRTTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKLS LPLDIFS--- FDYWGQGTLV TVSS BMS2h-758 (SEQ ID NO:438) EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-------- FDYWGQGTLV TVSSBMS2h-758-1 (SEQ ID NO: 439) EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQAPGKGLEWVSH ISSNGRFTYY ADSVKGRFTI SRDNSKNMLY LRMNSLRAED TAVYYCAETSGY-------- YEYWGQGTLV TVSS BMS2h-758-2 (SEQ ID NO: 440) EVQLLESGGGLVQPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-------- FEYWGQGTLV TVSS BMS2h-758-3(SEQ ID NO: 441) EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQA PGKGLEWVSHISSNGRFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS SY--------FEYWGQGTLV TVSS BMS2h-758-4 (SEQ ID NO: 442) EVQLLESGGG LVQPGGSLRLSCAASGFTFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYY ADSVKGRFTI SRDNSKNTLFLQMNSLRAED TAVYYCAETS GY-------- YEYWGHGTLV TVSS BMS2h-758-5 (SEQ ID NO:443) EVQLLESGGG LVQPGGSLRL SCAASGFAFG DYGMNWVRQA PGKGLEWVSH ISSNGRFTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETS GY-------- FEYWGQGTLV TVSSBMS2h-758-6 (SEQ ID NO: 444) EVQLLESGGG LVQPGGSLRL SCAASGFTFG DYGMNWVRQAPGKGLEWVSH ISSNGRFIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETSGY-------- FEYWGQGTLV TVSS BMS2h-759 (SEQ ID NO: 445) EVQLLESGGGLVQPGGSLRL SCAASGFTFR EYVMGWVRQA PGKGLEWVST INGLGNVTYY ADSVKGRFTISRDNTKNTLY LQMNSLRAEE TAVYYCAIQL PN-------- FDYWGQGTLV TVSS BMS2h-760(SEQ ID NO: 446) EVQLLESGGG LVQPGGSLRL SCAASGFTFG NDGMWWVRQA PGKGLEWVSFINVDGRETYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEWS PGRVQ-----FDYWGQGTLV TVSS BMS2h-761 (SEQ ID NO: 447) EVQLLESGGG LVQPGGSLRLSCAASGFTFG GWDMAWVRQA PGKGLEWVSS IAHEGGETYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKYV PGSPL----- FDYWGQRTLV TVSS BMS2h-762 (SEQ ID NO:448) EVQLLESGGG LVQPGGSLRL SCAASGFTFD QGWMYWVRQA PGKGLEWVSG IGSNGPRTSYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSG EY-------- FDYWGQGTLV TVSSBMS2h-763 (SEQ ID NO: 449) EVQLLESGGG LVQPGGSLRL SCAASGFTFR QSDMWWVRQAPGKGLEWVSV IGNNGEFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDNWLL------- FDYWGQGTLV TVSS BMS2h-764 (SEQ ID NO: 450) EVQLLESGGGLVQPGGSLRL SCAASGFTFD LSTMYWVRQA PGKGLEWVST IGGDGSHTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEGT QY-------- FDYWGQGTLV TVSS BMS2h-765(SEQ ID NO: 451) EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYTMEWVRQA PGKGLEWVSSIGVTGYDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGG QG--------FDYWGQGTLV TVSS BMS2h-766 (SEQ ID NO: 452) EVQLLESGGG LVQPGGSLRLSCAASGFTFG DYGMSWVRQA PGKGLEWVSY IDPLGRLTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAEDL SSLQYGVSPN FDYWGQGTLV TVSS BMS2h-767 (SEQ ID NO:453) EVQLLESGGG LVQPGGSLRL SCAASGFTFF HYSMSWVRQA PGKGLEWVSS IGPVGRETYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKMI QSPLFKD--- FDYWGQGTLV TVSSBMS2h-768 (SEQ ID NO: 454) EVQLLESGGG LVQPGGSLRL SCAASGFTFE WYDMYWVRQAPGKGLEWVSR IDSGGNQTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEASLWKWRL---- FDYWGQGTLV TVSS BMS2h-77 (SEQ ID NO: 455) EVQLLESGGGLVQPGGSLRL SCAASGFTFE EYGMAWVRQA PGKGLEWVST ISPLGISTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKHA TSQESLRS-FDYWGQGTLV TVSS BMS2h-770 (SEQID NO: 456) EVQLLESGGG LVQPGGSLRL SCAASGFTFS KYEMMWVRQA PGKGLEWVSAISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGP LPDAFWTRG-FDYWGQGTLV TVSS BMS2h-771 (SEQ ID NO: 457) EVQLLESGGG LVQPGGSLRLSCAASGFTFG TYSMAWVRQA PGKGLEWVST IDRHGLATYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKTP GSSWQTV--- FGYWGQGTLV TVSS BMS2h-772 (SEQ ID NO:458) EVQLLESGGG LVQPGGSLRL SCAASGFTFE SYPMGWVRQA PGKGLEWVSS IDHHGHSTYYADSAKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLL RVSMIFG--- FDYWGQGTLV TVSSBMS2h-773 (SEQ ID NO: 459) EVQLLESGGG LVQPGGSLRL SCAASGFTFV QYGMSWVRQAPGKGLEWVSW ISSSGTYTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAETSRM-------- FDYWGQGTLV TVSS BMS2h-774 (SEQ ID NO: 460) EVQLLESGGGLVQPGGSLRL SCAASGFTFR EYDMGWVRQA PGKGLEWVSL ISPPGRTTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKVV ILGYTNR--- FDYWGQGTLV TVSS BMS2h-775(SEQ ID NO: 461) EVQLLESGGG LVQPGGSLRL SCAASGFTFP NYGMLWVRQA PGKGLEWVSSINSSGMETYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFF RLNDHNSVFGFDYWGQGTLV TVSS BMS2h-776 (SEQ ID NO: 462) EVQLLESGGG LVQPGGSLRLSCAASGFTFK DYKMMWIRQA PGKGLEWVSS IVGSGSMTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKGP GY-------- FDYWGQGTLV TVSS BMS2h-777 (SEQ ID NO:463) EVQLLESGGG LVQPGGSLRL SCAASGFTFH NYAMGWVRRA PGKGLEWVSS IDEHGTITYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS LDRVWI---- FDYWGQGTLV TVSSBMS2h-778 (SEQ ID NO: 464) EVQLLESGGG LVQPGGSLRL SCAASGFTFA DYPMTWVRQAPGKGLEWVSS IYSAGSPTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKLYHREPILFG-FDYWGQGTLV TVSS BMS2h-78 (SEQ ID NO: 465) EVQLLESGGG LVQPGGSLRLSCAASGFTFE RYQMAWVRQA PGKGLEWVST ISSDGGGTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKPG HR-------- FDYWGQGTLV TVSS BMS2h-780 (SEQ ID NO:466) EVQLLESGGG LVQPGGSLRL SCAASGFTFG SYTMMWVRQA PGKGLEWVSE IDRTGERTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAEPG FASLP----- FDYWGQGTLV TVSSBMS2h-781 (SEQ ID NO: 467) EVQLLESGGG LVQPGGSLRL SCAASGFTFT DYTMYWVRQAPGKGLEWVSK ISPSGRSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDPFG-------- FDYWGQGTLV TVSS BMS2h-782 (SEQ ID NO: 468) EVQLLESGGGLVQPGGSLRL SCAASGFTFD DAEMFWVRQA PGKGLEWVSS IDARGLTTYY ADPVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAEAT SAMYP----- FDYWGQGTLV TVSS BMS2h-783(SEQ ID NO: 469) EVQLLESGGG LVQPGGSLRL SCAASGFTFR DYDMGWVRQA PGKGLEWVSTISPLGHFTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKSG FHEYTEG---FDYWGQGTLV TVSS BMS2h-784 (SEQ ID NO: 470) EVQLLESGGG LVQPGGSLRLSCAASGFTFD RAGMGWVRQA PGKGLEWVSL IGRGGDITYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKIR NLHWDVGRQ- FDYWGQGTLV TVSS BMS2h-80 (SEQ ID NO:471) EVQLLESGGG LVQPGGSLRL SCAASGFTFG RYQMAWVRQA PGKGLEWVSS ISSDGGGTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPS RR-------- FDYWGQGTLV TVSSBMS2h-81 (SEQ ID NO: 472) EVQLLESGGG LVQPGGFLRL SCAASGFTFE LYPMAWVRQAPGKGLEWVSS ISPVGFLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKGHEGSYTPRSA- FDYWGQGTLV TVSS BMS2h-82 (SEQ ID NO: 473) EVQLLESGGGLVQPGGSLRL SCAASGFTFV AYPMAWVRQA PGKGLEWVST IAPLGGNTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKRP EGLQIDSQN- FDYWGQGTLV TVSS BMS2h-83(SEQ ID NO: 474) EVQLLESGGG LVQPGGSLRL SCAASGFTFA LYQMAWVRQA PGKGLEWVSSIDSSGSDTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPE RD--------FDYWGQGTLV TVSS BMS2h-84 (SEQ ID NO: 475) EVQLLESGGG LVQPGGSLRLSCAASGFTFR QYQMAWARQA PGKGLEWVST IASDGVSTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKVG RD-------- FDYWGQGTLV TVSS BMS2h-85 (SEQ ID NO:476) EVQLLESGGG LVQPGGSLRL SCAASGFTFE QYDMRWVRQA PGKGLEWVSW IDEAGHETYYADSVKGRFTI SRDNSRNTLY LQMNSLRAED TAVYYCAKGM DG-------- FDYWGQGTLV TVSSBMS2h-92 (SEQ ID NO: 477) EVQLLESGGG LVQPGGSLRL SCAASGFTFV DYPMGWVRQAPGKGLEWVST ISTGGFSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKARYYYLSQIKN- FDYWGQGTLV TVSS BMS2h-93 (SEQ ID NO: 478) EVQLLESGGGLVQPGGSLRL SCAASGFTFD IYGMTWVRQA PGKGLEWVSS ISPLGLVTYY ADPVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKLK EHGDVP---- FDYWGQGTLV TVSS BMS2h-94(SEQ ID NO: 479) EVQLLESGGG LVQPGGSLRL SCAASGFTFE LYPMSWVRQA PGKGLEWVSTISPTGLLTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKFK RSGKTDDTN-FDYWGQGTLV TVSS BMS2h-95 (SEQ ID NO: 480) EVQLLESGGG LVQPGGSLRLSCAASGFTFR EYDMLWVRQA PGKGLEWVST IVGDGNGTYY ADSVKGRFTI SRDNSKNTLYLQMNSLRAED TAVYYCAKQD RQ-------- FDYWGQGTLV TVSS BMS2h-97 (SEQ ID NO:481) EVQLLESGGG LVQPGGSLRL SCAASGFTFE EYGMSWVRQA PGKGLEWVST ISPIGVTTYYADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKNA YDRKSN---- FDYWGQGTLV TVSSBMS2h-98 (SEQ ID NO: 482) EVQLLESGGG LVQPGGSLRL SCAASGFTFD RYVMVWVRQAPGKDLEWVSG ITPSGRRTYY ADSVKGRFTI SRDNSKDTLY LQMNSLRAED TAVYYCAKVLGRHFDPLLPS FDYWGQGTLV TVSS BMS2h-99 (SEQ ID NO: 483) EVQLLESGGGLVQPGGSLRL SCAASGFTFE DYAMSWVRQA PGKGLEWVST ITPGGFWTYY ADSVKGRFTISRDNSKNTLY LQMNSLRAED TAVYYCAKTS SGELQLVED-FDYWGQGTLV TVSS

TABLE 2 Human Anti-CD40L VH Domain Encoding Nucleotide SequencesBMS2h-10 (SEQ ID NO: 484)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTAGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATTGCTTATGATATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATGGATTGATGAGTGGGGTCTGCAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAAGACGCCTGAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-11 (SEQ ID NO:485) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGAGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGATGGTGAGGGTTCTGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCGGGGAGGAGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-111 (SEQ ID NO:486) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCGTTATCCTATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTCATGGTTCTGGTAGTGCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCCGTATACTAGTCGGCATAATAGTCTTGGGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-112 (SEQ ID NO: 487)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGATTATCCTATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGCCTGTTGGTATGAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATATGGGGGGACTAGTGGTAGGCATAATACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-113 (SEQ ID NO: 488)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGAGTATCCTATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGTTATTTCTCCTCTTGGTTTTACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGACTGGTGGGAGTGGTATTTTGAATTCTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-114 (SEQ ID NO: 489)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTTAGGGTTAGCAATTACGATTTGACCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTATCAACCATTAGTGCCACAAACGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGCGCGGCAGTGACGTGGTGGTTGTTGCGTCATAACGACAACTTGGGGTTTTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-115 (SEQ ID NO: 490)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTTAGCATTAGCTATAAGAATATGGCCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTATCAGCCATTAAGGCGGCAAACGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGCGCGACAGGGAGTCAGAAGAAGCGGACCTACACGTTCGACTTTTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-12 (SEQ ID NO: 491)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGTTGTATGAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGATATTTTGGGTTCGAGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATCTGTCGTGGCAGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-120 (SEQ IDNO: 492) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGTCTTATACGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAATCCTATGGGTTATCAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACATGGGGTGGGGAAGGGTACTAAGCCGCATAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-121 (SEQ ID NO: 493)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCTGTATAGGATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAGTGGTAGTGGTTTTCCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTCTGCATGATAAGACTCAGCATCATCAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-123 (SEQ ID NO: 494)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATTGAGTATCCTATGCGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTTATTTCTCCGTCTGGTGTGTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGATGAGTCTAGTACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-124 (SEQ IDNO: 495) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCGGTATGATATGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGGGAGTTCGGGTTATCCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAAGGATGCCTGGTTATTTTCCTGGGTTTGCTCGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-125 (SEQ ID NO: 496)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTGGCGGTATGCTATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTAATGATGAGGGTCGGGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAAGCGGGTGTCTAGTTCTGTGAATGCTCCGTATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-126 (SEQ ID NO: 497)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAATTATAGTATGAGTTGGGTCCGCCAGGCCCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGATCGTCTTGGTACGCATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAATACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGTGCTGGCTGATCTTATTGCTGGGCATGCGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-127 (SEQ ID NO: 498)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGTCGTATGATATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTTCGAGGTCTGGTTCTATGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATTTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGTTGATGCGCATGTTTATTATATGGAGCCTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-128 (SEQ ID NO: 499)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAGGTATCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTAGTTCTGATGGTGGGGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGTACTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-129 (SEQ ID NO:500) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACATTTCCGAAGTATGAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATGGTGATGGTAAGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCGGATCAGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-13 (SEQ ID NO:501) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTTATTATTCGATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTTCGCCTTTTGGTTGGGGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGGACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGGGGAGACGAGTGGTCCGATTTCTGAGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-130 (SEQ ID NO: 502)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTACAGCCTCCGGATTCACCTTTGCGGGTTATCAGATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTAATGAGGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGGAAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-131 (SEQ ID NO:503) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGTATGAGATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTACGTCGGATGGTCTGAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGCGAAACCGGGTATTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-132 (SEQ ID NO:504) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATGATATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGTTGATGATGGTCTTATGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGATGTTGCTTTTGACTACTGGGGTCAGGGGACCCTGGTCACCGTCTCGAAC BMS2h-133 (SEQ ID NO:505) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATTGGTTATGCTATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGGTCCTTTGGGTGCGACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGCCTGCTGGTACGAGTAGTCATAGTGTGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-134 (SEQ ID NO: 506)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGGATTATGAGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTAGTGATGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGTCGGTTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-135 (SEQ ID NO:507) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTAGGTATGTTATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTGAGGCTGATGGTCGTACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCTTACGGATCAGCATGTTATTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-136 (SEQ ID NO: 508)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGTTATCGTATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGCTCCGGATGGTAATTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTTGGGGGATGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-137 (SEQ IDNO: 509) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCGTATCCGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGGTCCTATTGGTTTTACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAATGAAGTCGCCTTATAAGCCGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-138(SEQ ID NO: 510)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTGGCTTATTGGATGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCTCCGTCGGGTACGCATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGTCGAGGACACCGCGGTATATTACTGTGCGAAATATACTGAGCCGGGGTTGGGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-139(SEQ ID NO: 511)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGAATTATGAGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGTGATTTCTGAGGTGGGTTCTCTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTCATGATAGTTCGATTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-14 (SEQID NO: 512) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTGGTCTTATGATATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTATGGCTTCGGGTGATGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGGATCGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-15 (SEQ ID NO:513) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGTTATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTTCTCCTATTGGTCTGACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATTTCCTTTGATTATTCTTCCTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-16(SEQ ID NO: 514)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGAGTATGCGATGATTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATTATTTCTCCGCTTGGTTTGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATCAGGATTCGTCTGATAGTCAGTATACGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-17 (SEQ ID NO: 515)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTATGGGATGGGGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGGTCCTCTGGGTCTTTGGACATACTACGCAGACTCCGCGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTCCGCTTGAGGGTTTGATTACGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-176 (SEQ ID NO: 516)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGCGTATGAGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATTATTGATTGGGATGGTAATTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGGGATAATGTTGGTATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-177 (SEQID NO: 517) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATTATATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTGATGAGTGGGGTTTTGCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATTGGGAGTTTACGTCTGATACGTCGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-178 (SEQ ID NO: 518)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTTTGATATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAATGATCAGGGTTCTCTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGATCAGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-179 (SEQ ID NO:519) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGCTTATGATATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTAGTCCTCAGGGTCAGCGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTGGGCAGTCGCGGATTCCTATGAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-18 (SEQ ID NO: 520)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTGAGTATGATATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATATATTAGTTCTGATGGTTATTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGCATGGGAGTCCGCGGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-180 (SEQID NO: 521) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGATTATGAGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACTAGTTTGGGTGAGAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGTCGTATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-181 (SEQ ID NO:522) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTTTTATCCTATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTGATGCTACGGGTACGAGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGTAATTATGGGAGTTCGTATACTATGGGGGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-182 (SEQ ID NO: 523)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGAGTATCCGATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGTCCTTCTGGTCCGAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTCCGTATTTTGATGTTATTCCTAGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-183 (SEQ ID NO: 524)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGGATTACGGTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTCAGTCGTCGGGTTTGCGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACGGGCTAATTCTCGTAGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-184 (SEQID NO: 525) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGATTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTAGTCATGGTGGGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGATAAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-185 (SEQ ID NO:526) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGCATTATCCGATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGTAGGCTGGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACGTGCTACGCCTGTGCCGATTAAGGGTTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-186 (SEQ ID NO: 527)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGACTCACCTTTGGGAGGTATGAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATTCGGATGGTTGGGTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAACCGGATTCGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-187 (SEQ ID NO:528) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTAGTTATTCTATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTAATCGGGGTGGTACTCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTGGAGGAGGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-188 (SEQ IDNO: 529) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGCGTTATAGGATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGGATTTCGAGGGATGGTTATCGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTATGACTGCGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-189 (SEQ IDNO: 530) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGATGTATCCGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTGAGCCGGCTGGTGATCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATCAGGAGCAGCCTTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-19 (SEQ IDNO: 531) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCCCCTTTCCGCAGTATCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTACTTCTGATGGTCTTGATACATATTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGAGCCTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-190 (SEQ ID NO:532) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTATGTATGATATGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTTGTCTGATGGTACGGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGGGGCTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-191 (SEQ ID NO:533) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTTGTATCCGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATGCGGGGGGTCATGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATTGGTGGGATTATCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-192 (SEQ IDNO: 534) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGCGGTATCCGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAATCGTTCGGGTATGCGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGGCATCAGGCGCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-193 (SEQ IDNO: 535) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGGGTATGCTATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAATGCGAATGGTATTCGGACATACTACGCCGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACGGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGGGGTTTGGAGGTGGGGGACTGGGCATAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-194 (SEQ ID NO: 536)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCAGTATGATATGCGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGCAGAATGGTACTAAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGAGGACTGGTAGGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-195 (SEQ IDNO: 537) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGACTTATGATATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTAATTGGCAGGGTGATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGGTTTGGTCATTATGTTGATGGTCTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-196 (SEQ ID NO: 538)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGGGTATGAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTGATATGGGTGATTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGGACTGCGTTTGACTACTGGGGTCCGGGAACCCTGGTCACCGTCTCGAGC BMS2h-197 (SEQ ID NO:539) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAAGTATAAGATGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTCCGAAGGGTCATTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAGGCCGATGACTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-198 (SEQ IDNO: 540) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCGGTATAATATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTCGGCCGCGGGGTGGGAAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCGGCGGGAGGGGTATACTGGTTCTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-199 (SEQ ID NO: 541)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAGGTATGGTATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTGGCCGAGGGGTCAGAAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGAATAGTCGGTATGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-2 (SEQ IDNO: 542) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGATTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTTCGGATGGTATTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTTCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAGTGGGAGGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-20 (SEQ ID NO:543) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGGTTATCAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTAGTTCGGAGGGTCTTACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGGGGCGTAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-200 (SEQ ID NO:544) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTAATTATAGTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTCGTCCTAATGGTACTAAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACGGTCGTCTGCGCATCTTCAGAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-201(SEQ ID NO: 545)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATTATTCGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGTCGTCATGGTGGGCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAAGGGGAGTACTTATCCTAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-202 (SEQID NO: 546) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTACAGCCTCCGGATTCACCTTTTCGCATTATGAGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGAGCCTTTTGGTGGTGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGTGTATCCTCAGGGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-203 (SEQ IDNO: 547) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATACTATGGGGTGGGTCCGTCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTCGGCCTGATGGTAAGATTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGTTTATTCTTCGTGTGCGATGTGTACTCCGCTTTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-204 (SEQ ID NO: 548)GAGGTGCAGCTGTTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCGGTATTCGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGATATTGGGCCGAGGGGTTTTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGGGTCGTGGTCAGCGTGATACTAGTCAGCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-205 (SEQ ID NO: 549)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCTTATCAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTACTTCGGGTGGTCTTAGTACGTACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGGAGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-206 (SEQ ID NO:550) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGTGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCTTATGAGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTTCTTCTGATGGTCTGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGGGTGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-207 (SEQ ID NO:551) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCTGGATTCACCTTTGATAAGTATTTGATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGTATTGAGCCTCTGGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGAGGCTTCGGGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-208 (SEQ IDNO: 552) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGGTTCACCTTTACTGAGTATGAGATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATAATGTGGGTAGTAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGGAAGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-209 (SEQ ID NO:553) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATGAGATGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTTCTAGGCAGGGTTTTGCTACATACTACGCAGACTCCGTGAAAGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCTGGAGCGGGATGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-21 (SEQ IDNO: 554) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAATTATGAGATGGGGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGTTATTTCTGAGTGGGGTTATTCTACATACTACGCAGACTCCGCGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTGTGGGTGGGACTCAGTATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-22(SEQ ID NO: 555)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATAATTATGAGATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCTTCGGGTGGTTCTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGGGTTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-23 (SEQ ID NO:556) GAGGTGCAGCTGTTGGAGTCCGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCTGTATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACGGGTGATGGTATTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGGGAGGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-24 (SEQ ID NO:557) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTAGTGAGGGTGGTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACACTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGTAAGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-24-1 (SEQ ID NO:558) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATCAGATGGCGTGGGTTCGCCAGGCTCCAGGGAAGGGACTAGAGTGGGTCTCAAGTATTACTAGTGAGGGTGGTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACAGTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGTAAGAATTTCGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-25 (SEQ ID NO:559) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACGTCGCAGGGTACTAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGATCGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-26 (SEQ ID NO:560) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTAGTTATGAGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTACGTCGGATGGTGGTACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGATAAGACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-27 (SEQ ID NO:561) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTTGTATGAGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTAGTGATGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGATTCTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-28 (SEQ ID NO:562) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATTATGATATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAGTGATAATGGTAATGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGGCGTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-29 (SEQ ID NO:563) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTCGTTATCAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCTTCTGATGGTGGGGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGGCGGGCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-30 (SEQ ID NO:564) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAGGTATCAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTTCTGATGATGGTGATTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTGGATAAGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-300 (SEQ ID NO:565) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATGATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTGATACGACGGGTGGGCAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGTAAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-301 (SEQ ID NO:566) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGAGTGAGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTCTTGATGAGGGTTCTGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGATAAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-302 (SEQ ID NO:567) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGGAGGAGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTACTGATGATGGTGATGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTAATGCGGGTGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-303 (SEQ IDNO: 568) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGTGTATGATATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGTTAATGATGGTTCTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGATAAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-304 (SEQ ID NO:569) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATACGGAGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGCGGATGATGGTTCTAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGTCAGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-31 (SEQ ID NO:570) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGGATGATGGTTCTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGATCTTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-32 (SEQ ID NO:571) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGTGTATCAGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATTTATTGTGCCTGGGGGTGATTTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACGTGGCCGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-4 (SEQ ID NO:572) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACGAGTGATGGTACTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTAATCCGCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-40 (SEQ ID NO:573) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGCGTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTGGGAGGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTCGTCGGTATGCTATTTTTACTTTTGATCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-400 (SEQID NO: 574) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCAGTATCCGATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCTACTAATGGTGTGAGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGACGGATATTATTTCGTCTTCGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-401 (SEQ ID NO: 575)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTTAATTATGATATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTTTTGTGTGGTCGGCTGATATTGATTTTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-402 (SEQ ID NO: 576)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGTGGTATGATATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACATATTGCGAGTTGGGGTGGTAAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGACGGTGAAGGATGGGGGGTATCTGATGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-403 (SEQ ID NO: 577)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGAGTATGCTATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTGGGCGGGATGGTGCGGTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGAAGGCGGCGAAGGAGCGGGGTTCTTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-404 (SEQ ID NO: 578)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGCTTATCAGATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTTGAGTGGGTCTCAACTATTAGTCCTAATGGTCTTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGTTGAGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-407 (SEQ ID NO:579) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTATGTATTCGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCGCCTCGTGGTGTTGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTAATTGGAATGGTGTGGATCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-408(SEQ ID NO: 580)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTACGTATATGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAATACGAATGGTCGTGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGATAGTAATATGTCGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-409 (SEQID NO: 581) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTTATTCGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAATGCGTCGGGTACTCTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATGGTAATAGGTCTGAGGTTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-41(SEQ ID NO: 582)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTTGAGTATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGCGAATGATGGTTCGACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGATCGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-410 (SEQ ID NO:583) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGATTATTTGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAATCAGGATGGTACTGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAAGTTCTCCGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-411 (SEQ ID NO:584) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATGCGATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAGTCGGGATGGTCATGTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTTCTTCTAAGGGGGGGACGTTTGCTAGTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-412 (SEQ ID NO: 585)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGCTGTTCCGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTACGGATGATGGTCTTCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCATATTTATGGGGATTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-413 (SEQID NO: 586) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCTTTATAGGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTAGTAGTGATGGTGATACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACATTGGTTGGGTACTACGTTGTCTTTGAGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-414 (SEQ ID NO: 587)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTATCGTTATACGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTTCGCCTAGGGGTAATATTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTGGTGTGGCGGGGGCGGAGTCGCCTGAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-415 (SEQ ID NO: 588)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGTTTGGTGCAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTGGGTTATTATATGAGTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGGGCCGATTGGTGGTGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTCAGAATATTTATGGTCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-416 (SEQID NO: 589) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCAGTATGATATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAGTCGTGATGGTGGGCGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGAGTATCCTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-417 (SEQ ID NO:590) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGCAGTATAGTATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTTGAGTGGGTCTCAACTATTTCGCCTCTGGGTTCTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAATGAGTAAGTTGTTGCTGTCGAGGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-418 (SEQ ID NO: 591)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTATGTATTCGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCGCCTCGTGGTGTTGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTAATTGGAATGGTGTGGATCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-419(SEQ ID NO: 592)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGCGTCATGGTATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACGCCTACTGGTAATACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATGCTCATGATGAGGGGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-42 (SEQID NO: 593) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTCCGTATGAGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGTTGGTGATGGTCTGGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGATCGGGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-420 (SEQ ID NO:594) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAGTACGCCTATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAGGGATACGGGTCTGGCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAGTGTTTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-421 (SEQ ID NO: 595)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATCTGGGGGATATGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTAGTGGGACGGGTCATACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTATGAATGATCAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-422 (SEQ IDNO: 596) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGATGAGGATATGTTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTAATTCGCTGGGTACTCATACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATCGTTTATGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-423 (SEQ ID NO:597) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTAATTATCAGATGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGATGCGACTGGTCGGGCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAGATCTACTAGGTCATTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-424 (SEQ ID NO:598) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGAATGCGGATATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTATTTGACTTCGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-425 (SEQ IDNO: 599) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGGATTATTCTATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGTCGGGTCTTACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGTCTCAGGCGGTTACTCGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-426(SEQ ID NO: 600)GAGGTGCAGCTGTTGGAGTCTGGGGGAGACTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGATGAGGGTATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTAATCAGCAGGGTTCGGCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGATTGGGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-427 (SEQ ID NO:601) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGATCAGCCGATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGGGCGCGTGGTGGGCCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGTTTGATATTATTGCTTGGGATCCTTTTAGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-428 (SEQ ID NO: 602)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATCAGTATCCTATGATGTGGGTTCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTCCTTCTGGTTTTTTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGAATCCTTTTATTACTACGTTTGACTACTGGGGTCAGGGAACCCTGGTGACCGTCTCGAGC BMS2h-429 (SEQID NO: 603) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGAATGGTTATTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTGATTATTCGCTTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-43 (SEQ IDNO: 604) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCTTATGAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGGTAGTGATGGTGGGCCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACTCCGCGGTATATTACTGTGCGAAACCTGATAGGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-430 (SEQ ID NO:605) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGCGGAGCAGATGACTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGCATGGTGATTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCGGACTTTGGTTGATTGGCCTACGAGTGAGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-44 (SEQ ID NO: 606)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGTCTTATGAGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGAGCCTACTGGTATTACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTCATTTTACTGAGCTTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-449 (SEQID NO: 607) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGGGAGCAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACGCTGCCTGGTCCGTATACATTCTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGAATGGGACGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-45 (SEQ ID NO:608) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATTATGCGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAAGATTGGGGCGCAGGGTCTTCATACATACTACGCAGGCTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGACGACGATGGATTATGAGAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-450(SEQ ID NO: 609)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGAGGTTGATATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGCTATTGGTAATAATGGTCTTAAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGCTCTGTCGTATAGGCCTCCTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-451 (SEQ ID NO: 610)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGATGATACTATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACGCTTAAGGGTCCGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGAGGGATGGGTTGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-452 (SEQ IDNO: 611) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTTCGTCTCCGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGGTCGGGATGGTAGTACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTTCGCCTTATCGGCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-453 (SEQ IDNO: 612) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGATTATTCGATGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTGTGAGTCATGGTGGTACTACATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTAAGGGTTATAATGCGCAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-454(SEQ ID NO: 613)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGAATGGTTATTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTGATTATTCGCTTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-455 (SEQ IDNO: 614) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATGATTATGATATGATTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAGTTCGCATGGTGATAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGATGTTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-456 (SEQ ID NO:615) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGAATGGTTATTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAATGGTCGGATTCTTTTGACTACAGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-457 (SEQ ID NO:616) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTCAGTCTAATGGTAATATTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTAATTCTCAGGTTGAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-458 (SEQID NO: 617) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGTGGAGCCTATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAATATTGGTCGTGATGGTTCGATGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGGGGAAGCATGGTACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-459 (SEQ IDNO: 618) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGGAGTATCGGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATGGATTGATGAGCGGGGTTCGCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGGCGGAAGGGTACTAAGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-46 (SEQID NO: 619) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGTTGTATGCTATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGGTGCTGTGGGTGAGACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGAGGCTAATAATCTTTCTGATAATCTTGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-460 (SEQ ID NO: 620)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGAATGGTTATTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGTCGGTTGAGTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-461 (SEQ IDNO: 621) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATAGTTATACGATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTAATCCTTGGGGTAGTCGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGTCTGGTGCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-462 0 (SEQ ID NO:622) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGTGATATGATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACTCAGCTTGGTAGTAGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGAATTGGCGGACTCTTACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-463 (SEQID NO: 623) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGCGCAGCCTCCGGATTCACCTTTAATGCTTATGGGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTCTTTCTGATGGTGTTATTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTGCTCGGGGTGCGAATTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-464 (SEQID NO: 624) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATTATATGATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTACGCCTCATGGTACGAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATTTAATGCTATTTTTAGTGAGGCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-465(SEQ ID NO: 625)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGGATTATTCTATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGTCGGGTCTTACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGTCTCAGGCGGTTACTCGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-466(SEQ ID NO: 626)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCTTTATGCGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTGGGAGGGATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACGGCGGTATATTACTGTGCGAAATTGGCTGGTTCGCTGAGGGGTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-467(SEQ ID NO: 627)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATAAGGCTAGTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACGCCTCATGGTTCGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGCGGTGGGGTGTTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-468 (SEQ IDNO: 628) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGGGTATAGTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGCTGGGCGTGGTGGTGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTTGTATATTTATCATAGTCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-469(SEQ ID NO: 629)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGCTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTGGTATGGAGATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTACTGGGACTGGTAGTACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTATCATCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-470 (SEQ ID NO:630) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGATGGTGGCTATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGCTCGGGATGGTAATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACGCCGCGGTATATTACTGTGCGAAAGTTTCGCCGACTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-471 (SEQ IDNO: 631) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGCATCAGGATATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTACGGATGATGGTGAGAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGATTATGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-472 (SEQ ID NO:632) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGTATAATATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACAGATTACGAGGGATGGTTCTAGGACATACTACGCAGACTCCGTGAGGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACTCCGCGGTATATTACTGTGCGAAACTGTCGAATATTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-473 (SEQ IDNO: 633) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATTCTATGATTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACGCCGTATGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAACTGATTATTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-474 (SEQ ID NO:634) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATACGTATAGTATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTTGAGTGGGTCTCAACTATTACTCCTTATGGTAGTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGGGTCTGGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-475 (SEQ ID NO:635) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGACTCTCCTGTGCAGCCTCCGGATTCACCTTTACTACGGGTCCTATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCGATTGGTATTGGGGGTGATACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTCTATTACTGTGCGAAATTGACTCCGTCTAATCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-476 (SEQ IDNO: 636) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGCAGTATCAGATGATGTGGGTTCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTCCTTCTGGTTTTTTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGAATCCTTTTATTAGTACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-477 (SEQID NO: 637) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTAATTATGATATGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTTCTGCTTTGGGTAATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAACGAACAGCCTGCGTGCCGAGGACACTGCGGTATATTACTGTGCGAAATGGCGTAGTGCTATTACTGGTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-478(SEQ ID NO: 638)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGTATCAGATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCGCCGTCGGGTATGAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGCGGTCGGTTGTTCGTCCTTGGCCGGGTGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-479 (SEQ ID NO: 639)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGATGAGAGTATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACTCCTCATGGTACTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTCATCTTAAGTTGTATGAGTCTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-480 (SEQ ID NO: 640)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTGGTGAGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTCCGATGGATGGTAGTGCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGGAGTACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-481 (SEQ ID NO:641) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATTTTATGCCGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGAGGGATGGTGCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTGCTTCGCCGGCGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-482 (SEQ IDNO: 642) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATGAGCCTATGCTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGGGTACGGGTACGACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTAATCAGGGTGATTTTATTAATCGGTTTCACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-483 (SEQ ID NO: 643)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATGCGTATAATATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCTCCGCGGGGTTCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCCGCCGCCTTCGTCTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-5 (SEQID NO: 644) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGGTATGAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACGAGTGATGGTACGAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGGCTGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-505 (SEQ ID NO:645) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTTATATGATGTATTGGGTCCACCAGGCTCCGGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCTCCTCAGGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACTTCGTGAGCTTCCTCGTCTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-506 (SEQID NO: 646) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAGTTATGCTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGATGCGAGTGGTGGTCCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGAATGGGAAGAAGTTTCCTTTTACTAAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-507 (SEQ ID NO: 647)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTAGTGTGCATATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTAATCTGACGGGTGTTGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTGCTACTACTAGGCAGGCGCATCCGTTGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-515 (SEQ ID NO: 648)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGGGTGAGATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGACTAATGGTCTTACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTACTCGTGATCTGGGTTTTGCCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-516 (SEQ IDNO: 649) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGAGATGGCTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATTTATTTCTCCTCGTGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGCTAAGACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-517 (SEQ ID NO:650) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATACGTATGAGATGCTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTTCTGTTGATGGTAGTATTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAACGCGGATGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-518 (SEQ ID NO:651) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTTCGTATGCTATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAATATTTCTCGTGATGGTTCGAAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGCAGTCTGGGGGGCTTCGGTCGGGTTTGACTACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-519 (SEQ ID NO: 652)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGACTCCGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGAGGGATGGTGCTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGGCCGAAGGGTATTGCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-520 (SEQID NO: 653) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTCCGCATGCTATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGTATTGATGGGGGGGGTTCGATGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGATCCTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-521 (SEQ ID NO:654) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGCGCAGCCTCCGGATTCACCTTTCATGCGGGGGAGATGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACGCTGCCTGGTGATATGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGAATACTGGGTATACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-522 (SEQ IDNO: 655) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGAATTATGGTATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCGTGGGATGGTTCTCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAAAATACGCGGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-523 (SEQ ID NO:656) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATGATGCGGATATGCTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTTGTCTCCGGGTGAGGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTGGTCTGCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-524 (SEQ ID NO:657) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTACTGATCAGATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCTCCTAGTGGTGCGTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGTCTTGGTGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-525 (SEQ ID NO:658) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCATCTTTGAGCAGTATCAGATGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTTCGCCTGATGGTACGCATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTAGTTTGCGTAAGATGGAGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-526(SEQ ID NO: 659)GAGGTGCAGCTGTTGGAATCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCAGGATGAGCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGCGTCTGATGGTATGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAATAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAACCTGGGAAGAATTTTGACCACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-527 (SEQ ID NO:660) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGCGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACTACTGGGGGTGAGCGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACGTTGGAATCTGTATACGGAGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-528(SEQ ID NO: 661)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGGTCAGCCGATGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGCTCCTGATGGTATTCATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAATTTGGGTCAGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-529 (SEQ IDNO: 662) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCGGTATCAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCTCCTAGTGGTACGTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATGGAAGGCGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-530 (SEQ ID NO:663) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTCATTCGACTATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTTATTTTGCCGTCGGGTAGTCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTTCTGATGAGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-531 (SEQ IDNO: 664) GAGGTGCAGCTGTCGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATGGGAATATGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCTAGTGATGGTGTGACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAGGGGTCAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-532 (SEQ IDNO: 665) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCTTCCGGATTCACCTTTGATGATTATATGATGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTAGTCCGCATGGTGTTTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATGGTTGCATACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-533 (SEQ ID NO:666) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGAATTATACGATGGCGTGGGGCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATTTATTGCTGGTCCGGGTAATTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGGAGTACTGCGACGTATAATAATGGTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-534 (SEQ ID NO: 667)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGAGTATAGTATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTAGTGGGAGTGGTCGTGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGCTTAAGCTGGTTAGGGCTCCTAATCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-535 (SEQ ID NO: 668)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCTAAGACTGGTCATTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTTCGCATTCGTTGGGGCCTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-54(SEQ ID NO: 669)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGCGTATAGGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTTCGCCTTCTGGTTCGGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTTTGACGGATTCGCCGTCGGGGCATTATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-55 (SEQ ID NO: 670)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGCGGTATGAGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTACTGCTCAGGGTCTTGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAACTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATATCTTACTGATTTTAGTAGTGGGCATCAGGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-553 (SEQ ID NO: 671)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGATTATGGTATGTCGTGGGTCCGCCAGGTTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGTATTAGTCATAATGGTATGTTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATATTGGCCGTCTACTAGTTGGGAGACTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-554 (SEQ ID NO: 672)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTCGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGAATGAGCCTATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGAGATGCAGGGTAAGAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAGGGGTCAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-555 1 (SEQ IDNO: 673) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGGAGGAGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGTATTGATAATCTGGGTAGTCCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACGCCGCGGTATATTACTGTGCGAAAACGATTTCTCATCAGTATGATAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-556(SEQ ID NO: 674)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGAGGAGGAGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGATGAGGGGGGTCGGTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATGGACGCCGCATAAGCAGTTGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-557(SEQ ID NO: 675)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCAGCTTTGCTGATGAGTATATGGTTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTGATCCGTTGGGTACTGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGGGACGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-558 (SEQ ID NO:676) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTACGCATGATATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTTCTGATGATGGTATTAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATTTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGATATGTCTCTTATTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-559 (SEQID NO: 677) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGTACTCCGATGGTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTAGTGGTGATGGTAGGAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCTTATGCGCTTACTTCGTCTAAGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-56 (SEQ ID NO: 678)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATGATTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTCATGGGACTGGTGGTCAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTTTGGCTGATAGGAGTGGGGGGGTTGTTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-560 (SEQ ID NO: 679)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGCGGAGACGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGTATTAGTAATGATGGTAATACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGAGTCTCTGATTAGTCCTGGTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-561(SEQ ID NO: 680)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGGTGAGTATATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAATGAGACTGGTTATATGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAATAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTTCTACGAGGGGGGTGCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-562 (SEQID NO: 681) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGTCGTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGCCTATGGGTGTTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTAATCAGCATGCTCATGATCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-563(SEQ ID NO: 682)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTCGCCTATGGGTACGTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGCTTTGACTGAGCCTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-564 (SEQID NO: 683) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTGATTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTCTTGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCGGTCCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGCTGAGGAGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-565 (SEQ ID NO:684) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGCCTCTCCTGTGCAGCCTCCGGATTCGCCTTTCCTAGGTATGGTATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAATATTGATCAGTTTGGTATGAAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGAGTATGCTTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-566 (SEQ ID NO:685) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAAGTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGCCTATGGGTGTTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCGGGGTAATACTTCGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-567 (SEQID NO: 686) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAATTATGATATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTGGGGCGGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTTTTCCGCGTGATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-568 (SEQ IDNO: 687) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGAAGTATGAGATGAGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTGGTCTGGATGGTTCGCCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGGGGGATCCGAATGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-569 (SEQ IDNO: 688) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCGACTAGTGAGATGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGGTATTGGGCCTGATGGTTTGACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATGCGGATTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-57 (SEQ ID NO:689) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGAGTATGATATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTGATACTGATGGTGGGGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGTCTGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-570 (SEQ ID NO:690) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTACAGCCTCCGGATTCACCTTTGAGAATGCTTCTATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGAGGGGCAGGGTAATGCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTTCGTCTTGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-571 (SEQ IDNO: 691) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGCGTAATGAGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACGCCGACTGGTACGTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGGATCCTGGTAATAGGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572 (SEQID NO: 692) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-1 (SEQID NO: 693) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGTTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTTTGACTACCGGGGTCAGGGGACCCTGGTCACCGTCTCGAGC BMS2h-572-10 (SEQID NO: 694) GAGGTGCAGCTGTTGGAGTCTGGTGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-11 (SEQID NO: 695) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCAGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGATTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC BMS2h-572-12 (SEQID NO: 696) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-13 (SEQID NO: 697) GAGGTGCAGTTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGACCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCTAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTAGGGAAGGAGAGTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-14 (SEQID NO: 698) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGCATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCAGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-15 (SEQID NO: 699) GAGGTGCGGCTATTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCAACTTTAATTGGCAGCTGATGGGTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCAGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-16 (SEQID NO: 700) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACGGCCTGGGGGGTCACTGCGTCTCTCCTGTGTAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-17 (SEQID NO: 701) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGACTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTATAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGATGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTTTGACTACCGGGGTCACGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-18 (SEQID NO: 702) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCAAGGCTCCTGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-19 (SEQID NO: 703) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCCCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-2 (SEQID NO: 704) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTTGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAAGTTTGACTACCTGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-21 (SEQID NO: 705) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGAATCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATCTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-22 (SEQID NO: 706) GAGGTGCAGCTGTTTGAGTCTGGGGGAGGCTCGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGGACCCTGGTCACCGTCTCGAGC BMS2h-572-23 (SEQID NO: 707) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCACCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCGGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCATCATCTCCCGCGACAATTCCAAGAACACGCTATATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-24 (SEQID NO: 708) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCGGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCACGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTGAATTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-3 (SEQID NO: 709) GAGGTGCGGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCACCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATCTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-4 (SEQID NO: 710) GAGGTGCAGCTGTTGGTGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-5 (SEQID NO: 711) GAGGTGCAGCTGTTGGTGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTATCTGCAAATGAACGGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTTTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-6 (SEQID NO: 712) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-601(SEQ ID NO: 713)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTCATGGGGTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACCCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-602(SEQ ID NO: 714)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCACCTGATGGGGTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAGTTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-603(SEQ ID NO: 715)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGCACCTGATGGCCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-604(SEQ ID NO: 716)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGGCTGGGTCCGGCAGGCTCCAGGGAAGGGTCTCGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-605(SEQ ID NO: 717)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGCCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATATTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-606(SEQ ID NO: 718)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGCACTTGATGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-607(SEQ ID NO: 719)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTCATGGGGTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-608(SEQ ID NO: 720)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGATGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-609(SEQ ID NO: 721)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGCAGCTCATGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-610(SEQ ID NO: 722)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGCAAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-611(SEQ ID NO: 723)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCGGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTCGGGAAGGACAGCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-612(SEQ ID NO: 724)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTCGGGAAGGACAGCAACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-613(SEQ ID NO: 725)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGCACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGCAAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-614(SEQ ID NO: 726)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGGAAGGACGCCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-615(SEQ ID NO: 727)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGCCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGGAAGGACAAGAACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-616(SEQ ID NO: 728)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGGAAGGAGAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-617(SEQ ID NO: 729)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGGAGGGACAGCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-618(SEQ ID NO: 730)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCGGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTCGGGAAGTACAGCAACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-619(SEQ ID NO: 731)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGCAAGGACAGCAGGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-620(SEQ ID NO: 732)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGGAAGGACGACAGCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-621(SEQ ID NO: 733)GAGGTGCAGCTGTTGGAGTTTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCTTGCGTTTTTCCTGTGCAGCTTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGTTCCGGCAGGCTCCAGGGAAGGGTTTAGAGTGGGTTTCAGGTATTGAGGGTCCAGGTGATGTTACATATTACGCAGATTCCGTGAAGGGCCGGTTCACCATTTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCTTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGGAGGGACAGCAATTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-622(SEQ ID NO: 734)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGGAAGGACAGCACCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-623(SEQ ID NO: 735)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGGAAGGAGAGCAGCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-624(SEQ ID NO: 736)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTTCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGCAAGGACAGCGCGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-625(SEQ ID NO: 737)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTCGGCAACGACAGCTACTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-626(SEQ ID NO: 738)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCTGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACGGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGGAAGGACAGCAGCTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-627(SEQ ID NO: 739)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGATATATTACTGTGTGAAAGTGGGCAAGGACAGCGCGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-630(SEQ ID NO: 740)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGGCTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGGAAGGACGCCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-631(SEQ ID NO: 741)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGGCTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGCAAGGACAGCAGGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-632(SEQ ID NO: 742)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGTGGCAGCTGATGGGCTGGGTCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGCAAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-633(SEQ ID NO: 743)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGATGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGTGAAAGTGGGGAAGGACGCCAAGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-634(SEQ ID NO: 744)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGATGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGCAAGGACAGCAGGTCGGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-635(SEQ ID NO: 745)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACTGGGAGCTGATGGGCTGGGCCCGGCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCAGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGTGAAAGTGGGCAAGGACAGCAAGTCCGACTACCGGGGTCAGGGAACCCTGGTCACCGTATCGAGC BMS2h-572-7 (SEQID NO: 746) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGATGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGTCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTACAAATGAACAGCCTGCGTGCCGAGGACTCCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTTTGACTACCTGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-572-8 (SEQID NO: 747) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGTAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCGCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTCGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTTTCGAGC BMS2h-572-9 (SEQID NO: 748) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTGGCAGCTGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGAGGGTCCTGGTGATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGGAAGGAGAGTAATTCTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-573 (SEQ IDNO: 749) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGGGTGGGAGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATGAGTCTGGTCTTAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGTGCGCCGCAGTATCAGATTACATTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-574(SEQ ID NO: 750)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTAATTATGGGATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATATATTTCGCGGAGGGGTTTGTTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGTCGCATTATATGAATAATGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-575(SEQ ID NO: 751)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGTGGATTATACGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTAGTCCGATTGGTACTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATCCTTATGGGATGGAGGATGGTCTGACGTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-576 (SEQ ID NO: 752)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGCGTATGATATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACGATTACGTCGGAGGGTCTTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTAGTGATTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-577 (SEQ ID NO:753) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGGGTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCGTGGGGGTTGGTTCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGACGAGTCAGTCGTCTACGGGGAGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-578 (SEQ ID NO: 754)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTCGGTATGATATGCTTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTTCGCCTACGGGTGCTCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTTGGTTCGACTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-579 (SEQ ID NO:755) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTTCCGTATTATATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCGGGTACGGGTGGGCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGACGCAGAATGCGACGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-58 (SEQID NO: 756) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGTTTATACTATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACGATTGATGAGTCTGGTCGTGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGTGTTTGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-580 (SEQ ID NO:757) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGTTTTATAAGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACTCCTAAGGGTCATCATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTTTTAAGGGTAAGGGTTGGACTCGTCCGAGTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-581 (SEQ ID NO: 758)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATGAGTATAGTATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGAGGCGTGGTTGGCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGTGCTGCTGGATTCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-582(SEQ ID NO: 759)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGAGTATCCGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTGCGCGTGGTCCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTAGGCATTGGCTTCGTAATGGTCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-583 (SEQ ID NO: 760)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTATGCAGTCGATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTACTGATGATGGTACTAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGATCGGGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-584 (SEQ ID NO:761) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGCGGCTGATATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTGATTACTAATGATGGTATTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGTGATCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-586 (SEQ ID NO:762) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATAAGTATAGGATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATAGTTCTGGTGAGCTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGAGGTTCCGATGGGGAATCAGACTTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-587 (SEQ ID NO: 763)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGATTATACTATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACGTCTCAGGGTGCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTACGGGTACGGATTCGTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-588 (SEQID NO: 764) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTATGAGATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATGTATTGGGCCGGGGGGTAAGCCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGGATGGGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-589 (SEQ ID NO:765) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTCAGTATGATATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCTTCGAGGGGTTGGCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCCGGGGGGTCGTCGGCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-59 (SEQID NO: 766) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCTGGATTATGCGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTTCTCCGATGGGTATGGGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGAGTGCTATTTCGTTTACTTCTGATATTTCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-590 (SEQ ID NO: 767)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATCCGATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCTTGGTCTGGTTTTCAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACCTGGTGTTGCGAGGATGCCTACTGGGATTGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-591 (SEQ ID NO: 768)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGCTTATGAGATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATAGTGCTGGTACTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTCTATTACTGTGCGGAACCTTTTGGGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-592 (SEQ ID NO:769) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGAGTATCCGATGAAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGATCGGCAGGGTGATCGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACGGTGCGGAGGGGTCTTCCTCGTCCGAGTCGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-593 (SEQ ID NO: 770)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTCGCCTATGGGTACGTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCTGAGTGTGTATTCGGGTCTTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-594 (SEQ ID NO: 771)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGCGCAGCCTCCGGATTCACCTTTTCTCATTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGATATTGATTATATTGGTAAGACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCTCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTTCGGATGAGGTGGGTGTTAATACTTCCAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-595 (SEQ ID NO: 772)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGCGGTATGATATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTACTGGTGTGTTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTTTGAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-596 (SEQ ID NO:773) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGCTTATCCGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTGATTTCTCATACGGGTCATGCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCATTGGCCTTTTGACTACCGGGGTCAGGGAACCCTGATCACCGTCTCGAGC BMS2h-597 0 (SEQ ID NO:774) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCAGGGGGGTCCCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATGAGTGGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGATATTAGCCCGGGTGGTTGGACTACATACTACGCCGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTTATCGTCCGTTTGATGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-598 (SEQID NO: 775) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGAGTCACCTTTGATGCTATTGAGATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCGATTTCGCGTCATGGTGAGTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGATGCTTGGTCTCGGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-599 (SEQ IDNO: 776) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAGTACGGATATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTTGGATAATGGTAGTAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTATCTGCAAATGAATAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGGGCGAGGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-600 (SEQ ID NO:777) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCTTCCGGATTCACCTTTGGTAGGCAGAGTATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATGATGATGGTTTTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGATCCGTGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-601 (SEQ IDNO: 778) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTACAGCCTCCGGATTCACCTTTAGTGATACGCAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGATGATGGGGGTGTGAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGATCGTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-602 (SEQ ID NO:779) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGAGTACGACGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGTGATTTCGGATGATGGTGGTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGATGGTTATGGTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-603 (SEQ IDNO: 780) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGGAGTGGGGATATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACGAATGATGGTACGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAATACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCTGATTCTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-61 (SEQ ID NO:781) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGCTTATGCTATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATATATTAGTCCGAATGGTACGGCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAATATGTGGGGATGCGTTGGAATTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-62(SEQ ID NO: 782)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGAGTTATGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACGAGTCTTGGTACTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGTAGGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-65 (SEQ ID NO:783) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATGAGTATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACTAGTGAGGGTAGTGGGACATACTACGCAGACTCCGTAAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTAATGGTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-66 (SEQ ID NO:784) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTGATTATGAGATGTTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTACTAGTGAGGGTCATTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGGACTTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-67 (SEQ ID NO:785) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTGATTATGAGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGATTCTGATGGTAGTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGTGTGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-68 (SEQ ID NO:786) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGATTATGAGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCTTCTACTGGTCAGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGTAATAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-69 (SEQ ID NO:787) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCTTGATTATGGTATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTTCGCCTCTTGGTCTTAGTACATACTACGCAGACTCCGTGAAGAGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGAGGTGAGGGTGGGTAGGGGTGTTCATCCTCCGAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-7 (SEQ ID NO: 788)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATTTGTATGAGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTACTAGTGATGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGGGGTGATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-70 (SEQ ID NO:789) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAATTATGCTATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGCTCCGCTGGGTGTTCCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAAGAAGGTTGGGGCGTGGCTGCAGTCGCGGAGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-701 (SEQ ID NO: 790)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGATTATGAGATGCATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGGTGCTTCTGGTCATTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATCTTGATATGCTGCTGTTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-702(SEQ ID NO: 791)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGAGTATGAGATGATGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTGCTGGTAATGGTTCTCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATAATGCTTTCTCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-703 (SEQ ID NO:792) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTATAATTATGATATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGATTCGATGGGTCTTGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGGTCTAATGCGAGTGATTGGGTTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-704 (SEQ ID NO: 793)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGTCGTATCATATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGCGGATACGGGTGATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACTGCGGTATATTACTGTGCGAAATTGCGTGGGATGGCTCGGGTTTGGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-705 (SEQ ID NO: 794)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTTATTATGATATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGATCTCATCTATTTCGGATCGTGGTCTTCAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATTTACGGAGATTCCGTTGGATTGGTTGGAGGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-706 (SEQ ID NO: 795)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGAGTTATAAGATGTTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTACTAATTCTGGTACTGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGATGTATCCGGATTTGGAGATTGTGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-707 (SEQ ID NO: 796)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGACTTATCGTATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTGATCAGGAGGGTTCTGCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAATAGTGGGACGAGGCCGGGGCTTCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-708 (SEQ ID NO: 797)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAGTTATGATATGCTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTGATGCGAGTGGTTATTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAATTGTTGAAGCTGTCGTTGAATCCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-709 1 (SEQ ID NO: 798)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTCATAATACTGGTTTGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGACTCAGCATCGTTTTGTTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-71(SEQ ID NO: 799)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTTATCCTATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAGTCCTTTGGGTCCTGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTGTTGATGGGGGAGTATTTGAATTCTAGGACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-710 (SEQ ID NO: 800)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATACGTATAGTATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATGGATTGATGCTGATGGTTGGGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAAACTGGGCATACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-711 (SEQ ID NO:801) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGATGGGGAGATGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTGTGGATCCTGGTGATTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGTGATCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-712 (SEQ ID NO:802) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTGAGTATGAGATGAAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGTCGGGTGGTCATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACGCCGCGGTATATTACTGTGCGATACCTCTTTCTAGTTTTGACTACTGGGGTCGGGGAACCCTGGTCACCGTCTCGAGC BMS2h-713 (SEQ ID NO:803) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTAATTATGTGATGATTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTTATTAATGGTGCTGGTGATATGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGGGGTGCGCGTTCGTTTGGGGTTCCGCCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-714 (SEQ ID NO: 804)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGATGGGGAGATGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTGTGGATCCTGGTGATTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGTGATCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-715 (SEQ ID NO:805) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGTAGCCTCCGGATTCACCTTTACGCTGTATAATATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAGTTATTTCTAGTAAGGGTGATAGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAAACGAGTAGTGTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-716 (SEQ ID NO:806) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGCGTATTATATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGTTAATAATGGTTTGTTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGCTGTTCATCCTTCGTATAGGGCGGAGTTGTTCGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-717 (SEQ ID NO: 807)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTTCGTATGAGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTGAGCCTGATGGTAGTAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCCGGATAATTTTACTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-718 (SEQID NO: 808) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAATAAGTATATGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATAGTCTTGGTCATTATACATACTACGCAGACTCTGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGGAGTTTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719 (SEQ ID NO:809) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-1 (SEQ ID NO:810) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCATGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC BMS2h-719-10 (SEQ IDNO: 811) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCATGGTGCAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-11 (SEQ IDNO: 812) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCAAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCGAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTTACTGAGTTTGACTATTGGGGTCAGGGTACCCTGGTCACCGTCTCGAGC BMS2h-719-12 (SEQ IDNO: 813) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGACCCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-13 (SEQ IDNO: 814) GAGGTGCAGCTGTTGGAGTCGGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCGTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTACAGATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGACCCGTTTACTGAGCTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-14 (SEQ IDNO: 815) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACGGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTTCTGTGCAGATCCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-15 (SEQ IDNO: 816) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCGCCTTTAAGAGGTATGAGATGACATGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCATATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTTACTGAGATTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-16 (SEQ IDNO: 817) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCCCCTTTAAGAGGTATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACCGGGCTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-17 (SEQ IDNO: 818) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCTTCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTTACTGAGATTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC BMS2h-719-18 (SEQ IDNO: 819) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACATCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCTTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGACGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACGGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-19 (SEQ IDNO: 820) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTGGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCAGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-2 (SEQ ID NO:821) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-20 (SEQ IDNO: 822) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACTCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGATTGACTACCGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-202 (SEQ IDNO: 823) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAAGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-203 (SEQ IDNO: 824) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACAGCTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-21 (SEQ IDNO: 825) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCATTTACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-213 (SEQ IDNO: 826) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGACCCGTTCACGGAGATGGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-214 (SEQ IDNO: 827) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGACCCGTTCACGGAGTTCGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-215 (SEQ IDNO: 828) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTATCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAGCCGTTCACGGAGTTGGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-218 (SEQ IDNO: 829) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCCCCAGGGAAGGGTCTGGAGTGGGTCTCATCGATTTCGTCCGACGGTTCCTTCACGTACTACGCCGAGTCGGTCAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-225 (SEQ IDNO: 830) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACACGTATGAGATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-226 (SEQ IDNO: 831) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAACAAGTATGAGATGATGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-3 (SEQ ID NO:832) GAGGTGCAGCTGTCGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAATACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGATCCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-4 (SEQ ID NO:833) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGACTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGGCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCAGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCAAGC BMS2h-719-5 (SEQ ID NO:834) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGGAAATGAACAGCATGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACAACTGGGGTCAGGGAACCCTCGTCACCGTCTCGAGC BMS2h-719-6 (SEQ ID NO:835) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCAGAACCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCAGGTCACCGTCTCGAGC BMS2h-719-7 (SEQ ID NO:836) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCAACTTTAAGAGGTATGAGATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCAGACCCGTTTACTGAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-8 (SEQ ID NO:837) GAGGTGCAGCTGTTGGAGTCTGGGGGAGACTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCACGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACAGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-719-9 (SEQ ID NO:838) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATGAGATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCTATTTCGTCGGATGGTTCTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAACCGTTTACTGAGTTTGACTACTGGGGTCGGGGAACCCTGGTCACCGTCTCGAGC BMS2h-72 (SEQ ID NO:839) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGCGTATCCTATGTCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTCCCCTCTTGGTTTGTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTTAGTGCTGGGGCGGAGACTCATGTTTATCGGCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-720 (SEQ ID NO: 840)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGGGTGTTGGGTCATACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTTATGTCGTTGAGGACGTTTGAGAATCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-722 (SEQ ID NO: 841)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGAAGTATCCTATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTGATGCTAATGGTAATAGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGGGACTTGGCGTAGGCATTTTGCGATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-723 (SEQ ID NO: 842)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCTGTATGATATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCTGATCTGGGTACGCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAATGGTTTTAGGGTTACGAGTAATGATCGTAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-724 (SEQ ID NO: 843)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACTGGTGGGGATATGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTGAGGGTGGTGGTGTGACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACTTGATCTTCGGACGGGTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725 (SEQID NO: 844) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCGGATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-1 (SEQID NO: 845) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCATCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTTCTGTGCGGATCCGTCGGATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-10 (SEQID NO: 846) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCGGATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-11 (SEQID NO: 847) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAGCAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCGGATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-12 (SEQID NO: 848) GAGGTGCAGCTGTTGGAGTCTGGGGGTGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTCCCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACGATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGTCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCGGATCCTACTATGTTTGTCTACTGGGGTCAGGGAACCCTTGTCACCGTCTCGAGC BMS2h-725-13 (SEQID NO: 849) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGCTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCTCTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCGGATCCTACTATGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-14 (SEQID NO: 850) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCATCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGTGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCAGATCCTACTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-15 (SEQID NO: 851) GAGGTGCAGCTGTTGGAGTCTGGGGGGGGCATGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCATGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCGGATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-16 (SEQID NO: 852) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCACACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCGGATCCTACTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-17 (SEQID NO: 853) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTGCAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACACTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGCGCGGAACCGTCGGATCCTACTAAGTTAGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-18 (SEQID NO: 854) GAGGTGCAGCTGTCGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCACCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCGGATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-19 (SEQID NO: 855) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCAGATCCGTCGGATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-2 (SEQID NO: 856)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGCGCGGAACCGTCGGATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCCGGTCACCGTCTCGAGC BMS2h-725-3 (SEQ ID NO: 857)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCGCTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACATGCTGTATCTGCAAATGAAAAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGCGCGGATCCGTCGGATCCTACTAAGTTTGTCTACTGGGGTCAAGGAACCCAGGTCACCGTCTCGAGC BMS2h-725-4 (SEQID NO: 858) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTTCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGATCCGTCGGATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-5 (SEQID NO: 859) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGTTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGATTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCGGATCCTACTAAGTTCGACTACTGGGGTCGGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-6 (SEQID NO: 860) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCACGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCCGATCCTACTAAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-7 (SEQID NO: 861) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTACTTGGACATATTACGCAGACCCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACACTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACTGCGGTATATTATTGTGCGGATCCGTCGGATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-8 (SEQID NO: 862) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCGTCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCGGATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-725-9 (SEQID NO: 863) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCTTATACTATGGGTTGGGTCCGCCAGGCTCCAGGGATGGGTCTGGAGTGGGTCTCACTTATTGGGGATCGTGGTTCTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGTCGGATCCTACTAAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-726 (SEQ IDNO: 864) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCCGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATTATAAGATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTCGGAGATAGGTAATCTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATAGCTCTGACGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-727 (SEQ ID NO:865) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGAGTTATCGTATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATATATTGATCCGCCGGGTAGTCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAAGTTTGAATTTGTCGTTTCCTTATATTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-728 (SEQ ID NO: 866)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCGGTATGAGATGCTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTTCTCATTCGGGTCGGACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGCAATTGGATGGTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-729 (SEQ ID NO:867) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGAGGTATTATATGGATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGGATTAATCATAATGGTTCTGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAATGCCGCAGGGTACTTCTGATTGGTATTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-73 (SEQ ID NO: 868)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCTAAGTATGATATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTCTGGAGGATGGTCTGACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGGGGCGTTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-74 (SEQ ID NO:869) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGATTATCCTATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTCTGTCTCCGGGTACGGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGAGAAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-741 (SEQ ID NO:870) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGGTGGTGAGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAATGATTCCGATGGATGGTAGTGCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGGGTGAGGTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-742 (SEQ ID NO:871) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGGAGTATCATATGAAGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTAGTAGGGATGGTATGAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATACAGCTTGCTTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-743 (SEQ ID NO:872) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTGATTATGAGATGCTTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTCTTCCGTCGGGTGGGGCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCTGGTTCGGGGAATGGGCCTATTCTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-744 (SEQ ID NO: 873)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGCATGATATGTTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGGGGCTGAGGGTGTTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCGACGATGTCTAATGGTTCTCAGTCGCGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-745 (SEQ ID NO: 874)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-1 (SEQ ID NO: 875)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTTTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-10 (SEQ ID NO: 876)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTTCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAACCTGCGTGCCGAAGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-11 (SEQ ID NO: 877)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTTCAAGAACACGCTGTATCTGCAGATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-12 (SEQ ID NO: 878)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGATTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCATGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-13 (SEQ ID NO: 879)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCTTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAACACTGAGATGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-14 (SEQ ID NO: 880)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGGTTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCTGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-15 (SEQ ID NO: 881)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCAGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCTGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACGCGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCTGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-16 (SEQ ID NO: 882)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-17 (SEQ ID NO: 883)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCCTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACAGGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGCACCCTGGTCACC GTTTCGAGCBMS2h-745-18 (SEQ ID NO: 884)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATCACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTCGTCACC GTCTCGAGCBMS2h-745-19 (SEQ ID NO: 885)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGAGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-2 (SEQ ID NO: 886)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTAGTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCAGAGGACTCCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-3 (SEQ ID NO: 887)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTAGAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCTGGGAAGGGTCTCGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAGCAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-4 (SEQ ID NO: 888)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTAGTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATCACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-5 (SEQ ID NO: 889)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCTGACTCCGTGAAGGGCCGGTTCATCATCTCCCGCGACAATTCCAAGAACACGCTGAATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-6 (SEQ ID NO: 890)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCTCCAGGGAGGGGTCTAGAGTGGGTCTCAGGTGTTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAATTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-745-7 (SEQ ID NO: 891)GAGGTGCAGCTGTTGGAGTCAGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGAAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTATTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTATTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGTBMS2h-745-8 (SEQ ID NO: 892)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTGATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAGCTCGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCCAGCBMS2h-745-9 (SEQ ID NO: 893)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTCGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATAATACTGAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTACTGAGGATGGTAATCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACTCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGTCTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-746 (SEQ ID NO: 894)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGTCGGCTGAGATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGTATTTCGAGGCCTGGTCAGGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-747 (SEQ ID NO: 895)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGATGGTACTATGGGGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTTATTTTGCCGTCGGGTAGTCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATTCGCTGACTAATCGTCCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-748 (SEQID NO: 896) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAAGTATGATATGCGGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGATATTGATGCTGTTGGTACTCGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATACCGGGGGGGACGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-749 (SEQ ID NO:897) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGATGTATGGTATGATGTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGAGGGTGCGGGTCATGCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACTGCGGTATATTACTGTGCGATAGTGCTTGGTATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-75 (SEQ ID NO:898) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCGGGATTCACCTTTTTGCAGTATCCGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTGTTGGTTTGACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATTGTTTGAGGGGTCGAGGATTCAGCGTGATGTGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-750 (SEQ ID NO: 899)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAAGTATCAGATGGGTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTCGGGGGTCTGGTCTTGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGCATACTACGCTGCATACGGAGGTGATTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-751 (SEQ ID NO: 900)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCGGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTCAGTATACGATGTATTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTTCTCATAGTGGTTCTAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGATATCGGGGCTGCATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-752 (SEQ ID NO:901) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGATTATGCGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACGTATTGGTGTGGAGGGTGGGGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGTTGCGGCTTTATCGTCTGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-753(SEQ ID NO: 902)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTAAGTATGATATGACGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAAGATTAATTCTGATGGTGGTCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGTTGCATGGTAGGGGGTTTGTTATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-754 (SEQ ID NO: 903)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGCGGTATGATATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGGATTAATTCTATGGGTCTGGCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATTATTCGGTTGCGCCGCATGGGTATCCTTTGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-755 (SEQ ID NO: 904)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGATTATTCGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTACTGATAATGGTACGTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATATGTCGCTTGCTACTTATCTGCAGTTTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-756 (SEQ ID NO: 905)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTATGGAGTATGATATGCTTTGGGTCCGCCAGGCTCCAGGGAAGGCTCTAGAGTGGGTCTCACGTATTTCGTCGGATGGTCTTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGGTGAGTGCGCTTGCTCCTTTTGATATTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-757 (SEQ ID NO: 906)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGAGTATAATATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTAATTTTGCTGGTCGGACGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTGTCTCTTCCTTTGGATATTTTTTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-758 (SEQ ID NO: 907)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGTGGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-1 (SEQ ID NO:908) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACATGCTGTATCTGCGAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGTGGTTATTATGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-2 (SEQ ID NO:909) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGCCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGTGGTTATTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-3 (SEQ ID NO:910) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCCCCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGTAGTTATTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-4 (SEQ ID NO:911) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGGTTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTTTCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGTGGTTATTATGAGTACTGGGGTCATGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-5 (SEQ ID NO:912) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCTGCCTCCGGATTCGCCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGTGGTTATTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-758-6 (SEQ ID NO:913) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGATTATGGTATGAATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCACATATTTCTTCTAATGGTCGTTTTATATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACTAGTGGTTACTTTGAATACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-759 (SEQ ID NO:914) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGGAGTATGTTATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTAATGGTTTGGGTAATGTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATACCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGAGACCGCGGTATATTACTGTGCGATACAGCTGCCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-760 (SEQ ID NO:915) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTAATGATGGGATGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATTTATTAATGTTGATGGTAGGGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAATGGTCTCCTGGGCGGGTTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-761 (SEQID NO: 916) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTGGTTGGGATATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGCTCATGAGGGTGGTGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATATGTTCCTGGGTCTCCTCTGTTTGACTACTGGGGTCAGAGAACCCTGGTCACCGTCTCGAGC BMS2h-762 (SEQID NO: 917) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCAGGGTTGGATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGGGATTGGTTCGAATGGTCCTCGGACATCCTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATCGGGGGAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-763 (SEQ ID NO:918) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGCAGAGTGATATGTGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGTTATTGGTAATAATGGTGAGTTTACATACTACGCAGACTCGGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAATTGGCTGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-764 (SEQ IDNO: 919) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCTTAGTACTATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTGGTGGGGATGGTAGTCATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGGAAGGTACGCAGTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-765 (SEQ ID NO:920) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTCGGCGTATACGATGGAGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGGGGTTACGGGTTATGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTGGTCAGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-766 (SEQ ID NO:921) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGGGATTATGGGATGTCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATATATTGATCCTCTGGGTCGTCTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGATTTGTCGTCGCTGCAGTATGGGGTGTCGCCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-767 (SEQ ID NO: 922)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTTTTCATTATTCTATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGGTCCGGTTGGTCGGGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATGATTCAGTCGCCGTTGTTTAAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-768 (SEQ ID NO: 923)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGTGGTATGATATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACGTATTGATAGTGGGGGTAATCAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAATAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGTCGCTTTGGAAGTGGAGGTTGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-77(SEQ ID NO: 924)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGGTATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCGCTGGGTATTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACATGCTACGTCTCAGGAGTCTTTGCGGTCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-770 (SEQ ID NO: 925)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGTAAGTATGAGATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGTCCTCTGCCTGATGCGTTTTGGACTAGGGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-771 (SEQ ID NO: 926)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTACTTATTCTATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTGATCGGCATGGTTTGGCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAACTCCTGGTTCTTCTTGGCAGACTGTTTTTGGCTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-772 (SEQ ID NO: 927)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGTCGTATCCTATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATCATCATGGTCATTCGACATACTACGCAGACTCCGCGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTGCTTAGGGTTTCGATGATTTTTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-773 (SEQ ID NO: 928)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGTGCAGTATGGGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTAGTAGTAGTGGTACGTATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTACGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAACGTCTAGGATGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-774 (SEQ ID NO:929) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCGGCCTCCGGATTCACCTTTCGGGAGTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTTATTTCGCCTCCTGGTCGTACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGTTGTGATTCTGGGTTATACGAATAGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-775 (SEQ ID NO: 930)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCCTAATTACGGGATGTTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTAATTCTTCGGGTATGGAGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATTTTTTCGTCTGAATGATCATAATTCTGTGTTTGGTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-776 (SEQ ID NO: 931)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAAGGATTATAAGATGATGTGGATCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGTTGGGTCTGGTTCGATGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGCCTGGTTATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-777 (SEQ ID NO:932) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCATAATTATGCTATGGGGTGGGTCCGCCGGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTGATGAGCATGGTACTATTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGATAGTCTGGATCGGGTTTGGATTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-778(SEQ ID NO: 933)GAGGTGCAGCTGTTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCTGATTATCCGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAGTATTTATTCTGCGGGTTCTCCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAACTTTATCATCGGGAGCCGATTCTTTTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTC TCGAGCBMS2h-78 (SEQ ID NO: 934)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGAGGTATCAGATGGCGTGGGTCCGCCAGGCTCCGGGGAAGGGTCTAGAGTGGGTCTCAACGATTAGTTCTGATGGTGGGGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGGTCATCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-780 (SEQ ID NO:935) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTTCTTATACTATGATGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAGAGATTGATCGGACGGGTGAGCGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAACCTGGGTTTGCTTCTCTTCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-781 (SEQID NO: 936) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTACGGATTATACTATGTATTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAAAGATTTCTCCGAGTGGTCGTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGATCCGTTTGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-782 (SEQ ID NO:937) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATGATGCGGAGATGTTTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTGATGCTCGTGGTTTGACGACATACTACGCAGACCCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGGAAGCGACGTCGGCTATGTATCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-783 (SEQID NO: 938) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGTGATTATGATATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTCTTGGTCATTTTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAATCTGGGTTTCATGAGTATACTGAGGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCG AGCBMS2h-784 (SEQ ID NO: 939)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCGTGCGGGTATGGGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCACTGATTGGGCGTGGTGGTGATATTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAATTCGTAATCTGCATTGGGATGTGGGGAGGCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-80 (SEQ ID NO: 940)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGGTCGTTATCAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCTATTTCTTCTGATGGTGGGGGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCGTCTCGTCGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-81 (SEQ ID NO:941) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTTCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGTTGTATCCGATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCATCGATTTCTCCGGTTGGTTTTCTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAGGGCATGAGGGGTCGTATACTCCGCGGTCGGCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-82 (SEQ ID NO: 942)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGTGGCGTATCCTATGGCGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAACTATTGCGCCTCTGGGTGGTAATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACGGCCGGAGGGGCTGCAGATTGATTCTCAGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-83 (SEQ ID NO: 943)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGCGTTGTATCAGATGGCTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATCGATTGATTCTTCTGGTAGTGATACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACCTGAGCGTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-84 (SEQ ID NO:944) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTAGGCAGTACCAGATGGCTTGGGCCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGCGTCGGATGGTGTTTCTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTTGGTCGTGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-85 (SEQ ID NO:945) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCAGTATGATATGAGGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCATGGATTGATGAGGCGGGTCATGAGACATACTATGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAGGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGGGATGGATGGGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-92 (SEQ ID NO:946) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGTTGATTATCCGATGGGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCTACGGGGGGTTTTTCGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGCGCGGTATTATTATCTTAGTCAGATTAAGAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-93 (SEQ ID NO: 947)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATATTTATGGGATGACTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTGGAGTGGGTCTCAAGTATTTCGCCTCTTGGTCTTGTTACATACTACGCAGACCCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACTGAAGGAGCATGGGGATGTTCCTTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-94(SEQ ID NO: 948)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGCTTTATCCGATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTTCTCCTACGGGTTTGTTGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAATTTAAGAGGAGTGGGAAGACTGATGATACTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGCBMS2h-95 (SEQ ID NO: 949)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTCGGGAGTATGATATGCTGTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTGTGGGGGATGGTAATGGTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAACAGGATCGTCAGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-97 (SEQ ID NO:950) GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGAGTATGGTATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACGATTTCGCCTATTGGTGTTACTACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAAATGCTTATGATCGGAAGTCTAATTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-98(SEQ ID NO: 951)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGATCGGTATGTGATGGTGTGGGTCCGCCAGGCTCCAGGGAAGGATCTAGAGTGGGTCTCAGGTATTACTCCGAGTGGTAGGAGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGGACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGACACCGCGGTATATTACTGTGCGAAAGTGTTGGGGCGTCATTTTGATCCTCTTCTGCCTTCGTTTGACTACTGGGGTCAGGGAACCCTGGTCACCGTCTCGAGC BMS2h-99 (SEQ ID NO: 952)GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGCGTCTCTCCTGTGCAGCCTCCGGATTCACCTTTGAGGATTATGCTATGAGTTGGGTCCGCCAGGCTCCAGGGAAGGGTCTAGAGTGGGTCTCAACTATTACTCCGGGTGGTTTTTGGACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCCGCGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGCGTGCCGAGGATACCGCGGTATATTACTGTGCGAAAACGTCTAGTGGGGAGTTGCAGTTGGTTGAGGATTTTGACTACTGGGGTCAGGGAACCCTGGTCACC GTCTCGAGC

TABLE 3 Anti-human CD40L VK Domain Amino Acid Sequences BMS2h-100 (SEQID NO: 953) DIQMTQSPSS LSASVGDRVT ITCRASQNIK HSLRWYQQKP GKAPRLLIYHRSQLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VRHRPYTFGQ GTKVEIKRBMS2h-101 (SEQ ID NO: 954) DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKPGKAPKLLIYH RSKLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VALFPYTFGQGTKVEIKR BMS2h-102 (SEQ ID NO: 955) DIQMTQSPSS LSASVGDRVT ITCRASQHIGHHLRWYQQKP GKAPKLLIYH RSHLQSGVPS RFSGSGSGTD FTLTISSLQP EDSATYYCQQWDRPPYTFGQ GTKVEIKR BMS2h-103 (SEQ ID NO: 956) DIQMTQSPSS LSASVGDRVTITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ VRAVPYTFGQ GTKVEIKR BMS2h-104 (SEQ ID NO: 957) DIQMTQSPSSLSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ VRFSPYTFGQ GTKVEIKR BMS2h-105 (SEQ ID NO: 958)DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYARPVTFGQ GTKVEIKR BMS2h-106 (SEQ IDNO: 959) DIQMTQSPSS LSASVGDRVT ITCRASQSIN HRLYWYQQKP GKAPKLLIYHRSRLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YKVRPNTFGQ GTKVEIKRBMS2h-107 (SEQ ID NO: 960) DIQMTQSPSS LSASVGDRVT ITCRASQAIG HRLRWYQQKPGKAPKLLIYH RSKLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSSPHTFGQGTKVEIKR BMS2h-108 (SEQ ID NO: 961) DIQMTQSPSS LSASVGDRVT ITCRASQAIGHRLRWYQQKP GKAPKLLIYH RSKLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQRAVRPFTFGQ GTKVEIKR BMS2h-109 (SEQ ID NO: 962) DIQMTQSPSS LSASVGDRVTITCRASQAIG HRLRWYQQKP GKAPKLLIYH RSKLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ TYYRPLTFGQ GTKVEIKR BMS2h-110 (SEQ ID NO: 963) DIQMTQSPASLSASVGDRVT ITCRASQDID PMLRWYQQKP GKAPKLLIYA GSILQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ TSIRPYTFGQ GTKVEIKR BMS2h-116 (SEQ ID NO: 964)DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-1 (SEQ IDNO: 965) DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDILWYQQKP GKAPKLLIYQTSILQSGVPS RFSGSESGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKRBMS2h-116-10 (SEQ ID NO: 966) DIQITQSPSS LSASVGDRVT ITCRASQPIGPDLLWYQQKP GKAPKLLIYQ TSILRSGVPS RFSGSGSGTD FTLTISSLQP EDLATYYCQQYWAFPVTFGQ GTKVEIKR BMS2h-116-11 (SEQ ID NO: 967) DIQMTQSPSS LSASVGDRVTITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS RFSGRGSGTD FTLTISSLQPEDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-12 (SEQ ID NO: 968) DIQMTQSPSSLSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YWTFPVTFGQ GTKVEIKR BMS2h-116-13 (SEQ ID NO: 969)DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPSRFSGSGSETD FTLTISNLQP EDFATYYCQQ YWAFPVTFGQ GTKVVIKR BMS2h-116-1312 (SEQID NO: 970) DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQTSILRSGVPS RFSGSGSETD FTLTISNLQP EDLATYYCQQ YWAFPVTFGK GTKVVIKRBMS2h-116-1313 (SEQ ID NO: 971) DIQMTQSPSS LSASVGDRVT ITCRASQPIGPDLLWYQQKP GKAPKLLIYQ TSILRSGVPS RFSGSGSETD FTLTISNLQP EDFATYYCQQYWAFPVTFGR GTKVVIKR BMS2h-116-1314 (SEQ ID NO: 972) DIQMTQSPSSLSASVGDRVT ITCRASQPIG PDLLWYRQKP GKAPKLLIYQ TSILRSGVPS RFSGSGSETDFTLTISNLQP EDFATYYCQQ YWAFPVTFGQ GTKVVIKR BMS2h-116-1319 (SEQ ID NO:973) DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSIMRSGVPSRFSGSGSETD FTLTISNLQP EDFATYYCQQ YWTFPVTFGQ GTKVEIKR BMS2h-116-1320 (SEQID NO: 974) DIQMTQSPSS LSAYVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQTSILRSGVPS RFSGSGSETD FTLTISNLQP EDFAKYYCQQ YWAFPVTFGQ GTKVVIKRBMS2h-116-138 (SEQ ID NO: 975) DIQMTQSPSS LSASVGDRVT ITCRASQPIGPDLLWYQQKP GKAPKLLIYQ TSILRSGVPS RFSGSGSETD FTLTISNLQP VDFATYYCQQYWAFPVTFGQ GTKVVIKR BMS2h-116-14 (SEQ ID NO: 976) DIQMTQSPSS LSASVGDRVTITCRASQPIG PDLLWFQQKP GKAPKLLIYQ TSILQSGVPS RFSGSESGTD FTLTISSLQPEDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-15 (SEQ ID NO: 977) DIQMTQSPSSLSASVGDRVT ITCRASQPIG PDLLWYRQKP GKAPKLLIYQ TSILQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YWTFPVTFGQ GTKVEIKR BMS2h-116-16 (SEQ ID NO: 978)DIQMTQSPSS LSASVGDRVT ITCRASQPID PDLLWYQQKP GKAPKLLIYQ TSILQSGVPSRFSGSGSGTV FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-17 (SEQID NO: 979) DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQTSILRSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKRBMS2h-116-2 (SEQ ID NO: 980) DIQMTQSPSS LSASVGDRVT ITCRASQPIE PDLLWYQQKPGKAPKLLIYQ TSILQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWASPVTFGQGTKVEIKR BMS2h-116-3 (SEQ ID NO: 981) DIQMTQSPSS LSASVGDRVT ITCRASQPIGPDLLWYQQKP GKAPKLLIYQ TSILQSGVPS RFSGSESGTD FTLTISSLQP EDIATYYCQQYWAFPVTFGQ GTRVEIKR BMS2h-116-4 (SEQ ID NO: 982) DIQMTQSPSS LSASVGDRVTITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILQSGVPS RFSGSESGTD FTLTISSLQPEDFATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-5 (SEQ ID NO: 983) DIQMTQSPSSLSASVGDRVA ITCRASQPIG PDILWYQQKP GKAPKLLIYQ TSILRSGVPS RFSGSGSGTDFTLTISSLQP EDSATYYCQQ YWAFPVTFGQ GTKVEIKR BMS2h-116-6 (SEQ ID NO: 984)DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKP GKAPKLLIYQ TSILRSGVPSRFSGSGSVTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVGIKR BMS2h-116-7 (SEQ IDNO: 985) DIQMTQSPSS LSASVGDRVT ITCRASQPID PDLLWYQQKP GKAPKLLIYQTSILQSGVPS RFSGSGSRTD FTLTISSLQP EDFATYYCQQ YWAFPVTFGQ GTKVEIKRBMS2h-116-8 (SEQ ID NO: 986) DIQMTQSPSS LSASVGDRVT ITCRASQPIG PDLLWYQQKPGKAPKLLIYQ TSILQSGVPS RFSGSGSGTD FTLTISGLQP EDFATYYCQQ YWAFPVTFGQGTKVEIKR BMS2h-116-9 (SEQ ID NO: 987) DIQMTQSPSS LSASVGDRVT ITCRASMPIGPDLLWYQQKP GKAPKLLIYQ TSILRSGVPS RFSGSESGTD FTLTISSLQP EDFATYYCQQYWAFPVTFGQ GTKVEIKR BMS2h-141 (SEQ ID NO: 988) DIQMTQSPSS LSASVGDRVTITCRASQWIG DTLTWYQQKL GKAPKLLIYG GSELQSGVPP RFSGSGSGTD FTLTISSLQPEDFATYYCQQ CISSPCTFGQ GTKVEIKR BMS2h-142 (SEQ ID NO: 989) DIQMTQSPSSLSASVGDRVT ITCRASQFIG DSLSWYQQKP GKAPKLLIYF SSILQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YHTSPTTFGR GTKVKIKR BMS2h-143 (SEQ ID NO: 990)DIQMTQSPSS LSASVGDRVT ITCRASQTIE TNLEWYQQKP GKAPKLLIYD SSQLQSGVPSRFSGSGSGTD FTLTISSLQP EDLATYYCQQ YHGYPTTFGQ GTKVEIKR BMS2h-144 (SEQ IDNO: 991) DIQMTQSPSS LSASVGDRVT ITCRASQMID QDLEWYQQKP GKAPKLLIYNASWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHGYPITFGQ GTKVEIKRBMS2h-145 (SEQ ID NO: 992) DIQMTQSPSS LSASVGDRVT ITCRASQTIY TSLSWYQQKPGKAPKLLIHY GSVLQSGVPS RFSGSGSGTD FTLTISSLQP EDSATYYCQQ VHQAPTTFGQGTKVEIKR BMS2h-146 (SEQ ID NO: 993) DIRMTQSPSS LSASVGDRVT ITCRASQWIGDSLAWYQQKP GKAPKLLIYG ISELQSGVPS RFSGSGSGTD FTLTISSLQP EDSATYYCQLSSSMPHTFGQ GTKVEIKR BMS2h-147 (SEQ ID NO: 994) DIQMTQSPSS LSASVGDRVTITCRASQEIE TNLEWYQQKP GKAPKLLIYD SSHLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ YHQNPPTFGQ GTKVEIKR BMS2h-149 (SEQ ID NO: 995) DIQMTQSPSSLSASVGDRVT ITCRASQWIG RQLVWYQQKP GKAPKLLIYG ATELQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ QSKGPLTFGH GTKVEIKR BMS2h-150 (SEQ ID NO: 996)DIQMTQSPSS LSASVGDRVT ITCRASQGIG TDLNWYQQKP GKAPKLLIYM GSYLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ IYSFPITFGQ GTKVEIKR BMS2h-154 (SEQ IDNO: 997) DIQMTQSPSS LSASVGDRVT ITCRASQDIE EMLHWYQQKP GKAPKLLIYFGSLLQSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HHTRPYTFGQ GTKVEIKRBMS2h-155 (SEQ ID NO: 998) DIQMTQSPSS LSASVGDRVT ITCRASQDIG MDLEWYQQIPGKVPKLLIYD ASYLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHKLPATFGQGTKVEIKR BMS2h-156 (SEQ ID NO: 999) DIQMTQSPSS LSASVGDRVT ITCRASQDIMDNLEWYQQKP GKAPKLLIYA ASWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQYHKLPVTFGQ GTKVEIKR BMS2h-157 (SEQ ID NO: 1000) DIQMTQSPSS LSASVGDRVTITCRASQNIG EDLEWYQQKP GNAPKLLIYS ASHLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ YSSYPVTFGQ GTKVEIKR BMS2h-158 (SEQ ID NO: 1001) DIQMTQSPSSLSASVGDRVT ITCRASQPID EDLEWYQQKP GNAPKLLIYS ASYLQSGVPS RFSGSGSGTDFTLTISRLQP EDFATYYCQQ YHLLPATFGQ GTKVEIKR BMS2h-159 (SEQ ID NO: 1002)DIQMIQSPSS LSASVGDRVT ITCRASQDIN EDLEWYQQKP GKAPKLLIYN ASMLQSGVPSRFSGSGSGTD FTLTISSLQP KDFATYYCQQ YHTNPTTFGQ GTKVEIKR BMS2h-160 (SEQ IDNO: 1003) DIQMTQSPSS LSASVGDRVT ITCRASQDIE ADLEWYQQKP GKAPKLLIYHSSELQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHMSPVTFGQ GTKVEIKRBMS2h-161 (SEQ ID NO: 1004) DIQMTQSPSS LSASVGDRVT ITCRASQDID SDLEWYQQKPGKAPMLLIYS SSDLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSLPVTFGQGTKVEIKR BMS2h-162 (SEQ ID NO: 1005) DIQMTQSPSS LSASVGDRVT ITCRASQDISDDLEWYQQKP GKAPKLLIYN SSFLQSGVPS RFSGSGSGAD FTLTISSLQP EDFATYYCQQYHSLPVTFGQ GTKVEIKR BMS2h-163 (SEQ ID NO: 1006) DIQMTQSPSS LSASVGDRVTITCRASQDIE GNLEWYQQKP GKAPKLLIYD SSQLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ YHHLPTTFGQ GTKVEIKR BMS2h-164 (SEQ ID NO: 1007) DIQMTQSPSSLSASVGDRVT ITCRASQSID TDLEWYQQKP GKAPKLLIYD GSWLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YRWIPVTFGQ GTKVEIKR BMS2h-165 (SEQ ID NO: 1008)DIQMTQSPSS LSASVGDRVT ITCRASQSIS TDLEWYQQKL GKAPKLLIYD ASLLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSSLPVTFGQ GTKVEIKR BMS2h-166 (SEQ IDNO: 1009) DIQMTQSPSS LSASVGDRVT ITCRASQPIT TSLEWYQQKP GKAPKLLIYDASMLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YWVTPVTFGQ GTKVEIKRBMS2h-167 (SEQ ID NO: 1010) DIQMTQSPSS LSASVGDRVT ITCRASQNIH TNLEWYQQKPGKAPKLLIYD GSMLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSANPVTFGQGTKVGIKR BMS2h-168 (SEQ ID NO: 1011) DIQMTQSPSS LSASVGDRVT ITCRASQWIHTDLEWYQQKP GKAPKLLIYD GSMLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQYSVSPVTFGQ GTKVEIKR BMS2h-169 (SEQ ID NO: 1012) DIQMTQSPSS LSASVGDRVTITCRASQSID NNLEWYQQKP GEAPKLLIYD GSLLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ YHLHPVTFGQ GTKVEIKR BMS2h-170 (SEQ ID NO: 1013) DIQMTQSPSSLSASVGDRVT ITCRASQDID TNLEWYQQKP GEAPKLLIYD RSTLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YDSYPVTFGQ GTKVEIKR BMS2h-171 (SEQ ID NO: 1014)DIQMTQSPSS LSASVGDRVT ITCRASQSIE SNLEWYQQKP GKAPKLLIYN ASELQSGVPSRFSGSGSGTD FTLTISSLRP EDFATYYCQQ YDQWPTTFGQ GTKVEIKR BMS2h-172 (SEQ IDNO: 1015) DIQMTQSPSS LSASVGDRVT ITCRASQAIG NTLRWYQQKP GKAPKLLIYLSSRLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LKKPPYTFGQ GTKVEIKRBMS2h-173 (SEQ ID NO: 1016) DIQMTQSPSS LSASVGDRVT ITCRASQKIK NRLAWYQQKPGKAPKLLIYE VSHLQSGVPS RFSGSGSGTD FTLTIGSLQP EDFATYYCQQ RRQSPYTFGQGTKVEIKR BMS2h-174 (SEQ ID NO: 1017) DIQMTQSPSS LSASVGDRVT ITCRASEDIGEELFWYQQKP GKAPKLLIYS ASTLQSEVPS RFSGSGSGTD FTLTISSLQH EDFATYYCQQVYEWPYTFGQ GTKVEIKR BMS2h-175 (SEQ ID NO: 1018) DIQMTQSPSS LSASVGDRVTITCRASQPIS GGLRWYQQKP GKAPKLLIYS TSMLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ LYSAPYTFGQ GTKVEIKR BMS2h-305 (SEQ ID NO: 1019) DIQMTQSPSSLSASVGDRVT ITCRASQDID QDLEWYQQKP GKAPKLLIYN VSLLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YSMNPVTFGQ GTKVEIKR BMS2h-306 (SEQ ID NO: 1020)DIQMTQSPSS LSASVGDRVT ITCRASQDIG NQLKWYQQKP GKAPKLLIYQ ASGLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDLRPQTFGQ GTKVEIKR BMS2h-307 (SEQ IDNO: 1021) DIQMTQSPSF LSASVGDRVT ITCRASQKIS TSLEWYQQKP GKAPRLLIYDSSWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YEYNPITFGQ GTKVEIKR BMS2h-33(SEQ ID NO: 1022) DIQMTQSPSS LSASVGDRVT ITCRASQTIG ESLHWYQQKP GKAPRLLIYFASLLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HHMLPSTFGQ GTKVEIKR BMS2h-35(SEQ ID NO: 1023) DIQMTQSPSS LSASVGDRVT ITCRASQFIG DSLSWYQQKP GKAPKLLIYFSSILQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YMDIPITFGQ GTKVEIKR BMS2h-36(SEQ ID NO: 1024) DIQMTQSPSS LSASVGDRVT ITCRASQDID HNLEWYQQKP GKAPKLLIYDSSMLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSIPVTFGQ GTKVEIKR BMS2h-37(SEQ ID NO: 1025) DIQMTQSPSS LSASVGDRVT ITCRASQQIE TNLEWYQQKP GKAPKLLIYDGSWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSLPATFGQ GTKVEIKR BMS2h-38(SEQ ID NO: 1026) DIQMTQSPSS LSASVGDRVT ITCRASQDIG NNLEWYQQKP GKAPRLLIYHGSWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDFNPTTFGQ GTKVEIKR BMS2h-39(SEQ ID NO: 1027) DIQMTQSPSS LSASVGDCVT ITCRASQNID GLLWWYQQKP GKAPKLLIYAGSGLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ KAFEPFTFGQ GTKVEIKRBMS2h-405 (SEQ ID NO: 1028) DIQMTQTPSS LSASVGDRVT ITCRASQSIG HDLEWYQQKPGKAPKLLIYN VSWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSHNPPTFGQGTKVEIKR BMS2h-406 (SEQ ID NO: 1029) DIQMTQSPSS LSASVGDRVT ITCRASQHIENDLEWYQQKP GKAPKLLIYS ASHLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQYHLQPTTFGP GTKVEIKR BMS2h-431 (SEQ ID NO: 1030) DIQMTQSPSS LSASVGDRVTITCRASQVIE GSLNWYQQKP GKAPKLLIYH RSILQSGVPS RFSGRGSGTD FTLTISSLQPEDFATYYCQQ TYQLPLTFGQ GTKVEIKR BMS2h-432 (SEQ ID NO: 1031) DIQMTQSPSSLSASVGDRVT ITCRASRPIN GKLFWYQQKP GKAPKLLIAF ASALQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCVQ QAVYPITFGQ GTKVEIKR BMS2h-433 (SEQ ID NO: 1032)DIQMTQSPSS LSASVGDRVT ITCRASQAIE TNLEWYQQKP GKAPKLLIYD GSLLQSGVPSRFSGRGSGTD FTLTISSLQP EDFATYYCQQ YHYQPATFGQ GTKVEIKR BMS2h-434 (SEQ IDNO: 1033) DIQMTQSPSS LSASVGDRVT ITCRASQDIE HDLEWYQQKP GKAPKLLIYSASQLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YQQQPTTFGQ GTKVEIKRBMS2h-435 (SEQ ID NO: 1034) DIQMTQSPSS LSASVGDRVT ITCRASSQIE ESLWWYQQKPGKAPKLLIAD VSLLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCAQ GVVEPRTFGQGTKVEIKR BMS2h-436 (SEQ ID NO: 1035) DIQMTQSPSS LSASVGDRVT ITCRASQYIGLDLEWYQQKP GKAPKLLIYA ASWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQYFRQPITFGQ GTKVEIKR BMS2h-437 (SEQ ID NO: 1036) DIQMTQSPSS LSASVGDRVTITCRASTPIG TMLDWYQQKP GKAPKLLIGH SSWLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCGQ HVRPPATFGQ GTKVEIKR BMS2h-437-1 (SEQ ID NO: 1037) DIQLTQSPTSLSATVGDRVT ITCRASTPIG TMLDWYQQKP GKAPKLLIGH SSWLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCGQ HVRHPATFGQ GTKVEIKR BMS2h-437-2 (SEQ ID NO: 1038)DIQMTQSPSS LSASVGDRVT ITCRASTPIG TMLDWYQQKP GKAPKLLIGH SSWLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCGQ HVRPPATFGQ GTKVGIKR BMS2h-437-3 (SEQ IDNO: 1039) DIQMTQSPSS LSASVGDRVT ITCRVSTPIG TMLDWYQQKP GKAPKLLIGHSSWLQSGVPP RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HVRPPATFGQ GTKVEIKRBMS2h-437-4 (SEQ ID NO: 1040) DIQMTQSPSS LSASVGDRVT ITCRASTPIGTMLDWYQQKP GKAPKLLIGH SSWLQSGVPS RFSGCGSGTD FTLTISSLQP EDFATYYCGQHVRPPATFGQ GTKVEIKR BMS2h-437-5 (SEQ ID NO: 1041) DIQMTQSPSS LSASVGDRVTITCRASTPIG TMIDWYQQKP GKAPKLLIGH SSWLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCGQ HVRPPATFGK GTKVEIKR BMS2h-438 (SEQ ID NO: 1042) DIQMTQSPSSLSASVGDRVT ITCRASQYID TNLEWYQQKP GKAPRLLIYD GSQLQSGVPS RFSGSGSGTDFTLIISSLQP EDFATYYCQQ YQVVPVTFGQ GTKVEIKR BMS2h-439 (SEQ ID NO: 1043)DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPRLLIVD SSGLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCGQ DRWSPATFGQ GTKVEIKR BMS2h-440 (SEQ IDNO: 1044) DIQMTQSPSS LSASVGDRVT ITCRASSRIQ HMLSWYQQKP GKAPKLLIGGHSGLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCAQ SCAWPLTFGQ GTKVEIKRBMS2h-441 (SEQ ID NO: 1045) DIQMTQSPSS LSASVGDRVT ITCRASRGID GDLWWYQQKPGKAPKLLIAD SSLLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ GAVRPMTFGQGTKVEIKR BMS2h-442 (SEQ ID NO: 1046) DIQMTQSPSS LSASVGDRVT ITCRASRGIDTDLWWYQQKP GKAPKLLIAD SSLLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQGAVRPMTFGQ GTKVEIKR BMS2h-443 (SEQ ID NO: 1047) DIQMTQSPSS LSASVGDRVTITCRASYTIP VALDWYQQKP GKAPKLLIAD ASLLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCAQ GWPGPQTFGQ GTKVEIKR BMS2h-444 (SEQ ID NO: 1048) DIQMTQSPSSLSASVGDRVT ITCRASQSIA TDLEWYQQKP GKAPKLLIYD TSMLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YSYNPSTFGQ GTKVEIKR BMS2h-445 (SEQ ID NO: 1049)DIQMTQSPSS LSASVGDRVT ITCRASVPIT EGLSWYQQKP GKAPKLLIQA NSWLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCGQ WEHVPATFGQ GTKVEIKR BMS2h-446 (SEQ IDNO: 1050) DIQMTQSPSS LSASVGDRVT ITCRASSMIL YGLDWYQQKP GKAPKLLIGGTSALQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WETVPATFGQ GTKVEIKRBMS2h-447 (SEQ ID NO: 1051) DIQMTQSPSS LSASVGDRVT ITCRASQPIN GLLIWYQQKPGKAPKLLIYA MSSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LARIPFTFGQGTKVGIKR BMS2h-448 (SEQ ID NO: 1052) DIQMTQSPSS LSASVGDRVT ITCRASQLIRTYLAWYQQKP GKAPKLLIYQ SSQLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQYNSYPDTFGQ GTKVEIKR BMS2h-47 (SEQ ID NO: 1053) DIQMTQSPSS LSASVGDRVTITCRASQWIG DSLSWYQQKP GKAPKLLIYF GSYLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ YLHTPSTFGQ GTKVEIKR BMS2h-484 (SEQ ID NO: 1054) DIQMTQSPSSLSASVGDRVT ITCRASQDIE ADLEWYQQKP GKAPKLLIYH SSELQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YGFNPPTFGQ GTKVEIKR BMS2h-485 (SEQ ID NO: 1055)DIQMTQSPSS LSASVGDRVT ITCRASSPIE YGLDWYQQKP GKAPKLLIGG GSALQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCGQ WEVQPATFGQ GTKVEIKR BMS2h-486 (SEQ IDNO: 1056) DIQMTQSPSS LSASVGDRVT ITCRASQRID TDLEWYQQKP GKAPKLLIYDSSQLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YHSAPATFGQ GTKVEIKRBMS2h-487 (SEQ ID NO: 1057) DIQMTQSPSS LSASVGDRVT ITCRASGWIG MSLEWHQQKPGKAPKLLIRG ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCSQ SRWPPVTFGQGTKVEIKR BMS2h-488 (SEQ ID NO: 1058) DIQMTQSPSS LSASVGDRVT ITCRASRNISNALSWYQQKP GKAPKLLILG ASWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCTQVWDRPFTFGQ GTKVEIKR BMS2h-489 (SEQ ID NO: 1059) DIQMTQSPSS LSASVGDRVTITCRASQDIM SALSWYQQKP GKAPKLLIYS TSILQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ VYLLPVTFGQ GTKVEIKR BMS2h-490 (SEQ ID NO: 1060) DIQMTQSPSSLSASVGDRVT ITCRASQEIG IDLEWYQQKP GKAPKLLIYA ASYLQSGVPS RFSSSGSGTDFTLTISSLQP EDFATYYCQQ YASNPPTFGR GTKVEIKR BMS2h-491 (SEQ ID NO: 1061)DIQMTQSPSS LSASVGDRVT ITCRASQMIG DWLNWYQQKP GKAPKLLIYR SSELQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ LYFWPRTFGQ GTKVEIKR BMS2h-492 (SEQ IDNO: 1062) DIQMTQSPSS LSASVGDRVT ITCRASQAIE LNLEWYQQKP GKAPKLLIYDASMLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDVYPPTFGQ GTKVEIKRBMS2h-492-1 (SEQ ID NO: 1063) DIQMTQSPSS LSASVGDRVT ITCRASQAIEHNLEWYQQKP GKAPKLLIYD ASMLQSGVPS RFSGSGSGTD FTLTISSLQP EDLATYYCQQYDAYPPTYGQ GTKVEIKR BMS2h-492-2 (SEQ ID NO: 1064) DIQMTQSPSS LSASVGDRVTITCRASRAIE TNLEWYQQKP GKAPKLLFYD ASMLQSGVPS RFGGSGSGTD FTLTISSLQPEDFATYYCLQ YDVYPPTFGQ GTKVEIKR BMS2h-492-3 (SEQ ID NO: 1065) DIQMTQSPSSLSATVGDRVT ITCRASQAIE TNLEWYQQKP GKAPKLLIYD ASMLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR BMS2h-492-4 (SEQ ID NO: 1066)DIQMTQSPSS LSASVGDRVT ITCRASQAIE HNLEWYQQKP GKAPKLLIYD ASMLQSGVPSRFSGRGSGTD FTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKR BMS2h-492-5 (SEQ IDNO: 1067) DIQMNQSPSS LSASVGDRVS ITCRASQAIE HNLEWYQQKP GKAPKLLIYDASMLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YDAYPPTFGQ GTKVEIKRBMS2h-492-6 (SEQ ID NO: 1068) DIQMTQSPSS LSASVGDRVT ITCRASQAIESNLEWYQQKP GKAPKLLIYD ASMLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQYDVYPPTFGQ GTKVEIKR BMS2h-492-7 (SEQ ID NO: 1069) DIQMTQSPSS LSASVGDRVTITCRASQAIE HNLEWYQQKP GKAPKLLIYD ASMLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ YDAYPPTFGQ GTKVEIKR BMS2h-493 (SEQ ID NO: 1070) DIQMTQSPSSLSASVGDRVT ITCRASQGID EDLEWYQQKP GKAPRLLIYS SSWLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ YFQYPPTFGQ GTKVEIKR BMS2h-494 (SEQ ID NO: 1071)DIQMTQSPSS LSASVGDRVT ITCRASQSID EDLEWYQQKP GKAPRLLIYS SSWLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ YFQYPPTFGQ GTKVEIKR BMS2h-494-1 (SEQ IDNO: 1072) DIQMTQSPSS LSASVGDRVT ITCRASQSID EDLEWYQQKP GKAPRLLIYSSSWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YSQYPPTFGQ GTKVEIKRBMS2h-494-2 (SEQ ID NO: 1073) DIQMTQSPSS LSASVGDRVT ITCRASQSIEEDLEWYQQKP GKAPRLLIYS SSWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQYFQYPPTFGH GTKVEIKR BMS2h-494-3 (SEQ ID NO: 1074) DIQMTQSPSS LSASVGDRVTITCRASQSID EDLEWYQQKP GKAPRLLIYS SSWLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYFCQQ YFQYPPTFGQ GTKVEIKR BMS2h-494-4 (SEQ ID NO: 1075) EIQMTQSPSSLSASVGDRVT MTCRASQSID KDLEWYQQKP GKAPRLLIYS SSWLQRGVPS RFSGSGSGTDFTLTISSLRP EDFATYYCQQ YFQYPPTLGQ GTKVEIKR BMS2h-494-5 (SEQ ID NO: 1076)DIQMTQSPSS LSASVGDRVT ITCRASQSID EDLEWYQQKP GKAPRLLIYS SSWLQSGVPSRFSGSGSGTD FTLTISGLQP EDIATYYCKQ YSQYPPTFGQ GTKVEIKR BMS2h-494-6 (SEQ IDNO: 1077) DIQMTQSPPS LSASVGDRVT ITCRASQSID KDLEWYQQKP GKAPRLLIYSSSWLQRGVPS RFSGSGSGTD FTLTISSLQP EDFATYHCQQ YFQYPPTFGQ GTKVEIKRBMS2h-495 (SEQ ID NO: 1078) DIQMTQSPSS LSASVGDRVT ITCRASEYIN AELAWYQQKPGKAPKLLIYG SSGLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCLQ NAMWPITFGQGTKVEIKR BMS2h-496 (SEQ ID NO: 1079) DIQMTQSPSS LSASVGDRVT ITCRASLDINNGLIWYQQKP GKAPRLLILG ASGLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCSQVRSRPFTFGQ GTKVEIKR BMS2h-497 (SEQ ID NO: 1080) DIQMTQSPSS LSASVGDRVTITCRASQDIL SALAWYQQKP GKAPKLLIYG SSVLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ NYSLPITFGQ GTKVEIKR BMS2h-498 (SEQ ID NO: 1081) DIQMTQSPSSLSASVGDRVT ITCRASSPIE SYLRWYQQKP GKAPKLLIRY VSVLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCGQ WFRAPVTFGQ GTKVEIKR BMS2h-499 (SEQ ID NO: 1082)DIQMTQSPSS LSASVGDRVT ITCRVSESIN AELHWYQQKP GKAPKLLISG FSGLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCVQ FAMWPFTFGQ GTKVEIKR BMS2h-500 (SEQ IDNO: 1083) DIQMTQSPSS LSASVGDRVT ITCRASMMIR FGLDWYQQKP GKAPKLLIGGGSSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ HERWPATFGQ GTKVEIKRBMS2h-501 (SEQ ID NO: 1084) DIQMTQSPSS LSASVGDRVT ITCRASQSIG TLLRWYQQKPGKAPKLLIYL TSVLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ MVYRPYTFGQGTKVEIKR BMS2h-502 (SEQ ID NO: 1085) DIQMTQSPSS LSASVGDRVT ITCRASQTIETNLEWYQQKP GKAPKLLIYD SSQLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQYDKVPATFGQ GTKVEIKR BMS2h-503 (SEQ ID NO: 1086) DIQMTQSPSS LSASVGDRVTITCRASHHIQ RYLSWYQQKP GKAPKLLILW GSQLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCGQ WWAPPPTFGQ GTKVEIKR BMS2h-503-1 (SEQ ID NO: 1087) DIQMTQSPSSLSASVGDRVT ITCRASHHIQ RYLSWYQQKP GKAPKLLILW GSQLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCGQ WWAPPQTFGQ GTKVEIKR BMS2h-503-2 (SEQ ID NO: 1088)DIQMTQSPSS LSASVGDRVT ITCRASHDIQ RYLSWYQQKP GKAPKLLILW GSQLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCGQ WWAPPQTFGQ GTKVEIKR BMS2h-504 (SEQ IDNO: 1089) DIQMTQSPSS LSASVGDRVT ITCRASQYID TNLEWYQQKP GKAPKLLIYDGSLLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ GAVVPVTFGQ GTKVEIKRBMS2h-508 (SEQ ID NO: 1090) DIQMTQSPSS LSASVGDRVT ITCRASQDIA FDLEWYQQKPGKAPKLLIYS ASMLQSGVPS RFSGSGSGSD FTLTISSLQP EDFATYYCQQ YNLQPPTFGQGTKVEIKR BMS2h-509 (SEQ ID NO: 1091) DIQMTQSPSS LSASVGDRVT ITCRASQNIATLLRWYQQKP GKAPKLLIYA GSMLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQMWQRPYTFGQ GTKVEIKR BMS2h-51 (SEQ ID NO: 1092) DIQMTQSPSS LSASVGDRVTITCRASQPIV DELDWYQQKP GKAPKLLIYA ASILQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCHQ WSTYPTTFGQ GTKVEIKR BMS2h-510 (SEQ ID NO: 1093) DIQMTQSPSSLSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIDG VSGLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCGQ DWDWPRTFGQ GTKVEIKR BMS2h-511 (SEQ ID NO: 1094)DIQMTQSPSS LSASVGDRVT ITCRASRNIR DWLRWYQQKP GKAPKLLIDW GSVLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCAQ TWDDPLTFGQ GTKVEIKR BMS2h-511-1 (SEQ IDNO: 1095) DIQMTQSPSS LSAFVGDRVT ITCRASRNIR DWLRWYQQKP GKAPKLLIDWGSELQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCAQ TWYDPLTFGH GTKVEIKRBMS2h-512 (SEQ ID NO: 1096) DIQMTQSPSS LSASVGDRVT ITCRASIDIH GGLTWYQQKPGKAPKLLIVG VSGLQSGVPS RFSGSGSGTD FTLTISNLQP EDFATYYCAQ VWRRPFTFGQGTKVEIKR BMS2h-513 (SEQ ID NO: 1097) DIQMTQSPSS LSASVGDRVT ITCRASQDIGSSLSWYQQKP GKAPKLLIYA SSLLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQTYALPVTFGQ GTKVEIKR BMS2h-514 (SEQ ID NO: 1098) DIQMTQSPSS LSASVGDRVTITCRASQQIE TNLEWYQQKP GKAPKLLIYD GSWLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ YKYLPVTFGQ GTKVEIKR BMS2h-52 (SEQ ID NO: 1099) DIQMTQSPSSLSASVGDRVT ITCRASQDIG SALRWYQQKP GKAPKLLIYL GSDLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ TQYFPTTFGQ GTKVEIKR BMS2h-53 (SEQ ID NO: 1100)DIQMTQSPSS LSASVGDRVT ITCRASQAIY GGLRWYQQKP GKAPKLLIYG ESMLQSGVPSRFSGSGSGTD FTLTISSLHP EDFATYYCQQ VYHKPFTFGQ GTKVEIKR BMS2h-536 (SEQ IDNO: 1101) DIQMTQSPSS LSASVGDRVT ITCRASQRIG VWLDWYQQKP GKAPKLLIYDGSFLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TFSSPSTFGQ GTKVEIKRBMS2h-537 (SEQ ID NO: 1102) DIQMTQSPSS LSASVGDRVP ITCRASQWIG DELYWYQQKPGKAPKLLIYS SSTLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SFQFPYTFGQGTKVEIKR BMS2h-538 (SEQ ID NO: 1103) DIQMTQSPSS LSASVGDRVT ITCRASSNITGPLEWYQQKP GKAPKLLIPG WSTLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQVWGEPVTFGQ GTKVEIKR BMS2h-539 (SEQ ID NO: 1104) DIQMTQSPSS LSASIGDRVTITCRASQRIA YGLHWYQQKP GKAPRLLIGG RSGLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCVQ PGMPPDTFGQ GTKVEIKR BMS2h-540 (SEQ ID NO: 1105) DIQMTQSPSSLSASVGDRVT ITCRASKQIV GGLSWYQQKP GKAPKLLIGR HSGLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCVQ GVWAPGTFGQ GTKVEIKR BMS2h-541 (SEQ ID NO: 1106)DIQMTQSPSS LSASVGDRVT ITCRASPAIA AKLDWYQQKP GKAPKLLIGA DSGLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWAGPPTFGQ GTKVEIKR BMS2h-542 (SEQ IDNO: 1107) DIQMTQSPSS LSASVGDRVT ITCRASRTIA DGLDWYQQKP GKAPKLLIGAYSGLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWEGPPTFGQ GTKVEIKRBMS2h-543 (SEQ ID NO: 1108) DIQMTQSPSS LSASVGDRVT ITCRASQRIY GFLDWYQQKPGKAPKLLIYG VSSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TLAWPFTFGQGTKVEIKR BMS2h-544 (SEQ ID NO: 1109) DIQMTQSPSS LSASVGDRVT ITCRASQDIRDWLMWYQQKP GKAPKLLIYW GSFLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQLYDTPYTFGQ GTKVEIKR BMS2h-545 (SEQ ID NO: 1110) DIQMTQSPSS LSASVGDRVTITCRASQNIN TGLDWYQQKP GKAPKLLIYD SSALQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ TSYYPYTFGQ GTKVEIKR BMS2h-546 (SEQ ID NO: 1111) DIQMTQSPSSLSASVGDRVT ITCRASQKIF GWLDWYQQKP GKAPKLLIYG TSKLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCQQ VYSLPYTFGQ GTKVEIKR BMS2h-547 (SEQ ID NO: 1112)DIQMTQSPSS LSASVGDRVT ITCRASSNIG ADLDWYQQKP GKAPKLLIGG ASGLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWNGPPTFGQ GTKVEIKR BMS2h-548 (SEQ IDNO: 1113) DIQMTQSPSS LSASVGDRVT ITCRASSPIY DGLDWYQQKP GKAPKLLISGASWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWLGPPTFGQ GTKVEIKQBMS2h-549 (SEQ ID NO: 1114) DIQMTQSPSS LSASVGDRVT ITCRASSRIY NGLHWYQQKPGKAPKLLIGG RSGLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCAQ VGEAPSTFGQGTKVEIKR BMS2h-550 (SEQ ID NO: 1115) DIQMTQSPSS LSASVGDRVT ITCRASRFINEELDWYQQKP GKAPKLLISW SSWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCVQPGGGPGTFGQ GTKVEIKR BMS2h-551 (SEQ ID NO: 1116) DIQMTQSPSS LSASVGDRVTITCRASRDIL DELDWYQQKP GKAPRLLIGG GSGLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCGQ LWHGPPTFGQ GTKVEIKR BMS2h-552 (SEQ ID NO: 1117) DIQMTQSPSSLSASVGDRVT ITCRASSPIY TGLHWYQQKP GKAPKLLIGG RSGLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCMQ VGTAPATFGQ GTKVEIKR BMS2h-585 (SEQ ID NO: 1118)DIRMTQSPSS LSASVGDRVT ITCRASQNIS RRLLWYQQKP GKAPKLLIYS SSRLQSGVPSRFGGSGSGTD FTLTISSLQP EDFATYYCQQ TYSYPHTFGQ GTKVEIKR BMS2h-604 (SEQ IDNO: 1119) DIQMTQSPSS LSASVGDRVT ITCRASSPIP QDLYWYQQKP GKAPKLLIVGISQLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWSAPATFGQ GTKVEIKRBMS2h-605 (SEQ ID NO: 1120) DIQMTQSPSS LSASVGDRVT ITCRASKSID GMLDWYQQKPGKAPKLLIPG FSGLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ SVEAPWTFGQGTKVEIKR BMS2h-606 (SEQ ID NO: 1121) DIQMTQSPSS LSASVGDRVT ITCRASRYIAHPLDWYQQKP GKAPKLLIPG SSVLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQSVVVPWTFGQ GTKVEIKR BMS2h-607 (SEQ ID NO: 1122) DIQMTQSPSS LSASVGDRVTITCRASRTIE GGLDWYQQKP GKAPKLLIMG GSGLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCGQ LWVGPPTFGQ GTKVEIKR BMS2h-608 (SEQ ID NO: 1123) DIQMTQSPSSLSASVGDRVT ITCRASKFIR DELYWYQQKP GKAPRLLIGG SSLLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCGQ LWRAPATFGQ GTKVEIKR BMS2h-609 (SEQ ID NO: 1124)DIQMTQSPSS LSASVGDRVT ITCRASKPIY GGLEWYQQKP GKAPRLLIGG GSVLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCGQ VWGGPVTFGQ GTKVEIKR BMS2h-610 (SEQ IDNO: 1125) DIRMTQSPSS LSASVGDRVT ITCRASRPIS GCLDWYQQKP GKAPKLLIDGASGLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ WWEYPPTFGQ GTKVEIKRBMS2h-611 (SEQ ID NO: 1126) DIQMTQSPSS LSASVGDRVT ITCRASKPIV RDLEWYQQKPGKAPKLLIHG VSTLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LEAAPATFGQGTKVEIKR BMS2h-612 (SEQ ID NO: 1127) DIQMTQSPSS LSASVGDRVT ITCRASRDIGDWLYWYQQKP GKAPRLLIVW ASVLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCAQWGTPPTTFGQ GTKVEIKR BMS2h-613 (SEQ ID NO: 1128) DIQMTQSPSS LSASVGDRVTITCRASNRIE YGLDWYQQKP GKAPKLLISG SSRLQSGVPS RFSSSGSGTD FTLTISSLQPEDFATYYCGQ LEAAPATFGQ GTKVEIKR BMS2h-614 (SEQ ID NO: 1129) DIQMTQSPSSLSASVGDRVT ITCRASRNIG HFLDWYQQKP GKAPKLLILG GSSLQSGVPS RFSGSGSGTDFTLTISSLQP EDFATYYCGQ LVEPPATFGQ GTKVEIKR BMS2h-615 (SEQ ID NO: 1130)DIQMTQSPSS LSASVGDRVT ITCRASSSIY SDLYWYQQKP GKAPKLLIDG WSGLQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCGQ LHRAPATFGQ GTKVEIKR BMS2h-616 (SEQ IDNO: 1131) DIQMTQSPSS LSASVGDRVT ITCRASRFIT DRLDWYQQKP GKAPKLLIGGVSGLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ SSELPWTFGQ GTKVEIKRBMS2h-617 (SEQ ID NO: 1132) DIQMTQSPSS LSASVGDRVT ITCRASRKIG SELYWYQQKPGKAPKLLIGG RSRLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQ LWEPPATFGQGTKVEIKR BMS2h-618 (SEQ ID NO: 1133) DIQMTQSPSS LSASVGDRVT ITCRASRNIGNGLDWYQQKP GKAPKLLIGE GSRLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCGQLWHTPPTFGQ GTKVEIKR BMS2h-619 (SEQ ID NO: 1134) DIQMTQSPSS LSASVGDRVTITCRASRNIY GWLSWYQQKP GKAPRLLIGG WSGLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCAQ DYTLPGTFGQ GTKVEIKR BMS2h-730 (SEQ ID NO: 1135) DIQMTQSPSSLSASVGDRVT ITCRASQDIK DWLHWYQQKP GKAPKLLIYF ASGLQSGVPS RFSGSGSGTDFTLTISSLQP EDSATYYCQQ HYSTPYTSGQ GTKVEIKR BMS2h-731 (SEQ ID NO: 1136)DIQMTQSPPS LSASVGDRVT ITCRASQLIS SHLDWYQQKP GKAPKLLVYD ASELQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ HRSLPFTFGQ GTKVEIKR BMS2h-732 (SEQ IDNO: 1137) DIQMTQSPSS LSASVGDRVT ITCRASQWIG GALAWYQQKP GKAPRLLIYQISVLQSGIPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YIRSPFTFGQ GTKVEIKRBMS2h-733 (SEQ ID NO: 1138) DIQMTQSPSS LSASVGDRVT ITCRASQSIG AALNWYQQKPGKAPKLLIYG LSSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ LFRLPLTFGQGTKVEIKR BMS2h-734 (SEQ ID NO: 1139) DIQMTQSPSS LSASVGDRVT ITCRASQPIGGRLVWYQQKP GKAPKLLIYG SSILQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQYAEAPITFGQ GTKVEIKR BMS2h-735 (SEQ ID NO: 1140) DIQMTQSPSS LSASVGDRVTITCRASQNIG SSLIWYQQKP GKAPTLLIYY SSKLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ SLSSPYTVGQ GTKVEIKR BMS2h-736 (SEQ ID NO: 1141) DIQMTQSPSSLSASVGDRVT ITCRASQWIG SELAWYQQKP GKAPKLLIYW TSNLQSGVPS RFSGSGSGTDFTLTISNLQP EDFATYYCQQ ILETPLTFGQ GTKVEIKR BMS2h-737 (SEQ ID NO: 1142)DIQMTQSPSS LSASVGDRVT ITCRASQKIW DALYWYQQKP GKAPKLLIYR GSILQSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ FYRWPHTFGQ GTKVEIKR BMS2h-738 (SEQ IDNO: 1143) DIQMTQSPSS LSASVGDRVT ITCRASQHIE DSLRWYQQKP GKAPKLLIYYGSVLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ MYKFPITFGQ GTKVEIKRBMS2h-739 (SEQ ID NO: 1144) DIQTTQSPSS LSASVGDRVT ITCRASQRIN SSLLWYQQKPGKAPKLLIYD TSTLQSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQQ IWGSPPTFGQGTKVEIKR BMS2h-740 (SEQ ID NO: 1145) DIQMTQSPSS LSASVGDRVT ITCRASQSIPVGLNWYQQKP GKAPRLLIYS GSTLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQDWYYPNTFGQ GTKVEIKR BMS2h-785 (SEQ ID NO: 1146) DIQMTQSPSS LSASVGDRVTITCRASQPIY GWLNWYQQKP GKAPKLLIYL TSGLQSGVPS RFSGSGSGTD FTLTISSLQPEDFATYYCQQ IHSSPFTFGQ GTKVEIKR BMS2h-8 (SEQ ID NO: 1147) DIQMTQSPSSLSASVGDRVT ITCRASQFID TSLEWYQQKP GKAPKLLIYD GSHLQSGVPS RFSGSGSGTDFTLTISSLQP EDLATYYCQQ YWVLPLTFGQ GTKVEIKR BMS2h-86 (SEQ ID NO: 1148)DIQMTQSPSS LSASVGDRVT ITCRASQDIG DALFWYQQKP GKAPKLLIYY SSMLQSGVPSRFSGGGSGTD FTLTISSLQP EDFATYYCQQ RHSTPATFGQ GTKVEIKR BMS2h-87 (SEQ IDNO: 1149) DIQMTQSPSS LSASVGDRVT ITCRASQDID ESLMWYQQKP GKAPRLLIYGVSYLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ RWKAPFTFGQ GTKVEIKR BMS2h-88(SEQ ID NO: 1150) DIQMTQSPSS LSASVGDRVT ITCRASQEIV EDLYWYQQKP GKAAKLLIYGASWLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TRRRPYTFGQ GTKVEIKR BMS2h-89(SEQ ID NO: 1151) DIQMTQSPAS LSASVGDRVT ITCRASQDID PMLRWYQQKP GKAPKLLIYAGSILQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TLVTPYTFGQ GTKVEIKR BMS2h-90(SEQ ID NO: 1152) DIQMTQSPSS LSASVGDRVT ITCRASQSIS DALFWYQQKP GKAPRLLIYYGSVLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ RFQEPVTFGQ GTKVEIKR BMS2h-91(SEQ ID NO: 1153) DIQMTQSPSS LSASVGDRVT ITCRASQQIS DELNWYQQKP GKAPKLLIYAVSILQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ WLSFPSTFGQ GTKVEIKR

TABLE 4 Human Anti-CD40L VK Domain Encoding Nucleotide SequencesBMS2h-100 (SEQ ID NO: 1154)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGAGCAAGTCAGAATATTAAGCATTCGTTACGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATCATCGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGTTAGGCATCGTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-101 (SEQ ID NO: 1155)GACATCCAGATGACCCAGTCTCCATCCTCTCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGTTGCTTTGTTTCCCTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-102 (SEQ ID NO: 1156)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCATATTGGTCATCATTTAAGGTGGTACCAGCAGAAACCAGGGAAAGCCCCCAAGCTCCTGATCTATCATAGGTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTGCTACGTACTACTGTCAACAGTGGGATAGGCCGCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-103 (SEQ ID NO: 1157)GACATCCAGATGACCCAGTCCCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGTGCGGGCTGTGCCTTATACGTTTGGCCAAGGGACCAAGGTGGAAATTAAACGG BMS2h-104 (SEQ ID NO: 1158)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGTTCGTTTTTCTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-105 (SEQ ID NO: 1159)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTCTTATGCTAGGCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-106 (SEQ ID NO: 1160)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAAAGTATTAATCATAGGTTATATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAGGATTTTGCTACGTACTACTGTCAACAGTATAAGGTTAGGCCTAATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-107 (SEQ ID NO: 1161)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATTTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACTTATTCGTCTCCTCATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-108 (SEQ ID NO: 1162)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTACAACCTGAAGATTTTGCTACGTACTACTGTCAACAGAGGGCGGTGAGGCCTTTTACGTTCGGCCAAGGGACCAAAGTGGAAATCAAACGG BMS2h-109 (SEQ ID NO: 1163)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGGGCATCGGTTACGTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATCGGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACTTATTATCGTCCTCTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-110 (SEQ ID NO: 1164)GACATCCAGATGACCCAGTCTCCAGCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATCCTATGTTAAGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCGGGTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACTAGTATTAGGCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116 (SEQ ID NO: 1165)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-1 (SEQ ID NO: 1166)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATATACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATCTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGAATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-10 (SEQ ID NO: 1167)GACATCCAGATAACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATATTGCGAAGTGGAGTCCCATCACGTTTCAGTGGCAGTGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATCTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-11 (SEQ ID NO: 1168)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTTCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGAGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-12 (SEQ ID NO: 1169)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAACCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCTTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGCGGATCTGGGACTGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGACTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-13 (SEQ ID NO: 1170)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGTAATCAAACGG BMS2h-116-1312 (SEQ ID NO: 1171)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATCTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCAAAGGGACCAAGGTGGTAATCAAACGG BMS2h-116-1313 (SEQ ID NO: 1172)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCGAGGGACCAAGGTGGTAATCAAACGG BMS2h-116-1314 (SEQ ID NO: 1173)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGAGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCGGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGTGTCCCATCACGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGTAATCAAACGG BMS2h-116-1319 (SEQ ID NO: 1174)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTATGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGACTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-1320 (SEQ ID NO: 1175)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATATGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACCCTCACCATCAGCAATCTGCAACCTGAAGATTTTGCTAAGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGTGATCAAACGG BMS2h-116-138 (SEQ ID NO: 1176)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGAGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGTAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTAGTAATCAAACGG BMS2h-116-14 (SEQ ID NO: 1177)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTTCCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGAATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-15 (SEQ ID NO: 1178)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATCGGTCCTGATTTACTGTGGTACCGGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGACTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-16 (SEQ ID NO: 1179)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGATCCTGACTTACTGTGGTACCAGCAGAAACCAGGTAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGTTTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCATTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-17 (SEQ ID NO: 1180)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCAGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAGCCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-2 (SEQ ID NO: 1181)GACATCCAGATGACCCAGTCTCCATCATCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGAACCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTCTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-3 (SEQ ID NO: 1182)GACATCCAGATGACCCAGTCACCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCTAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGCGGCAGTGAATCCGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATATTGCAACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAGGGTGGAAATCAAACGG BMS2h-116-4 (SEQ ID NO: 1183)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCTTCACGTTTCAGTGGCAGTGAATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-5 (SEQ ID NO: 1184)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCGCCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATATACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGTCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-6 (SEQ ID NO: 1185)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCGTCACGTTTCAGTGGCAGTGGATCTGTGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGGAATCAAGCGG BMS2h-116-7 (SEQ ID NO: 1186)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGATCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTAGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-8 (SEQ ID NO: 1187)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAGCAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-116-9 (SEQ ID NO: 1188)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTATGCCTATTGGTCCTGATTTACTGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATCAGACGTCCATTTTGCGAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGAATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGCTTTTCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-141 (SEQ ID NO: 1189)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGGATACGTTAACGTGGTACCAGCAGAAACTAGGGAAAGCCCCTAAGCTCCTGATCTATGGTGGTTCCGAGTTGCAAAGTGGGGTCCCACCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTGTATTAGTAGTCCTTGTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-142 (SEQ ID NO: 1190)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTTTATTGGTGATTCTTTATCTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTTTCTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATACTTCGCCTACTACGTTCGGCCGAGGGACCAAGGTGAAAATCAAACGG BMS2h-143 (SEQ ID NO: 1191)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGACTATTGAGACTAATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATTCTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTAGCTACGTACTACTGTCAACAGTATCATGGGTATCCTACGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-144 (SEQ ID NO: 1192)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGATGATTGATCAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAATGCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATGGTTATCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-145 (SEQ ID NO: 1193)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGACGATTTATACTTCGTTAAGTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCATTATGGTTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTGCTACGTACTACTGTCAACAGGTTCATCAGGCTCCTACGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-146 (SEQ ID NO: 1194)GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGGATTCTTTAGCGTGGTACCAGCAGAAGCCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTATTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTGCTACGTACTACTGTCAACTGTCTAGTAGTATGCCTCATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-147 (SEQ ID NO: 1195)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGAGATTGAGACGAATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATTCGTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATCAGAATCCTCCGACGTTCGGCCAAGGAACCAAGGTGGAAATCAAACGG BMS2h-149 (SEQ ID NO: 1196)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGAGGCAGTTAGTTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGGGCGACCGAGTTGCAAAGTGGGGTCCCATCACGTTTTAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCAGTCGAAGGGTCCTCTTACGTTCGGCCATGGGACCAAGGTGGAAATCAAACGG BMS2h-150 (SEQ ID NO: 1197)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGGGATTGGTACTGATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATATGGGTTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGATTTATTCTTTTCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-154 (SEQ ID NO: 1198)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGGAGATGTTACATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTTGGTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTAGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCATCATACTCGTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-155 (SEQ ID NO: 1199)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGATGGATTTAGAGTGGTACCAGCAGATACCAGGGAAAGTCCCTAAGCTCCTGATCTATGATGCGTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATAAGCTTCCTGCGACGTTTGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-156 (SEQ ID NO: 1200)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTATGGATAATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCGGCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATAAGTTGCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-157 (SEQ ID NO: 1201)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGAGCAAGTCAGAATATTGGGGAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAATGCCCCTAAGCTCCTGATCTATAGTGCGTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTCTAGTTATCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-158 (SEQ ID NO: 1202)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCCGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCGATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAATGCCCCTAAGCTCCTGATCTATAGTGCGTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGACTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATCTTCTGCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-159 (SEQ ID NO: 1203)GACATCCAGATGATCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTAATGAGGATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAATGCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTAAAGATTTTGCTACGTACTACTGTCAACAGTATCATACTAATCCTACTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-160 (SEQ ID NO: 1204)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGGCGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATTCTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGAAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATATGTCGCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-161 (SEQ ID NO: 1205)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATAGTGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTATGCTCCTGATCTATTCTTCGTCCGATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATAGTCTGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-162 (SEQ ID NO: 1206)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTTCGGATGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAATTCGTCCTTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGGCAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATAGTTTGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-163 (SEQ ID NO: 1207)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGGGTAATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATTCGTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATCATCTTCCTACGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-164 (SEQ ID NO: 1208)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATACGGATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGGGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCGGTGGATTCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-165 (SEQ ID NO: 1209)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTAGTACTGATTTAGAGTGGTACCAGCAGAAACTAGGGAAAGCCCCTAAGCTCCTGATCTATGATGCTTCCCTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTCGAGTCTGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-166 (SEQ ID NO: 1210)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTACGACGTCTTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGCGTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTGGGTTACGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-167 (SEQ ID NO: 1211)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACCTGCCGGGCAAGTCAGAATATTCATACGAATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTCGGCTAATCCTGTTACGTTCGGCCAAGGGACCAAGGTGGGAATCAAACGG BMS2h-168 (SEQ ID NO: 1212)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTCATACGGATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATAGTGTGTCGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-169 (SEQ ID NO: 1213)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATAATAATTTAGAGTGGTACCAGCAGAAACCAGGGGAAGCCCCTAAGCTCCTGATCTATGATGGGTCCCTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTTACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATCTTCATCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-170 (SEQ ID NO: 1214)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATACGAATTTAGAGTGGTATCAGCAGAAACCAGGGGAAGCCCCTAAGCTCCTGATCTATGATCGTTCCACGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATTCTTATCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-171 (SEQ ID NO: 1215)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTCTATTGAGTCTAATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAATGCGTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCGACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATCAGTGGCCTACGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-172 (SEQ ID NO: 1216)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACTATCACTTGCCGGGCAAGTCAGGCTATTGGTAATACTTTACGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCTTAGTTCCAGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCTGAAGAAGCCTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-173 (SEQ ID NO: 1217)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAAGATTAAGAATCGGTTAGCGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAGGTTTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCGGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGAGGAGGCAGTCGCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-174 (SEQ ID NO: 1218)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTGAGGATATTGGGGAGGAGTTATTTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCGGCGTCCACGTTGCAAAGTGAGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACATGAAGATTTTGCTACGTACTACTGTCAACAGGTTTATGAGTGGCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-175 (SEQ ID NO: 1219)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTTCTGGGGGTTTAAGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTACTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCTTTATTCTGCTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-305(SEQ ID NO: 1220)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATCAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAATGTTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTCTATGAATCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-306 (SEQ ID NO: 1221)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGAATCAGTTAAAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGGCTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATTTGAGGCCTCAGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-307 (SEQ ID NO: 1222)GACATCCAGATGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGTGACCGTGTCACCATCACTTGCCGGGCGAGTCAGAAGATTTCTACGTCTTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATGATTCTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGAGTATAATCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-33 (SEQ ID NO: 1223)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGACGATTGGGGAGAGTTTACATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTTTGCTTCCCTGTTGCAAAGTGGGGTCCCATCGCGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCATCATATGCTTCCTTCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-35 (SEQ ID NO: 1224)GACATCCAAATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTTTATTGGTGATTCTTTATCTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTTTCTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATATGGATATTCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-36 (SEQ ID NO: 1225)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATCATAATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATAGTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATTCTATTCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-37 (SEQ ID NO: 1226)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCAGATTGAGACGAATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATAGTTTGCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-38 (SEQ ID NO: 1227)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGTAATAATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATCATGGGTCCTGGTTGCAAAGTGGGGTCCCATCGCGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTTACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATTTTAATCCTACTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-39 (SEQ ID NO: 1228)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACTGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTGATGGTCTGTTATGGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCGGGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGAAGGCTTTTGAGCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-405 (SEQ ID NO: 1229)GACATCCAGATGACCCAGACTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGGTCATGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAATGTGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTTACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATAGTCATAATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-406 (SEQ ID NO: 1230)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACTATCACTTGCCGGGCAAGTCAGCATATTGAGAATGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTGCTTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATCTTCAGCCTACGACGTTCGGCCCAGGGACCAAGGTGGAAATCAAACGG BMS2h-431 (SEQ ID NO: 1231)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACTATCACTTGCCGGGCAAGTCAGGTTATTGAGGGTAGTTTAAATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATAGGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCCGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACTTATCAGCTTCCTTTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-432 (SEQ ID NO: 1232)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTCCTATTAATGGTAAGTTATTTTGGTACCAGCAGAAACCAGGCAAAGCCCCTAAGCTCCTGATCGCGTTTGCTTCCGCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGTGCAGCAGGCTGTGTATCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-433 (SEQ ID NO: 1233)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCTATTGAGACGAATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGGGTCCCTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGAGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATTATCAGCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-434 (SEQ ID NO: 1234)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGCATGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCGGCGTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCAGCAGCAGCCTACTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-435 (SEQ ID NO: 1235)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTTCGCAGATTGAGGAGTCTTTATGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGCGGATGTTTCCCTGTTGCAAAGTGGAGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGGTGTGGTGGAGCCTCGTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-436 (SEQ ID NO: 1236)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTATATTGGTCTGGATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCGGCAGCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-437 (SEQ ID NO: 1237)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-437-1 (SEQ ID NO: 1238)GACATCCAGTTGACCCAGTCTCCAACCTCCCTGTCTGCAACTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCTGGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACTGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCGTCATCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAGCGG BMS2h-437-2 (SEQ ID NO: 1239)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGACAGCATGTGCGTCCTCCTGCGACGTTCGGCCAAGGGACCAAGGTGGGAATCAAACGG BMS2h-437-3 (SEQ ID NO: 1240)GACATCCAGATGACCCAGTCTCCGTCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGTAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCACCACGTTTCAGTGGCAGCGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-437-4 (SEQ ID NO: 1241)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCTGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-437-5 (SEQ ID NO: 1242)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTACGCCGATTGGTACTATGATAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCATTCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCATGTGCGTCCTCCTGCGACGTTCGGCAAAGGGACCAAGGTGGAAATCAAACGG BMS2h-438 (SEQ ID NO: 1243)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACATGCCGGGCAAGTCAGTATATTGATACTAATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATGATGGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCATCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCAGGTTGTGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-439 (SEQ ID NO: 1244)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGTGGATTCTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGTCAGGATCGTTGGTCTCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-440 (SEQ ID NO: 1245)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTTCGCGGATTCAGCATATGTTATCTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGGCATTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAATCGTGTGCGTGGCCTCTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-441 (SEQ ID NO: 1246)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGGGGTATTGATGGTGATTTATGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGCGGATTCTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGGGGGCTGTTCGGCCTATGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-442 (SEQ ID NO: 1247)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGGGGTATTGATACTGATTTATGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGCGGATTCTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGGGGGCTGTTCGGCCTATGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-443 (SEQ ID NO: 1248)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTTATACTATTCCGGTTGCTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGCTGATGCGTCCTTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGGTTGGCCGGGGCCTCAGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-444 (SEQ ID NO: 1249)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGCGACGGACTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATACTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATAGTTATAATCCTTCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-445 (SEQ ID NO: 1250)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTGTGCCTATTACTGAGGGTTTATCGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCAGGCTAATTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTGGGAGCATGTTCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-446 (SEQ ID NO: 1251)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGTATGATTCTTTATGGTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGTACTTCCGCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTGGGAGACGGTTCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-447 (SEQ ID NO: 1252)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTAATGGGCTTTTAATTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCGATGTCCAGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTTGGCTCGGATTCCTTTTACGTTCGGCCAAGGGACCAAGGTGGGAATCAAACGG BMS2h-448 (SEQ ID NO: 1253)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGAGCAAGTCAGCTGATTCGGACTTATTTAGCGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCAGTCTTCTCAGTTGCAAAGTGGTGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATAATTCTTATCCTGATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-47 (SEQ ID NO: 1254)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGGATTCGTTAAGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTTGGTTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTTGCATACTCCTTCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-484 (SEQ ID NO: 1255)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGAGGCGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCATTCTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGGTTTTAATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-485 (SEQ ID NO: 1256)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTTCTCCTATTGAGTATGGTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGGGGGGGTCCGCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTGGGAGGTTCAGCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-486 (SEQ ID NO: 1257)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCGGATTGATACTGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATAGTTCACAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATCATAGTGCGCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-487 (SEQ ID NO: 1258)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTGGGTGGATTGGTATGTCTTTAGAGTGGCACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCGTGGGGCTTCCTCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTAGTCAGTCTCGGTGGCCGCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-488 (SEQ ID NO: 1259)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTAATATTTCGAATGCTTTATCGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTGGGGCTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTACTCAGGTGTGGGATAGGCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-489 (SEQ ID NO: 1260)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTATGTCGGCTTTATCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTACTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGTTTATTTGCTGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-490 (SEQ ID NO: 1261)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGAGATTGGGATTGATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCTTCTTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTAGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGCTTCTAATCCTCCTACGTTCGGCCGAGGGACCAAGGTGGAAATCAAACGG BMS2h-491 (SEQ ID NO: 1262)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGATGATTGGGGATTGGTTAAATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTATCGTAGTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTTGTATTTTTGGCCTCGTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-492 (SEQ ID NO: 1263)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCGATTGAGCTTAATTTAGAGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATGTTTATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-492-1 (SEQ ID NO: 1264)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCCAGTCAGGCGATTGAGCATAATTTAGAGTGGTACCAGCAGAAGCCAGGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTCCAACCTGAAGATTTAGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTACGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-492-2 (SEQ ID NO: 1265)GACATCCAGATGACACAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGGGCGATAGAGACTAATTTAGAGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGTTCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCGGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCTACAGTATGATGTTTATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-492-3 (SEQ ID NO: 1266)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCAACTGTAGGAGACCGTGTCACCATCACTTGTCGTGCAAGTCAGGCGATTGAGACTAATTTAGAGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGACTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-492-4 (SEQ ID NO: 1267)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCGATTGAGCATAACTTAGAGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGAGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-492-5 (SEQ ID NO: 1268)GACATCCAGATGAACCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCTCCATCACTTGCAGGGCAAGTCAGGCTATTGAGCATAATTTAGAGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCACGCTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-492-6 (SEQ ID NO: 1269)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCGATTGAGTCTAATTTAGAGTGGTACCAGCAAAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATGTTTATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-492-7 (SEQ ID NO: 1270)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGTGCAAGTCAGGCGATTGAGCATAATTTAGAGTGGTACCAGCAGAAACCAGGGAAGGCCCCTAAGCTCCTGATCTATGATGCTTCCATGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATGCTTATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-493 (SEQ ID NO: 1271)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-494 (SEQ ID NO: 1272)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-494-1 (SEQ ID NO: 1273)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGACCGTGTCACCATCACTTGCAGGGCAAGTCAGAGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTCTCAGTATCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-494-2 (SEQ ID NO: 1274)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGAAGAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGCGGGGTCCCATCACGTTTCAGTGGGAGTGGCTCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCATGGGACCAAGGTGGAAATCAAACGG BMS2h-494-3 (SEQ ID NO: 1275)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTTCTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-494-4 (SEQ ID NO: 1276)GAGATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATGACTTGCCGGGCAAGTCAGAGTATTGATAAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGAGGGGTCCCATCACGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCGACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATTTTCAGTATCCTCCGACGTTGGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-494-5 (SEQ ID NO: 1277)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGAGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATGAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGGTCTGCAACCTGAAGATATCGCTACGTACTACTGTAAACAGTATTCTCAGTATCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-494-6 (SEQ ID NO: 1278)GACATCCAGATGACCCAGTCCCCACCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGATAAGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCTAGTTCCTGGTTGCAAAGAGGGGTCCCATCACGTTTCAGTGGGAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACCACTGTCAACAGTATTTTCAGTATCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-495 (SEQ ID NO: 1279)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTGAGTATATTAATGCTGAGTTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGGAGTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCTGCAGAATGCGATGTGGCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-496 (SEQ ID NO: 1280)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCTGGATATTAATAATGGTTTAATTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTTGGGTGCGTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTTCGCAGGTGCGTTCTCGGCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-497 (SEQ ID NO: 1281)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTCTGAGTGCGTTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGGAGTTCCGTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCAGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGAATTATAGTCTTCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-498 (SEQ ID NO: 1282)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTTCTCCTATTGAGTCGTATTTAAGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCAGGTATGTGTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTGGTTTCGGGCGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-499 (SEQ ID NO: 1283)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGTAAGTGAGTCTATTAATGCTGAGTTACATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTCTGGGTTTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGTGCAGTTTGCGATGTGGCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-500 (SEQ ID NO: 1284)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTATGATGATTAGGTTTGGGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGTGGGTCCTCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCATGAGCGGTGGCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-501 (SEQ ID NO: 1285)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGGTACTCTTTTACGTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCTTACTTCCGTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGATGGTTTATCGTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-502 (SEQ ID NO: 1286)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGACTATTGAGACTAATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATTCTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGATAAGGTTCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-503 (SEQ ID NO: 1287)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCATCATATTCAGAGGTATTTATCGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTTGGGGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTGGTGGGCTCCTCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-503-1 (SEQ ID NO: 1288)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCATCATATTCAGAGGTATTTATCGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTTGGGGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTGGTGGGCTCCTCCTCAGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-503-2 (SEQ ID NO: 1289)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCATGATATTCAGAGGTATTTATCGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCTTTGGGGTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTGGTGGGCTCCTCCTCAGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-504 (SEQ ID NO: 1290)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACATGCCGGGCAAGTCAGTATATTGATACTAATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGGGGGCTGTTGTGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-508 (SEQ ID NO: 1291)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGCTTTTGATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCGGCGTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGTCAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATAATCTTCAGCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-509 (SEQ ID NO: 1292)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTGCTACGCTGTTACGTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGGTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGATGTGGCAGCGTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-51 (SEQ ID NO: 1293)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGTTGATGAGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCATCAGTGGTCTACTTATCCTACGACGTTCGGCCAAGGGACCAAGGTGGAAATTAAACGG BMS2h-510 (SEQ ID NO: 1294)GACATCCAGATGACCCAATCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTAATCGATGGTGTTTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGGATTGGGATTGGCCTCGTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-511 (SEQ ID NO: 1295)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGGAATATTCGTGATTGGTTACGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGATTGGGGGTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGACGTGGGATGATCCTCTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-511-1 (SEQ ID NO: 1296)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATTTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGGAATATTCGTGATTGGTTACGGTGGTACCAACAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGATTGGGGGTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGACGTGGTATGATCCTCTGACGTTCGGCCACGGGACCAAGGTGGAAATCAAACGG BMS2h-512 (SEQ ID NO: 1297)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTATTGATATTCATGGTGGTTTAACTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGTGGGGGTTTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGTGTGGCGTAGGCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-513 (SEQ ID NO: 1298)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGAGTTCGTTATCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTTCTTCCCTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACTTATGCTCTTCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-514 (SEQ ID NO: 1299)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCAGATTGAGACGAATTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATAAGTATCTGCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-52 (SEQ ID NO: 1300)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGTGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGTCTGCGTTAAGGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTGGGTTCCGATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACGCAGTATTTTCCTACGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-53 (SEQ ID NO: 1301)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGCGATTTATGGGGGGTTACGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGGGAGTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCATCCTGAAGATTTTGCTACGTACTACTGTCAACAGGTTTATCATAAGCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-536 (SEQ ID NO: 1302)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACGTGCCGGGCAAGTCAGCGTATTGGGGTGTGGTTAGATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGGTTCCTTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACTTTTTCGAGTCCTTCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-537 (SEQ ID NO: 1303)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCCCCATCACTTGCCGGGCAAGTCAGTGGATTGGGGATGAGTTATATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAGTTCTTCCACTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTCGTTTCAGTTTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-538 (SEQ ID NO: 1304)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGTAATATTACGGGGCCGTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCCTGGTTGGTCCACTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGTCAGGTGTGGGGGGAGCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-539 (SEQ ID NO: 1305)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCGTCTATAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCGTATTGCTTATGGTTTACATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGGGGGCGGTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGTGCAGCCTGGGATGCCGCCTGATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-540 (SEQ ID NO: 1306)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAAGCAGATTGTTGGTGGTTTATCTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGCGTCATTCTGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGTGCAGGGGGTTTGGGCTCCTGGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-541 (SEQ ID NO: 1307)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCCTGCTATTGCTGCTAAGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGCGGATTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGTCAGCTGTGGGCGGGGCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-542 (SEQ ID NO: 1308)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTACTATTGCTGATGGGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGGCGTATTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGTCAGCTTTGGGAGGGTCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-543 (SEQ ID NO: 1309)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGGATTTATGGGTTTTTAGATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGGGTGTCCTCGTTGCAAAGTGGGGTCCCATCACGTTTTAGTGGCAGCGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACTTTGGCGTGGCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-544 (SEQ ID NO: 1310)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTCGGGATTGGTTAATGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTGGGGTTCCTTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCTGTATGATACTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-545 (SEQ ID NO: 1311)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTAATACGGGTTTAGATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATAGTTCCGCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACGTCGTATTATCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-546 (SEQ ID NO: 1312)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAAGATTTTTGGTTGGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGGACTTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGTTTATTCGCTTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-547 (SEQ ID NO: 1313)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTTCGAATATTGGGGCGGATTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGGGGGCGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCTGTGGAATGGGCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-548 (SEQ ID NO: 1314)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGTCCGATTTATGATGGTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTCTGGTGCTTCCTGGTTGCAAAGTGGGGTCCCATCACGCTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGTCAGTTGTGGTTGGGTCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACAG BMS2h-549 (SEQ ID NO: 1315)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTTCGCGTATTTATAATGGTTTACATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGTCGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCTCAGGTGGGGGAGGCTCCTTCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-550 (SEQ ID NO: 1316)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGGTTTATTAATGAGGAGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTCGTGGTCTTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGTGCAGCCGGGGGGTGGTCCTGGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-551 (SEQ ID NO: 1317)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGGGATATTCTGGATGAGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGTGGGGGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGTCAGCTGTGGCATGGGCCTCCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-552 (SEQ ID NO: 1318)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGTCCTATTTATACGGGTTTACATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGGCGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTATGCAGGTTGGGACGGCTCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-585 (SEQ ID NO: 1319)GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTTCTAGGCGGTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTCTTCTTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCGGTGGCAGTGGATCTGGGACGGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACGTATAGCTATCCTCATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-604 (SEQ ID NO: 1320)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGTCCGATTCCGCAGGATTTATATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGTTGGGATTTCCCAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTTGTGGAGTGCGCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-605 (SEQ ID NO: 1321)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAAGTCTATTGATGGGATGTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCCTGGTTTTTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTCGGTTGAGGCGCCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-606 (SEQ ID NO: 1322)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGGTATATTGCTCATCCTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCCGGGTTCGTCCGTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGTCAGTCGGTTGTGGTGCCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-607 (SEQ ID NO: 1323)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGGACGATTGAGGGTGGTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCATGGGGGGTTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTTGTGGGTGGGTCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-608 (SEQ ID NO: 1324)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAAGTTTATTAGGGATGAGTTATATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGTGGTTCGTCCTTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCTGTGGCGGGCGCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-609 (SEQ ID NO: 1325)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAAGCCGATTTATGGTGGTTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGGGGGGGTTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGGTGTGGGGGGGTCCTGTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-610 (SEQ ID NO: 1326)GACATCCGGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGGCCGATTAGTGGTTGTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGATGGGGCTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTGGTGGGAGTATCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-611 (SEQ ID NO: 1327)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAAGCCTATTGTGAGGGATTTAGAGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCCATGGTGTGTCCACGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCTTGAGGCGGCGCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-612 (SEQ ID NO: 1328)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGGGATATTGGTGATTGGTTATATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGTTTGGGCGTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGTGGGGGACTCCTCCTACGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-613 (SEQ ID NO: 1329)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAATCGTATTGAGTATGGTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTCGGGGTCTTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTAGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCTTGAGGCGGCGCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-614 (SEQ ID NO: 1330)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGGAATATTGGGCATTTTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTTGGGGGGGTCCTCGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTTGGTGGAGCCTCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-615 (SEQ ID NO: 1331)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTTCGAGTATTTATAGTGATTTATATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGATGGGTGGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCTGCATCGTGCTCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-616 (SEQ ID NO: 1332)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGGTTTATTACTGATCGTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGTGTTTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGAGTTCGGAGTTGCCTTGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-617 (SEQ ID NO: 1333)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGTAAGATTGGTAGTGAGTTATATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGTGGTAGGTCCCGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGTTGTGGGAGCCTCCTGCGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-618 (SEQ ID NO: 1334)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTAGGAATATTGGTAATGGTTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCGGGGAGGGGTCCCGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGGGCAGCTTTGGCATACTCCTCCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-619 (SEQ ID NO: 1335)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCGGAATATTTATGGTTGGTTATCGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCGGTGGGTGGTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTGCGCAGGATTATACGTTGCCTGGTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-730 (SEQ ID NO: 1336)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTAAGGATTGGTTACATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTTGCGTCCGGTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTCTGCTACGTACTACTGTCAACAGCATTATAGTACGCCTTATACGTCCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-731 (SEQ ID NO: 1337)GACATCCAGATGACCCAGTCTCCACCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTTGATTTCTTCTCATTTAGATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGGTCTATGATGCTTCCGAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCATCGCAGTCTGCCTTTTACGTTCGGCCAAGGGACCAAGGTAGAAATCAAACGG BMS2h-732 (SEQ ID NO: 1338)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGTGGGGCGTTAGCGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTTATCTATCAGATTTCCGTTTTGCAAAGTGGGATCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATATTCGGTCTCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-733 (SEQ ID NO: 1339)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAGTATTGGGGCGGCGTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTCTGTCCTCTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCTGTTTAGGCTTCCTTTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-734 (SEQ ID NO: 1340)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTGGGGGTCGTTTAGTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGGTCTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTATGCTGAGGCTCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-735 (SEQ ID NO: 1341)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAATATTGGGTCTAGTTTAATTTGGTACCAGCAGAAACCAGGGAAAGCCCCTACGCTCCTGATCTATTATTCGTCCAAGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTCTTTGTCGAGTCCTTATACGGTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-736 (SEQ ID NO: 1342)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTGGATTGGGAGTGAGTTAGCGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTGGACGTCCAATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAATCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGATTCTGGAGACTCCTTTGACGTTTGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-737 (SEQ ID NO: 1343)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGAAGATTTGGGATGCTTTATATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATCGTGGGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTTTTATCGGTGGCCTCATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-738 (SEQ ID NO: 1344)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCATATTGAGGATTCTTTACGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTATGGTTCCGTGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGATGTATAAGTTTCCTATTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-739 (SEQ ID NO: 1345)GACATCCAGACGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCGGATTAATTCTTCTTTACTGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATACTTCCACTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTAGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTCGCTACGTACTACTGTCAACAGATTTGGGGTTCGCCTCCTACGTTCGGCCAGGGGACCAAGGTGGAAATCAAACGG BMS2h-740 (SEQ ID NO: 1346)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTCGATTCCTGTTGGTTTAAATTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTCTGGGTCCACTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGGATTGGTATTATCCTAATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-785 (SEQ ID NO: 1347)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCCTATTTATGGTTGGTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTTGACGTCCGGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGATTCATAGTTCTCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-8 (SEQ ID NO: 1348)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTTTATTGATACGTCGTTAGAGTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGATGGGTCCCATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTAGCTACGTACTACTGTCAACAGTATTGGGTTCTTCCTCTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-86 (SEQ ID NO: 1349)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGGGGATGCTTTATTTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATTATTCTTCCATGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCGGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCGGCATAGTACTCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-87 (SEQ ID NO: 1350)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATGAGTCTTTAATGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATGGGGTGTCCTATTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTCGCTACGTACTACTGTCAACAGCGGTGGAAGGCTCCTTTTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-88 (SEQ ID NO: 1351)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTTACCATCACTTGCCGGGCAAGTCAGGAGATTGTGGAGGATTTATATTGGTATCAGCAGAAACCAGGGAAAGCCGCTAAGCTCCTGATCTATGGTGCGTCCTGGTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACGCGTAGGCGTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-89 (SEQ ID NO: 1352)GACATCCAGATGACCCAGTCTCCAGCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGGATATTGATCCTATGTTAAGGTGGTACCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCGGGTTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGACGCTGGTGACTCCTTATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-90 (SEQ ID NO: 1353)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGTCGATTTCGGATGCGTTATTTTGGTACCAGCAGAAACCAGGGAAAGCCCCTAGGCTCCTGATCTATTATGGTTCCGTTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGCGTTTTCAGGAGCCTGTGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGG BMS2h-91 (SEQ ID NO: 1354)GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCCGCATCTGTAGGAGACCGTGTCACCATCACTTGCCGGGCAAGTCAGCAGATTAGTGATGAGTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGTGTCCATTTTGCAAAGTGGGGTCCCATCACGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCTACGTACTACTGTCAACAGTGGTTGAGTTTTCCTTCGACGTTTGGCCAAGGGACCAAGGTGGAAATCAAACGG

Example 1 Generation of Human Anti-CD40L Variable Domains BMS2h-2Through BMS2h-785

The following example describes the generation of the 2h lineage ofanti-human CD40L variable domains, designated BMS2h-2 through BMS2h-785.Following recombinant expression of a repertoire of singleimmunoglobulin variable domains on the surface of phage, selection isperformed by contacting the phage repertoire with immobilized targetantigen, washing to remove unbound phage, and propagating the boundphage. This process is frequently referred to as “panning.” It isapplicable to the screening of single immunoglobulin variable domains,as well as other antibody fragments that can be expressed on a displaylibrary, e.g., scFv, Fab, and Fab′. Alternatively, phage may bepre-selected for the expression of properly folded member variants bypanning against an immobilized generic ligand (e.g., protein A orprotein L) that is only bound by folded members. This has the advantageof reducing the proportion of non-functional members, thereby increasingthe proportion of members likely to bind a target antigen. Pre-selectionwith generic ligands is taught in WO 99/20749, for example. Thescreening of phage antibody libraries is generally described, forexample, by Harrison et al., Meth. Enzymol. 267: 83-109 (1996).

Screening is commonly performed using purified antigen immobilized on asolid support, for example, plastic tubes or wells, or on achromatography matrix, for example Sepharose™ (Pharmacia). Screening orselection can also be performed on complex antigens, such as the surfaceof cells (Marks et al., BioTechnology 11: 1145 (1993); de Kruif et al.,Proc. Natl. Acad. Sci. USA 92: 3938 (1995)). Another alternativeinvolves selection by binding biotinylated antigen in solution, followedby capture on streptavidin-coated beads.

dAb Selection for Clone BMS2h-719 and BMS2h-7xx Series:

Three rounds of selection using decreasing concentrations of antigen(500 nM at round 1; 50 nM at round 2; 50 nM or 5 nM at round 3 dependingon the library output used) were performed in parallel againstbiotinylated (1.2 moles biotin/mole CD40L) human CD40L monomer triplemutant (T211E, S222Y, H224K, [108-261] Construct #7) provided byBristol-Myers Squibb. Phage from the naïve 4G and 6G Domantis dAblibraries were combined into the pools a) to g) indicated below beforeinitiating selections:

a) 4G VH CDR3 lengths between 7-10 amino acids.

b) 4G VH CDR3 lengths between 11-15 amino acids.

c) 4G VH CDR3 lengths between 7-15 amino acids.

d) 4G VK

e) 6G VH CDR3 lengths between 7-9

f) 6G VH CDR3 lengths between 10-15

g) 6G VK

Each round of selection involved adding the desired concentration ofbiotinylated CD40L to a mixture of 200 μl of phage (from one of thenaïve library pools indicated above, or subsequent selection outputphage) and 1000 μl of 2% MPBS (Phosphate Buffered Saline) containing 2%(w/v) Marvel [Premier Foods, UK]) and incubating at room temperature for1 hour by mixing end-over-end. The biotinylated antigen phage complexwas then captured by adding 100 μl of resuspended Dynabeads M-280Streptavidin [Invitrogen, UK] and incubated for 5 minutes with mixingend-over-end at room temperature. The Dynabeads were then recoveredusing a KingFisher magnetic separator [Thermo Fisher Scientific, UK] andwashed 7×1 ml PBST (PBS containing 0.1% (v/v) polyoxyethylenesorbitan 20monolaurate [Sigma-Aldrich, UK]) followed by 1×1 ml PBS. Bound phageretained on the washed Dynabeads were eluted by incubation with 500 μlof trypsin-PBS (50 μl of 10 mg/ml trypsin [Sigma-Aldrich, UK] dissolvedin 50 mM Tris-HCl pH 7.4, 1 mM CaCl₂ added to 450 μl PBS). Thephage-containing solution was recovered and 250 μl used to infect 1.75ml of logarithmic growth phase E. coli TG1 (at an OD₆₀₀ of 0.4) for 30minutes at 37° C. The E. coli TG1 phage infected culture was centrifugedat 11,600 g in a micro centrifuge for 1 minute and the resulting cellpellet resuspended in 1 ml 2×TY (16 g Tryptone, 10 g Yeast Extract and 5g NaCl in 1 litre, autoclaved for 15 minutes at 121° C.) and plated ontoa 9 cm Petri dish containing TYE media supplemented with 15 μg/mltetracycline. The plates were incubated overnight at 37° C. then 2 ml of2×TY supplemented with 15% glycerol was added to each plate and cellsloosened with a glass spreader and mixed thoroughly. Fifty microlitresof the scraped bacteria was used to inoculate 50 ml of 2×TY supplementedwith 15 μg/ml tetracycline and grown overnight at 37° C. with shaking at250 rpm. The overnight culture was centrifuged at 3,300 g for 15 min topellet the bacteria. To precipitate phage, 10 ml PEG/NaCl (20%Polyethylene glycol 8000, 2.5 M NaCl) was added to 40 ml supernatant.The phage/PEG solution was mixed and left on ice for 1 h, then spun at3,300 g for 30 min at 4° C. and the supernatant discarded. The pelletwas resuspended in 2 ml PBS and spun at 11,600 g for 10 min in a microcentrifuge to remove the remaining bacterial debris. The resultantsupernatant containing phage was then used for the next round ofselection against the appropriate concentration of biotinylated CD40Lmonomer triple mutant antigen.

Phage ELISA

Monoclonal phage ELISAs were carried out following selection rounds 2and 3. All washes were performed using 3 washes of 250 μl PBST followedby 3 washes of 250 μl PBS. The plates were coated overnight at 4° C.with 50 μl/well of 1 μg/ml NeutrAvidin [Thermo Scientific, UK] in 0.2Mcarbonate-bicarbonate buffer, pH 9.4. The plates were washed and thenblocked with 2% MPBS for 1 hour at room temperature. The plates werethen washed and incubated with 50 μl/well of ˜1.0 μg/ml biotinylatedhuman CD40L monomer triple mutant in 2% MPBS. The plates were washed and25 μl/well phage supernatants added to an equal volume of 2% MPBS andincubated for 1 hour at room temperature. The plates were washed andbound phage detected with 50 μl/well anti-M13-HRP conjugate [GEHealthcare, UK] diluted 1:5000 in 2% MPBS and incubated for 1 hour atroom temperature. The plates were washed and the ELISA developed using50 μl/well SureBlue 1-Component TMB MicroWell Peroxidase solution [KPLInc, USA]. The colorimetric reaction was stopped by the addition of anequal volume of 1 M HCl and the ELISA plate read at 450 nm. Specificphage were identified by comparison to wells coated with NeutrAvidin butwithout biotinylated CD40L monomer triple mutant.

Recovery of dAb Genes from MidiPrep pDOM4 Plasmid

The dAb V-genes from the following round 3 outputs were recovered by DNArestriction enzyme digestion of the phage vector pDOM4:

a) 4G VH CDR3 lengths between 7-10 amino acids (50 nM antigenconcentration).

b) 4G VH CDR3 lengths between 11-15 amino acids (50 nM antigenconcentration).

c) 4G VH CDR3 lengths between 11-15 amino acids (5 nM antigenconcentration).

d) 4G VH CDR3 lengths between 7-15 amino acids (50 nM antigenconcentration)..

e) 4G VK (50 nM antigen concentration).

f) 4G VK (5 nM antigen concentration).

g) 6G VH CDR3 lengths between 7-9 (50 nM antigen concentration).

h) 6G VH CDR3 lengths between 10-15 (5 nM antigen concentration).

Approximately 20 μg of MidiPrep [Qiagen, UK] DNA was digested with SalIand NotI as follows: 20 μl DNA (˜1 μg/μl) was mixed with 1.5 μl SalI (20U/μl) [NEB, UK] and 3 μl Nod (10 U/μl) [NEB, UK], 4 μl Buffer 3 [NEB,UK], 0.4 μl BSA (10 mg/ml) [NEB, UK] and tissue culture grade water[Sigma, UK] added to 40 μl. Samples were incubated for 5 hours at 37° C.in an air incubator following which the digested dAb genes were isolatedby running the digestion mix on a 2% agarose gel [E-gel, Invitrogen,UK], the appropriate DNA bands excised and cleaned using a PCRpurification kit [Qiagen, UK]. The purified V-genes were ligated into aSalI and NotI double digested pDOM5 expression vector.

Soluble dAb ELISA

Binding dAbs were identified as follows. Ninety-six individual coloniescontaining dAb V-genes cloned into the soluble dAb expression vectorpDOM5 were picked from each output into 200 μl Terrific Broth containingOnEx Autoinduction media [Novagen, UK] and incubated overnight at 37° C.with shaking at 250 rpm in Costar 96 Well Cell Culture Clusters [CorningIncorporated, USA] sealed with a gas permeable adhesive plastic strip.The cultures were centrifuged to pellet the cells and the supernatantsassayed by antigen binding ELISA for dAbs that bound to CD40L monomertriple mutant and IZ-CD40L mutant (CD40L containing an isoleucine zippertrimerization domain, supplied by Bristol-Myers Squibb). MaxiSorp 96well immunoplates [Nunc, USA] were coated overnight at 4° C. with 50μl/well of 1 μg/ml NeutrAvidin in 0.2 M carbonate-bicarbonate buffer, pH9.4. All washes were as described for the phage ELISA. The plates wereblocked for 1 hour at room temperature with 200 μl of PBS containing 1%Tween 20. The plate was then washed and incubated for 1 hour at roomtemperature with 50 μl/well of 1 μg/ml biotinylated human CD40L monomertriple mutant in PBST or 1 μg/ml biotinylated human IZ-CD40L mutant inPBST (both antigens supplied by Bristol-Myers Squibb). The ELISA platewas washed and dAb-containing culture supernatant clarified bycentrifugation at 1,800 g for 10 min at 4° C., then added to the ELISAplate (30 μl/well) to which was added an equal volume of PBST. Theplates were incubated for 1 hour at room temperature and then washed.Bound dAb was detected by adding 50 μl/well 9E10 [anti-myc IgG,Sigma-Aldrich, UK] diluted 1:2000 in PBST and incubating for 1 hour atroom temperature; the ELISA plate was then washed and 50 μl/wellanti-mouse Fc-HRP [Sigma-Aldrich, UK] diluted 1:2000 in PBST added andincubated for 1 hour at room temperature. The plates were washed and theELISA developed by adding 50 μl/well SureBlue 1-Component TMB MicroWellPeroxidase solution [KPL Inc, USA] and the colour allowed to develop.The colourimetric reaction was stopped by the addition of an equalvolume of 1 M HCl and the ELISA plate read at 450 nm. Antigen bindingdAbs were identified by comparison of the signal intensity from humanCD40L monomer triple mutant and human IZ-CD40L mutant wells with controlwells not containing antigen.

Expression & Purification of dAb at 50 ml Scale

Unique dAbs were identified by DNA sequencing ELISA positive clones. Theunique dAbs identified were expressed as follows in 250 ml baffledflasks, to which was added:

a) 50 ml of Terrific Broth [Sigma-Aldrich, UK].

b) 100 μg/ml carbenicillin [Sigma-Aldrich, UK].

c) 1 drop of antifoam A204 [Sigma-Aldrich, UK].

d) Novagen Overnight Express Autoinduction Kit [Novagen, UK].

A bacterial scrape from a fresh confluent 9 cm diameter agar plate orfrom a glycerol stock of the desired dAb clone was used to inoculate theTerrific Broth, then the flask sealed with Milliwrap PTFE membrane[Millipore, UK], and incubated for 48 hrs, 250 rpm shaking at 30° C. Thebacterial overnight culture was clarified by centrifugation and the VHor VK dAb purified using Streamline Protein A [GE Healthcare, UK] orProtein L agarose [generated in-house] respectively. The resultingpurified proteins were assayed by RBA to determine which clones couldinhibit the binding of CD40L for CD40.

CD40L Bead Receptor Binding Assay

Inhibitory dAbs were initially identified by screening purified dAb in aCD40L bead receptor binding assay (RBA). Sphero streptavidin polystyrenebeads (0.5% w/v, 6.7 μm diameter) [Saxon, Europe] were prepared andwashed according to the manufacturer's instructions. The beads were thenpelleted at 11,600 g for 1 minute, the supernatant discarded and thebeads resuspended in 1 ml PBS by vortexing. The washing step wasrepeated twice more, the supernatant discarded and the beads resuspendedin 1 ml (0.5 mg/ml) of biotinylated human IZ-CD40L in PBS and incubatedovernight at room temperature with end-over-end rotation. Followingincubation, the beads were pelleted and washed three times with 1 ml PBSas before and then resuspended in 0.5 ml PBS containing 0.1% bovineserum albumin (BSA). The antigen coated beads were then diluted 1:10 inPBS containing 0.1% BSA prior to use. The reagents for the RBA assaywere added as follows to duplicate wells in a 384-well black sided clearbottomed FMAT plate [Applied Biosystems, UK]:

-   -   a) 12.5 μl dAb protein or buffer control. The dAb titration        starting concentration was typically 10 μM (final concentration)        which was diluted 1:3.3 (i.e., 30 μl sample added to 70 μl PBS        containing 0.1% BSA) to produce an 8-point titration effect        curve.    -   b) 12.5 μl CD40-Fc [supplied by Bristol-Myers Squibb, USA; lot        CY24Feb06-1] at 0.2 μg/ml (for a final concentration of 0.05        μg/ml) diluted in PBS containing 0.1% BSA.    -   c) 12.5 μl Mixture of mouse anti-human Fc [Sigma-Aldrich, UK] at        2 μg/ml (for a final concentration of 0.5 μg/ml) and goat        anti-mouse Alexa Fluor 647 [Invitrogen, UK] at 1 μg/ml (for a        final concentration of 0.25 μg/ml) diluted in PBS containing        0.1% BSA.    -   d) 12.5 μl IZ-CD40L coated beads described above were added to        the centre of the well so they did not disperse to the edge of        the well.

Following addition of the reagents to the 384 well plate, it wasincubated at room temperature for 6 hours in the dark and then read inan AB8200 FMAT system [Applied Biosystems, UK].

Example 2 dAb Selection for Clone BMS2h-572

Three rounds of selection using decreasing concentrations of antigen(300 nM at round 1; 30 nM at round 2; 3 nM at round 3) were performed inparallel against biotinylated (1.42 moles biotin/mole trimer) humanisoleucine zipper-CD40L (IZ-hCD40L) provided by Bristol-Myers Squibb.Phage from the naïve 4G and 6G Domantis dAb libraries were combined intothe pools a) to h) indicated below before initiating selections:

a) 4G VH CDR3 lengths between 7-9 amino acids.

b) 4G VH CDR3 lengths between 10-12 amino acids.

c) 4G VH CDR3 lengths between 13-15 amino acids.

d) 4G VK

e) 6G VH CDR3 lengths between 7-9

f) 6G VH CDR3 lengths between 10-12

g) 6G VH CDR3 lengths between 13-15

h) 6G VK

Each round of selection involved adding the desired concentration ofbiotinylated CD40L to a mixture of phage (from one of the naïve librarypools indicated above, or subsequent selection output phage) in 1000 μlof 2% MPBS (Phosphate Buffered Saline containing 2% (w/v) Marvel[Premier Foods, UK]) and incubating at room temperature for 1 hour bymixing end-over-end. The biotinylated antigen phage complex was thencaptured by adding 100 μl of resuspended Dynabeads M-280 Streptavidin[Invitrogen, UK] (rounds 1 and 3) or 50 μl of M-280 tosylactivatedDynabeads (Invitrogen) that had been coupled with NeutrAvidin [ThermoFisher Scientific, UK] (round 2) and incubated for 5 minutes with mixingend-over-end at room temperature. The Dynabeads were then recoveredusing a KingFisher magnetic separator [Thermo Fisher Scientific, UK] andwashed 7×1 ml PBST (PBS containing 0.1% (v/v) polyoxyethylenesorbitan 20monolaurate [Sigma-Aldrich, UK]) followed by 1×1 ml PBS. Bound phageretained on the washed Dynabeads were eluted by incubation with 500 μlof trypsin-PBS (50 μl of 10 mg/ml trypsin [Sigma-Aldrich, UK] dissolvedin 50 mM Tris-HCl pH 7.4, 1 mM CaCl₂ added to 450 μl PBS). Thephage-containing solution was recovered and 250 μl used to infect 1.75ml of logarithmic growth phase E. coli TG1 (at an OD₆₀₀ of 0.4) for 30minutes at 37° C. The E. coli TG1 phage infected culture was centrifugedat 11,600 g in a micro centrifuge for 1 minute and the resulting cellpellet resuspended in 1 ml 2×TY (16 g Tryptone, 10 g Yeast Extract and 5g NaCl in 1 litre, autoclaved for 15 minutes at 121° C.) and plated ontoa 9 cm Petri dish containing TYE media supplemented with 15 μg/mltetracycline. The plates were incubated overnight at 37° C. then 2 ml of2×TY supplemented with 15% glycerol was added to each plate and cellsloosened with a glass spreader and mixed thoroughly. Fifty microlitresof the scraped bacteria was used to inoculate 50 ml of 2×TY supplementedwith 15 μg/ml tetracycline and grown overnight at 37° C. with shaking at250 rpm. The overnight culture was centrifuged at 3,300 g for 15 min topellet the bacteria. To precipitate phage, 10 ml PEG/NaCl (20%Polyethylene glycol 8000, 2.5 M NaCl) was added to 40 ml supernatant.The phage/PEG solution was mixed and left on ice for 1 h, then spun at3,300 g for 30 min at 4° C. and the supernatant discarded. The pelletwas resuspended in 2 ml PBS and spun at 11,600 g for 10 min in a microcentrifuge to remove the remaining bacterial debris. The resultantsupernatant containing phage was then used for the next round ofselection against the appropriate concentration of biotinylatedIZ-hCD40L.

Phage ELISA

Monoclonal phage ELISAs were carried out following selection rounds 2and 3. All washes were performed using 3 washes of 250 μl PBST followedby 3 washes of 250 μl PBS. The plates were coated overnight at 4° C.with 50 μl/well of 1 μg/ml IZ-hCD40L in PBS. The plates were washed andthen blocked with 2% MPBS for 1 hour at room temperature. The plateswere washed and 25 μl/well phage supernatants added to an equal volumeof 2% MPBS and incubated for 1 hour at room temperature. The plates werewashed and bound phage detected with 50 μl/well anti-M13-HRP conjugate[GE Healthcare, UK] diluted 1:5000 in 2% MPBS and incubated for 1 hourat room temperature. The plates were washed and the ELISA developedusing 50 μl/well SureBlue 1-Component TMB MicroWell Peroxidase solution[KPL Inc, USA]. The colorimetric reaction was stopped by the addition ofan equal volume of 1 M HCl and the ELISA plate read at 450 nm. Specificphage were identified by comparison to wells that were not coated withantigen but otherwise identically treated.

Recovery of dAb Genes from pDOM4 Plasmid

The dAb V-genes from round 2 and 3 outputs were recovered by SalI andNotI restriction enzyme digestion of the phage vector pDOM4 and ligatedinto a SalI and NotI double digested pDOM5 expression vector.

Soluble dAb ELISA

Binding dAbs were identified as follows. Ninety-six individual coloniescontaining dAb V-genes cloned into the soluble dAb expression vectorpDOM5 were picked from each output into 200 μl Terrific Broth containingOnEx Autoinduction media [Novagen, UK] and incubated overnight at 37° C.with shaking at 250 rpm in Costar 96 Well Cell Culture Clusters [CorningIncorporated, USA] sealed with a gas permeable adhesive plastic strip.The cultures were centrifuged to pellet the cells and the supernatantsassayed by antigen binding ELISA for dAbs that bound to IZ-hCD40L.MaxiSorp 96 well immunoplates [Nunc, USA] were coated overnight at 4° C.with 50 μl/well of 1 μg/ml IZ-hCD40L in PBS. All washes were asdescribed for the phage ELISA. The plates were blocked for 1 hour atroom temperature with 200 μl of PBS containing 1% Tween 20. The ELISAplate was washed and dAb-containing culture supernatant clarified bycentrifugation at 1,800 g for 10 min at 4° C., then added to the ELISAplate (30 μl/well) to which was added an equal volume of PBST. Theplates were incubated for 1 hour at room temperature and then washed.Bound dAb was detected by adding 50 μl/well 9E10 [anti-myc IgG,Sigma-Aldrich, UK] diluted 1:2000 in PBST and incubating for 1 hour atroom temperature; the ELISA plate was then washed and 50 μl/wellanti-mouse Fc-HRP [Sigma-Aldrich, UK] diluted 1:2000 in PBST added andincubated for 1 hour at room temperature. The plates were washed and theELISA developed by adding 50 μl/well SureBlue 1-Component TMB MicroWellPeroxidase solution [KPL Inc, USA] and the colour allowed to develop.The colorimetric reaction was stopped by the addition of an equal volumeof 1 M HCl and the ELISA plate read at 450 nm. Antigen binding dAbs wereidentified by comparison of the signal intensity from IZ-hCD40L wellswith control wells not containing antigen.

Example 3 Identification of Clones BMS2h-503-1, BMS2h-719-2, andBMS2h-572-6

BMS2h-503, BMS2h-719 and BMS2h-572 dAbs were subjected to error-proneaffinity maturation to generate BMS2h-503, BMS2h-719 and BMS2h-572lineages, respectively. This was performed using random mutagenesiswhere on average 3.6 amino acid changes were introduced per dAb. Phagelibraries (average size 6×10⁸) were selected using biotinylatedmonomeric and trimeric human CD40L with alternatingstreptavidin/neutravidin bead capture of the antigen (as described).Three rounds of selections using decreasing concentrations of antigen(100 nM at round 1; 10 nM at round 2; 1 nM at round 3) were performed.Sequencing was used to monitor diversity following each selection round.Selection outputs (round 2 selected on CD40L trimer for BMS2h-572; round3 selected on CD40L trimer for BMS2h-503 and round 3 selected on CD40Lmonomer for BMS2h-719) were sub-cloned into soluble expression vectorpDOM13 (no C terminal tag) (as described) and screened as monoclonalbacterial micro-culture supernatants by BIAcore for improved off-ratescompared to parental clones on both monomeric and trimeric CD40L.Identified improved variants were DNA sequenced and unique dAbsexpressed, purified and then assayed using the BMS2h bead RBA as well ascellular CD40L driven assays (as described). As a result, BMS2h-503-1(sequence listed in TABLE 3), BMS2h-719-2 and BMS2h-572-6 dAbs(sequences listed in TABLE 1) were identified. Activities of these dAbsare listed in TABLE 5 below.

Formatting BMS2h-503-1, BMS2h-719-2 and BMS2h-572-6 as Fc Fusions

BMS2h-572-6, BMS2h-503-1 and BMS2h-719-2 dAbs were cloned into pDOM38vector containing Fc tail derived from human IgG1 to create DMS0502,DMS0500 and DMS0501, respectively. BMS2h-572-6, BMS2h-503-1 andBMS2h-719-2 dAbs were also cloned into pDOM38 vector containing Fc tailderived from human IgG4 to create DMS0505, DMS0506 and DMS0504,respectively. The constructs were transiently expressed in HEK293 cellsand the proteins were purified using Protein A. Purified Fc fusions wereanalysed by Biacore for binding to monomeric and trimeric CD40L as wellas in various cell assays (as described).

Identification of Clones BMS2h-572-608, BMS2h-572-614 and BMS2h-572-619

BMS2h-572-6 dAb was subjected to affinity maturation using doped oligoapproach. Four doped libraries were constructed for this dAb:

Library 1-5 residues in CDR1 diversifiedLibrary 2-6 residues in CDR2 diversifiedLibrary 3-13 residues in CDR2 diversifiedLibrary 4-7 residues in CDR3 diversified

In each library, diversification was performed using nnS codons where nretained a large fraction of the parent base (85%) and split the restbetween the equimolar amounts of the remaining three bases (5% each) andS stood for G or C. Phage libraries (average size 8×10⁸) were selectedusing biotinylated monomeric and trimeric human CD40L with alternatingstreptavidin/neutravidin bead capture of the antigen (as described).Libraries 2 and 3 were pulled together during the selection process.Three rounds of selections using decreasing concentrations of antigen(50 nM at round 1; 5 nM at round 2; 1 nM at round 3 with 200 fold excessof competitor—non biotinylated CD40L trimer) were performed. Sequencingwas used to monitor diversity following each selection round. Selectionoutputs (rounds 2 and 3) were sub-cloned into soluble expression vectorpDOM13 (no C terminal tag) (as described) and screened as monoclonalbacterial micro-culture supernatants by BIAcore for improved off-ratescompared to parental clones on both monomeric and trimeric CD40L.Identified improved variants were DNA sequenced and unique dAbsexpressed, purified and then assayed using the BMS2h bead RBA as well ascellular CD40L driven assays (as described). As a result, BMS2h-572-608,BMS2h-572-614 and BMS2h-572-619 dAbs were identified.

Construction of Clone BMS2h-572-633

Sequence analysis revealed that all of the amino acid differencesbetween BMS2h-572-608 and the parental dAb BMS2h-572-6 were located inCDR1 and the differences between BMS2h-572-614 and parental dAbBMS2h-572-6 were located in CDR3. Both matured dAbs shared CDR2 with theparental dAb BMS2h-572-6. This created an opportunity to construct acombination mutant which had CDR1 of BMS2h-572-608 and CDR3 ofBMS2h-572-614. Firstly, CDR1 region of BMS2h-572-608 was PCR amplified.Secondly, CDR2+CDR3 fragment of BMS2h-572-614 was PCR amplified. Thiswas followed by SOE PCR assembly of the two fragments to create acombination mutant BMS2h-572-633. The assembled dAb PCR product wascloned into soluble expression vector pDOM13 (no C terminal tag),sequence verified, expressed, purified and then assayed using the BMS2hbead RBA as well as cellular CD40L driven assays (as described).

Formatting BMS2h-572-633 as Fc Fusion

BMS2h-572-633 dAb was cloned into pDOM38 vector containing Fc tailderived from human IgG1 to create DMS0507. The construct was transientlyexpressed in HEK293 cells and the protein was purified using Protein A.Purified Fc fusion was analysed by Biacore for binding to monomeric andtrimeric CD40L as well as in various cell assays (as described).

Example 4 CD40L Activity Cell Assays

Anti-human CD40L dAbs were assayed functionally for their ability toantagonize CD40L activities. The CD40L activities tested were B cellproliferation and cytokine production by hCD40L-driven activation ofprimary monocytes-derived dendritic cells (DCs). Unless otherwise noted,all assays were performed in RPMI media supplemented with 10% fetal calfserum (FCS). The results of various assays, described in detail below,are shown in TABLE 5 and TABLE 6.

Soluble 1Z-hCD40L-Driven Primary Human B Cell Proliferation:

1×10⁵ tonsillar human B cells were incubated with 0.6 μg/ml of IZ-hCD40Lalong with varying titration of dAb or mAb in a final volume of 200μl/well in a 96-well round bottom plate. The plates were incubated at37° C. for 72 hours following which thymidine (³H; 0.5 μci/well) wasadded for 6 hours. B cell proliferation was quantified based onthymidine incorporation. All assays, unless otherwise noted, wereperformed in RPMI media supplemented with 10% fetal calf serum (FCS).

CHO-hCD40L-Driven Primary Human B Cell Proliferation:

CHO cells were transfected with human CD40L to generate a stable cellline expressing high levels of CD40L on the cell surface. CHO-CD40Lcells were irradiated at 10,000 Rads before incubation with human Bcells. 1×10⁵ tonsillar human B cells were incubated with 1×10³ CHO-CD40Lcells (1:100 ratio of CHO-CD40L: human B cells) along with varyingtitration of dAb or mAb in a final volume of 200 μl/well in a 96-wellround bottom plate. The plates were incubated at 37° C. for 72 hoursfollowing which thymidine (³H; 0.5 μci/well) was added for 6 hours. Bcell proliferation was quantified based on thymidine incorporation. Allassays, unless otherwise noted, were performed in RPMI mediasupplemented with 10% fetal calf serum (FCS).

Primary T Cell-Driven Human B Cell Proliferation:

T cells were isolated from human peripheral blood mononuclear cells(PBMCs) and enriched using via sheep red blood cell (SRBC) affinity.Enriched human T cells were cultured with PM-LCLs (EBV-transformed Bcell line; irradiated at 10,000 Rads) at a 5:1 ratio (T:LCL) for 6 daysat 37° C. to generate a population of allogeneic T cells. At day 6, theexpanded T cells were isolated and irradiated at 3000 Rads, and thencultured (5×10⁴ T cells/well) with primary human tonsillar B cells(1×10⁵ B cells/well) at a 1:2 ratio in 96-well flat bottom plated coatedwith anti-CD3 mAb (OKT3). Varying titrations of dAbs/mAbs were added toeach well; the final volume in each well was 200 μl. Test plates wereincubated at 37° C. for 3 days. Human B cell proliferation wasdetermined via the addition of thymidine (³H; 0.5 μci/well) to thecultures for the last 18 hours. All assays, unless otherwise noted, wereperformed in RPMI media supplemented with 10% fetal calf serum (FCS). Insome instances, the supernatant was harvested and measured for thepresence of IL-6.

CHO-hCD40L-Driven Activation of Primary Human Monocytes-DerivedDendritic Cells (DCs):

Human PBMCs were enriched for monocytes by depleting T cells via SRBCresetting. The monocyte-enriched PBMCs were cultured with 10 ng/mlGM-CSF and 5 ng/ml IL-4 in 6-well plates for six days at 37° C. Thecultured plates were replenished with fresh media (with GM-CSF and IL-4)on days 2 and 5. The immature DCs were used in cell assays on day 6.8×10⁴ immature DCs were cultured with 4×10³ CHO-hCD40L cells (irradiatedat 10,000 Rads) along with varying titrations of dAbs/mAbs in a 96-wellflat bottom plate. After 24 hours, supernatants were harvested andtested for the presence of various cytokines (IL-12, TNF, IL-23). DCactivation was determined by the levels of cytokine production. Allassays, unless otherwise noted, were performed in RPMI mediasupplemented with 10% fetal calf serum (FCS).

TABLE 5 Potency of Monomeric dAb Molecules in Various Primary CellAssays hIZCD40L-driven CHO-hCD40L-driven Human B Cell Human B Cell T-Bcell CHO-hCD40L-driven Proliferation Proliferation MLR DC ActivationClone EC50 (nM) EC50 (nM) EC50 (nM) IL-12 EC50 (nM) 2h116-13 130.0 ±40.0 1300.0, 700.0  888.0, >2000.0, 1000.0 2h116-1312 23.0 ± 3.0 530.0 ±300.0 234 ± 46 112.0 ± 47.0  2h116-1313 29.0 ± 4.0 211.0, 334.0 258 ± 79136.0 ± 51.0  2h116-1314  41.0 ± 10.0 1300.0, 4400.0  1687 ± 1150 664.0± 353.0 2h116-1319 180.0 ± 57.0 >7000.0 2h116-1320 20.0 ± 7.0 138.0 ±60.0  191 ± 72 32.0 ± 10.0 2h437 5700.0 ± 1800  2h437-4 203.0 ±90.0 >7000.0 1329.0 ± 412.0  2h492 >7000.0 2h492-3 1100.0 ±400.0 >7000.0 2h492-4 1700.0 ± 900.0 >7000.0 2h492-5 2300.0 ± 700.02h492-6  6300.0 ± 1400.0 2h492-7 1900.0 ± 600.0 2h494  6100.0 ± 1200.02h494-2  4800.0 ± 2300.0 2h494-3 >7000.0 2h494-4  590.0 ± 250.0 >7000.02h494-6  2000.0 ± 2100.0 >7000.0 2h503 4200.0 ± 316.0 >7000.0 2h503-124.0 ± 2.0 2300.0 ± 700.0  756.0 ± 333.0 2h503-104 16.0, 19.0 2h503-244.0 ± 6.0 3000.0 ± 1000.0 1562.0 ± 96.0  2h572 >7000.0 2h572-6 208.0 ±73.0 >7000.0 >7000.0 >2000.0, 608.0 ±260.0 2h572-604 254.0, 354.0 >700.0  387.0 2h572-608  96.0 ± 19.0 >7000.0 152.0 ± 61.0  2h572-610109.0 ± 34.0 >7000.0 207.0 ± 87.0  2h572-614  93.0 ± 53.0 >7000.0 135.0± 54.0  2h572-616 204.0, 340.0 >7000.0 608.0 ± 136.0 2h572-617 157.0,189.0 >7000.0 338.0 ± 101.0 2h572-619  90.0 ± 62.0  421.0,1496.0 >7000.0 188.0 ± 41.0  2h572-622 301.0, 293.0 >7000.0 281.0 ±127.0 2h572-623 181.0, 261.0 >7000.0 280.0 ± 73.0  2h572-630 103.0 ±71.0 246.0 ± 240.0 2h572-631 108.0 ± 77.0 230.0 ± 200.0 2h572-632 117.0± 91.0 241.0 ± 190.0 2h572-633  20.0 ± 15.0 53.0 ± 60.0 2h572-634  31.0± 18.0 77.0 ± 67.0 2h572-635  29.0 ± 19.0 52.0 ± 26.0 2h572-9 324.0,243.0 >2000.0 2h572-11 140.0 ± 33.0 >7000.0 671.0 ± 165.0 2h572-12 79.0,76.0  225.0, >2000.0 2h572-14 134.0 ± 12.0 >7000.0 882.0 ± 310.02h572-15 168.0 ± 67.0 >7000.0 876.0 ± 391.0 2h572-22 357.0, 305.052h702 >7000.0 2h703 >7000.0 2h706 >7000.0 2h707 >7000.0 2h710 >7000.02h712 >7000.0 2h717 >7000.0 2h719  600.0 ± 640.0 134.0, 646.0 2h719-2 82.0 ± 39.0 >7000.0 196.0 ± 150.0 2h719-202  29.0 ± 12.0 79.0 ± 29.02h719-203 81.0, 96.0 2h719-213 62.0, 98.0 2h719-214 66.0, 89.0 2h719-21592.0, 91.0 2h719-218 57.0, 60.0 2h719-225 253.0, 198.0 176.0 ± 84.0 2h719-226 164.0, 247.0 812.0 ± 53.0  2h719-12  358.0 ± 159.0 266.0 ±66.0  2h719-13 50.0 ± 8.0 659.0, 683.0, 219.0 ± 88.0  4450.0, 1750.02h719-17 132.0 ± 50.0 236.0, 268.0 113.0 ± 49.0  2h719-19 138.0 ± 31.0202.0, >7000.0, 184.0 ± 99.0  >7000.0, 3800.0, 5400.0 2h722 >7000.02h723 >7000.0 2h725  6400.0 ± 1200.0 2h725-2 >7000.0 2h725-9 >7000.02h725-19 >7000.0 2h726 >7000.0 2h730 >7000.0 2h731  5800.0 ± 2500.02h744 >7000.0 2h745 6400.0, 3500.0, >7000.0 2h745-1 >7000.02h745-2 >7000.0 2h745-9 >7000.0 2h745-13 >7000.0 2h745-14 >7000.02h746 >7000.0 2h747 >7000.0 2h752 >7000.0 2h754 6600.0 ± 900.0 2h7576400.0 ± 800.0 2h758  5900.0 ± 1500.0 2h758-1 >7000.0 2h758-2 >7000.02h758-3 >7000.0 2h758-4 >7000.0 2h758-5 >7000.0 2h765 >7000.02h766 >7000.0 2h774 >7000.0 2h775 >7000.0 2h780 >7000.0 2h781 >7000.02h782 >7000.0 2h783 >2000.0 2h784 >4700.0 2h785 3700.0, >7000.0

TABLE 6 Potency of Fc*-formatted Molecules in Various Primary CellAssays CHO- CHO- CHO- CHO- CHO- hIZCD40L- hCD40L- hCD40L- hCD40L-hCD40L- hCD40L- driven driven T-B cell driven driven driven driven HumanB Cell Human B Cell T-B cell MLR DC Activation DC Activation DCActivation DC Activation Proliferation Proliferation MLR IL-6 IL-12 EC50IL-6 EC50 IL-23 EC50 TNF EC50 Clone EC50 (nM) EC50 (nM) EC50 (nM) EC50(nM) (nM) (nM) (nM) (nM) 2h116-1320-Fc 13.0 ± 2.0  >130.0 244.0 ± 112.014.0 ± 11.0 2h503-1 Fc 4.0 ± 0.5 60.0 ± 20.0 45 ± 6  2.8 ± 2.0 2h503-1IgG1 4.5 ± 1.0 67.0 ± 40.0  39.5 ± 12.04 1.4 ± 0.7 2h503-1 IgG4 2.5 ±1.0 69.0 ± 50.0 48.3 ± 8.8  18.1 ± 6.4  2h572-6 Fc 0.6 ± 0.4 3.0 ± 1.01.9 ± 0.7 0.22 ± 0.18 2h572-6 IgG1 1.0 ± 0.4 10.0 ± 5.0  3.1 ± 1.4 2.9 ±1.7 0.58 ± 0.36 2h572-6 IgG4 0.9 ± 0.2 11.0 ± 5.0  3.2 ± 1.5 1.3 ± 0.51.1 ± 0.5 2h572-6-CT 1.0 ± 0.5 6.0 ± 6.0 13.6 ± 9.2  8.1 ± 3.1 3.0 ± 1.9Long Fc 2h572-633 Fc 3.5 ± 0.6 3.0 ± 3.0 0.15 ± 0.02 0.11 ± 0.02 0.34 ±0.17 2h572-634 Fc 3.0 ± 0.0 3.5 ± 3.0 0.23 ± 0.08 0.19 ± 0.03 0.42 ±0.05 2h572-635 Fc 2.0 ± 0.8 2.5 ± 1.0 0.16 ± 0.09 0.11 ± 0.02 0.445 ±0.14  2h572-619- 1.5 ± 0.6   2.0 0.40 ± 0.1   0.3 ± 0.07 1.8 ± 1.3Ctshort Fc 2h572-619- 1.6 ± 0.5 2.0 ± 1.0 0.72 ± 0.45 0.43 ± 0.12 1.4 ±0.6  1.5 ± 0.36 1.5 ± 0.46 2.0 ± 0.7 Ctlong Fc 2h572-619- 0.9 ± 0  1.0 ±0.6 0.226, 0.216 0.1, 0.1 1.2 ± 0.6 N297Qshort Fc 2h572-619- 0.98 ± 0.052.0 ± 0.0 0.480, 0.474 0.22, 0.11  1.1 ± 0.23 N297Qlong Fc 2h572-608- 1.0 ± 0.05 2.0 ± 0.0 0.93 ± 0.4  N297Qshort Fc 2h572-608- 2.0 ± 1.0 2.0± 1.0 0.468 ± 0.156 0.38 ± 0.06  1.6 ± 0.74 CT Long Fc 2h572-614- 2.0 ±1.0 2.0 ± 0.5 0.283 ± 0.038 0.25 ± 0.02  1.4 ± 0.68 CT Long Fc2h572-633- 3.0 ± 0.7 1.0 ± 1.0 0.174 ± 0.077 0.13 ± 0.07 1.9 ± 1.3 1.3 ±0.3 1.2 ± 0.3   1.7 ± 0.43 CT Long Fc 2h572-633- 5.0 ± 0.5 1.0 ± 0.50.161 ± 0.053 0.13 ± 0.04 2.3 ± 1.5 1.5 ± 0.7 2.9 ± 1.3 CT-Fc SP52h572-634- 2.0 ± 1.0 1.0 ± 0.6 0.162 ± 0.029 0.13 ± 0.02  1.5 ± 0.91 CTLong Fc 2h572-635- 3.0 ± 1.0 2.0 ± 0.6 0.149 ± 0.014 0.13 ± 0.01  1.6 ±0.93 CT Long Fc 2h719-2 Fc 1.0 ± 0  0.7 ± 0.4  6 ± 1.4 0.13 ± 0.082h719-2 IgG1 1.0 ± 0.5 6.0 ± 0.3 13.8 ± 10.6 2.2 ± 1.3 0.35 ± 0.232h719-2 IgG4 1.5 ± 0.6 16.0 ± 13.0 15.9 ± 10.9 2.1 ± 0.7  1.1 ± 0.482h719-202- 1.8 ± 0.5 1.7 ± 0.7 0.66 ± 0.26 N297Qshort Fc 2h719-202- 3.0± 1.0 2.5 ± 0.6 1.7 ± 0.7 1.3 ± 0.3 3.1 ± 2.0 CT Long Fc *FIG. 3provides sequences of various Fc domains. FIG. 4 shows examples ofvarious Fc-formatted dAbs.

Example 5 Binding Kinetics and CD40L Affinity of Various Antibodies

BMS-986004 is a dimeric fusion protein, composed of a modified Fcfragment of IgG1 linked to the C-terminus of the dAb BMS2h-572-633.Surface plasmon resonance (SPR) was used to characterize the kineticsand affinity of BMS-986004 or the monovalent component domain antibodyBMS2h-572-633 binding to CD40L. The BMS-986004 values were compared tothose for the benchmark antibodies 5c8-IgG1 and 5c8-CT and themonovalent component 5c8 FAB fragment. The SPR experiments utilized ahCD40L construct containing an N-terminal isoleucine zipper motif(IZ-hCD40L) which facilitates the specific assembly of the CD40Lmolecule into the native trimeric form. A biotinylated version ofIZ-hCD40L (biot-IZ-hCD40L) with equivalent binding activity was alsoutilized for some SPR experiments.

The monovalent BMS2h-572-633 domain antibody binds biot-IZ-hCD40L with aKd of 7.8 nM, compared to an affinity of 5.4 nM for the monovalent 5c8FAB fragment, TABLE 7. Because BMS-986004 is bivalent, and the IZ-hCD40Ltarget is trivalent, the SPR binding data are influenced by avidityregardless of whether CD40L target is on the chip surface or insolution. To estimate the avidity-influenced binding affinity, the SPRdata for BMS-986004 binding to a biot-IZ-hCD40L surface was fitted to a1:1 Langmuir model, suggesting a dissociation constant of less than 1nM, TABLE 7. Similar results were obtained for 5c8-IgG1 and 5c8-CT.

TABLE 7 IZ-hCD40L kinetic and affinity values as determined using SPR(Biacore) Anti- Temper- CD40L ature ka kd Kd Ab (° C.) Model (M−1s−1)(s−1) (nM) BMS-986004 25 1:1 2.3E+06* 2.6E−04* 0.11* Langmuir 2h572-63325 1:1 1.0E+06  8.1E−03  7.8 Langmuir 5c8-IgG1 25 1:1 5.4E+05* 2.3E−04*0.42* Langmuir 5c8-CT 25 1:1 5.8E+05* 1.3E−04* 0.22* Langmuir 5c8 FAB 251:1 1.4E+05  7.6E−04  5.4 fragment Langmuir *Value is influenced byavidity due to analyte bivalency.

FIG. 5 shows SPR sensorgram data for the binding of 12.5-0.39 nMBMS-986004 (2:1 dilution series) to biot-IZ-hCD40L captured on astreptavidin SPR sensor chip at 25° C. Colored lines show thedouble-referenced sensorgram data, and black lines show the 1:1 Langmuirfit to the data, with an avidity-influenced apparent Kd value of 0.11nM.

The affinity and thermodynamics of BMS-986004 binding to CD40L were alsocharacterized in solution using isothermal titration calorimetry (ITC)at temperatures ranging from 15-37° C. These data suggested the presenceof multiple thermodynamically distinct binding modes (FIG. 6) with Kdvalues for the different modes beyond the high-affinity limit ofdetection (Kd<2 nM) (TABLE 8), consistent with the SPR data. Theaffinity of the monovalent 5c8 FAB fragment for IZ-hCD40L as determinedby ITC (3.5 nM) was also consistent with the value determined by SPR.

TABLE 8 IZ-hCD40L affinity as determined using ITC Molecule in the ITCsyringe Molecule in the ITC cell Kd (nM) BMS-986004 IZ-hCD40L <2 5c8-CTIZ-hCD40L <2 IZ-hCD40L BMS-986004 <2 IZ-hCD40L 5c8-CT <2 IZ-hCD40L 5c8FAB fragment 3.5

Example 6 Fc Receptor Affinity of Various Antibodies

The Fc-domain of BMS-986004 (termed “CT”) was engineered from a wildtype IgG1 Fc domain to retain the ability to bind FcRn, but to disruptthe binding to Fcγ receptors. To confirm that the engineered moleculehas the desired Fc receptor binding profile, the binding affinities ofBMS-986004 for human FcRn, and the human Fcγ receptors CD64 (FcγRI),CD32a (FcγRIIa), CD32b/c (FcγRIIb/c), CD16a (FcγRIIIa), CD16b (FcγRIIIb)were measured using SPR, in comparison to 5c8-IgG1 and 5c8-CT. For theseexperiments, BMS-986004 was captured via the domain antibody domains ona biot-IZ-hCD40L sensor surface, and the soluble Fc receptor proteinswere tested for binding to the exposed Fc domain. Likewise, 5c8-IgG1 and5c8-CT were captured on a biot-IZ-hCD40L surface via the FAB domains,with soluble FcR binding.

BMS-986004 bound FcRn with Kd of 670 nM at pH 6.0 which is the relevantpH for binding within the endosome, TABLE 9. However, binding wassignificantly reduced (Kd >5000 nM) at neutral pH suggesting efficientrelease of from FcRn under these conditions. BMS-986004 bound CD64 witha Kd of 0.6 nM, and had a statistically weak affinity for CD32a,CD32b/c, CD16a and CD16b (Kd >3000 nM). Both 5c8-IgG1 and 5c8-CT had asimilar FcRn affinity as BMS-986004. 5c8-CT, which has the identical“CT” Fc region as BMS-986004, also had a similar FcγR binding propertiesas BMS-986004, whereas 5c8-IgG1, which has a wild type IgG1 Fc domain,bound more strongly to FcγRs, TABLE 9.

TABLE 9 Fc receptor affinity as determined using SPR (Biacore).BMS-986004 5c8-IgG1 5c8-CT Sample pH Kd (nM) Kd (nM) Kd (nM) hFcRn 6 670590 720 hFcRn 7.1 >5000 >5000 >5000 CD64 7.1 0.6 <0.05 0.9 ± 0.4 CD32a7.1 >3000 ~10⁻⁷ M* >3000 CD32b/c 7.1 >3000 >3000 >3000 CD16a 7.1 >3000240 ± 40 >3000 CD16b 7.1 >3000 >3000 >3000 *CD32a binding to 5c8-IgG1was biphasic. Kd was estimated as ~10⁻⁷ M based on steady state fit todominant binding even. This Kd is in range of literature reported KD forCD32a binding to IgG1.

Example 7 In-Vitro Cell-Based Assays

The potency of BMS-986004 was evaluated in various primary immune cellassays to ensure robust potency across different cell types. The primaryhuman B cell proliferation assays were conducted two ways, as describedin detail above in Example 4: (1) recombinant CD40L trimer was used todrive B cell proliferation; and (2) CHO cells expressing CD40L on themembrane (CHO-CD40L) were utilized to induce B cell proliferation. Theutility of CHO-CD40L cells was particularly important to ensure thatsignals from membrane-bound CD40L were inhibited equally well whencompared to the soluble CD40L trimer. The CHO-CD40L cells were also usedto drive the activation of primary human DCs differentiated fromculturing PBMC-derived monocytes in presence of GM-CSF and IL-4.Similarly, the T-B MLR assay measured B cell activation driven by CD40Lpresent on activated T cells. In all of the above described primaryassays, BMS-986004 was equipotent to the benchmark 5c8 mAb: potenciesranged from was single-digit nM to sub-nM, depending on the assay (TABLE10).

TABLE 10 Potency of BMS-986004 in Various Primary Cell Assays CHO-CD40LCHO-CD40L CHO-CD40L Trimer CHO-CD40L T-B MLR DC Assay DC Assay DC AssayB cell Assay B Cell Assay T-B MLR IL-6 IL-12 IL-6 TNF-a mAb/dAb-Fc EC50(nM) EC50 (nM) EC50 (nM) EC50 (nM) EC50 (nM) EC50 (nM) EC50 (nM) 5c8 8.0± 3.0 2.0 ± 2.0 0.54 ± 0.37 0.23 ± 0.09 2.0 ± 1.5 5c8-IgG1 5.0 ± 1.0 2.0± 2.0 0.34 ± 0.13 0.21 ± 0.06 0.92 ± 0.94 0.73 ± 0.5 2.3 ± 1.3BMS-986004 5.0 ± 0.5 1.0 ± 0.5 0.16 ± 0.05 0.13 ± 0.04 3.1 ± 1.6  1.9 ±0.6 3.6 ± 1.1

Example 8 Assessment of Whole Blood Receptor Occupancy (RO)

A receptor occupancy method was developed to measure CD40L targetengagement by BMS-986003 in cynomolgus whole blood samples and,subsequently, in BMS-986004 in human whole blood samples. BMS-986003 isa dAb which shares the same amino acid sequence as BMS-986004, exceptfor a non-native glycine residue at its amino-terminus.

Occupancy is measured on CD4+ T cells by flow cytometry using ananti-CD40L mAb that competes for binding to CD40L withBMS-986003/BMS-986004, and is cross-reactive with human and cynomolgusCD40L. In the presence of bound dAb, the anti-CD40L detection mAb isblocked from binding to CD40L in a concentration-dependent manner,providing a measure of target occupancy. Given that basal CD40L isexpressed at low levels on resting T cells in peripheral blood, RO wasassessed in both unstimulated blood samples and in samples wherephytohemagglutinin (PHA) was used to induce up-regulation of CD40L onthe T cell surface. Binding potency curves were generated following exvivo whole blood treatment with BMS-986003 and BMS-986004. The averageEC₅₀ and EC₉₀ values obtained are shown in TABLE 11.

TABLE 11 Binding Potency of BMS-986003 and BMS-986004 on CD4+ T-cells inex vivo Whole Blood Receptor Occupancy Assay Average EC₅₀, Average EC₉₀,n nM nM BMS-986003 Human (basal) 1 0.9 3 Human (PHA-induced) 6 0.8 9Cyno (basal) 3 0.6 3 Cyno (PHA-induced) 3 0.4 2 BMS-986004 Human (basal)3 0.4 3 Human (PHA-induced) 3 0.7 5

The target binding potency in whole blood for BMS-986003 and BMS-986004closely correlates between human and cynomolgus monkey. The EC₅₀ valuesfor BMS-986003 and BMS-986004 are also similar when bound to basal andPHA-induced CD40L. Additionally, these values are comparable to thoseobtained in human in vitro cell based assays (see TABLE 10). Based onthe measured EC₉₀ values, full target saturation in peripheral bloodshould be achieved at concentrations ≦10 nM.

To support the preclinical PK/PD profile of BMS-986003 and BMS-986004,RO was assessed in both the cynomolgus KLH study (immunization withkeyhole limpet hemocyanin) with BMS-986003 and the IV bridging studywith BMS-986004. Further details of these findings can be found inExamples below.

Example 9 In Vivo Pharmacology

To show efficacy of a CD40L dAb in mouse disease models, a mouse CD40LdAb 2m126-24 was formatted with mouse IgG1 Fc with D265A point mutationto further lower the Fc effector function. This mouse surrogate dAb2m126-24-Fc shows potency comparable to BMS-986004 and MR-1, a hamsteranti-mouse CD40L antibody (TABLE 12).

TABLE 12 In vitro Potency Comparison Trimer B cell CHO-CD40L B cellCHO-CD40L DC mAb/dAb-Fc Assay EC50 (nM) Assay EC50 (nM) Assay IL-6 EC50(nM) 5c8 8.0 ± 3.0 2.0 ± 2.0 Human {open oversize brace} BMS-986004 5.0± 0.5 1.0 ± 0.5 1.9 ± 0.6 2m126-24-Fc 4.7 ± 0.9  0.4 ± 0.06 0.5 ± 0.2Mouse {open oversize brace} MR-1 (mAb) 1.7 ± 0.4 0.6 ± 0.2 0.6 ± 0.3

Inhibition of KLH Induced Antibody Response by the Mouse CD40L dAb

Female BALB/c mice were injected intraperitoneally (i.p.) with 250 μgKLH on day 0. Mice were dosed subcutaneously (s.c.) with MR-1 orBMS-2m-126-24-Fc at indicated doses on day −1 and day 6. Blood wascollected and the serum was analyzed for anti-KLH IgM on day 7 and IgGon day 14 by ELISA. Serum from BALB/c mice collected on day 14 afterimmunization with KLH was pooled and used as a positive comparator, andthe data is expressed as a ratio of the titre of the test serum to thetitre of the pooled BALB/c serum. As shown in FIG. 7, BMS-2m-126-24-Fcdemonstrated a dose dependent suppression of IgG titers with maximaleffect shown at 3 mg/kg, with ED50 calculated to be 0.26 mg/kg. Both theCD40L dAb and the antibody were tested at 1 mg/kg, showing 70% vs. 30%reduction in IgG response, respectively. Similar exposure of the dAb andthe antibody were observed at 1 mg/kg, suggesting that the dAb isslightly more potent than the antibody at suppressing KLH-induced IgGresponse. In conclusion, the CD40L dAb has demonstrated at least thesame level of efficacy as the anti-CD40L antibody at inhibiting a T celldependent antibody response.

Inhibition of TNBS-Induced Colitis by the Mouse CD40L dAb

Male SJL/J mice were intrarectally administered with 2.5 mgTrinitrobenzene sulfonic acid (TNBS) in 50% EtOH via a catheter inserted4 cm distal to the anus. Mice were dosed once s.c. with MR-1 orBMS-2m-126-24-Fc at indicated doses 4 hours prior to TNBS injection.FIG. 8 presents the changes in the mean body weight and the percentsurvival of groups of mice treated with PBS/IgG or varying dose levelsof MR-1 or the dAb. Abatacept was used as a positive control (20 mg/kg,i.p. every other day). A typical profile of TNBS-induced colitis wasshown in the IgG control group: loss of body weight, peaking at day 3-4;colitis-related death occurring at day 3 and beyond; and the survivedmice showing signs of recovery after day 4. Treatment with the CD40L dAbor the antibody (both tested at 2, 8 and 20 mg/kg) caused adose-dependent inhibition of the body-weight loss and the increase insurvival rate; both compounds at 8 mg/kg yielded a degree of efficacythat is comparable to that of Abatacept at 20 mg/kg. In conclusion, themouse CD40L dAb BMS-2m-126-24-Fc has demonstrated comparable efficacy tothe anti-CD40L antibody MR-1 in an acute TNBS-induced colitis model.

Synergistic Effect Between CTLA4 Ig and the Mouse CD40L dAb in a Mouse“Heart-to-Ear” Transplant Model

Heart grafts from neonatal (48-72 hrs) C57B1/6 mice were implanted intoa subcutaneous pocket created in the ear pinnae of BALB/c mice. Micewere treated with CTLA4-Ig (i.p. 2×/wk), BMS-2m126-24-Fc (s.c. 1×/wk),or combination of both at indicated doses, with first dosing initiatedthe day prior to transplantation. Time to rejection was defined by theabsence of cardiac contractility for three consecutive days as assesseddaily by the electrocardiogram (ECG) device of allograft. As expected,without any treatment, C57BL/6 mice that received the neonatal BALB/cheart rejected the graft shortly thereafter, with median survival time(MST) of 12 days. The monotherapy with 3, 20 mg/kg of the dAb or 25mg/kg of CTLA4-Ig had no or little impact on prolonging the survival ofthe allograft (MST: 12, 15 and 13 days respectively). However, in thegroups treated with combination of 20 mg/kg of the dAb and 25 mg/kg ofCTLA4-Ig, the graft survival was significantly prolonged showing MST of35 days (FIG. 9). This data has provided rationale for combining CD40LdAb with belatacept in human renal transplant patients. Futuretransplant studies in non-human primates will further define the doselevel and assess the potential effect on tolerance induction with CD40LdAb BMS-986004.

Example 10 In Vivo Nonclinical Pharmacokinetics (PK) andPharmacodynamics (PD)

Various in vivo studies were conducted to characterize the PK and PD ofBMS-986004, BMS-986003, and a mouse CD40L dAb-Fc surrogateBMS-2m-126-24-CT, in the nonclinical setting. The key findings aresummarized below.

ELISA to Measure BMS-986004 dAb

Enzyme-linked immunosorbency assay (ELISA)-based bioanalytical methodswere developed to support the PK studies, acute and chronic efficacystudies in mice, and exploratory PK/PD studies employing cynomolgusmonkeys. In all cases, whole blood was obtained and plasma prepared inthe presence of EDTA, the samples were then subjected to ELISA analysis.

Plasma concentrations of BMS-986004 were measured with an ELISA assaythat utilized human CD40L antigen to capture the analyte from testsamples. Test samples were thawed at 4° C., mixed well and diluted 1:100in assay diluent composed of 1×PBS, 0.05% Tween-20, and 1% BSA (PTB).Subsequent dilutions of the sample were made using 1% normal monkeyplasma/PTB as diluent. This allowed the test analyte to be assayed atseveral dilutions (10²-10⁵) while keeping the sample matrix at 1%.

Recombinant trimeric human CD40L was obtained from Protein Structure andScience (PSS), LVL and was bound to 96 well plates at a finalconcentration of 2 μg/mL. Test samples, quality control (QC) samples andthe standards were detected with affinity-purified rabbit anti-heavychain (Vh) domain framework polyclonal antibody (Covance ResearchProducts, Denver, Pa.) diluted to a concentration of 0.25 μg/ml in PTB,followed by horseradish peroxidase-labeled donkey anti-rabbit polyclonalsecondary antibody (Jackson Immunoresearch, West Grove, Pa.) withsubstrate (TMB—tetramethylbenzidine) added, and the enzymatic reactionstopped with 1 M phosphoric acid. Absorbance was measured at awavelength of 450 nm. The analysis of BMS-986004 in test samples wasconducted using a standard curve. Standard curve calibrators prepared onthe day of each run in 1% monkey plasma were used to define the dynamicrange of the bioanalytical method. The range of resulting standard curvein 100% plasma was 10-1200 ng/mL. The reference standard for BMS-986004was obtained from Biologics Process and Product Development (BPPD), HPW.The reference standard material was representative of the manufacturingbatch and was used in the study protocol. Standard curves and QCs wereevaluated using criteria for accuracy and precision of ≦20% which wasconsidered to be acceptable for assay performance. Test samples werequantified using a 4-parameter logistic fit regression model weighted byreciprocal concentration (1/x) derived from the calibrators.

Performance of the QC samples, measured by the deviation of thecalculated concentration from its nominal value indicated the referencematerial was stable in neat monkey plasma at concentrations of 30-1000ng/ml when stored at −70° C. for over 2 months.

ELISA to Measure a Mouse Surrogate dAb

Mouse CD40L-specific dAb BMS-2m-126-24-CT was measured in mouse plasmasamples to provide exposure data in support of several acute and chronicefficacy studies as well as PK assessment.

While the assay format for mouse dAbs was quite similar to that forhuman dAbs in monkey samples, there were a few differences. The mouseplasma matrix was diluted to 1:10 (10%) in assay diluent, and allsubsequent dilutions of test samples were made using 10% mouse matrix.Likewise, all standards and QCs were also incubated on ELISA plates in10% mouse plasma. The concentration of BMS-2m-126-24-CT in test samplesfrom mice was measured using mouse CD40L to capture the analyte. As themouse dAb has Vk framework, all test samples, QCs, and the standardswere detected with affinity purified rabbit anti-kappa (Vk) domainpolyclonal antibody (Covance Research Products, Denver, Pa.) diluted toa concentration of 0.5 μg/mL in PTB. The rest of the assay and analysisprocedure was similar to the procedure for the analysis of human CD40LdAbs. Acceptance criteria for back-calculated concentrations ofstandards and QCs were also similar to those for human CD40L dAbs. Thequantitative range of BMS-2m-126-24-CT as determined from the standardcurve was 12.5 to 600 ng/mL in neat sample matrix.

Nonclinical Pharmacokinetics

TABLE 13 summarizes the PK parameters for BMS-986004, BMS-986003, andBMS-2m-126-24-CT in nonclinical animal species.

TABLE 13 Single-dose PK Parameters (mean ± SD) from Two NonclinicalAnimal Species Dose Cmax Tmax AUC0-inf T½ CLTp Vss F Species dAb Route(mg/kg) (μM) (h) (μM · h) (h) (mL/h/kg) (L/kg) (%) Mouse BMS-2m- IV  1 —— 6.9 101 1.85 0.26  — 126-24-CT (N = 3) SC  1 0.063 24 10 100 — — 100 (N = 3) 10 0.68  24 114 120 — — 100  (N = 3) Monkey BMS-986003 IV  2 — —40 106 0.67 0.067 — (N = 2) SC   0.2 0.019 ± 0.004 60 ± 72 4.0 ± 2.7 85± 29 — — 88 (N = 4)  2  0.22 ± 0.075 33 ± 43 29.7 ± 4.9  68 ± 11 — — 74(N = 4) 20 1.48 ± 0.34 11 ± 9  175 ± 27  105 ± 18  — — 44 (N = 4)BMS-986004 IV 11 — — 241 ± 18  124 ± 12  0.59 ± 0.04 0.098 ± 0.01 — (N =4) 5c8-IgG1 IV 20 — — 1800 ± 74  400  0.074 0.042 (N = 4)

BMS-986004 and BMS-986003 exhibited comparable PK profiles in monkeys(FIG. 11A and FIG. 11B). After IV administration, the plasmaconcentrations of BMS-986004 and BMS-986003 exhibited a bi-exponentialdecline up to 504 and 408 h, respectively. Accelerated clearance wasobserved afterward in 50% of monkeys enrolled in both studies.Immunogenicity testing of the plasma samples collected at 38 d afterBMS-986004 treatment suggested that all monkeys developed anti-drugantibody (ADA); and that the monkeys with higher ADA levels showedfaster clearance. Although no immunogenicity test was conducted for theIV PK study with BMS-986003, a similar level of immunogenicity wasobserved in monkeys after subcutaneous dosing with BMS-986003 in thePK/PD study, suggesting both proteins were immunogenic in monkeys. Theterminal half-life (T½) of 124 and 106 h for BMS-986004 and BMS-986003was, therefore, determined using the exposures collected up to two weeks(336 h) only. The steady-state volume of distribution (Vss) ofBMS-986004 and BMS-986003 was 0.098 and 0.074 L/kg, respectively. Thevalues are greater than the plasma volume (0.06 L/kg) but less than thevolume of extracellular fluid (0.2 L/kg), suggesting that the proteinslargely reside in the extracellular space. The total body plasmaclearance (CLTp) of BMS-986004 and BMS-986003 was 0.59 and 0.65 mL/h/kg,respectively.

The PK parameters of BMS-986004 in monkeys were compared to those ofabatacept, a similar size protein (78.5 vs 78-kDa BMS-986004, based onamino acid sequence), with the same modified human IgG1 Fc format. Asexpected, the parameters of BMS-986004 were nearly identical with thoseof abatacept (CLTp of 0.6 mL/h/kg, Vss of 0.087 L/kg, T½ of 5 d),suggesting the humans PK of BMS-986004 and abatacept is likely to besimilar.

The absorption of BMS-986003 after subcutaneous (SC) administration wasevaluated in the monkey PK/PD study. The monkeys were administered withBMS-986003 as single subcutaneous doses of 0 (vehicle control), 0.2, 2and 20 mg/kg, at 24 h prior to the immunization with keyhole limpethemocyanin (KLH), a T cell-dependent antigen. After dosing, BMS-986003was slowly absorbed, with a Tmax ranging from 6-96 h (FIG. 12). Theexposure of BMS-986003 appeared to be less than dose-proportional acrossall dose levels. With a dose ratio of 1:10:100, the average Cmax andAUC0-inf ratios were 1:12:80 and 1:7:44, respectively. With the exposurefollowing the IV dose (2 mg/kg) as reference, and assuming linear PKafter IV dosing, the SC bioavailability of BMS-986003 was 88%, 74%, and44% at 0.2, 2, and 20 mg/kg, respectively. The terminal T½ wasconfounded by the immunogenicity observed with most of the monkeys at 2to 5 weeks after dosing. Therefore, the T½ was estimated to be 85, 66,and 105 h at 0.2, 2 and 20 mg/kg, respectively.

The PK of 5c8-IgG1, an anti-human CD40L monoclonal antibody used as apositive control in the PK/PD study, was evaluated after IVadministration at 20 mg/kg (FIG. 12). 5c8-IgG1 exhibited 10-fold higherplasma exposures and 4-fold longer T½ when compared to BMS-986003 givenSC at the same dose (TABLE 13).

The PK of the mouse surrogate dAb-Fc fusion protein, BMS-2m-126-24-CT,was evaluated in mice following single IV and SC administration (TABLE13). After a single IV (1 mg/kg), the plasma concentrations followed amono-exponential decline with a terminal T½ of 101 h (FIG. 13). The CLTpwas 1.85 mL/h/kg; and the Vss was at 0.26 L/kg, indicating extracellulardistribution. After single SC doses of 1 and 10 mg/kg, BMS-2m-126-24-CTwas slowly absorbed with a Tmax of 24 h. The systemic exposuresincreased in a dose-proportional manner. With a dose ratio of 1:10, theCmax and AUC0-inf increased in the proportion of 1:11. The terminal T½was 100 and 120 h at 1 and 10 mg/kg, respectively. The ratio of thedose-adjusted exposure (AUC0-inf) after SC and IV administration wasgreater than 1, suggesting complete absorption after SC administration.

Pharmacokinetic/Pharmacodynamic Modeling

The PD of BMS-986003 was measured as the suppression of anti-KLHantibody response in the PK/PD study. BMS-986003 suppressed 70% theantibody response to KLH

$\left( {{\% \mspace{14mu} {response}\mspace{14mu} {suppressed}} = {\left( {1 - \frac{{AUEC}_{0\text{-}1008h\mspace{14mu} {IgG}\mspace{14mu} {titers}}{treatedgroup}}{{AUEC}_{0\text{-}1008h\mspace{14mu} {IgG}\mspace{14mu} {titers}}{vehicle}\mspace{14mu} {group}}} \right)*100}} \right)$

at the highest dose of 20 mg/kg. Marginal (15%) and no suppression ofthe antibody response occurred at 2 and 0.2 mg/kg. In comparison,5c8-IgG1 exhibited 10-fold higher plasma exposures and 4-fold longer T½than BMS-986003 at the same dose level (20 mg/kg). As a result, 5c8-IgG1suppressed 97% anti-KLH antibody response. In order to compare the invivo potency between BMS-986003 and 5c8-IgG1, PK/PD modeling wasperformed using SAAM II (version 1.2.1, Seattle, Wash.). The plasmaconcentrations of BMS-986003 following SC administration were describedusing a first-order absorption kinetics coupled with a 2-compartmentmodel, where the elimination occurred in both central and peripheralcompartments. Because of complications from immunogenicity and possiblenonlinear absorption, the PK data were fitted individually at each dose.

For 5c8-IgG1, a two-compartment model with central elimination was used.The anti-KLH antibody response, expressed as the average value of IgGtiters, was modeled using a 6-compartment signal transduction model. Thekinetics of KLH in the body was assumed to be a 1-compartment model. Theinhibition of the IgG production by BMS-986003 and 5c8-IgG1 wasdescribed using an Imax model, with a maximum inhibition equal to 100%.As shown in FIG. 14, the model-fitted curves were able to describe boththe PK and PD profile. The plasma IC50 of BMS-986003 and 5c8-IgG1 forthe suppression of KLH-induced IgG production was estimated to be 74±14and 60±18 nM, respectively. These results demonstrated that the potencyof these two molecules was comparable in vivo.

The CD40L receptor occupancy (RO) of BMS-986004 was measured in the IVPK study. Following IV administration of 11 mg/kg, the RO of BMS-986004on the peripheral-blood mononuclear cells (PBMC) was time- andconcentration-dependent. PK/PD modeling was performed to estimated an ROEC50. The plasma concentrations were modeled using a modifiedtwo-compartment model with an additional ADA-mediated first orderelimination constant introduced at 504 h after dosing; and the RO wasmodeled using an Emax model

$\left( {{{RO}\mspace{14mu} \%} = \frac{E\; {\max^{*}{Cp}^{\gamma}}}{{{EC}\; 50^{\gamma}} + {Cp}^{\gamma}}} \right).$

As shown in FIG. 15, the fitted curves were able to describe bothexposure and RO, with an estimated RO EC50 of 3.4±0.3 nM and the γ (hillfactor) of 3.1±0.1. In comparison, the RO EC50 was ˜22-fold lower thanthe anti-KLH antibody response IC50 of 74±14 nM, suggesting that >95% ROis required in order to achieve appreciable (>50%) anti-KLH antibodysuppression.

Example 11 Nonclinical Toxicology Single-Dose PK/PD Study

The objectives of this study were to 1) determine the tolerability ofBMS-986003, including its potential immunogenicity, when givensubcutaneously as a single dose to monkeys; 2) evaluate its PD (e.g.,inhibition of the antibody response to T-cell-dependent antigen) and PKprofiles; 3) evaluate the receptor occupancy of BMS-986003 andperipheral T-cell counts following subcutaneous dosing; and 4) aid doseselection for renal transplant studies and first-in-human dosing.

BMS-986003 was administered s.c. in the posterior thorax as single dosesof 0 (vehicle control), 0.2, 2, or 20 mg/kg to groups of 2 cynomolgusmonkeys per sex. An additional two monkeys/sex received a singleintravenous dose of 20 mg/kg 5c8-IgG1, a monoclonal antibody to humanCD40L that was used as a positive control in this study. All doses wereadministered at 2 mL/kg in the vehicle (PBS; pH 7.2). To assess theeffects on the T-cell dependent antibody response, animals wereimmunized at approximately 24 hours after dosing with test article orimmediately after dosing the positive control with 10 mg of KLH byintramuscular injection (posterior quadriceps or caudal thigh). Criteriafor evaluation included survival, PK, immunogenicity, PD (inhibition ofthe antibody response to the T-cell-dependent antigen, KLH), clinicalsigns, body weights, food consumption, peripheral-bloodimmunophenotyping, receptor occupancy, and clinical-pathologyevaluations (hematology, serum chemistry, and coagulation). Animals werereturned to stock following a 6-week post-dose observation period.

At doses ≦20 mg/kg, BMS-986003 was slowly absorbed (Tmax=6-96 h) andCmax and AUCtot values increased in a less than dose-proportional manneracross all dose groups and there were no apparent gender differences.The T½ values estimated ranged from 69-104 h across all doses.BMS-986003 was substantially immunogenic; all monkeys developed apositive anti-drug antibody (ADA) response during the 6-week post-doseperiod. At 0.2 and 2 mg/kg, the mean group total ADA response peaked atDay 22 at mean group end point titers (EPT) of 4203 and 6469,respectively. At 20 mg/kg, the ADA response, while positive, wassomewhat delayed and partially suppressed, consistent with targetpharmacology, peaking at Day 36 at a mean group EPT of 1828. Furthercharacterization of the antibodies demonstrated the majority of bindingto the dAb (non-Fc) portion of the molecule and these antibodies wereshown to block the binding of BMS-986003 to CD40L in 2 differentimmunoassay formats suggesting that the ADA were neutralizing. Inaddition, the formation of ADA appeared to accelerate the elimination ofBMS-986003 in several monkeys.

Mean PK parameters for BMS-986003 are presented in TABLE 14.

TABLE 14 Pharmacokinetic Summary BMS-986003 5C8-IgG1 SC IV Mean 0.2mg/kg 2 mg/kg 20 mg/kg 20 mg/kg Parameter (N = 4) (N = 4) (N = 4) (N =4) Gender Male/Female Male/Female Male/Female Male/Female AUC(0-inf)219/407 2165/2477 14195/13114 267750/272250 μg · h/mL CLTp Not Not Not  ND/0.074 mL/h/kg applicable applicable applicable T½ h  69/101 68/69107/104 ND/400 Cmax  69/101 45/49 88/91 Not μg/mL applicable Tmax h24/96 51/15  6/15 Not applicable Molecular weight used for conversionwas 78104 Da for BMS-986003, 150000 Da for 5c8-IgG1 mAb. ND = notdetermined,; AUCextra for males was above 20%, therefore the T½ was notreported.

There were no BMS-986003- or 5c8-IgG1-related clinical observations oreffects on body weights or clinical pathology parameters except 1 maletreated with 5c8-IgG1 had decreased red blood cells (0.74×control),hemoglobin (0.73×predose), and hematocrit (0.75×predose) on Day 8, and 3of 4 monkeys receiving 5c8-IgG1 had decreased lymphocytes (0.53× to0.65×predose) on Day 8, suggestive of lymphocyte depletion.

CD40L receptor occupancy was generally time- and dose-dependent and moresustained following administration of 20 mg/kg BMS-986003, consistentwith higher and more sustained exposures at this dose and PD activity.For BMS-986003, mean peak receptor occupancy on peripheral-bloodmononuclear cells (PBMC) was achieved at 24 hrs (97%), 6 hrs (99%) or 48hrs (99%) post-dose, decreasing to <90% occupancy at 240, 360, or 696hrs and to <50% occupancy at 360, 696, or 1032 hrs, at 0.2, 2, or 20mg/kg, respectively. In comparison, for 5c8-IgG1 at 20 mg/kg, mean peakreceptor occupancy on PBMC was achieved at 48 hours 100%), and wassustained at ≧97% for the entire study (1032 hr or through Day 44).

BMS-986003 suppressed the antibody response to KLH only at the high doseof 20 mg/kg. On Days 8-30 at 20 mg/kg, there was a 69 to 83% suppressionof the geometric group mean antibody response to KLH, relative to thecontrol group, with a peak suppression of 83% occurring on Day 16. Nosuppression of the antibody response occurred at 0.2 or 2 mg/kgBMS-986003. These data demonstrate that BMS-986003 at a sustainedreceptor occupancy of >90% for at least 1 month and at sustained plasmaconcentrations above ˜10 μg/mL through Day 11 is able to inhibit aT-cell dependent antibody response in cynomolgus monkeys. For thepositive control antibody, 5c8-IgG1, suppression of 74-97% of thegeometric group mean antibody response to KLH occurred on Days 8-30,with peak suppression of 97% by Day 16 which was generally sustainedthrough Day 30.

No biologically relevant BMS-986003 related changes in absolute numbersof B cells (CD45+, CD20+, CD3−), total T (CD45+, CD3+) cells, helper T(CD45+, CD3+, CD4+, CD8−) cells, cytotoxic T (CD45+, CD3+, CD4−, CD8+)cells, or natural killer (CD45+, CD3−, CD16+) cells occurred during thestudy, which confirmed lack of any Fc effector function. However, on Day8, 3 of 4 monkeys treated with 20 mg/kg 5c8-IgG1 had decreasedT-lymphocytes (0.53×-0.66×predose), both helper T-cell (0.64× to0.77×predose) and cytotoxic (0.40× to 0.61×predose) T-cell populations,suggestive of depletion.

In conclusion, BMS-986003 administered as single SC doses of 0.2, 2, or20 mg/kg (AUC≦14195 μg*hr/mL) was well tolerated in cynomolgus monkeyswith no adverse drug-related effects. The positive control, 5c8-IgG1, ata dose of 20 mg/kg, resulted in complete, sustained inhibition of theantibody response to KLH and sustained receptor occupancy of nearly 100%through 30 days post-dose. Mild depletion of T-cells was also noted byDay 8 in monkeys receiving 5c8-IgG1 (0.40× to 0.77×predose), which wasnot observed with BMS-986003. BMS-986003 was able to suppress anantibody response to KLH at 20 mg/kg (peak suppression of 83%) followingKLH immunization on Day 1 and had sustained receptor occupancy of ≧90%through Day 22 and ≧50% through Day 29. Similar dampening of theimmunogenicity to BMS-986003 occurred at 20 mg/kg. However, lowerBMS-986003 doses of 0.2 and 2 mg/kg did not suppress the antibodyresponse to KLH or the anti-drug antibody response. The lack ofpharmacology at the lower doses also correlated with decreasing receptoroccupancy (i.e., <90% by Day 11 [0.2 mg/kg] or 16 [2 mg/kg]; <50% by Day16 [0.2 mg/kg] or 30 [2 mg/kg]) and accelerated clearance, presumablydue to the formation of ADA. The inhibition of TDAR is consistent withthe mechanism of action of this compound and was not considered adverse.

Example 12 Evaluation of the Risk for TE/Thrombosis

It has been hypothesized that the TE associated with administration ofthe anti-CD40L monoclonal antibodies is mediated by anti-CD40L mAb-CD40Limmune complex (IC)-mediated cross linking of platelets, facilitated byIC binding to FcgRIIa, an IgG Fc receptor, causing activation andaggregation (FIG. 10). Blocking the interaction of Fc moiety of IgG withFcgRIIa is, therefore, expected to mitigate platelet cross linking andthrombosis. The following methods and approaches were designed toevaluate the risk of TE and/or thrombosis.

In Vitro Platelet Activation Assays

Several in vitro assays were conducted to test the hypothesis thatplatelets are activated by CD40L mab/sCD40L IC in a FcgRIIa-dependentmanner. The positive control 5c8-IgG1 was used to validate the assaysprior to testing BMS-986003 and BMS-986004. Blood from human donors ormice expressing hFcgRIIa receptor on platelets were used for thesestudies. Platelet activation was detected by flow cytometry usingantibodies against the well-validated platelet activation markersP-selectin (CD62P) and PAC-1 (activated GPIIb/IIIa). Briefly, blood wasdiluted 1:25 in modified Tyrodes-HEPES containing 1 mM CaC12 to whichdetection antibodies and test reagents was added, incubated, andanalyzed for platelet activation. Initial experiments determined thatsCD40L or 5c8IgG1 alone did not activate platelets, but different immunecomplex ratios of 1:1 to 1:8 of 5c8:sCD40L significantly activatedplatelets. Subsequent experiments used 5c8-IgG1 or 5c8-mIgG2a IC, mostlyat a 1:3 molar ratio of 5c8:sCD40L.

Platelet Activation by 5c8/sCD40L IC can be Blocked by Anti-FcgRIIaAntibody

Studies were conducted with the FcgRIIa blocking antibody IV.3 to testwhether activation of platelets by 5c8/sCD40L IC was indeedFcgRIIA-mediated. Blood from human donors was pre-incubated with 0.5μg/μl of the FcgRIIa blocking antibody IV.3 prior to dilution andincubation with detection antibodies as described above. Adenosinediphosphate (ADP), a platelet activator via a different mechanism, wasused as a positive control. As illustrated in FIG. 16, plateletactivation by 5c8/sCD40 IC was completely blocked by IV.3, whileactivation by ADP was not inhibited by the blocking antibody, indicatingthat activation by the IC is FcgRIIa-mediated.

Selection of Inert Fc Tails

A requirement for potential candidate molecules was absence of bindingto FcgRIIa to prevent potential platelet activation. Several 5c8constructs containing different mutations derived from IgG1 (e.g. 5c8-CTand N297Q) or IgG4 (e.g., 5c8-S228P) were expressed and screened for Fctails that did not activate platelets using different molar ratios ofsCD40L to mAbs. Wild-type and most mutated constructs activatedplatelets except for 5c8-CT and 5c8-N297Q (FIG. 17). Absence of Fc(5c8-Fab2) also did not activate platelets further confirming thatIC-platelet activation is Fc-mediated. The CT tail was chosen to formatthe dAb candidates BMS-986003 and BMS-986004.

Effect of FcgRIIa Polymorphism on Platelet Activation

The gene for FcgRIIa is variable at codon 131, resulting in His-Arg(CAT/CGT) polymorphism. The genotype distribution in approximately 100individuals with about equal distribution of Caucasians and AfricanAmericans was A/A (His homozygous; 14%), A/G (His/Arg heterozygous;60%), and G/G (Arginine homozygous; 26%) for Caucasian Americans and A/A(30%), A/G (51%), and G/G (19%) for African-Americans. Reilly et al.,Clin. Diagn. Lab. Immunol. 1: 640-644 (1994). Fc-dependent plateletaggregation was noted in samples from R131 individuals when treated withanti-CD9 in mIgG2 or mIgG1 Fc format, while platelets from H131individuals aggregated only with anti-CD9 as mIgG2 format; this suggeststhat Fc-dependent aggregation with an IgG1 mAb could potentiallysegregate a patient population into low and high responders, which haspreviously been reported with this polymorphism. Tomiyama et al., Blood80: 2261-2268 (1992). To address any potential differences in plateletactivation with the IgG1 and CT Fc tail, 19 donors were genotyped forhFcgRIIa polymorphism and samples tested for platelet activation. Thedonor pool polymorphism (RR; 42%, HH; 21%, HR; 37%) was sufficient toevaluate any potential differences in platelet activation to the IgG1format. Representative of literature reports, platelet activation with5c8-IgG1/sCD40L IC was similar across all genotyped individuals. Noactivation was found with 5c8-CT/sCD40L IC (FIG. 18), suggesting no orminimal risk of increased TE in a patient population with an antibodyformatted with the CT tail.

BMS-986004: Platelet Activation in Human Blood Donors

The experiments described above using 5c8, supported selection of theCT-tail as the best format for BMS-986004 (also calledBMS2h-572-633-CT-L2). Blood obtained from 6 donors was treated with5c8-IgG1, 5c8-CT, F(ab)₂, and BMS-986004. Platelets were activated by5c8-IgG1 but not by any of the other constructs, including BMS-986004(FIG. 19), suggesting that this dAb has no or low risk for causingplatelet activation and TE in clinical studies.

BMS-986003: Platelet Activation in Blood from Mice Expressing hFcgRIIa

To further confirm that activation of platelets by anti-CD40L antibodieswas mediated by FcgRIIa receptor, blood from transgenic mice expressingthe human receptor (R131 genotype) was treated with 5c8-IgG1, 5c8-IgG2a,dAb-IgG1, 5c8-CT, and BMS-986003 (also called BMS-2h572-633-CT).Platelets were specifically activated by 5c8-IgG1, 5c8-IgG2a, anddAb-IgG1/sCD40L IC in blood from mice expressing hFcgRIIa, but notwild-type littermates. 5c8-CT and BMS-986003 did not activate platelets,further confirming a low risk for TE with the presently disclosedantibodies (FIG. 20).

Example 13 Epitope Binding Experiments

FIG. 25 shows SPR sensorgram data for experiments designed to testwhether or not monovalent dAb molecules BMS2h-503-1, BMS2h-572-6,BMS2h-719-17, and the monovalent anti-CD40L 5c8 Fab fragment competewith each other for binding to CD40L. Experiments were performed usingbiotinylated CD40L (biot-IZ-hCD40L) that was captured on a streptavidinsensor chip surface. The tests involved the sequential injection of aspecified molecule (phase “a”), immediately followed by injection of thesame molecule in the presence of a second specified molecule (phase“b”), followed by dissociation (phase “c”). Competition for binding isidentified as a reduction (blocking) of the binding signal for thesecond molecule in the presence of the first, with the level of blockingbeing governed by the association and dissociation kinetics of eachmolecule. For each pair of molecules tested, the binding of the secondmolecule was shown to be reduced when the first molecule was present.These result suggest that BMS2h-503-1, BMS2h-572-6, BMS2h-719-17, and5c8 Fab compete with each other for binding to biot-IZ-hCD40L.

FIG. 26 shows SPR sensorgram data for binding of the indicateddAb-CT-long and the 5c8-CT-long molecules to either human CD40L monomer(triple CD40L mutant (T211E, S222Y, H224K, [108-261])) or to CD40Ltrimer (IZ-hCD40L). The dAb-CT-long and the 5c8-CT-long molecules werecaptured via their “CT-long” Fc-domain on an immobilized anti-human IgGFc (Biacore, GE Healthcare) antibody sensor chip surface. The data inthe top 3 panels show that human CD40L monomer binds specifically toBMS2h-719-202-CT-long and 5c8-CT-long, but does not bind to any of theindicated dAb-CT-long molecules that contain dAbs from the BMS2h-572-6lineage. In contrast, the bottom 3 panels show that CD40L trimer(IZ-hCD40L) binds strongly to all the tested dAb-CT-long molecules fromthe BMS2h-572-6 lineage, as well as to BMS2h-719-202-CT-long and5c8-CT-long. These results suggest that the molecules from theBMS2h-572-6xx-CT-long lineage are specific for an epitope that is onlypresent on the CD40L trimer and not present on monomeric human CD40L,whereas BMS2h-719-202-CT-long and 5c8-CT-long bind to an epitope that ispresent on both the CD40L monomer and trimer.

Although the present embodiments have been described in detail withreference to examples above, it is understood that various modificationscan be made without departing from the spirit of these embodiments, andwould be readily known to the skilled artisan.

What is claimed is:
 1. An isolated antibody polypeptide comprising afirst variable domain that specifically binds human CD40L, wherein CD40Lcomprises the amino acid sequence of SEQ ID NO: 1, wherein the aminoacid sequence of the first variable domain comprises (a) a CDR1 regionwhich differs from the CDR1 region of BMS2h-572-633 by up to three aminoacids, (b) a CDR2 region which differs from the CDR2 region ofBMS2h-572-633 by up to three amino acids, (c) a CDR3 region whichdiffers from the CDR3 region of BMS2h-572-633 by up to three aminoacids, (d) a FR1 region which differs from the FR1 region ofBMS2h-572-633 by up to three amino acids, (e) a FR2 region which differsfrom the FR2 region of BMS2h-572-633 by up to three amino acids, (f) aFR3 region which differs from the FR3 region of BMS2h-572-633 by up tothree amino acids, and (g) a FR4 region which differs from the FR4region of BMS2h-572-633 by up to three amino acids; and wherein theantibody polypeptide inhibits binding of CD40L to CD40 with an EC50 of100 pM to 100 nM.
 2. The antibody polypeptide of claim 1, wherein theamino acid sequence of the first variable domain comprises (a) a CDR1region which differs from the CDR1 region of BMS2h-572-633 by up tothree amino acids, (b) a CDR2 region which differs from the CDR2 regionof BMS2h-572-633 by up to three amino acids, and (c) a CDR3 region whichdiffers from the CDR3 region of BMS2h-572-633 by up to three aminoacids.
 3. The antibody polypeptide of claim 1, wherein the amino acidsequence of the first variable domain differs from the amino acidsequence of BMS2h-572-633 by up to 10 amino acids.
 4. The antibodypolypeptide of claim 3, wherein the amino acid sequence of the firstvariable domain differs from the amino acid sequence of BMS2h-572-633 byup to 5 amino acids.
 5. The antibody polypeptide of claim 4, wherein theamino acid sequence of the first variable domain differs from the aminoacid sequence of BMS2h-572-633 by up to 2 amino acids.
 6. The antibodypolypeptide of claim 5, wherein the first variable domain differs fromthe amino acid sequence of BMS2h-572-633 by 1 amino acid.
 7. Theantibody polypeptide of claim 1, wherein the antibody polypeptide isselected from the lineage group of BMS2h-572, and wherein the amino acidsequence of the first variable domain further comprises: (a) a CDR1region having a sequence Trp-X₁-Leu-Met-Gly (SEQ ID NO: 2), wherein X₁is Glu or Gln; (b) a CDR2 region having a sequenceGly-Ile-Glu-Gly-Pro-Gly-Asp-Val-Thr-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (SEQID NO: 3); and (c) a CDR3 region having a sequenceLys-X₂-Y₂-Z₂-Ser-Asp-Tyr (SEQ ID NO: 4), wherein X₂ is Asp or Glu, Y₂ isAla or Ser, and Z₂ is Lys, Asn, or Arg.
 8. The antibody polypeptide ofclaim 7, wherein the amino acid sequence of the first variable domainfurther comprises: (a) a FR1 region having a sequenceGlu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Asn(SEQ ID NO: 5); (b) a FR2 region having a sequenceTrp-X₁-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser (SEQ ID NO: 6),wherein X₁ is Ala or Val; (c) a FR3 region having a sequenceArg-Thr-Phe-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Val-Lys-Val-Gly(SEQ ID NO: 7); and (d) a FR4 region having a sequenceArg-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser (SEQ ID NO: 8).
 9. Theantibody polypeptide of claim 1, wherein the first variable domaincomprises the amino acid sequence of BMS2h-572-633.
 10. The antibodypolypeptide of claim 1, wherein the antibody polypeptide is a domainantibody (dAb).
 11. The antibody polypeptide of claim 10, wherein theantibody polypeptide is a fusion polypeptide comprising the firstvariable domain and an Fc domain.
 12. The fusion polypeptide of claim11, wherein the fusion polypeptide comprises an IgG4 Fc domain.
 13. Thefusion polypeptide of claim 11, wherein the fusion polypeptide comprisesan IgG1 Fc domain.
 14. The fusion polypeptide of claim 11, wherein thefusion polypeptide comprises a CT-Long domain.
 15. The fusionpolypeptide of claim 11, wherein the fusion polypeptide comprises aCT-short domain.
 16. The fusion polypeptide of claim 11, wherein thefusion polypeptide comprises a N297Q Long Fc domain.
 17. The fusionpolypeptide of claim 11, wherein the fusion polypeptide comprises aN297Q Short Fc domain.
 18. The antibody polypeptide of claim 1, whereinthe antibody polypeptide further comprises a second variable domain thatspecifically binds a second antigen, wherein the second antigen is anantigen other than human CD40L.
 19. The antibody polypeptide of claim18, wherein the second antigen is a cluster of differentiation (CD)molecule or a Major Histocompatibility Complex (MHC) Class II molecule.20. The antibody polypeptide of claim 18, wherein the second antigen isserum albumin (SA).
 21. A nucleic acid encoding the antibody polypeptideof claim
 1. 22. A vector comprising the nucleic acid of claim
 21. 23. Anisolated host cell comprising the vector of claim
 22. 24. Apharmaceutical composition comprising a therapeutically-effective amountof the antibody polypeptide of claim 1 and a pharmaceutically acceptablecarrier.
 25. The pharmaceutical composition of claim 24, furthercomprising an immunosuppressive/immunomodulatory and/oranti-inflammatory agent.
 26. A method of treating an immune disease in apatient in need of such treatment, comprising administering to thepatient a therapeutically effective amount of the pharmaceuticalcomposition of claim
 24. 27. The method of claim 26, wherein theisolated antibody polypeptide is administered in combination with animmunosuppressive/immunomodulatory and/or inflammatory agent.
 28. Themethod of claim 26, wherein the immune disease is an autoimmune diseaseor a graft-related disease.
 29. The method of claim 26, wherein theimmune disease is a graft-related disease.
 30. The method of claim 29,wherein the graft-related disease comprises solid organ, tissue and/orcell transplant rejection.
 31. The method of claim 29, wherein thegraft-related disease is graft versus host disease (GVHD).
 32. Themethod of claim 29, wherein the graft-related disease is an acutetransplant rejection.
 33. The method of claim 29, wherein thegraft-related disease is a chronic transplant rejection.
 34. The methodof claim 29, wherein the isolated antibody polypeptide isco-administered with a CTLA4 mutant molecule.
 35. The method of claim34, wherein the CTLA4 mutant molecule is L104EA29Y-Ig (belatacept). 36.The method of claim 26, wherein the immune disease is selected from thegroup consisting of Addison's disease, allergies, ankylosingspondylitis, asthma, atherosclerosis, autoimmune diseases of the ear,autoimmune diseases of the eye, autoimmune hepatitis, autoimmuneparotitis, colitis, coronary heart disease, Crohn's disease, diabetes,including Type 1 and/or Type 2 diabetes, epididymitis,glomerulonephritis, Graves' disease, Guillain-Barre syndrome,Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenicpurpura, inflammatory bowel disease, immune response to recombinant drugproducts, systemic lupus erythematosus, male infertility, multiplesclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever,rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome,spondyloarthropathies, thyroiditis, transplant rejection, vasculitis,AIDS, atopic allergy, bronchial asthma, eczema, leprosy, schizophrenia,inherited depression, chronic fatigue syndrome, Alzheimer's disease,Parkinson's disease, myocardial infarction, stroke, autism, epilepsy,Arthus's phenomenon, anaphylaxis, alcohol addiction, and drug addiction.37. The method of claim 26, wherein the immune disease is selected fromthe group consisting of myasthenia gravis, idiopathic thrombocytopenicpurpura, and systemic sclerosis.
 38. An isolated antibody polypeptidecomprising a first variable domain, wherein said antibody polypeptidespecifically binds human CD40L, wherein CD40L comprises the amino acidsequence of SEQ ID NO: 1, wherein the antibody polypeptide competes withthe binding of BMS2h-572-633, and wherein the antibody polypeptideinhibits binding of CD40L to CD40 with an EC50 of 100 pM to 100 nM. 39.The isolated antibody polypeptide of claim 38, wherein the firstvariable domain comprises the amino acid sequence of one of the antibodypolypeptides selected from the lineage group consisting of BMS2h-572,BMS2h-719, BMS2h-503, and BMS2h-116.
 40. The isolated antibodypolypeptide of claim 39, wherein the first variable domain comprises anamino acid sequence at least 95% identical to BMS2h-572-6,BMS2h-572-608, BMS2h-572-614, BMS2h-572-619, BMS2h-572-633,BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202, BMS2h-719-203,BMS2h-719-213, BMS2h-719-214, BMS2h-719-215, BMS2h-719-218,BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312, BMS2h-116-1313,or BMS2h-116-1320.
 41. The isolated antibody polypeptide of claim 40,wherein the first variable domain comprises the amino acid sequence ofBMS2h-572-6, BMS2h-572-608, BMS2h-572-614, BMS2h-572-619, BMS2h-572-633,BMS2h-572-634, BMS2h-572-635, BMS2h-719-2, BMS2h-719-202, BMS2h-719-203,BMS2h-719-213, BMS2h-719-214, BMS2h-719-215, BMS2h-719-218,BMS2h-719-225, BMS2h-503-1, BMS2h-503-2, BMS2h-116-1312, BMS2h-116-1313,or BMS2h-116-1320.